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PHYSIOLOGICAL ASPECTS OF BROWN ADIPOSE TISSUE
ANATOMY AND ORIGIN OF BROWN ADIPOSE TISSUE
In 1551, the Swiss naturalist Konrad Gessner first described brown adipose tissue (BAT) as 
being “neither fat, nor flesh (nec pinguitudo, nec caro), but something in between” (1,2). Now, 
some 460 years later, we know that Gessner had guessed the origin of brown adipocytes 
correctly – they are not typical fat-storing cells or flesh (muscle cells), but rather have 
 characteristics of both white adipocytes and muscle cells, as well as several characteristics 
unique to brown fat cells. 
Brown and white adipocytes form separate tissues that are histologically and functionally 
distinct (TABLE 1), although both cell types are sometimes found intermingled (3). While the 
amount of white adipose tissue (WAT) is roughly 20% of total body weight, adult humans 
are estimated to have only 100-200 grams of BAT. Furthermore, a white adipocyte contains 
a large vacuole filled with triglycerides (TG), which is fully compatible with its function to 
store lipids, surrounded by a thin layer of cytoplasm. The cytoplasm contains the nucleus 
and cell organelles, including a few mitochondria that mediate the formation of ATP, the 
main energy supplier of cells. In contrast, a brown adipocyte contains several small lipid 
droplets that are surrounded by a large number of mitochondria that mediate its energy-
combusting function in the cytoplasm (see below). The iron-containing proteins in mito-
chondria, which are part of the respiratory chain, give BAT its brownish color. 
Brown adipocytes are present in (at least) two forms. They may form brown fat pads, 
which are located in neonates in the subscapular area and in adults along the aorta and 
in the supraclavicular region (4). In addition, individual brown adipocytes are also found 
scattered within other tissues, such as WAT and muscle, there forming a pool of ‘peripheral 
White adipose tissue Brown adipose tissue
Microscopic image
Amount in body Approx. 12 - 35 kg Approx. 100 - 200 g
Morphology Cells filled with a large lipid droplet
Low number of mitochondria 
Cells filled with multiple small lipid droplets
High number of mitochondria
Location Throughout the whole body In specific fat pads mainly located between 
the shoulders and along the great vessels; 
groups of cells within white adipose tissue 
and muscle
Function Storage of fat Combustion of fat toward heat
TABLE 1 - Comparison between white and brown adipose tissue
Proefschrift_MB.indb   13 05-05-14   11:57
1
14 
brown adipocytes’ (5,6). These cells are also called ‘beige adipocytes’, since their phenotype 
lies between white and brown adipocytes. The two types of brown adipocytes have dif-
ferent origins (FIGURE 1).
Brown adipocytes present in the brown fat pads derive from Myf5+ precursor cells; these 
precursor cells can differentiate into both brown adipocytes and skeletal muscle cells, 
depending on the presence of stimuli such as bone morphogenetic protein 7 (BMP7) (5,7,8). 
Thus, the brown adipocytes in fat pads and muscle cells share a common precursor cell and, 
therefore, brown adipocytes are much more ‘flesh-like’ than previously suspected (3).
 The existence of peripheral brown adipocytes (or beige adipocytes) was initially disco-
vered in the WAT depot from animals that were chronically exposed to cold, resulting in a 
FIGURE 1 - Differentiation of mesenchymal stem cells towards brown adipocytes. Myf5-positive precursor 
cells can differentiate towards muscle cells or brown adipocytes, depending on the presence of BMP7. Muscle 
cells express myogenin, and brown adipocytes PRDM16. This type of brown adipocyte is present in fat pads. 
Myf5-negative precursor cells differentiate toward peripheral brown adipocytes (‘beige adipocytes’) under 
influence of, amongst other factors, BMP7, cold stimulation (= ß-adrenergic stimulation) and PPAR-γ agonists. 
Myf5, myogenic factor 5; BMP7, bone morphogenetic protein-7; PRDM16, PR domain containing 16; PPAR-γ, 
 peroxisome proliferator-activated receptor-γ. 
Adapted from: Boon et al, NTvG 2013 (14).
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PHYSIOLOGICAL ASPECTS OF BROWN ADIPOSE TISSUE
shift in color from white to brownish (9). The precise origin of these peripheral brown adipo-
cytes is currently a topic of intensive study. Cell fate tracking studies have shown that 
peripheral brown adipocytes that emerge in WAT in response to cold exposure do not 
express Myf5, and are therefore Myf5- precursor cells (5). More specifically, in both WAT and 
muscle, a subpopulation of Myf5- precursor cells called the Sca1+ adipose progenitors have 
been identified that are capable of differentiating into peripheral brown adipocytes (10). It is 
likely that also other, yet to be discovered, types of precursor cells are present in WAT and 
muscle that can give rise to peripheral brown adipocytes. In addition, peripheral brown 
 adipocytes may arise from transdifferentiation of white adipocytes (11). 
Several factors can stimulate the differentiation of Myf5+ precursor cells in the brown fat 
pads into brown adipocytes (e.g. BMP7), as well as the differentiation of Myf5- precursor cells 
into peripheral brown adipocytes (e.g. BMP7, cold induction, and peroxisome proliferator-acti-
vated receptor-γ (PPARγ)-agonists) (8,10-13). These stimuli are, therefore, considered interest-
ing therapeutic targets to activate BAT by enhancing its differentiation. 
HEAT PRODUCTION BY BROWN ADIPOSE TISSUE
While the main function of WAT is the storage of energy in the form of TG, BAT burns 
TG-derived fatty acids (FA) toward heat. This results from the process of ‘uncoupling’, in which 
energy is released as heat instead of being used for generation of ATP, leading to increased 
energy expenditure. A detailed description of the physiology of the brown adipocyte is 
explained below and shown in FIGURE 2 (14).
Each brown adipocyte is individually innervated by a sympathetic nerve (15,16). The most 
well-known stimulus resulting in activation of BAT by the sympathetic nervous system is 
cold. All sensory input on temperature is coordinated in the temperature center within the 
preoptic chiasma/anterior hypothalamic nuclei of the brain, located in front of the third 
ventricle (17). This area receives input from sensory nerve fibers in the skin. Upon stimulation, 
the sympathetic nerve locally releases noradrenalin, which binds to adrenergic receptors on 
the brown adipocyte. Activation of these receptors results in a fast induction of intracellular 
lipolysis, induced by activation of adipose triglyceride lipase (ATGL) and hormone sensitive 
lipase (HSL) through phosphorylation, resulting in release of FA from TG-filled lipid droplets. 
FA are directed to the mitochondria where they either allosterically activate uncoupling 
 protein 1 (UCP1) present in the inner membrane of the mitochondrion or can undergo 
 oxidation. In addition, adrenergic stimulation enhances transcription and synthesis of UCP1 
to enhance the total mitochondrial content of UCP1 (3). Of note, while it has been irrefutably 
proven that in rodents, the ß3-adrenergic receptor is the main receptor by which BAT is sym-
pathetically activated (3), the dominant adrenergic receptor in humans (i.e., α or ß) remains 
to be identified (see CHAPTER 2).
The synthesis of ATP that is required as energy source in tissues such as the heart and 
skeletal muscle, e.g. to mediate muscle contraction, starts with the conversion of FA, and to 
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a lesser extent glucose, into acetyl coenzyme A that participates in the citric acid cycle in the 
mitochondrion. The cytric acid cycle generates energy-rich complexes, such as NADH and 
FADH2, which donate their electrons during oxidative phosphorylation to the electron trans-
port chain, thereby creating a gradient of H+-ions from the matrix toward the inner mem-
brane space across the inner mitochondrial membrane. The energy stored in this gradient is 
then used by the enzyme ATP synthase to convert ADP into energy-rich ATP, while protons 
are transported back into the mitochondrial matrix. However, brown/beige adipocytes 
express UCP1 that forms pores in the inner mitochondrial membrane causing leakage of 
protons back to the matrix. Therefore, the energy created by the proton gradient is not used 
FIGURE 2 - Activation of brown adipose tissue. In the resting state, the energy-rich complexes NADH and 
FADH2 that are generated from the citric acid cycle in the mitochondrial matrix during combustion of 
 glucose and fatty acids, release their energy in the form of electrons to the electron transport chain in the 
inner membrane of the mitochondrion. This results in build-up of an H+-gradient across the inner membrane 
(see right panel). In cell types such as myocytes, the energy of this H+-gradient is used by the enzyme ATP 
synthase to convert ADP into ATP. However, in the mitochondria of brown adipocytes UCP-1 proteins are 
 present in the inner membrane that uncouple the H+-gradient from ATP synthesis. This occurs when a sym-
pathetic neuron activates the brown adipocyte by secretion of noradrenalin, which binds to adrenergic recep-
tors on the brown adipocyte membrane (see left figure). This results in formation of cAMP and eventually 
activation and synthesis of UCP-1. Leakage of H+ across the inner membrane via UCP-1 results in production of 
heat instead of ATP. The synthesis of UCP-1 is also stimulated by the active thyroid hormone T3. cAMP, cyclic 
AMP; UCP-1, uncoupling protein-1; T3, tri-iodothyronine; T4, thyroxine; D2, type 2 deiodinase. 
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for generation of ATP, but rather dissipates as heat, a process called ‘nonshivering thermo-
genesis’ (3,18). The greater the density of mitochondria (or the amount or activity of UCP-1) 
in BAT, the more FA will be burnt and released as heat when BAT is activated. Of note, FA 
derived from intracellular TG stores (rather than those directly taken up from the plasma) 
are the main activators of UCP1 and substrates for mitochondrial uncoupling, as thermo-
genesis is defective in mice that lack ATGL (19), indicating that FA taken up by brown adipo-
cytes are not directly used for combustion. Therefore, maintenance of intracellular TG stores 
is essential for BAT non-shivering thermogenesis.
Accordingly, after intracellular lipolysis, the intracellular TG stores of the brown adipo-
cyte need to be replenished. This is mediated via three mechanisms: 1) uptake of glucose 
followed by de novo lipogenesis, 2) uptake of albumin-bound free FA, and 3) uptake of 
TG-derived FA from very-low-density lipoproteins and chylomicrons in the plasma (3,20,21). 
While uptake of glucose by the brown adipocyte is mediated by the glucose transporters 
GLUT-1 and GLUT-4, uptake of FA is mainly mediated by the FA transporter CD36. Of note, a 
previous study of Bartelt et al (20) suggested that, upon cold exposure, BAT takes up 
TG-derived FA from chylomicron-sized (~250 nm) lipoprotein-like particles via whole particle 
uptake. However, this is in contrast to TG-derived FA uptake by WAT and muscle and is not in 
line with the increased expression of LPL and CD36 that occurs upon cold exposure in BAT. 
Thus, whether the uptake of chylomicron-derived FA by BAT truly occurs via whole particle 
uptake and by which mechanism VLDL-derived FA are taken up, remains to be investigated. 
In addition to cold, thyroid hormone is also involved in the activation of BAT. After uptake 
of T3 and T4 by the brown adipocyte and intracellular conversion of T4 into T3 by the enzyme 
type-2-deiodinase (D2), the active thyroid hormone T3 is translocated into the nucleus and 
binds to a thyroid hormone responsive element located on the promoter of the UCP1 gene 
(22). This leads to increased transcription of UCP1 and consequently to increased conversion 
of energy into heat. Furthermore, T3 is able to stabilize the UCP1 mRNA, thereby reducing 
its degradation in the cell (3). During cold-induction, the activity of D2 is increased in BAT, 
leading to locally increased amounts of T3. This is an additional and necessary mechanism 
to stimulate thermogenesis by BAT (23).
PRESENCE OF FUNCTIONAL BROWN  
ADIPOSE TISSUE IN ADULT HUMANS 
In mammals, the primary function of BAT thus is the production of heat to prevent a 
decrease in core body temperature. Production of heat by active BAT during cold exposure is 
called ‘non-shivering thermogenesis’ (NST), which is distinct from ‘shivering thermogenesis’ 
resulting from skeletal muscle contractions. In neonates, NST is particularly important, since 
they have a relatively large body surface area and little capacity to shiver due to underdevel-
opment of their muscles (3). Although BAT remains present in large quantities in rodents 
and other mammals, in humans the amount of BAT declines fast after infancy.
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Although in adult humans skeletal muscle contributes largely to heat production, BAT is 
still present. Already in 1981, Huttunen et al (24) demonstrated in a post-mortem study that 
adults who lived in cold environments had significant amounts of BAT, suggesting a role for 
NST in humans under cold circumstances. However, it was only in the last decade that BAT 
has been shown to be functionally active in human adults. This was the direct consequence 
of the evolvement of new imaging techniques, particularly the 18F-fluorodeoxyglucose 
(18F-FDG) positron emission tomography-computed tomography (PET-CT) scan. 18F-FDG is 
an analogue of glucose that is taken up by metabolically active tissues without being 
metabolized. Accordingly, 18F-FDG PET-CT scans are widely used as a diagnostic tool in the 
field of oncology to visualize tumors, as they take up high amounts of FDG. Interestingly, 
it was frequently observed that FDG uptake occurred at sites other than tumor tissue and 
the brain, specifically in anatomical areas that were described earlier to contain BAT (24,25). 
FDG uptake in regions corresponding to BAT occurred especially in patients feeling cold at 
the timing of FDG administration and warming of patients prior to scanning or administration 
FIGURE 3 - 18F-fluorodeoxyglucose (FDG)-PET-CT scan visualizing brown adipose tissue in adult humans after 
exposure to cold and under thermoneutral conditions. Brown adipose tissue (BAT) can be visualized by use of 
an FDG-PET-CT scan. To this end, the subject (left) is exposed to cold (16°C) for 2 hours in order to activate BAT. 
After 1 hour of cold induction, the radioactive tracer 18F-FDG is injected intravenously. 18F-FDG, a glucose-
analog, is taken up by organs which have a high glucose metabolism, especially the brain, heart and BAT. After 
2 hours of cold induction, the uptake of 18F-FDG is visualized by means of a low-dose-CT-scan, immediately 
followed by a PET-scan. The CT-scan is used for localization of the uptake areas. The activity and volume of the 
BAT are quantified by autocontouring the areas of FDG uptake, by use of a previously set threshold. The right 
figure shows FDG uptake after 2 hours of exposure to thermoneutral temperature (22°C). 
Images were reproduced from van Marken Lichtenbelt et al. (29), with permission. 
Cold Exposure Thermoneutral Conditions
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of the ß blocker propranolol prevented the uptake in those areas (26,27). The presence of 
active BAT in adult humans was confirmed in 2009, when the FDG-positive areas in the BAT 
regions were shown to histologically resemble murine BAT and furthermore express high 
levels of UCP1, the bona fide marker of BAT (28-30). 
Currently, the cold-induced 18F-FDG PET-CT scan is the ‘gold standard’ for determination 
of BAT volume and BAT activity in human subjects. Exposing subjects to a cold environment 
before FDG administration is of crucial importance, as under thermoneutral conditions 
 generally no FDG uptake by BAT can be seen due to lack of sympathetic stimulation of BAT 
(29) (FIGURE 3). Thus, to visualize BAT, subjects are usually cooled for approximately 2 hours at 
a temperature just above their shivering temperature, followed by infusion of 18F-FDG and 
performance of the PET-CT scan (29-32). The method of cooling differs between research 
institutes and may either consist of water (e.g. water-perfused mattresses) or air cooling 
(e.g. air-climated room). Furthermore, the environmental temperature may remain fixed 
(approximately 15-17°C) or a personalized cooling protocol may be used in which every 
 subject is cooled slightly above his/her own shivering temperature. At the moment, no 
 consensus consists as to which cooling protocol is superior since they all have their pros and 
cons. However, that cooling is crucial for proper BAT visualization is no matter of debate. Of 
note, research by Van Marken Lichtenbelt and others with 18F-FDG PET-CT scans showed 
that, after cold induction, BAT is present in nearly 100% of young adults (29). 
A recent topic of debate is on how ‘brown’ human BAT actually is. Distinction between 
classical brown and beige adipocytes cannot be simply made on the basis of an FDG PET-CT 
scan, as both types of brown adipocytes take up high amounts of glucose when stimulated 
(33). Recent genotyping of human BAT biopsies, obtained from the supraclavicular area from 
subjects who showed FDG uptake in this area, demonstrated that human BAT more closely 
resembles the beige fat found in WAT depots in mice rather than the classical murine BAT 
(6). Therefore, a former vision was that human BAT solely consists of ‘beige’ adipocytes. A 
recent study by Cypess et al (34) refuted this vision. Different depots of neck adipose tissue 
were isolated from adult human volunteers and gene expression, differentiation capacity 
and basal oxygen consumption were compared to different mouse adipose depots. 
Although the variation in the properties of human neck adipose tissue was substantial 
between subjects, they showed that some human samples have many similarities with the 
classical BAT found in rodents. Intriguingly, it appeared that the unstimulated energy 
expenditure of the human BAT samples is similar to that of mouse interscapular BAT, under-
scoring the energy-combusting potential of this adipose tissue in humans.
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INVOLVEMENT OF BROWN ADIPOSE TISSUE IN METABOLIC DISEASE
METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS
Triglycerides (TG) and cholesterol, the most common lipids in our diet, are essential for the 
human body by serving various functions. TG, esters composed of a glycerol backbone and 
three fatty acids, are the main source of energy in the body: TG-derived fatty acids (FA) can 
be combusted in the heart and skeletal muscle to generate adenosine triphosphate (ATP), 
and in brown adipose tissue (BAT) to generate heat. In case of a positive energy balance, FA 
are stored as TG in white adipose tissue (WAT), which can subsequently be lipolyzed and 
combusted elsewhere toward ATP in times of need. Cholesterol does not provide energy but 
rather is an essential constituent of cell membranes as well as the precursor for the synthesis 
of bile acids and steroid hormones.
Since lipids are hydrophobic and thus not soluble in blood, they are transported in so-
called lipoproteins. A lipoprotein consists of a lipid-rich core containing TG and esterified 
cholesterol (i.e., cholesteryl esters), surrounded by a shell composed of phospholipids and 
unesterified cholesterol. In the shell, various apolipoproteins are embedded that can function 
as building blocks for the synthesis of lipoproteins within cells including enterocytes and 
hepatocytes, and in plasma as cofactors and modulators of enzyme activity, (phospho)lipid 
transfer factors, and receptor ligands. Apolipoproteins thus regulate the intracellular 
 synthesis of lipoproteins, their metabolism in the circulation and their uptake by peripheral 
tissues. Lipoproteins can be divided in different classes based on their density, namely (from 
lowest to highest density) chylomicrons, very low density lipoproteins (VLDL), intermediate 
density lipoprotein (IDL), low density lipoprotein (LDL) and high density lipoprotein (HDL). 
The lipoproteins in these classes not only differ in their density, but also in size, and have 
a different combination of apolipoproteins embedded in their shell, mediating different 
functions.
In the blood, cholesterol is primarily transported within the cholesterol-rich lipoproteins 
LDL and HDL. In contrast, dietary and endogenously derived TG are carried in chylomicrons 
and VLDL, which are therefore called TG-rich lipoproteins (TRLs) (1). After a meal, dietary TG 
and cholesterol are taken up by enterocytes the intestine, assembled into chylomicrons and 
subsequently released via the lymph into the circulation. During fasting, the liver ensures a 
supply of TG to peripheral tissues by secretion of TG-rich VLDL particles, which are assembled 
by hepatocytes from exogenous lipids derived from chylomicrons or endogenous lipids 
derived from de novo lipogenesis (2). Once chylomicrons and VLDL arrive in the circulation, 
lipoprotein lipase (LPL) that is present on the capillary beds of adipose tissue and muscle 
hydrolyzes TG into glycerol and free fatty acids (FFA). The liberated FFA can subsequently be 
taken up by white adipocytes to be stored as TG or by muscle cells and brown adipocytes to 
be combusted towards ATP and heat, respectively (3,4). Cellular uptake of FFA is mediated by 
various cell surface receptors, including FA transport proteins (FATP) and CD36 (5). During 
lipolysis, the TRL becomes enriched with the apolipoprotein apoE. The TRL remnant is either 
rapidly cleared by the liver via binding of apoE to mainly the LDL receptor or LDL-related 
 protein (LRP) (6), or is further hydrolyzed to generate LDL. Therefore, there is a continuous 
flux of FA from the intestine and liver (i.e. TG production) towards organs for storage (i.e., 


































liver and WAT) or combustion (i.e., liver, muscle and BAT), followed by clearance of cholester-
ol-enriched TRL remnants by the liver and subsequent re-initiation of this cycle (FIGURE 1) (7). 
In addition, lipolysis of intracellular TG in WAT, e.g. under conditions of fasting, contributes 
to a flux of FA from WAT to liver (e.g. for VLDL-TG synthesis), muscle and BAT (i.e. combustion).
FIGURE 1 - Schematic representation of TG-rich lipoprotein metabolism. Following a meal, dietary trigly-
cerides (TG) and cholesterol are taken up by the intestine and assembled within chylomicrons, which are 
released in the circulation. The liver assembles endogenous lipids to form very low-density lipoproteins 
(VLDL), the predominant carrier of circulating TG under low food supply. TG from both types of TG-rich 
 lipoproteins are rapidly hydrolyzed into glycerol and free fatty acids (FFA) by lipoprotein lipase (LPL), present 
on the capillary bed, resulting in formation of chylomicron remnants and VLDL remnants. These remnants are 
rapidly cleared by the liver mainly via the LDL receptor (LDLr) or LDL related protein (LRP). FFA can be taken up 
by peripheral organs via cellular FA transporters such as CD36 and subsequently be stored by white adipose 
tissue or combusted by brown adipose tissue and muscle. Finally, TG stores within the white adipose tissue 
can be lipolyzed and released in the bloodstream as FFA, which can subsequently be transported to the liver 
to be assembled into new VLDL-TG particles, or be combusted by the brown adipose tissue and muscle. 
Adapted from: Boon and Geerling et al., 2013 (7).
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INVOLVEMENT OF BAT IN TG METABOLISM
As briefly mentioned in CHAPTER 1, BAT may contribute to clearance of plasma FA by two 
mechanisms; uptake of albumin-bound FA as well as uptake of FA derived from TG within from 
VLDL and chylomicrons, the latter likely being dependent on the presence of endothelium- 
bound LPL in BAT (8). The magnitude of the TG clearance capacity of BAT became clear only 
recently when Bartelt et al (8) demonstrated that mice that are housed at 4°C for 24 hours, a 
major trigger for BAT activation, show a massive lowering of plasma TG levels. Furthermore, 
BAT activation by means of cold exposure is able to correct hyperlipidemia in hyperlipidemic 
ApoA5 knockout mice (8). In contrast, animals in which BAT is surgically denervated become 
rapidly obese and hypertriglyceridemic (9). These findings underscore the involvement of 
BAT in total energy expenditure and TG clearance, at least in mice.
Also in humans, BAT likely substantially contributes to TG metabolism. In a recent study 
by Ouellet et al (10), human subjects were cooled for 2 hours followed by infusion of the FA 
tracer 18F-fluoro-thiaheptadecanoic acid (18F-FTHA) and performance of a PET-CT scan. 
Indeed, cold exposure resulted in enhanced FA uptake by BAT as compared to muscle and 
WAT. It is likely that human BAT also utilizes FA from circulating lipoproteins, though this has 
not been investigated yet. Furthermore, 2 hours of cold exposure results in a rapid increase 
in BAT CT radio density, suggestive of lowering of intracellular TG stores in BAT. Indeed, as 
 mentioned in CHAPTER 1, intracellular TG are the main fuel for BAT thermogenesis in animal 
models (11). In room temperature-acclimated rats, short-term acute cold exposure leads to a 
massive depletion of intracellular lipid droplets in BAT (12). A similar depletion of intracellular 
lipid in BAT was found at necropsy in newborn infants and adults who died from hypothermia 
(13). Thus, a fast initial combustion of intracellular TG upon acute BAT activation may well 
explain why short-term cold exposure does not result in acute lowering of plasma TG in 
human subjects (10). Likely, prolonged BAT activation will result in lowering of plasma TG levels 
in human subjects as a consequence of increased clearance from the plasma towards BAT.
INVOLVEMENT OF BAT IN NON-SHIVERING 
THERMOGENESIS
When mammals are exposed to a cold environment, various physiological responses occur 
in order to maintain core body temperature. First, blood perfusion will be redirected. This is 
marked by peripheral vasoconstriction and consequently less blood flow towards the skin 
and other distally located tissues in order to retain the heat in the core, a response called 
‘insulation’ (14,15). Furthermore, thermogenesis will be enhanced so that additional heat is 
produced (15,16). This cold-induced thermogenesis can globally be divided into two com-
ponents, ‘shivering thermogenesis’ (e.g. heat production due to muscle contractions) and 
‘non-shivering thermogenesis’ (NST) (15). In rodents, NST occurs in BAT as a consequence 
of uncoupling of ATP synthesis by UCP1, as described in CHAPTER 1, and results in increased 
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resting energy expenditure (REE) (4). Of note, UCP1 knockout mice that lack the capacity to 
produce heat by NST rely on shivering thermogenesis in the cold (17). 
In adult humans, short-term well-controlled cold exposure may enhance REE by as much 
as 30% (10,18-21). Since shivering does not occur in these cooling protocols (see CHAPTER 1), 
the increase in REE is likely due to increased uncoupling by BAT. Indeed, cold acclimation 
increases NST, BAT volume and activity but not uncoupling in muscle in human subjects, 
supporting the vision that muscle is likely not involved in NST in humans (22). 
Interestingly, REE correlates with BAT activity in several studies (22,23) and lean subjects 
with BAT activity have significantly higher levels of NST than those that do not show BAT 
 activity (24). Lastly, using PET with 11C-acetate, cold-induced oxidative metabolism in BAT 
in human subjects has been demonstrated, confirming the contribution of BAT in NST in 
humans (10).
INVOLVEMENT OF BAT IN PATHOLOGY
Pheochromocytomas
Pheochromocytomas are neuroendocrine tumors that secrete excessive amounts of 
noradrenalin, an important activator of BAT. Indeed, on 18F-FDG-PET-CT-scans in patients 
with this tumor, an increased mass and activity of BAT is seen, accompanied by increased 
energy expenditure (25,26). Moreover, after resection of the tumor FDG uptake as well as 
energy expenditure decrease dramatically (27), supporting that the increased energy 
expenditure typical for this condition is likely due to increased BAT-mediated NST. 
Furthermore, pheochromocytoma patients exhibit increased browning of visceral WAT (28), 
which may also contribute to the enhanced energy expenditure. Whether this browning is 
due to increased transdifferentiation of white into brown adipocytes or differentiation of 
brown preadipocytes present in the visceral WAT towards mature brown adipocytes (see 
CHAPTER 1) remains to be determined. 
Hyperthyroidism/hypothyroidism
Mouse studies have shown that thyroid hormone may activate BAT both directly (via the T3 
receptor in BAT) and indirectly (via the sympathetic nervous system) (29,30). Interestingly, 
energy expenditure is increased in patients with hyperthyroidism and decreased in patients 
with hypothyroidism. A recent study showed that hyperthyroidism in human patients 
increases glucose uptake in BAT independently of BAT perfusion (31). Therefore, the weight 
loss and excessive transpiration in hyperthyroidism, and the weight gain and reduced cold 
tolerance in hypothyroidism, can at least be partly attributed to an increased and decreased 
activity of BAT, respectively.
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Obesity, dyslipidemia and type 2 diabetes 
When energy intake exceeds energy expenditure (i.e. positive energy balance), TG is stored 
in WAT. In addition, TG may be stored ectopically in organs such as skeletal muscle and liver, 
resulting in malfunction of these organs. A prolonged positive energy balance may result in 
development of overweight and obesity. Currently, over 50% of the Dutch population is 
overweight (25 < BMI < 30 kg/m2) and more than 10% is already obese (BMI > 30 kg/m2) (32). 
Obesity is strongly associated with development of other disorders and diseases, such as 
dyslipidemia, type 2 diabetes, cardiovascular disease and cancer (33).
Interestingly, recent studies point towards a role of disturbed BAT function in develop-
ment of obesity and related disorders. In human adults, the amount of BAT is inversely 
 correlated with BMI and percentage of body fat (23). More specifically, BAT volume is inversely 
correlated with parameters of central obesity, such as visceral fat volume on CT-scan and 
waist circumference (34). These findings suggest that obesity is associated with a low level 
of BAT activity. Indeed, excision of BAT or sympathetic denervation of BAT in mice results in 
hypertrigly ceridemia and obesity (9). Thus, in humans, a reduced activity of BAT may predis-
pose to  obesity and obesity-related diseases such as dyslipidemia and type 2 diabetes by 
accumu lation of TG in the blood and subsequent storage in WAT as well as in ectopic fat 
depots such as skeletal muscle and the liver. This is associated with reduced insulin sensitivity 
of these organs and eventually type 2 diabetes. Furthermore, since BAT is also involved in 
clearance of plasma glucose (i.e. for de novo lipogenesis, see CHAPTER 1) (35), BAT could also 
contribute to glucose homeostasis, particularly in resting conditions when glucose utilization 
by skeletal muscle is minimal. A low activity of BAT might thus not only predispose to T2DM 
via the above described relation to obesity, but also via reduced glucose uptake at rest (36). 
However, the lower BAT activity found in overweight and obese human subjects may also at 
least in part be a consequence of their increased subcutaneous white fat layer, which may 
substantially contribute to the maintenance of body temperature, making active BAT redun-
dant (37). 
MANIPULATING ACTIVITY AND VOLUME OF BAT 
The incidence of obesity is rapidly increasing, resulting in concomitantly enhanced morbidity 
and mortality. Therefore, novel therapeutic as well as preventive strategies are highly 
 warranted. Current strategies to combat obesity are mostly aimed at targeting the energy 
intake side of the energy balance (e.g. caloric restriction), but these have not proven to be 
effective on the long term (38). Thus, identifying methods to increase activity of resident BAT 
or to induce growth of new BAT is of particular interest, since this will result in increased 
REE and consequently lowering of plasma TG and glucose levels as well as weight loss. 
Theoretically, BAT volume and activity can be increased in different ways. Generally, a 
 distinction is made between methods that activate already present brown adipocytes, and 
methods that stimulate the recruitment of new BAT. 
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1 Stimulation of existing BAT
Stimulation of sympathetic nervous system
BAT is strongly innervated by the sympathetic nervous system (see CHAPTER 1, FIGURE 2) (4). 
The main activator of this pathway is cold. Several studies have shown a relation between 
the volume and activity of BAT and the outdoor temperature, with the highest activity 
 during the coldest month of the year (39). Therefore, the simplest method to activate BAT is 
cold induction, for instance via creating a colder living and/or working environment. Indeed, 
a recent study by Van der Lans et al (22) showed that cold acclimation of healthy adult 
humans for 10 days results in increased BAT activity and volume, accompanied by increased 
NST. Whether this will result in weight loss and lowering of plasma TG and glucose in obese 
human subjects remains to be determined. 
In addition to indirect activation of adrenergic receptors by cold, sympathicomimetics 
could also be used. In mouse models, activating the ß3 adrenergic receptor was very 
success ful with respect to inducing weight loss (40). Unfortunately, no weight loss was 
observed in humans treated with a ß3 adrenergic receptor agonist (41,42). However, a recent 
study suggests that the α1 or α2 adrenergic receptor may be of superior importance in 
humans (Sondergaard et al., unpublished). Therefore, novel studies should focus on further 
identification and targeting of the relevant receptors for clinical purposes.
Furthermore, sympathetic outflow towards BAT may be manipulated by targeting brain 
regions that control these sympathetic outflow neurons. The major brain region involved in 
the regulation of sympathetic outflow towards BAT is the hypothalamus (4). Lowering of 
hypothalamic AMP-activated protein kinase (AMPK), a cellular energy sensor, has been 
shown to enhance sympathetic outflow towards BAT (43). Interestingly, nicotine, the main 
constituent of cigarette smoke, lowers hypothalamic AMPK activation and enhances BAT 
activation and energy expenditure in mice (44). This may well explain why cessation of 
smoking results in weight gain in human subjects (45). Future studies should thus be directed 
at identifying novel compounds that may activate BAT via lowering of hypothalamic AMPK.
Stimulation of non-adrenergic receptors in BAT
Next to adrenergic receptors, a variety of other receptor types are present in BAT. As mentioned, 
the T3 receptor is highly expressed within the nucleus of the brown adipocyte and activation 
of this receptor markedly enhances BAT activation (29). In addition, the bone morphogenetic 
protein (BMP) receptor is well expressed on brown adipocytes and in vitro treatment of 
brown adipocytes with BMP7 results in massive activation, at least in part via the intracellular 
p38 mitogen-activated protein (MAP) kinase pathway (46). Of note, the cardiac natriuretic 
peptides ANP and BNP have been shown to activate BAT via the same intracellular mechanism, 
resulting in massively enhanced energy expenditure, and this effect was mediated via the 
NP clearance receptor in BAT (47). Our current knowledge on the receptor types present in 
BAT and their functions is far from complete. Therefore, future studies may reveal new 
receptors that could provide novel therapeutic handles to activate BAT. 
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Stimulation of AMP-activated protein kinase in BAT 
One strategy to identify novel mechanisms for BAT activation is to study compounds that 
are already in clinical use and result in lowering of body weight and plasma TG levels. These 
compounds may, at least in part, exert their effects via activation of BAT. For instance, 
 metformin is one of the most widely used glucose-lowering agents for the treatment of 
type 2 diabetes and is now considered as the first-line drug therapy for patients (48,49). 
Besides its glucose-lowering effect, metformin also markedly reduces plasma TG levels (50), 
the mechanism of which is currently unknown. In addition, metformin is among the few 
anti-diabetic drugs that does not result in weight gain, but even evokes a mild decrease 
in body weight. Interestingly, metformin is a well-known activator of the cellular energy 
sensor AMP-activated protein kinase (AMPK) in various tissues (51) and recent studies point 
towards a role for AMPK in BAT differentiation, and likely also activation, as it stimulates 
mitochondrial biogenesis and UCP-1 activation (52). Future studies should unravel whether 
the TG-lowering effect of metformin is indeed mediated by BAT activation and whether the 
mechanism involves activation of intracellular AMPK in BAT. 
Furthermore, the cannabinoid 1 receptor (CB1R) inverse agonist rimonabant has been 
shown to result in long-term maintained weight loss and reduction of dyslipidemia in 
obese patients (53-56). Rimonabant was considered one of the most promising therapeutic 
drugs to treat obesity, until the appearance of central psychiatric side effects resulted in its 
removal from the market in 2008. Nevertheless, several lines of evidence indicate that the 
effect of CB1R blockade is not restricted to a central mode of action, especially since the CB1R 
has been shown to be present in several peripheral tissues including the liver (57), skeletal 
muscle (58) and white adipocytes (59). Interestingly, treatment of rodents with rimonabant 
resulted in enhanced thermogenesis and energy expenditure (60), suggesting a role for BAT 
in the beneficial effects of CB1R blockade. Furthermore, in liver and white adipose tissue, 
CB1R blockade activated intracellular AMPK (61,62). Thus, BAT may be involved in the beneficial 
effects of rimonabant on obesity and dyslipidemia and this is possibly mediated by activation 
of intracellular AMPK. 
2 Recruitment of new BAT
Stimulating differentiation 
Irisin is a recently discovered hormone that, at least in mice, is secreted by skeletal muscle 
during exercise. Of note, exogenous administration of irisin in mice was able to induce 
‘browning’ of subcutaneous WAT. This resulted in an increase in energy expenditure, a lowering 
in body weight and an improvement in glucose tolerance (63). Therefore, irisin was regarded 
a novel and promising anti-obesity hormone that acted via recruitment of peripheral, beige 
adipocytes. However, a recent study provided evidence against a possible beneficial effect of 
irisin in humans (64). FNDC5, the gene encoding the precursor of irisin, shows a mutation in 
humans resulting in only 1% of the full-length protein. Thus, the beneficial effect of irisin in 
mice can likely not be translated to humans and the search for other compounds that may 
enhance recruitment of BAT is highly warranted. 
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One of the key regulators in the differentiation of adipocytes is PPARγ. Animal studies 
have shown that PPARγ agonists can recruit precursor cells of BAT and, in addition, can 
induce browning of white adipocytes, thereby obtaining UCP-1 (65). PPARγ agonists are 
already used in the treatment of T2DM: the thiazolinediones (TZDs). Research has shown 
that the improvement in insulin sensitivity with TZDs is partly caused by an accelerated 
clearance of glucose by BAT (66). Remarkably, though, use of TZDs leads to weight gain 
(partly due to fluid retention) and a different (disadvantageous) fat distribution, making 
their use as a weight loss agent less likely. Moreover, prescription of these agents is limited 
due to side effects such as heart failure and osteoporotic fractures (67,68).
In addition, as mentioned in CHAPTER 1, BMP7 is a potent inducer of BAT growth both in 
vitro and in vivo, resulting in enhanced energy expenditure and prevention of weight gain 
(46). The importance of BMP7 in BAT development appeared from BMP7 knock-out mice, 
which exhibit marked BAT paucity (46). Of note, BMP7 plays a pivotal role not only in the dif-
ferentiation of BAT, but also in the development of bone (69,70), cartilage (71) and kidney 
(72). As such, BMP7 may be used in the treatment of several other pathological conditions 
besides obesity, such as incomplete fracture healing, osteoarthritis and renal fibrosis (73). 
Although the role of BMP7 in recruitment of brown adipocytes in the brown fat pads has 
been well-established, the precise mechanism by which BMP7 exerts this effect (i.e., direct 
effect or involvement of sympathetic activation by the hypothalamus) and the efficiency of 
BMP7 to recruit beige adipocytes in vivo are currently unknown and elucidation of the 
mechanism may provide interesting directions for future studies.
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SOUTH ASIANS: A POPULATION WITH A DISADVANTAGEOUS METABOLIC PHENOTYPE
EPIDEMIOLOGY OF CVD IN SOUTH ASIANS
The South Asian population originally descends from the Indian subcontinent (India, 
Pakistan, Bangladesh, Nepal and Sri Lanka) and comprises approximately 20% of the total 
world population. Currently, over 200,000 South Asians are living in the Netherlands, 
 especially in The Hague. The burden and mortality of cardiovascular diseases (CVD) are 
 significantly higher among both native and migrant South Asians in comparison to subjects 
of white Caucasian descent (1-3). The age standardized mortality rate for CVD is around 50% 
higher in South Asian countries than in Western countries (3). Furthermore, individuals are 
affected by CVD at a younger age and as a result India suffers the highest loss in potentially 
productive years of life due to cardiovascular deaths (2;4;5). In 2030, this loss is estimated to 
be ten times higher than in the United States, whereas the population size is only three 
times larger (2). CVD risk is also higher in migrant South Asians living in Western countries. 
Studies consistently show that the risk of CVD among South Asian immigrants is at least 
two-fold increased compared to native populations as well as other immigrant groups. In 
Canada, the prevalence of CVD among South Asian immigrants is 10.7%, compared to 5.4% 
and 2.4% for people from European and Chinese descent, respectively (4). Furthermore, 
South Asians in the UK show a 40-60% higher mortality rate from coronary heart disease 
compared to European whites (1;6;7). In addition, in all of these studies South Asian immi-
grants were affected at a younger age than control groups.
The exceptionally high CVD risk in South Asians poses a major health and socioeconomic 
burden. Therefore, it is important to gain more insight in the pathogenesis of CVD in this 
population. It is likely that at least part of the excess risk is explained by genetic factors, 
since both South Asians in native countries as well as migrated South Asians are at increased 
risk. In addition, environmental factors, such as changes secondary to urbanization and 
migration, may play a role. Indeed, the risk of CVD appears to increase as South Asians move 
from rural India to urban India to immigrant populations (8).
When considering underlying causes for the increased CVD risk in the South Asian popu-
lation, the pathogenesis of CVD should be discussed first. 
PATHOGENESIS OF CARDIOVASCULAR DISEASE
The major cause of CVD is atherosclerosis, which is present many years before any clinical 
symptoms of CVD become manifest, including ischemic heart disease, cerebrovascular 
 accident and peripheral arterial occlusive disease. 
Atherosclerosis development starts with endothelial damage and dysfunction, often 
promoted by inflammatory mediators or shear stress induced by nonlaminar blood flow. 
This results in enhanced recruitment of inflammatory leukocytes such as monocytes and 
T-lymphocytes towards the damaged site, and migration of monocytes into the subendothelial 
intima followed by transformation into macrophages. At the same time, low-density lipo-
Proefschrift_MB.indb   39 05-05-14   11:58
3
40 
protein (LDL) particles may infiltrate into the vessel wall and become oxidized (e.g. due to 
release of reactive oxygen species or cigarette smoke). Macrophages within the vessel wall 
can take up oxidized LDL via receptors such as scavenger receptor A (SRA) and CD36, and 
become lipid-laden foam cells (9). What follows is an inflammatory status in which leukocytes 
and local endothelial cells excrete pro-inflammatory cytokines, including interferon γ (IFN-γ), 
tumor-necrosis factor- (TNF-) and growth factors, further stimulating leukocyte recruit-
ment, accumulation of macrophages as well as proliferation of smooth muscle cells in the 
vascular intima, which produce elastin and collagen (10). This all sequentially leads to 
plaque formation, plaque expansion and formation of a fibrous cap. High-density lipo-
protein (HDL) supposedly has an atheroprotective role, primarily by removing cholesterol 
from atherosclerotic plaques and transporting it back to the liver for excretion via the bile. 
Furthermore, it prevents LDL from oxidation and has anti-inflammatory properties (11).
From the above-mentioned pathophysiology it becomes clear that the development of 
atherosclerosis may be promoted by metabolic as well as inflammatory risk factors. 
Metabolic or ‘classical’ risk factors include dyslipidemia (marked by elevated LDL-C and 
decreased HDL-C levels), hypertension (resulting in nonlaminar blood flow), and smoking 
(resulting in endothelial dysfunction) (12). Furthermore, insulin resistance and central 
 obesity are metabolic risk factors that are associated with increased CVD risk (13-15). Most of 
these classical cardiovascular risk factors are highly present in South Asians. In addition, 
although the precise mechanism is still under debate, also inflammatory or ‘nonclassical’ risk 
factors may contribute to development of CVD. Among these are systemic inflammation 
(marked by elevated C-reactive protein and/or TNF- levels), as well as HDL dysfunction and 
endothelial dysfunction which can both give rise to inflammation (16). 
Next, we will discuss the classical (metabolic) and nonclassical (inflammatory) risk 
 factors for CVD in South Asian subjects. 
CLASSICAL CVD RISK FACTORS 
IN SOUTH ASIANS
Dyslipidemia
Dyslipidemia, often comprising increased levels of LDL-C and triglycerides and decreased 
levels of HDL-C, is one of the main risk factors for CVD. South Asians were consistently 
shown to have higher triglyceride and lower HDL-C levels (7;17;18). Some studies also reported 
higher LDL-C levels in South Asian subjects compared to white Caucasians (4;19). 
Obesity
South Asians have a disadvantageous fat distribution pattern with relatively thin extremities 
and higher abdominal adiposity (20;21). Furthermore, at a similar level of BMI, body fat 
 percentage is higher in South Asians compared to white Caucasians (20;22). South Asians 
also have a tendency for higher deposition of fat within cells of non-adipose tissues such as 
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muscle and liver, so called “ectopic” sites. Petersen et al. (23) showed that in healthy lean 
South Asians hepatic triglyceride content was two-fold higher than in healthy lean white 
Caucasians. This higher triglyceride content was associated with hepatic insulin resistance 
and increased levels of pro-inflammatory cytokines. Storage of fat in these ectopic sites has 
a disruptive effect on glucose metabolism and it is now increasingly recognized that hepatic 
steatosis may be causally related to hepatic insulin resistance, the metabolic syndrome, 
 systemic inflammation and even CVD (23-26).
Insulin resistance
Insulin resistance and elevated fasting glucose levels are more prevalent in non-diabetic 
South Asians compared to non-diabetic white Caucasians (7;18). In South Asians, the high 
rate of type 2 diabetes (T2D) is most striking. In 35-60 year old South Asian males living 
in the UK, diabetes prevalence was 16% compared with only 4% among European whites 
(7;18;27). Other studies, amongst which one conducted in the Netherlands, have reported an 
even higher prevalence of up to 25.4% for both South Asian men and women (28;29). 
Furthermore, the onset of diabetes is over 10 years earlier in South Asians (28), and diabetes 
occurs at a lower BMI compared to white Caucasians: the risk of developing T2D of a South 
Asian with a BMI of 21 kg/m2 is comparable to the risk of a white Caucasian with a BMI of 
30 kg/m2 (3;19). Finally, South Asians often develop more diabetes-related complications, 
such as diabetic nephropathy and retinopathy (30). 
Thus, in South Asians a disadvantageous metabolic profile consisting of central obesity, 
insulin resistance, and dyslipidemia, is highly prevalent. It is commonly assumed that an 
ethnic susceptibility towards a disturbed energy homeostasis (e.g. lower oxidation of 
 glucose and fatty acids by mitochondria) might underlie this phenotype (31). In line with 
this, South Asian subjects have lower energy expenditure (32). As no efficient treatment is 
available for their disadvantageous phenotype, unravelling its cause is of great importance 
and may be beneficial in preventing, at least in part, the development of T2D and CVD in the 
South Asian population. 
Excess risk 
Studies have shown that after correction for the above-mentioned classical risk factors, 
 ethnicity still remains an independent determinant of cardiovascular events in the South 
Asian population (1;4;7). Thus, residual risk is present suggesting that additional factors 
(i.e. nonclassical cardiovascular risk factors) may play a role. Aberrancies in several pathways 
may contribute to these nonclassical risk factors which are shortly summarized as ‘inflamma-
tory’ factors. These factors will be shortly discussed in the following section; inflammation, 
HDL dysfunction and endothelial activation. 
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NON-CLASSICAL CVD RISK FACTORS 
IN SOUTH ASIANS
C-reactive protein 
As mentioned above, inflammation is a well-recognized key player in the pathogenesis of 
atherosclerosis and may, therefore, be considered a risk factor for CVD. Besides promoting 
initiation of atherosclerosis development through monocyte attraction, it may lead to insta-
bility of the fibrous cap of the atherosclerotic plaque, resulting in rupture of the plaque and 
a subsequent cardiovascular event. C-reactive protein (CRP), which is synthesized by the 
liver in response to inflammatory factors released by macrophages and adipocytes (33;34), is 
a sensitive marker of inflammation (35). In a study of Chambers et al (17), CRP levels were 
found to be significantly higher in South Asians compared with Europeans even after 
adjustment for conventional risk factors such as age, smoking and body mass index, 
 suggesting a chronic state of low grade inflammation in this population. However, in their 
study the difference in CRP levels was predominantly explained by greater central obesity 
and insulin resistance in South Asians. Visceral adipose tissue has been found to be a major 
source of cytokine release into the circulation (17;36). Intriguingly, the increased risk of CVD 
in South Asians was associated with a larger amount of visceral adipose tissue (37). Not only 
do South Asians have more visceral adipose tissue, their adipocytes appear to be more 
inflammatory as well. Several studies reported that South Asian adipocytes release higher 
 levels of pro-inflammatory cytokines, such as CRP, interleukin 6 (IL-6) and TNF- in comparison 
to white Caucasians (23;38), indicating a chronic inflammatory state. 
HDL dysfunction 
Multiple studies have consistently shown lower HDL-C levels in South Asians compared to 
white Caucasians (6;17;21;39-42). The cardiovascular protective effects of HDL have been 
attributed to several atheroprotective properties. Firstly, HDL stimulates cholesterol efflux 
from foam cells present in atherosclerotic plaques by acting as cholesterol acceptor and 
transporting cholesterol back to the liver for excretion into the bile (43). Secondly, HDL 
 prevents LDL from oxidation (44-46). Thirdly, HDL has anti-inflammatory properties; during 
the early phase of atherosclerosis development, HDL may prevent leukocyte adhesion to 
endothelial cells by lowering expression of monocyte chemotactic protein 1 (MCP-1) and 
vascular cell adhesion molecule (VCAM-1) and by counteracting platelet-activating factor 
(PAF) induced adhesion of leukocytes (44-47). Fourthly, HDL induces vasodilatation through 
stimulation of nitric oxide (NO) release by endothelial cells (54). This results in lower 
endothelial shear stress and thereby slows down initiation of atherosclerosis development. 
Thus, dysfunction of HDL may not only directly aggrevate atherosclerosis development as a 
consequence of lower cholesterol uptake from the vascular wall, but also indirectly through 
induction of inflammation as well as endothelial dysfunction. 
Recent evidence suggests that HDL functionality may be more importantly linked to 
CVD than plasma HDL-C levels per se (48;49). In trials that aimed at raising HDL-C levels, e.g. 
with dalcetrapib (50) or niacin (51) on top of statin, no decrease in the occurrence of cardio-
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vascular endpoints was observed. Furthermore, several studies showed that HDL is dysfunc-
tional in patients with coronary atherosclerosis, in men with cardiovascular risk factors, and 
in patients with an acute phase response after surgery (52-55).
Remarkably, little is known about HDL functionality in South Asians. To date only one 
cross-sectional, uncontrolled pilot study assessed the anti-oxidative capacity of HDL in 
South Asian immigrants living in the USA. They found dysfunctional HDL in 50% of the 
 participants, which was significantly correlated with carotid intima media thickness, a 
 surrogate marker of atherosclerosis (56). However, they lacked a control group of another 
ethnicity, so no statements could be made on the implication of this percentage for their 
increased risk of CVD. Future studies in this direction are, therefore, highly warranted.
Endothelial activation 
Endothelial activation is regarded an important initiating factor in the pathogenesis of 
 atherosclerosis and CVD (57). Endothelial activation is characterized by a proadhesion, proin-
flammatory, and procoagulatory milieu that favours all stages of atherogenesis. A hallmark 
of endothelial activation is a reduction in the bioavailability of endothelium-derived NO. An 
impaired NO-mediated vasodilatory response has been demonstrated in patients with 
 cardiac risk factors or established atherosclerosis (58;59). Furthermore, the degree of impair-
ment is related to the severity and extent of coronary artery disease (60). 
Interestingly, previous studies have demonstrated reduced flow-mediated vasodilatation 
in South Asians compared to white Caucasians, pointing to endothelial activation and lower 
NO bioavailability (27;61). Of note, NO is mainly produced by the endothelium as a conse-
quence of an interaction with HDL (62;63). Hence, besides a susceptibility for endothelial 
activation, dysfunctionality of HDL with respect to its ability to induce endothelial NO 
 production is another possible explanation for the lower NO bioavailability in South Asians. 
Circulating endothelial progenitor cells (EPCs), mobilized from the bone marrow, have 
an important role in the repair and regeneration of the endothelium (64-66). The number of 
circulating EPCs is lower in patients with established coronary artery disease, is predictive 
of future cardiovascular events, and is positively correlated with measures of endothelial 
function (67;68). Intriguingly, South Asians have lower circulating numbers of EPCs com-
pared to white Caucasians, which may lead to a reduced capacity for endothelial repair 
(61;69). Furthermore, exercise-induced EPC mobilization was reduced in South Asian men 
(69). Interestingly, NO appears to be critical for EPC mobilization in response to exercise (69). 
Hence, the reduced exercise mediated EPC mobilization in South Asians may be secondary 
to their reduced NO bioavailability. Future studies should be directed at further investigating 
endothelial activation in this population and at developing strategies that enhance EPC 
mobilization by augmenting NO bioavailability.




In conclusion, South Asians are more liable to develop CVD at an early age, and classical risk 
factors associated with CVD, including dyslipidemia, central obesity and insulin resistance, 
are more prevalent in this ethnicity compared to subjects of white Caucasian origin. The 
underlying cause for this highly prevalent disadvantageous metabolic phenotype is currently 
unknown. Of note, these ‘metabolic’ risk factors seem to account for only part of the 
increased risk in South Asians as ethnicity remains an independent determinant of cardio-
vascular events. Nonclassical ‘inflammatory’ risk factors, i.e. higher levels of inflammation, 
HDL dysfunction, and endothelial activation may be involved in the residual CVD risk in 
South Asians (see FIGURE 1), although the presence of these risk factors requires further 
investigation as it has not always been properly studied. Furthermore, which of these fac-
tors plays a dominant role and is therefore the most promising therapeutic target to lower 
the excess CVD risk in South Asians remains to be investigated. 
FIGURE 1 - Proposed underlying mechanisms in the high cardiovascular risk in the South Asian population. 
Classical (metabolic) risk factors, i.e. central obesity, insulin resistance and type 2 diabetes, and dyslipidemia 
are highly prevalent in the South Asian population. Furthermore, dysfunctional HDL and endothelium may 
enhance inflammation and these nonclassical risk factors may contribute to the ‘residual’ CVD risk of the 
South Asian population. Whether the high prevalence of metabolic and inflammatory factors in the South 
Asian population is due to a common (disadvantageous) factor remains to be determined. CVD, cardiovascular 
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As is evident from CHAPTER 1 and 2 described in the first part of the thesis, brown adipose 
 tissue (BAT) is a recently identified player in energy metabolism in human adults and a 
promising new target to treat obesity and related diseases. Interestingly, as described in 
CHAPTER 3, South Asians have lower energy expenditure, which may thus theoretically be 
caused by a reduction in BAT activity. Therefore, the studies of which the results are 
described in this thesis were aimed at 1) gaining more insight in the physiology of BAT, 2) 
identifying novel targets that may activate BAT, and 3) investigating the involvement of BAT 
in metabolism in humans with a focus on potential differences between South Asians and 
white Caucasians. 
In the second part of this thesis, the role of BAT in metabolism and obesity is investigated 
using mouse studies. Since fatty acids (FA) are the main fuel for thermogenesis in BAT, and 
intracellular FA stores rapidly diminish upon BAT activation, BAT is required to take up FA 
from the plasma. It has been previously suggested that BAT takes up FA by uptake of whole 
lipoproteins (i.e. chylomicrons and VLDL), but this is in contrast to selective TG-derived FA 
uptake as exerted by white adipose tissue and muscle. Therefore, in CHAPTER 4, we aimed to 
investigate the mechanism by which BAT takes up lipoprotein-TG-derived FA by performing 
kinetic studies using glycerol tri[3H]oleate and [14C]cholesteryl oleate double-labeled lipo-
protein-mimicking particles. Next, we focused on novel tools and targets that may activate 
BAT, thereby enhancing clearance of plasma TG and increasing energy expenditure. Based 
on the discovery that BMP7 can activate BAT, in CHAPTER 5, we investigated the mechanism 
by which BMP7 activates BAT, with focus on the role of the sympathetic nervous system, by 
treating high-fat fed lean mice and diet-induced obese mice with BMP7 under regular room 
temperature and thermoneutral temperature. In CHAPTER 6, the mechanism by which the 
anti-diabetic drug metformin lowers plasma TG was investigated. To this end, we performed 
VLDL-TG production and TG clearance experiments in dyslipidemic APOE*3-Leiden.CETP 
transgenic mice, as well as mechanistic studies in vitro using a brown adipocyte line, and 
put special focus on activation of intracellular AMPK. In CHAPTER 7, we investigated whether 
the TG-lowering effect of systemic cannabinoid 1 receptor blockade that was previously 
found in patients treated with rimonabant was mediated by activation of BAT in diet-
induced obese APOE*3-Leiden.CETP transgenic mice. We further explored the underlying 
mechanism by performing experiments at thermoneutrality as well as using a strictly 
peripheral cannabinoid 1 receptor blocker. The brain is an important activator of BAT, 
 especially in case of cold exposure. In CHAPTER 8 we aimed to gain more insight in mediators 
that modulate BAT activity via the brain by studying the role of the melanocortin system on 
BAT function. To this end, we antagonized the central melanocortin 3 and 4 receptor in 
APOE*3-Leiden.CETP mice and studied BAT function and activity. To investigate whether BAT 
activation could protect against atherosclerosis development, in CHAPTER 9, we treated 
 dyslipidemic APOE*3-Leiden.CETP mice with the ß3-adrenergic agonist CL316243 and studied 
energy expenditure, lipid metabolism and atherosclerosis development. 
In the third part of the thesis, human studies on the role of BAT in metabolism and 
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 obesity are described. A well-known cause of obesity is long term high-fat feeding, which 
may result in development of insulin resistance and eventually type 2 diabetes. To gain more 
insight in underlying mechanisms responsible for the development of high-fat diet induced 
insulin resistance, in CHAPTER 10 we studied the effects of short-term high fat feeding on 
macrophage markers in skeletal muscle in healthy male subjects. The South Asian population 
is especially prone to develop obesity and related disorders, such as type 2 diabetes and 
 cardiovascular disease (CVD). In CHAPTER 11, we investigated whether the high CVD risk in 
the South Asian population may be due to an ethnic susceptibility to develop endothelial 
activation. To this end, we measured markers for endothelial activation in cord blood of 
South Asian and white Caucasian neonates. In CHAPTER 12, we investigated whether HDL 
dysfunction may be present in the South Asian population by measuring different measures 
of HDL functionality in 3 cohorts of South Asian subjects and matched white Caucasian 
subjects (i.e., neonates, adolescents and adults). The highly prevalent disadvantageous 
 metabolic phenotype consisting of obesity, dyslipidemia and insulin resistance likely also 
underlies the high CVD risk in the South Asian population. Therefore, in CHAPTER 13 we inves-
tigated whether a lower BAT volume or activity may be present in the South Asian popula-
tion by performing cold-induced 18F-FDG PET-CT scans in healthy lean Dutch South Asian 
and matched white Caucasian subjects. Since the 18F-FDG PET-CT scan is currently the ‘gold 
standard’ to determine BAT volume and activity, but its use is limited by cost and radiation 
exposure, in CHAPTER 14 we investigated whether supraclavicular skin temperature, the 
 location at which most BAT is located, may serve as a quantitative measure of 18F-FDG 
uptake in human subjects by use of wireless iButtons. 
Finally in the fourth part of the thesis, the results from these studies and their impli-
cations are discussed in CHAPTER 15 and summarized in CHAPTER 16.
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ATGL adipose triglyceride lipase 
BAT brown adipose tissue
FA fatty acid
HSL hormone sensitive lipase 
LPL lipoprotein lipase 
MGL  monoglyceride lipase 
TG triglyceride 
TRL triglyceride-rich lipoprotein
UCP1 uncoupling protein 1
(g,s)WAT (gonadal, subcutaneous) white adipose tissue
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ABSTRACT
The ability of brown adipose tissue (BAT) to produce heat upon cold and other stimuli 
is dependent on burning of intracellular triglyceride (TG) stores that need to be 
replenished by the uptake of TG-derived fatty acids (FA) from plasma. According to 
the current dogma, BAT takes up TG-rich lipoproteins (TLRs) as whole particles. 
However, the demonstrated critical involvement of LPL and CD36 would be more 
consistent with selective uptake of TG-derived FA by BAT. Therefore, the aim of the 
present study was to assess which mechanism prevails in the uptake of FA by BAT. 
Glycerol tri[3H]oleate ([3H]TO) and [14C]cholesteryl oleate ([14C]CO) labeled lipoprotein-
mimicking TRLs with a mean diameter of 45, 80 and 150 nm (ranging from VLDL to 
chylomicrons) were synthesized and intravenously injected (0.2 mg TG/mouse) into 
male C57Bl/6J mice. The distribution of the radiolabels over the various organs was 
determined at 15 min after injection. For particles of 45, 80 and 150 nm, the uptake  
of 3H-activity by BAT exceeded that of all other organs, and was much higher (28, 28, 
and 20% of injected dose/g) than the uptake of 14C-activity (2, 3 and 4% of injected 
dose/g), indicating highly selective uptake of TG-derived FA by BAT as compared to 
the uptake of the particle core. Under conditions of increased BAT activity (housing 
for 24 h at 7°C), the uptake of both 3H-activity (67, 57, and 47% of injected dose/g) and 
14C-activity (6, 8, and 24% of injected dose/g) by BAT increased, while retaining the 
selectivity for uptake of FA over CO. In conclusion, BAT takes up TRL-derived TG by 
means of selective FA uptake and this is consistent for TRLs ranging from small VLDL 
to small chylomicrons. 




Brown adipose tissue (BAT) is an important player in energy homeostasis due to its ability to 
combust energy towards heat by virtue of the presence of uncoupling protein 1 (UCP1), a 
process called non-shivering thermogenesis (1). The most well-known trigger for activation 
of BAT is cold, which increases sympathetic outflow from the hypothalamic temperature 
centre towards BAT. Here, nerve endings release noradrenalin that binds to adrenergic 
receptors on the brown adipocyte membrane (2). Activation of an intracellular signalling 
cascade subsequently leads to a fast induction of intracellular lipolysis, mediated by adipose 
triglyceride lipase (ATGL), hormone sensitive lipase (HSL) and monoglyceride lipase (MGL), 
resulting in release of fatty acids (FA) from triglyceride (TG)-filled lipid droplets (3). FA are 
directed to the mitochondria where they either allosterically activate UCP1 present in the 
inner membrane of the mitochondrion or undergo oxidation in the mitochondrial matrix 
(2). UCP1 dissipates the proton gradient across the inner mitochondrial membrane that is 
generated by the respiratory chain, resulting in production of heat. Of note, FA used for 
 activation of UCP1 and oxidation are mainly derived from intracellular TG stores as mice that 
lack ATGL exhibit defective thermogenesis (4). Therefore, maintenance of intracellular TG 
stores is essential for BAT non-shivering thermogenesis.
Replenishment of intracellular TG stores within the brown adipocyte is mediated via 
three mechanisms; uptake of glucose followed by de novo lipogenesis, or uptake of albumin-
bound FA and lipoprotein-derived FA from the plasma followed by incorporation of FA within 
TG (2;3;5). Circulating TG-rich lipoproteins (TRLs), i.e. very-low-density lipoproteins (VLDL) and 
chylomicrons, are the main source of FA for TG stores in BAT (3). These types of TRLs differ in 
their apolipoprotein composition as well as their size (VLDL: 30-80 nm and chylomicrons: 
100-500 nm).
Only recently, BAT appeared as a major player in plasma TG clearance. Bartelt et al. (5) 
showed that 24 h of cold exposure markedly enhanced clearance of glycerol tri[3H]oleate-
labeled TRLs which was specifically mediated by BAT (5;6). The authors suggested that upon 
cold exposure, BAT took up TG from chylomicron-sized (~250 nm) TRL-like particles via whole 
particle uptake. However, they also demonstrated that BAT activation by cold was accom-
panied by enhanced expression of LPL and CD36, the presence of both appeared critical for 
TG uptake (5;6), which is in line with selective uptake of TG-derived FA by CD36 after liberation 
via LPL as occurs in skeletal muscle, heart and WAT.
Therefore, the aim of the present study was to investigate the mode of FA uptake by BAT 
in mice while modulating BAT activity using various ambient temperatures (7°C-28°C), by 
using glycerol tri[3H]oleate and cholesteryl [14C]oleate double-labeled TRL-mimicking 
 particles with diameters ranging from VLDL to chylomicrons (45-150 nm). These emulsion 
particles have been previously shown to acquire apolipoproteins including apoCs and apoE 
in the circulation (7), thereby truly mimicking the TRL metabolism in vivo.
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MATERIALS AND METHODS
Animals and diet
For all studies described in this manuscript, 8-10 week old male C57Bl/6J mice (Jackson 
Laboratory, Bar Harbor, ME) were used. Mice were housed in conventional cages with a 
12:12-h light-dark cycle and had free access to chow food and water. All mouse experiments 
were performed in accordance with the Institute for Laboratory Animal Research Guide for 
the Care and Use of Laboratory Animals and have received approval from the Departmental 
Ethical Review Board (Leiden University Medical Center, Leiden, The Netherlands).
Acclimation to ambient temperature
Mice were single-housed one week prior to the experiment at an environmental temperature 
of 21°C, and randomized based on fasting plasma triglyceride (TG) levels, total cholesterol (TC) 
levels and body weight in two groups that were exposed to an ambient temperature of 7°C or 
21°C for 24 h while being fasted the last 4 h before performing a terminal kinetic experiment 
with TG-rich emulsion particles (see below). In a second experiment, mice were randomized 
into two groups that were exposed for 4 h to an ambient temperature of 21°C or 28°C, while 
being fasted, prior to the kinetic experiment. For each temperature group, mice were divided 
into three groups that received lipoprotein-mimicking TG-rich emulsion particles of different 
size (average 45, 80 or 150 nm, n=6 per group).
Plasma parameters
At randomisation and after exposure to different ambient temperatures (prior to the clearance 
experiment), a blood sample was collected from the tail vein of 4 h fasted mice into capillaries. 
Capillaries were placed on ice and centrifuged, and plasma was assayed for TG and TC using 
commercially available enzymatic kits from Roche Diagnostics (Mannheim, Germany).
Preparation of labeled TRL-mimicking emulsion particles
TRL-mimicking emulsion particles were prepared from 100 mg of total lipid including 
 triolein (70 mg), egg yolk phosphatidylcholine (22.7 mg), lysophosphatidylcholine (2.3 mg), 
cholesteryl oleate (3.0 mg) and cholesterol (2.0 mg) (7;8). For preparation of double-labeled 
TRL-mimicking emulsion particles, before sonification the radioactive tracers glycerol 
tri[3H]oleate ([3H]TO) (100 µCi) and [14C]cholesteryl oleate ([14C]CO) (10 µCi) were added. 
Sonification was performed using a Soniprep 150 (MSE Scientific Instruments, UK) that is 
equipped with a water bath for temperature (54°C) maintenance, at 10 µm output (8). The 
emulsion was fractionated by consecutive density gradient ultracentrifucation steps in a 
Beckman SW 40 Ti rotor. After centrifugation for 27 min at 20,000 rpm at 20°C, an emulsion 
fraction containing chylomicron-like particles (average size 150 nm) was removed from the 
top of the tube by aspiration and replaced by NaCl buffer of similar density (i.e. 1.006 g/mL). 
After a subsequent centrifugation step for 27 min at 40,000 rpm large VLDL-like particles 
(average size 80 nm) were obtained in a similar manner. A third centrifugation step for 3 h 
at 40,000 rpm yielded small VLDL-like particles (average size 45 nm). Characterization of 
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emulsion fractions was done by determination of TG concentration (as described under 
Plasma parameters) and radioactivity or fluorescence for radioactively or fluorescently 
labeled emulsion particles, respectively. Emulsions were stored at 4°C under argon and used 
for in vivo kinetic experiments within 5 days following preparation. 
In vivo clearance of labeled TRL-mimicking emulsion particles
To study the in vivo clearance of labeled TRL-mimicking emulsion particles, mice were fasted 
for 4 h and injected intravenously with 200 µL of emulsion particles (0.2 mg TG per mouse). 
Blood samples were taken from the tail vein at 2, 5, 10 and 15 min after injection to deter-
mine the serum decay of [3H]TO and [14C]CO. Plasma volumes were calculated as 0.04706 × 
body weight (g) (9). After taking the last blood sample, mice were cervically dislocated and 
perfused with ice-cold PBS containing 10 U/mL heparin via the heart to remove blood from 
the organs. Subsequently, the liver, heart, spleen, hindlimb muscle, gonadal white adipose 
tissue (gWAT), subcutaneous WAT (sWAT) and interscapular brown adipose tissue (BAT) 
were collected. Organs were dissolved overnight at 55°C in Tissue Solubilizer (Amersham 
Biosciences, Rosendaal, The Netherlands), and 3H and 14C activity were quantified. Uptake of 
[3H]TO- and [14C]CO-derived radioactivity by the organs was expressed per gram wet tissue 
weight.
Statistical analysis
Differences between groups were determined using unpaired two-tailed Student’s tests 
with the SPSS 20.0 software package for Windows (SPSS, Chicago, United States). Probability 
values less than 0.05 were considered statistically significant. Data are presented as mean 
± SEM. 
RESULTS
BAT selectively takes up fatty acids from TRL-mimicking particles at 21°C 
To study the mode of FA uptake by BAT, we generated [3H]TO and [14C]CO double-labeled 
TRL-mimicking particles with a diameter of 45, 80 and 150 nm (i.e. representing small 
VLDL, large VLDL and chylomicrons). These particles allow us to follow the uptake of FA 
([3H]oleate) and the remnant core ([14C]CO]) simultaneously. The clearance and distribution 
of the radiolabels was determined in mice that were exposed to regular room temperature 
(21°C), cold (7°C) or thermoneutrality (28°C) prior to the kinetic experiment.
In mice exposed at the regular temperature of 21°C, the plasma clearance of [3H]TO was 
faster (FIGURE 1A-C) than that of [14C]CO (FIGURE 1D-F), for particles of 45, 80 and 150 nm, 
respectively. This indicates that for all particles the uptake of FA by organs precedes the 
uptake of CO, suggestive of initial peripheral LPL-mediated TG hydrolysis followed by the 
uptake of core remnants by the liver. Indeed, in metabolic tissues that express LPL (i.e., muscle, 
WAT and BAT) the uptake of 3H-activity (FIGURE 2A-C) was higher than that of 14C-activity 
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FIGURE 1 - Cold exposure enhances serum clearance of double-labeled TRL-mimicking particles. Glycerol 
tri[3H]oleate ([3H]TO) and [14C]cholesteryl oleate ([14C]CO) labeled TRL-mimicking particles of different size 
(45, 80 and 150 nm) were injected intravenously into 4-hour fasted mice that had been exposed to an ambient 
temperature of 21°C (open symbols) or 7°C (closed symbols) for 24 h prior to the experiment. Blood was 
 collected at the indicated time points and [3H]TO activity A-C  as well as [14C]CO activity D-F  were measured 
in plasma. 
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FIGURE 2 - Cold exposure enhances fatty acid uptake from double-labeled TRL-mimicking particles by BAT. 
Glycerol tri[3H]oleate ([3H]TO) and [14C]cholesteryl oleate ([14C]CO) labeled TRL-mimicking particles of different 
size (45, 80 and 150 nm) were injected intravenously into 4-hour fasted mice that had been exposed to 
an ambient temperature of 21°C (open symbols) or 7°C (closed symbols) for 24 h prior to the experiment. 
After 15 min, mice were sacrificed and uptake of [3H]TO-derived activity A-C  and [14C]CO activity D-F  was 
determined in various organs, and expressed as percentage of the injected dose per gram wet tissue weight.
Values are means ± SEM (n=6) *P<0.05, **P<0.01, ***P<0.001 compared to the 21°C group. BAT, brown adipose tissue; TRL, triglyceride-rich lipoprotein; 
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(FIGURE 2D-F), whereas the uptake of 14C-activity by the liver was much higher than that of 
3H-activity. Remarkably, the uptake of 3H-activity by BAT exceeded that of all other organs, 
and was much higher (28, 28, and 20% of injected dose/g) (FIGURE 2A-C) than the uptake of 
14C-activity (2, 3 and 4% of injected dose/g) (FIGURE 2D-F), indicating highly selective uptake of 
TG-derived FA without substantial uptake of core remnants by BAT.
Cold exposure enhances selective fatty acid uptake from TRL-mimicking particles by BAT
Housing mice for 24 h at 7°C accelerated the plasma clearance of [3H]TO for particles of 45, 
80 and 150 nm (FIGURE 1A-C), due to a selective, markedly enhanced uptake of 3H-activity by 
BAT (+139%, P<0.01; +111%, P<0.05, and +150%, P<0.001) (FIGURE 2A-C). Accordingly, 24 h of cold 
exposure resulted in a -43% reduction in plasma TG levels (0.58 ± 0.05 vs. 0.33 ± 0.02, 
P<0.001). Likewise, the plasma decay of [14C]CO was accelerated (FIGURE 1D-F) which was 
accompanied by an increased retention of 14C-label by BAT (+168%, P<0.05; +181%, P<0.001, 
and +464%, P<0.001) (FIGURE 2D-F). Despite the increased retention of 14C-label in BAT, the 
selectivity of uptake of 3H-label over 14C-label was still retained, especially for the 45 and 
80 nm sized particles. In fact, the majority of [3H]TO-depleted [14C]CO-containing core 
 remnants were still taken up by the liver (FIGURE 2). In contrast, [14C]CO uptake by BAT was 
low for both the 45 nm particle (2% per g and 6% per g for 21°C and 7°C, respectively) and the 
80 nm particle (3% per g and 7% per g for 21°C and 7°C, respectively) (FIGURE 2), pointing to 
selective FA uptake by BAT with minimal remnant particle retention.
As a measure for the selective retention of FA versus core remnants, we calculated the 
lipolysis index for all organs as the ratio of 3H-activity (%/g) and 14C-activity (%/g) (FIGURE 3). 
This index indicates whether the organs primarily take up TG-depleted particles (lipolysis 
index < 1), unmodified particles (lipolysis index = 1), or FA derived from particles (lipolysis 
index > 1). For particles of 45, 80 and 150 nm, the lipolysis index of the liver was far below 1, 
confirming its primary role in the uptake of core remnants. Albeit that the uptake by the 
spleen increased with particle size, the lipolysis index approximated 1 for all particle sizes, 
consistent with its recognized involvement in uptake of whole particles through phagocytosis 
(10;11). For all particles sizes, the lipolysis index of classical organs involved in the selective 
uptake of lipoprotein TG-derived FA (i.e., skeletal muscle, WAT) exceeded 1, consistent with 
highly selective uptake of FA over CO. In analogy, BAT showed a similarly high lipolysis index 
for particles of all sizes. The lipolysis index of BAT for the 150 nm-sized particles was lower 
than that of the 45 nm and 80 nm-sized particles, but this was also found for skeletal muscle 
and WAT. Thus, these data suggest that TG-derived FA from different sized TRLs (ranging 
from small VLDL to small chylomicrons) are taken up by skeletal muscle, WAT and BAT mainly 
by selective FA uptake.
The lipolysis index did not differ much between housing at 21°C and 7°C. For particles of 
all sizes, the lipolysis index in the liver was lower upon cold exposure, indicating internalization 
of remnants after further TG depletion. Cold exposure reduced the lipolysis index in muscle 
and BAT with respect to uptake of the 150 nm-sized particles, indicating relatively more 
retention and/or uptake of the particle core compared to 21°C.
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FIGURE 3 - Lipolysis index in muscle, WAT and BAT points to selective FA uptake at 21°C and 7°C. Glycerol 
tri[3H]oleate ([3H]TO) and [14C]cholesteryl oleate ([14C]CO) labeled TRL-mimicking particles of different size 
(45, 80 and 150 nm) were injected intravenously into 4-hour fasted mice that had been exposed to an ambient 
temperature of 21°C (open symbols) or 7°C (closed symbols) for 24 h prior to the experiment. After 15 min, 
mice were sacrificed and uptake of [3H]TO-derived activity and [14C]CO activity was determined in various 
organs, and expressed as percentage of the injected dose per gram wet tissue weight. Lipolysis index was 
calculated for all organs as the ratio of 3H-activity (%/g) and 14C-activity (%/g) for particles of 45 nm A , 80 nm 
B  and 150 nm C . 
Values are means ± SEM (n=6) *P<0.05, **P<0.01, ***P<0.001 compared to the 21°C group. BAT, brown adipose tissue; TRL, triglyceride-rich lipoprotein; 
(s,g)WAT, subcutaneous, gonadal white adipose tissue.
Exposure to thermoneutral temperature lowers selective fatty acid uptake from TRL-mimicking 
particles by BAT 
To investigate the mode of VLDL and chylomicron-derived FA uptake by BAT in case of 
reduced sympathetic input towards BAT (2), we repeated the clearance experiments with 
double-labeled TRL-mimicking particles of all sizes in mice that were exposed to regular 
room temperature (21°C) versus thermoneutrality (28°C) for 4 hours prior to the experiment. 
For particles of 45, 80 and 150 nm, plasma [3H]TO clearance was attenuated at 28°C (FIGURE 
4A-C), mainly due to lower uptake of 3H-activity by BAT (-66%, P<0.01, -74%, P<0.01 and -76%, 
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FIGURE 4 - Thermoneutrality attenuates serum [3H]TO clearance of double-labeled TRL-mimicking particles 
accompanied by lower uptake of [3H]TO-derived activity by BAT. Glycerol tri[3H]oleate ([3H]TO) and [14C]
chole steryl oleate ([14C]CO) labeled TRL-mimicking particles of different size (45, 80 and 150 nm) were injected 
intravenously into 4-hour fasted mice that had been exposed to an ambient temperature of 21°C (open symbols) 
or 28°C (closed symbols) for 4 h prior to the experiment. Blood was collected at the indicated time points and 
[3H]TO activity was measured in plasma A-C . In addition, uptake of [3H]TO-derived activity was determined in 
various organs, and expressed as percentage of the injected dose per gram wet tissue weight D-F . 
Values are means ± SEM (n=6) *P<0.05, **P<0.01, ***P<0.001 compared to the 21°C group. BAT, brown adipose tissue; TRL, triglyceride-rich lipoprotein; 
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FIGURE 5 - Thermoneutrality attenuates serum [14C]CO clearance of double-labeled TRL-mimicking particles 
accompanied by lower [14C]CO uptake by BAT. Glycerol tri[3H]oleate ([3H]TO) and [14C]cholesteryl oleate ([14C]
CO) labeled TRL-mimicking particles of different size (45, 80 and 150 nm) were injected intravenously into 
4-hour fasted mice that had been exposed to an ambient temperature of 21°C (open symbols) or 28°C (closed 
symbols) for 4 h prior to the experiment. Blood was collected at the indicated time points and [14C]CO activity 
was measured in plasma A-C . In addition, uptake of [14C]CO-derived radioactivity was determined in various 
organs, and expressed as percentage of the injected dose per gram wet tissue weight D-F . 
Values are means ± SEM (n=6) *P<0.05, **P<0.01, ***P<0.001 compared to the 21°C group. BAT, brown adipose tissue; TRL, triglyceride-rich lipoprotein; 
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FIGURE 6 - Lipolysis index in muscle, WAT and BAT points to selective FA uptake at thermoneutrality. Glycerol 
tri[3H]oleate ([3H]TO) and [14C]cholesteryl oleate ([14C]CO) labeled TRL-mimicking particles of different size 
(45, 80 and 150 nm) were injected intravenously into 4-hour fasted mice that had been exposed to an ambient 
temperature of 21°C (open symbols) or 28°C (closed symbols) for 4 h prior to the experiment. After 15 min, 
mice were sacrificed and uptake of [3H]TO-derived radioactivity and [14C]CO radioactivity was determined in 
various organs, and expressed as percentage of the injected dose per gram wet tissue weight. Lipolysis index 
was calculated for all organs as the ratio of 3H-activity (%/g) and 14C-activity (%/g) for particles of 45 nm A , 
80 nm B  and 150 nm C . 
Values are means ± SEM (n=6) *P<0.05, **P<0.01, ***P<0.001 compared to the 21°C group. BAT, brown adipose tissue; TRL, triglyceride-rich lipoprotein; 






















































TG levels by a marked +88% (0.42 ± 0.02 vs. 0.79 ± 0.04, P<0.001). Again, plasma [14C]CO 
 clearance was slower for all particle sizes as compared to [3H]TO clearance (FIGURE 5A-C) and 
the liver was the main contributor of [14C]CO uptake (FIGURE 5D-F). Thermoneutrality had an 
opposite effect on [14C]CO uptake by BAT as compared to cold exposure, resulting in lower 
uptake and a lipolysis index comparable to WAT and muscle, even for the 150 nm sized particle. 
In addition, thermoneutrality enhanced [3H]oleate uptake by liver, resulting in an increase 
in lipolysis index. Thus, these data demonstrate that, also at thermoneutral temperature, 
TRL-derived FA from different sized TRLs are taken up through selective FA uptake by BAT. 




BAT has recently been identified as a major player in TG metabolism (5), but the mechanism 
by which BAT takes up FA from TG-rich VLDL and chylomicrons had not been fully established 
yet. In the present study, by performing kinetic studies with [3H]TO and [14C]CO double-
labeled TRL-mimicking particles of different size (ranging from VLDL to chylomicrons), we 
provide strong evidence that BAT takes up FA by selective delipidation of the TRL, followed 
by uptake of the remnant particle by the liver. This mechanism is independent of environ-
mental temperature, as it was evident at thermoneutrality, room temperature as well as 
after cold induction. 
Lipoprotein lipase (LPL), expressed on endothelial cells of the capillary bed of metaboli-
cally active tissues, is crucially involved in hydrolysis of TG-rich lipoproteins, resulting in 
release of FA and subsequent uptake by the adjacent tissue (12). Cellular uptake of FA is 
mediated by various cell surface receptors, including FA transport proteins and CD36 (13). 
BAT activation has repeatedly been shown to result in massive enhancement of LPL activity 
as well as increased CD36 expression (5;6). In fact, the LPL/CD36 route is required for 
TRL-derived FA uptake by BAT as inhibition of local LPL activity in BAT through injection of 
tetrahydrolipstatin abolished uptake of [3H]oleate and CD36-/- mice show cold intolerance 
due to inability to take up FA by BAT (5). Therefore, it would make physiological sense if 
in BAT, as in muscle and WAT, VLDL and chylomicron-derived TG are taken up after 
LPL-mediated delipidation of the particle, resulting in the generation of core remnants that 
can subsequently been taken up by the liver.
Besides for muscle and WAT, the present study supports that this mechanism also holds 
true for BAT, as we found high uptake of [3H]TO-derived activity and low [14C]CO uptake in 
BAT following injection of emulsion particles with sizes ranging from VLDL to chylomicrons. 
Accordingly, lipolysis indices in BAT were high as compared to liver and comparable to those 
found in WAT and muscle. As these results were found both at thermoneutrality, room 
 temperature and upon cold exposure, it is suggested that the mode of TRL-derived FA 
uptake is independent of BAT activation status. Accordingly, a study by Laplante et al (6) 
showed that BAT activation by means of PPARγ agonism resulted in enhanced uptake of [3H]
oleate from VLDL-like emulsion particles. However, as no non-releasable core label was used 
in their study, no definitive statements could be made on whether the uptake truly repre-
sented selective FA uptake. However, in their study [3H]oleate uptake in BAT highly correlated 
with the enhanced LPL activity that occurred in the tissue, suggesting that clearance of 
VLDL-TG and uptake of the radiolabeled FA was mainly determined by LPL-mediated hydrolysis 
of TG.
A remarkable finding of the present study was that the uptake of 3H-activity per gram 
organ was higher in BAT as compared to all other organs. This supports the importance 
of BAT in TG metabolism even at normal room temperature. Considering the uncovered 
 mechanism of FA uptake by BAT, this may suggest that LPL activity and/or CD36 expression 
in BAT exceeds that of other metabolic organs, such as WAT. Future studies are needed to 
confirm this hypothesis.
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Furthermore, upon cold exposure we found somewhat higher 14C-activity in BAT after 
injection of the 150 nm sized TRL-mimicking particles as compared to the smaller (45 and 80 
nm) VLDL-like particles. This is in line with the previous study of Bartelt et al (5) in which 
retention of chylomicron-like particles of ~250 nm was found in BAT. This may suggest that 
chylomicron-like particles remain bound to the capillaries in BAT during lipolysis. On the 
underlying mechanism for the specific retention of larger particles we can only speculate. 
As larger chylomicron-like particles have a higher surface area than VLDL-like particles 
through which they can bind to heparan sulfate proteoglycans on endothelial cells through 
electrostatic interactions, the avidity for binding may be higher than for smaller particles. It 
could be hypothesized that cold induction further enhances HSPG expression on endothelium 
to further maximize interaction of the TG-rich particles with LPL resulting in enhanced 
 lipolysis. This may thus be an efficient mechanism to maximize FA uptake by BAT. Future 
studies should focus on elucidating this mechanism, for instance by measuring HSPG 
expression in BAT upon cold exposure.
The magnitude of the TG clearance capacity of BAT became clear only recently when 
Bartelt et al (5) demonstrated that mice that are housed at 4°C for 24 h show a massive 
 lowering of plasma TG levels. These data are in full accordance with the present study in 
which we found that cold exposure for 24 h resulted in 43% reduction in plasma TG levels. 
The findings that metabolically active BAT stores exist in adult humans (14-16) and that BAT 
volume and activity are lower in obese subjects (15), have increased interest in the therapeutic 
potential of BAT to combat obesity and related disorders, such as dyslipidemia. Also in 
humans, BAT likely substantially contributes to TG metabolism. In a recent study by Ouellet 
et al (17), human subjects were cooled for 2 h followed by infusion of the FA tracer 18F-fluoro-
thiaheptadecanoic acid (18F-FTHA) and performance of a PET-CT scan. Indeed, cold exposure 
enhanced FA uptake by BAT as compared to muscle and WAT. Based on our studies, it is likely 
that human BAT also utilizes FA from circulating lipoproteins, though this has not been 
investigated yet.
In conclusion, we show that, in mice, BAT takes up lipoprotein-derived FA by means of 
selective FA uptake rather than uptake of lipoproteins. Future studies should elucidate 
whether this is also the primary mechanism of FA uptake by BAT in humans. 
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ATGL Adipose triglyceride lipase 
BAT Brown adipose tissue
BMP7 Bone morphogenetic protein 7
DEXA Dual-energy X-ray absorptiometry
EE Energy expenditure 
FDG Fluorodeoxyglucose
HSL Hormone-sensitive lipase 
LPL Lipoprotein lipase 
PET Positron emission tomography
Q-RT-PCR Quantitative real-time PCR 
TC Total cholesterol 
TG Triglyceride
UCP-1 Uncoupling protein-1
WAT White adipose tissue
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ABSTRACT
Brown adipose tissue (BAT) dissipates energy stored in triglycerides as heat via the 
uncoupling protein UCP-1 and is a promising target to combat hyperlipidemia  
and obesity. BAT is densely innervated by the sympathetic nervous system, which 
increases BAT differentiation and activity upon cold exposure. Recently, Bone 
Morphogenetic Protein 7 (BMP7) was identified as an inducer of BAT differentiation. 
We aimed to elucidate the role of sympathetic activation in the effect of BMP7 on 
BAT by treating mice with BMP7 at varying ambient temperature, and assessed the 
therapeutic potential of BMP7 in combating obesity. High-fat diet fed lean C57Bl6/J 
mice were treated with BMP7 via subcutaneous osmotic minipumps for 4 weeks at 
21°C or 28°C, the latter being a thermo neutral temperature in which sympathetic 
activation of BAT is largely diminished. At 21°C, BMP7 increased BAT weight, increased 
the expression of Ucp1, Cd36 and hormone-sensitive lipase in BAT, and increased 
total energy expenditure. BMP7 treatment markedly increased food intake without 
affecting physical activity. Despite that, BMP7 diminished white adipose tissue (WAT) 
mass, accompanied by increased expression of genes related to intracellular lipolysis 
in WAT. All these effects were blunted at 28°C. Additionally, BMP7 resulted in extensive 
‘browning’ of WAT, as evidenced by increased expression of BAT markers and the 
appearance of whole clusters of brown adipocytes via immunohistochemistry, 
 independent of environmental temperature. Treatment of diet-induced obese C57Bl6/J 
mice with BMP7 led to an improved metabolic phenotype, consisting of a decreased 
fat mass and liver lipids as well as attenuated dyslipidemia and hyperglycemia. In 
conclusion, together, these data show that BMP7-mediated recruitment and acti vation 
of BAT only occurs at subthermoneutral temperature, and is thus likely dependent on 
sympathetic activation of BAT, and that BMP7 may be a promising tool to combat 
 obesity and associated disorders.




Human adipose tissue is broadly classified as either white adipose tissue (WAT) or brown 
adipose tissue (BAT). WAT functions as an energy storage depot characterized by a large 
intracellular lipid droplet per adipocyte and is furthermore a prominent endocrine organ, 
producing hormones that regulate appetite and satiety (1). In contrast, BAT is an energy 
 dissipation depot characterized by multi-locular lipid droplets per adipocyte and a wealth 
of densely packed mitochondria. Uncoupling protein-1 (UCP-1) in these mitochondria uncou-
ples respiration from ATP synthesis, leading to heat production (2). 
The most well-known trigger for activation of BAT is cold, which increases sympathetic 
outflow from the hypothalamic temperature centre towards BAT, leading to release of 
noradrenalin and increased thermogenesis. Recently, a second alternative pathway was 
demonstrated to control thermogenesis, in which alternatively activated (M2) macrophages 
release noradrenalin to activate BAT locally (3). 
Fatty acids are an important substrate for BAT thermogenesis. The fatty acids originate 
from triglyceride (TG)-rich lipoproteins and are released upon local lipoprotein lipase (LPL) 
activity (4). Mouse studies have shown that BAT has a great clearance capacity for TG. Cold 
exposure drastically accelerates plasma TG clearance as a result of increased uptake into 
BAT and thereby corrects hyperlipidemia in pathophysiological settings (5). 
The recent findings that metabolically active BAT stores exist in adult humans and that 
BAT volume and activity are lower in obese subjects (6-8), have increased interest in the 
therapeutic potential of BAT to combat obesity and related disorders, such as dyslipidemia. 
In both rodents and humans, brown adipocytes are present in well-localized fat pads, as well 
as scattered in other tissues, such as WAT and muscle, there forming a ‘peripheral’ pool of 
brown adipocytes (9). The latter are also called ‘brite’ cells because their phenotypic charac-
teristics lie between those of white and brown adipocytes (10). Mouse studies demonstrate 
that cold exposure and other triggers like PPARγ agonism induce bright cell formation 
 (11-13). Identification of signalling pathways that regulate differentiation of the two types of 
brown adipocytes could lead to the development of novel therapies for obesity and related 
disorders. 
Bone Morphogenetic Protein 7 (BMP7) is an important inducer of brown adipocyte 
 differentiation. In vitro treatment of a variety of precursor cells, such as C3H10T1/2 mesen-
chymal cells and Myf5+ precursor cells, with BMP7 resulted in the development of fully 
 differentiated brown adipocytes with high UCP-1 expression (14, 15). Moreover, short-term 
adenoviral overexpression of BMP7 in different mouse models confirmed the ability of BMP7 
to increase interscapular brown fat mass and oxygen consumption (14). However, the poten-
tial of BMP7 to induce BAT activity in a more therapeutic regimen is currently unknown. 
Moreover, the role of ambient temperature in the effects of BMP7 on brown fat function and 
energy metabolism, and the therapeutic potential of BMP7 to treat dyslipidemia and obesity 
has not been reported yet. 
Therefore, the aim of the present study was to elucidate the role of ambient tempe-
rature, which determines the sympathetic output to BAT, in the effect of BMP7 on BAT and 
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to asses the therapeutic potential of BMP7 in combating obesity and related disorders. 
We show here that treatment of C57Bl6/J mice with BMP7 via osmotic minipumps for 
4 weeks effectively increased BAT differentiation, BAT activity and total energy expenditure, 
and decreased white fat mass. These effects were blunted at 28°C (thermoneutral tempera-
ture) and are thus likely dependent on the degree of sympathetic activation. Furthermore, 
BMP7 markedly enhanced brite cell formation in WAT independent of environmental 
tempe rature. Of note, treatment of diet-induced obese C57Bl6/J mice with BMP7 diminished 
fat mass and liver lipid content and attenuated dyslipidemia and hyperglycemia. Together, 
our results show that that low subthermoneutral ambient temperature, at which sympa-
thetic activation is present, is required for BMP7-mediated recruitment and activation of BAT 
and suggest that BMP7 may be a therapeutic tool to ameliorate obesity, and related disorders. 
RESEARCH DESIGN AND METHODS
Animals
Male C57Bl/6J mice (Jackson Laboratory, Bar Harbor, ME) were housed in conventional cages 
with a 12:12-h light-dark cycle and had free access to food and water. All animal experiments 
were approved by the institutional ethics committee on animal care and experimentation 
at Leiden University Medical Center.
Mechanistic studies on the effect of BMP7 on BAT 
4-week old C57Bl/6J mice were randomized according to their body weight and plasma 
 triglyceride (TG) and total cholesterol (TC) levels into 6 groups (n=9). Mice were housed at 
21°C or at 28°C (i.e. thermoneutral temperature) and received soluble recombinant BMP7 
(obtained from the Vukicevic lab, Zagreb, Croatia) (33 µg/kg/day or 100 µg/kg/day) or vehicle 
(saline) for 4 weeks while being fed a high-fat diet (45% energy as lard, D12451, Research Diet 
Services). BMP7 or saline was administered at a constant rate via an osmotic minipump 
(model 1004, Alzet DURECT Corp), which was implanted subcutaneously in the left back 
region. Mice were weighed twice a week. 
18F-FDG PET scans
After 7 days of treatment, mice underwent an 18F-fluorodeoxyglucose (FDG) positron emis-
sion tomography (PET) scan to quantify the metabolic volume of different BAT depots (inter-
scapular, neck and back). After 2 h fasting, mice were anesthetized using isoflurane and i.p. 
injected with 18F-FDG (20 MBq). Then, mice were allowed to awake, and were placed in their 
cage for 1 h (phase of tracer uptake). Scans were performed with the microPET system (uPET 
Focus 120, Siemens). Data for accumulation of 18F-FDG on the PET images were determined on 
the basis of radioactive counts per volume, corrected for the injected dose per gram of animal 
weight. A volume of interest was manually drawn around the different BAT depots, with a 
 cut-off value of 50% of the maximum inside the volume, to determine BAT metabolic volume. 




Indirect calorimetry was performed in fully automatic metabolic cages (LabMaster System, 
TSE Systems, Bad Homburg, Germany) during the fourth week of treatment. After 20 h accli-
matization, oxygen uptake (V˙ O2), carbon dioxide production (V˙ CO2) and caloric intake 
were measured for 5 consecutive days. Carbohydrate and fat oxidation rates were calculated 
from V˙ O2 and V˙ CO2 as described previously (16). Total energy expenditure (EE) was calcu-
lated from the sum of carbohydrate and fat oxidation. Physical activity was measured using 
infrared sensor frames. 
RNA isolation and Q-RT-PCR analysis
Total RNA was isolated with the Nucleospin® RNA II Kit (Macherey-Nagel) according to the 
manufacturer’s instructions. 1 µg of total RNA was reverse-transcribed with iScript cDNA 
synthesis kit (Bio-Rad), and the obtained cDNA was purified with Nucleospin Extract II kit 
(Macherey-Nagel). Real-time PCR was carried out on the IQ5 PCR machine (Bio-Rad) using 
the Sensimix SYBR Green RT-PCR mix (Quantace). Melt curve analysis was included to assure 
a single PCR product was formed. Expression levels were normalized using ß2-microglobulin 
and 36b4 as housekeeping genes. Primer sequences are listed in TABLE 1. 
Histology 
Interscapular BAT and gonadal WAT were removed and fixed directly in 4% paraformalde-
hyde, dehydrated and embedded in paraffin. Sections (5 µm) were dewaxed in xylene, rehy-
drated in ethanol and treated with 3% H2O2 (Sigma) in absolute methanol for 30 min. Next, 
sections were immersed in 10 mM citrate buffer (pH=6.0), boiled for 10 min and cooled 
down at room temperature. Slides were blocked during 60 min with normal goat serum 
(1:75 in PBS) and incubated overnight at 4°C with rabbit monoclonal anti-UCP-1 antibodies 
(Abcam) diluted 1:300 in normal goat serum (1:75). Next, sections were incubated for 60 min 
with biotinylated goat α-rabbit secondary antibodies (Vector Labs) diluted 1:600 in normal 
goat serum (1:75). Immunostaining was amplified using Vector Laboratories Elite ABC kit 
(Vector Labs) and the immunoperoxidase complex was visualized with Nova Red (Vector 
Labs). Counterstaining was performed with Mayer’s hematoxylin (1:4). 
Isolation of peritoneal macrophages
Mouse peritoneal cells were collected by flushing the peritoneal cavity with 10 ml sterile ice-
cold PBS, as previously described (17). Cells were centrifuged at 1,200 rpm for 5 min at 4°C 
and resuspended in RPMI1640 medium supplemented with 10% heat-inactivated fecal calf 
serum. Total leukocyte counts were determined using a Beckman Counter. Cells were plated 
overnight at 1x106 cells/ml in 500 µl in a 24 wells plate. Cells were subsequently lysed in 
buffer with ß-mercaptoethanol (100:1) and RNA was isolated as described above. 
Studies on BMP7 in a diet-induced obesity model 
8-week old C57Bl/6J mice were fed a high-fat diet (45% energy, D12451, Research Diet 
Services) for 12 weeks to induce obesity. Mice were then randomized according to their body 
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weight and plasma TG, TC and glucose levels into groups that received soluble recombinant 
BMP7 (100 µg/kg/day) or vehicle (saline) for 4 weeks via subcutaneous osmotic minipumps 
while being fed a high-fat diet. Mice were weighed twice a week.
Dual-energy X-ray absorptiometry (DEXA) scan 
After 4 weeks treatment, body composition was measured by DEXA using the Norland 
pDEXA Sabre X-ray Bone Densitometer. Mice were anaesthetized intraperitoneally with 
a combination of 6.25 mg⁄kg acepromazine (Alfasan), 6.25 mg⁄kg midazolam (Roche) and 
0.31 mg⁄kg fentanyl (Janssen-Cilag). The total body of the mice was scanned, yet the heads 
were excluded from the analyses. 
Plasma parameters
At baseline and after 4 weeks of treatment, plasma was obtained via tail vein bleeding after 
4 h fasting and assayed for TC, TG, and phospholipids using the commercially available enzy-
matic kits from Roche Molecular Biochemicals. Plasma glucose levels were measured using 
a commercially available kit and standardized according to the instructions of the manu-
facturer (Instruchemie, Delfzijl, The Netherlands). 
Liver lipid extraction
Lipids were extracted from livers consistent with a modified protocol from Bligh and Dyer 
(18). In short, a small piece of liver was homogenized in ice-cold methanol. Lipids were 
removed after centrifugation by adding 1,800 µl of CH3OH-CHCl3 (3:1 vol/vol) to 45 µl 
of homogenate. The CHCl3 phase was dried and suspended in 2% Triton X-100. Hepatic 
 triglyceride (TG), total cholesterol (TC) and phospholipid (PL) concentrations were measured 
using commercial kits, as explained above. Liver lipids were expressed per milligram of 
 protein, which was determined using the BCA protein assay kit (Pierce).
In vitro treatment of bone-marrow derived macrophages with BMP7
Bone marrow-derived macrophages were obtained from C57Bl6/J mice and cultured for 
8 days in LCM (RPMI1640 medium, supplemented with 10% FCS and 15% L929-conditioned 
medium). Then, cells were rinsed with PBS, lifted with a warm Lidocain/EDTA/PBS solution, 
washed in RPMI1640 and plated in LCM at 106 cells/ml in 500 µl in a 24 wells plate. Cells 
were either stimulated with soluble recombinant BMP7 (8.3 nM) or vehicle for 24 hours 
or with BMP7 or vehicle for 18 hours + 6 hours LPS treatment (10 ng/ml). The supernatant 
was collected for measurement of IL-6, IL-12 and TNF by commercial ELISA (Invitrogen) and 
NO2- by Griess assay, as described before (19). RNA was isolated with the Roche RNA isola-
tion kit as described by the suppliers. 
Statistical analysis
All data are represented as means ± SEM unless indicated otherwise. Data were analyzed 
with SPSS 17.0 using one-way ANOVA (when three groups were compared) Student T-tests 
(when two groups were compared) or, in case the data were not normally distributed, using 
















































nonparametric tests. Statistical analysis for the indirect calorimetry data were performed 
on 12-hour averages per parameter, based on the light-dark cycle. Data were generated for 
the light period between 7:00 AM and 7:00 PM and for the dark period between 7:00 PM 
and 7:00 AM. Normality checks were performed and comparisons were made using either 
one-way ANOVA or nonparametric tests. Probability values less than 0.05 were considered 
statistically significant.
RESULTS
BMP7 increases BAT volume and UCP-1 expression at 21°C, but not at thermoneutrality
To investigate whether BMP7 administered via constant low-dose release by osmotic 
 minipumps is capable of increasing BAT volume and activity in vivo, 4-week old C57Bl6/J 
mice (n=9 per group) were treated with BMP7 at 33 µg/kg/day, 100 µg/kg/day or saline for 
4 weeks. Mice were housed at either 21°C or 28°C, the latter being a thermoneutral tempe-
rature at which sympathetic activity towards BAT is virtually absent (20). At 21°C, BMP7 
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day (+20%, P<0.05) and at 100 µg/kg/day (+30%, P<0.01), while at 28°C no effects of BMP7 
were seen (FIGURE 1A). 18F-FDG PET-scans acquired one week after BMP7 treatment (100 µg/
kg/day) in mice that were housed at 21°C, showed that BAT metabolic volume in the neck 
region had already increased by +175% (P<0.001, FIGURES 1B-C). Furthermore, 100 µg/kg/day of 
BMP7 increased expression of Ucp1 in BAT as measured by qPCR (+115%, P<0.05, FIGURE 1D). 
and increased UCP-1 protein judged from immunohistochemistry (FIGURE 1E). At 28°C, expres-
sion of Ucp1 was markedly downregulated compared to 21°C (-97%, P<0.001), consistent with 
virtually absent sympathetic activity (FIGURE 1D). Moreover, lipid droplet size was markedly 
increased, pointing to less active BAT (FIGURE 1E). Importantly, at 28°C the effect of BMP7 on 
Ucp1 expression was completely abolished (FIGURES 1D-E). 
E
FIGURE 1 - Systemic administration of BMP7 increases BAT volume and UCP-1 expression in mice at 21°C, but 
not at thermo neutrality. 4-week-old C57Bl/6J mice were treated for 4 weeks with BMP7 (33 or 100 µg/kg/day) 
or saline via a subcutaneously located osmotic minipump at an environmental temperature of 21°C or 28°C. 
A  Weight of the interscapular brown fat pads, after quantitative removal, of mice housed at 21°C (left) and 
28°C (right).  B  Representative pictures of 18F-FDG PET scans that were taken in control and BMP7 (100 µg/kg/
day) treated animals (housed at 21°C) after one week of treatment, from which BAT metabolic volume C  was 
determined. Arrows indicate neck BAT depots. D  Expression of Ucp1 in BAT measured by Q-RT-PCR of mice 
housed at 21°C (left) and 28°C (right). E  Representative pictures of immunohistochemical UCP-1 stainings of 
BAT in control and BMP7 (100 µg/kg/day) treated animals housed at 21°C (top) and 28°C (bottom). Arrows 
point to UCP-1 positive cells.
Values are means + SEM (n=9) and expression of genes was corrected for the housekeeping genes ß2-microglobulin and 36b4. *P<0.05, ***P<0.001 
compared to the control group. 
21°C Control 21°C BMP7
28°C Control 28°C BMP7





























































BMP7 dose-dependently increases energy expenditure, related to increased fat oxidation at 
21°C, but not at thermoneutrality
After three weeks of treatment with BMP7, whole body energy metabolism and food intake 
of mice was assessed with a metabolic cage system. At 21°C, BMP7 significantly and dose-
dependently increased energy expenditure, fatty acid and carbohydrate oxidation (up to 
+45%, +37% and +26% respectively, P<0.05), while physical activity levels were unaltered 
(FIGURE 2A). Because fatty acid and carbohydrate oxidation were both increased, respiratory 
exchange ratio did not change upon BMP7 treatment (data not shown). Of note, BMP7 treat-
ment resulted in a marked increase in food intake, both at 33 µg/kg/day (+28%, P<0.05) and 
at 100 µg/kg/day (+37%, P<0.01) (FIGURE 2B). At 28°C, these effects were fully absent (SUP PLE-
MENTARY FIGURES 1A-B). As fatty acids are an important substrate for energy expenditure in 
BAT, we determined the expression of the scavenger receptor Cd36, hormone-sensitive 
lipase (Hsl), and adipose triglyceride lipase (Atgl), the latter two involved in intracellular 
lipolysis. At 21°C, BMP7 increased expression of Cd36 (up to +95%, P<0.05, FIGURE 2C). and Hsl 
(up to +82%, P<0.05, FIGURE 2D) but not of Atgl (FIGURE 2E) in BAT, suggesting increased cellular 
uptake of fatty acids via CD36 and liberation of intracellular fatty acids from TG via HSL for 
oxidation purposes. At 28°C, basal expression of Cd36, Hsl and Atgl was lower and unaffected 
by BMP7 (FIGURES 2C-E). 
BMP7 decreases gonadal white fat weight and increases expression of genes related to 
lipolysis at 21°C, but not at thermoneutrality
Despite the increased energy expenditure, BMP7 treatment did not affect body weight 
development, not at thermoneutrality (SUP PLEMENTARY FIGURE 1C) nor at 21°C (SUP PLEMENTARY 
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FIGURE 2A). This might in part be explained by an increase in bone mineral content induced 
by BMP7 treatment (+20%, P<0.05) (SUP PLEMENTARY FIGURE 2B), a well-known effect of BMP7 
(21). To investigate whether BMP7 treatment affected white fat content in vivo, we quanti-
tatively removed and weighed the right gonadal white fat pad (gWAT). In line with our calo-
rimetric data (FIGURE 2A), BMP7 decreased gWAT weight at 21°C (-12%, P<0.05), but not at 28°C 
(FIGURE 3A). To gain more insight into the underlying mechanism, we studied expression of 
genes related to lipolysis in this fat pad. Indeed, BMP7 increased gene expression of both Hsl 
(+150%, P<0.05, FIGURE 3B) and Atgl (+50%, P<0.05, FIGURE 3C) at 21°C, suggesting increased TG 














































FIGURE 2 - BMP7 increases energy expenditure and fat oxidation at 21°C. 4-week-old C57Bl/6J mice were 
treated for 4 weeks with BMP7 (33 or 100 µg/kg/day) or saline via a subcutaneously located osmotic mini-
pump at an environmental temperature of 21°C or 28°C. A  Energy expenditure, activity levels and fat and 
carbohydrate oxidation measured during 5 consecutive days in the fourth week of treatment via fully auto-
matic metabolic cages in mice housed at 21°C. Measurements were corrected for free fat mass (FFM) B  Food 
intake measured during the fourth week of treatment in mice housed at 21°C. C-E  Expression of Cd36 C  , Hsl 
D  and Atgl E  in BAT measured by Q-RT-PCR of mice housed at 21°C (left) or 28°C (right). 
Values are means + SEM (n=9) and expression of genes was corrected for the housekeeping genes ß2-microglobulin and 36b4. *P<0.05, ** P<0.01 
compared to the control group. 













































































BMP7 induces brite cell formation independent of environmental temperature 
In WAT, brite cells are present that contribute to total energy expenditure through uncoupling 
by UCP-1 (22). Therefore, we studied if BMP7 treatment induced brite cell formation. Indeed, 
BMP7 markedly increased UCP-1 expression in gWAT, both at 21°C (+920%, P<0.05) and 28°C 
(+760%, P<0.05) (FIGURE 3D). Moreover, immunohistochemical staining of UCP-1 in gWAT 
 confirmed that, at both temperatures, BMP7 induced the appearance of fields of UCP-1 
 positive cells with brown cell-like morphology, so-called ‘browning’ of white fat (FIGURE 3E). 
BMP7 alters M1/M2 balance in BAT and WAT at 21°C, but not at thermoneutrality 
Recently, M2 macrophages were shown to be crucial for BAT function via release of 
noradrenalin (3). Recruitment and activation of these macrophages is induced by sympa-
thetic stimulation of BAT (3). Therefore, we investigated whether BMP7 could influence the 
presence of M2 macrophages in BAT, thereby possibly contributing to BMP7-induced BAT 
activation. Indeed, after 4 weeks of BMP7 treatment, expression of the M2 markers Mrc1 
tended to and Cd163 was increased in BAT (+94%, P=0.068 and + 232%, P<0.05 respectively) 
(FIGURES 4A-B), while the M1 markers Nos2 and Tnf (FIGURES 4C-D) were unaltered. Interestingly, 
at 28°C, basal expression of all tested macrophage markers was largely diminished, which is 
in line with diminished sympathetic activation, and expression was not influenced by BMP7 
C D
A B
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E
21°C Control 21°C BMP7
28°C Control 28°C BMP7
FIGURE 3 - BMP7 reduces white fat weight and induces browning of white adipose tissue. 4-week-old 
C57Bl/6J mice were treated for 4 weeks with BMP7 (33 or 100 µg/kg/day) or saline via a subcutaneously located 
osmotic minipump at an environmental temperature of 21°C or 28°C. A  Weight of the right gonadal white 
fat pad, after quantitative removal, after which expression of Hsl B , Atgl C  and Ucp1 D  was measured by 
Q-RT-PCR of mice housed at 21°C (left) or 28°C (right). (E) Representative pictures of immunohistochemical 
UCP-1 stainings of WAT in the control and BMP7 (100 µg/kg/day) animals housed at 21°C (top) and 28°C (bottom). 
Values are means + SEM (n=9) and expression of genes was corrected for the housekeeping genes ß2-microglobulin and 36b4. *P<0.05 compared 
to the control group. 
treatment (FIGURES 4B,D). Moreover, mice that received BMP7 treatment showed increased 
expression of M2 markers in gWAT, but only at 21°C (SUP PLEMENTARY FIGURES 3A-C). In addition, 
isolated peritoneal macrophages from mice that had been treated with BMP7 (100 µg/kg/
day) at 21°C showed increased expression of the M2 markers Mrc1 and Cd163, while expres-
sion of the M1 markers Tnf and Nos2 was markedly diminished (FIGURE 4E). Thus, both in the 
adipose tissue and in the peritoneal cavity, the M1/M2 balance was altered towards M2 after 
in vivo BMP7 treatment at 21°C. 
To investigate whether BMP7 directly affects macrophage polarisation, we treated bone-
marrow derived macrophages with BMP7 for 24 h in vitro. However, no effect was seen on 
expression of M1 or M2 markers as measured via Q-RT-PCR (FIGURE 4F), nor on cytokine 
 production by macrophages after stimulation with LPS (SUP PLEMENTARY FIGURES 4A-D), sug-
gesting that BMP7 alters M1/M2 balance in vivo via an indirect mechanism. 


































































































































FIGURE 4 - BMP7 results in altered M1/M2 balance in BAT and peritoneal macrophages. 4-week-old C57Bl/6J 
mice were treated for 4 weeks with BMP7 (33 or 100 µg/kg/day) or saline via a subcutaneously located osmotic 
minipump at an environmental temperature of 21°C or 28°C. Expression of the M2 markers Mrc1 A  and Cd163 
B  and the M1 markers Nos2 C  and Tnf D  was measured in BAT by Q-RT-PCR of mice housed at 21°C (left) and 
28°C (right). E  After 4 weeks of treatment, peritoneal macrophages were isolated and markers of M2 and M1 
macrophages were measured by Q-RT-PCR of mice housed at 21°C. F  Bone-marrow derived macrophages 
were isolated from untreated C57Bl/6J mice and treated ex vivo with BMP7 (8.3 nM) for 24 hrs. The expression 
of markers for M2 and M1 macrophages was measured via Q-RT-PCR. 
Values are means + SEM (n=9 for in vivo and n=3 for in vitro) and expression of genes was corrected for the housekeeping genes ß2-microglobulin 
and 36b4. *P<0.05 compared to the control group. 
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BMP7 decreases obesity and attenuates liver lipid accumulation, dyslipidemia, and hyper-
glycemia in diet-induced obese mice 
To investigate if BMP7 could improve the metabolic phenotype in diet-induced obesity, 
C57Bl6/J mice were fed a high-fat diet for 12 weeks and then treated with BMP7 (100 µg/kg/
day) or saline for four weeks via subcutaneous osmotic minipumps in the presence of a high-
fat diet. After 4 weeks of treatment, BMP7 tended to decrease body weight (-7%, P=0.09) 
(FIGURE 5A) but significantly reduced total fat mass (-7%, P<0.05) as measured by DEXA analysis 
(FIGURE 5B). Furthermore, in liver, BMP7 markedly reduced triglyceride (TG) accumulation (-40%, 
P<0.01) as well as phospholipids (-21%, P<0.05), but not total cholesterol (TC). In addition, BMP7 
lowered plasma TG (-25%, P<0.05) and total cholesterol levels (-10%, P<0.05) (FIGURE 5D), and 
diminished hyperglycemia (-27%, P<0.01). Overall, these data are in full accordance with 
increased fatty acid and carbohydrate oxidation induced by BMP7 treatment and underscore 
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FIGURE 5 - BMP7 decreases obesity and attenuates liver lipid accumulation, dyslipidemia and hyperglycemia 
in diet-induced obese mice. 8-week-old C57Bl/6J mice were fed a high-fat diet for 12 weeks and then treated 
for 4 weeks with BMP7 (100 µg/kg/day) or saline via a subcutaneous osmotic minipump at an environmental 
temperature of 21°C while feeding a high-fat diet A  Body weight development (gram) B  Total fat mass as 
measured via DEXA-scan (expressed as percentage of body weight) C  Liver content of triglycerides (TG), total 
cholesterol (TC) and phospholipids (PL) D  Plasma triglyceride (TG) and total cholesterol (TC) levels. E  Plasma 
glucose levels. 
Values are means + SEM (n=9). *P<0.05, **P<0.01 compared to the control group. 
DISCUSSION 
Given its potential to dissipate energy instead of storing it, BAT is considered a promising 
target to treat obesity and related disorders, such as dyslipidemia and hyperglycemia (23). In 
this study, we show that 4 weeks treatment of mice with the endogenous growth factor 
BMP7 effectively increased BAT volume and formation of brite cells in WAT and boosted 
whole-body metabolism. We furthermore demonstrate that at thermoneutral temperature 
nearly all effects of BMP7 on BAT were absent, suggesting that sympathetic activation 
importantly contributes to the effect of BMP7 on BAT differentiation and activity. Moreover, 
BMP7 was able to diminish white fat content, liver lipid accumulation as well as to reduce 
dyslipidemia and hyperglycemia in diet-induced obese mice, underscoring the therapeutic 
potential of BMP7 in combating obesity and related disorders.
Our data are in line with a previous study performed by Tseng et al. (14), in which transient 
adenoviral overexpression of BMP7 increased BAT volume and oxygen consumption. We 
show that BMP7 markedly stimulates BAT volume and activity in mice only at subthermo-
neutral temperature, accompanied by a reduction in diet-induced obesity, liver lipid accu-
mulation, dyslipidemia and hyperglycemia, and an altering of the M1/M2 balance in BAT and 
WAT towards increased anti-inflammatory M2 macrophages. 
Interestingly, we found that treating mice for 4 weeks with BMP7 not only diminished 
white fat content in diet-induced obese mice, but also markedly lowered liver lipid accumu-
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lation, plasma TG levels and, to a lesser extent, plasma cholesterol levels. The lowering in 
plasma lipid levels is probably the direct consequence of the increased BAT activity induced 
by BMP7. That is, fatty acids derived from LPL-mediated hydrolysis of TG-rich lipoproteins 
form an important substrate for BAT thermogenesis (2). Indeed, expression of CD36 in BAT, 
a scavenger receptor that is rate-limiting for the uptake of fatty acids from plasma into BAT 
(24), was significantly upregulated in BAT of BMP7 treated mice. Moreover, a recent study 
by Bartelt et al. (5) shows that BAT has a tremendous capacity to clear plasma TG. 4 h of cold 
induction (4°C) normalized plasma TG levels in severely hypertriglyceridemic apoA5 knock-
out mice (5). Since increased plasma TG levels are an independent risk factor for cardio-
vascular disease in both men and women (25) BMP7 might thus be an interesting treatment 
modality to manage cardiovascular disease through attenuating dyslipidemia via targeting 
BAT. 
Despite an improved metabolic phenotype in both lean and diet-induced obese mice 
upon BMP7 treatment, we did not observe effects on body weight development. This might 
in part be due to the fact that BMP7 is capable of inducing bone formation (21). Indeed, in 
our study, BMP7 treated mice exhibited increased bone mineral content as measured via 
DEXA-scan. In addition, part of the beneficial effect of BMP7 on energy expenditure might 
be offset by the increase in food intake (up to +37%) we observed. This is probably rather a 
consequence of the increased uncoupling due to BAT activation (26) then a direct effect of 
BMP7 on food intake, since we did not observe this effect at thermoneutrality. Moreover, 
a recent study by Townsend et al (27) showed that intracerebral infusion of BMP7 resulted in 
a decrease in food intake rather than an increase. 
A striking finding in our study is that at thermoneutrality, BMP7 exerted virtually no 
effect on BAT, suggesting that sympathetic activation of BAT is a prerequisite for the effects 
of BMP7 on BAT differentiation and activity. 
A first explanatory mechanism for this finding may involve the intracellular signaling 
route by which BMP7 induces UCP-1 upregulation in brown adipocytes. The pathway 
involves binding of BMP7 to the BMP-receptor II subtype and induction of the p38 MAPK 
route, in which the accessory proteins TAB1 an XIAP1 modulate downstream signaling. Via 
binding to and activation of still unknown transcription factors, this leads to upregulation 
of UCP-1 expression (28,29). Interestingly, protein kinase A (PKA), a downstream target of the 
thermogenic ß3-adrenergic receptor, also induces p38 MAPK (29). Thus, via p38 MAPK, the 
ß3-adrenergic and BMP7 signaling routes are intertwined. Possibly, p38 MAPK should be 
activated above a certain threshold before BMP7 can induce its downstream effects on 
UCP-1 expression This might explain why at thermoneutrality, in which sympathetic activity 
and thus ß3 signalling towards BAT are largely diminished, BMP7 was unable to increase BAT 
volume and activity. 
A second mechanism that could explain the ineffectiveness of BMP7 at thermoneutral 
temperature may involve a central mode of action of BMP7. A central player involved in BAT 
activation is the hypothalamus, which projects onto sympathetic nerves that densely inner-
vate BAT (2). Various circulating peptides have been shown to be capable of activating BAT 
via the hypothalamus, such as GLP-1 (30) and BMP8B, another member of the BMP family 
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(31). In addition, Townsend et al. (27) showed that central administration of BMP7 resulted in 
reduced food intake, confirming that BMP7 is at least capable of exerting central effects. 
However, it remains to be determined whether subcutaneously administered BMP7 is able 
to enter the hypothalamus to subsequently exert central actions. 
Interestingly, we showed that treatment of mice with BMP7 resulted in an altered M1/M2 
macrophage balance in both BAT, gWAT and the peritoneal cavity, with increased expression 
of M2 markers. M2 macrophages have recently been shown to importantly contribute to 
BAT thermogenesis by releasing noradrenalin (3). Possibly the increased presence of M2 
macrophages in BAT in response to BMP7 treatment contributed to the increased BAT activity 
found in these mice. However, since the initial paper describing the involvement of M2 mac-
rophages in BAT function has been under debate recently, future studies should further 
explore the necessity of M2 macrophages in mediating the effects of BMP7 on BAT. 
Furthermore, whether the effect of BMP7 on macrophage polarisation is either direct or 
indirect, in response to changes in BAT, remains to be determined. Although we could not 
show in our in vitro experiments a direct effect of BMP7 on M1/M2 skewing in bone-marrow 
derived macrophages, a recent study in which human THP-1 monocytes were treated with 
BMP7 demonstrated significant polarization of monocytes into M2 macrophages (32). 
However, since the change in M1/M2 balance did not happen at thermoneutral temperature 
suggests that environmental factors are at least in part involved in the effects of BMP7 on 
macrophage polarisation. 
In this study, we show that BMP7 not only increased the volume of the interscapular 
brown fat pad, but also show for the first time that BMP7 markedly induced appearance of 
brite cells in WAT, so-called ‘browning’ of WAT. This could have been caused by either trans-
differentiation of white fat cells into brite adipocytes, or differentiation of brite precursor 
cells that are present in WAT towards brite adipocytes. Both mechanisms are plausible. 
White fat cells have been shown to be capable of transdifferentiating towards brite adipo-
cytes and they furthermore have the BMP-II receptor (21,33). Moreover, in WAT, Myf5- precursor 
cells are present that can differentiate into brite cells in vitro (9, 34). Future studies are needed 
to elucidate the mechanism by which BMP7 induces ‘browning’ of WAT in more detail. 
However, since we found that brown fat cells obviously appeared as clusters in WAT, it is 
more plausible that BMP7 primarily acted on precursor cells resulting in proliferation and 
subsequent differentiation. Intriguingly, browning happened independent of environmental 
temperature. This could be explained by the fact that WAT, in contrast to BAT, is less dense 
innervated by the sympathetic nervous system and thus probably less dependent on its 
activation (2). In addition, UCP-1 expression might be differentially regulated in bright cells 
compared to the brown adipocytes present in the brown fat pads. 
Brite cells have been suggested to contribute importantly to total energy expenditure, 
as these cells are more abundant in obesity-resistant strains of mice (35,36). In our study, 
mice that were treated with BMP7 at 28°C displayed an increase of brite fat cells without 
activating brown fat pads. This was however not sufficient to raise total energy expenditure. 
Interestingly, the recently indentified hormone irisin, which is released from muscle after 
exercise, selectively induced browning of subcutaneous WAT depots, without affecting 
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 differentiation or activity of brown fat pads, and did lead to an increase in total energy 
expenditure (21). 
In conclusion, BMP7 stimulates BAT volume, activity and total energy expenditure only at 
subthermoneutrality, suggesting that intact sympathetic activation is a prerequisite for the 
effects of BMP7 on BAT. Furthermore, we found that BMP7 diminishes obesity and liver lipid 
accumulation, and attenuates dyslipidemia and hyperglycemia in diet-induced obese mice. 
We anticipate that BAT may be a promising novel treatment goal, and BMP7 a treatment 
modality, in fighting obesity and related disorders.
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SUPPLEMENTARY FIGURE 1 - BMP7 does not affect energy expenditure, fat oxidation, food intake and 
weight development at thermo neutrality. 4-week-old C57Bl/6J mice were treated for 4 weeks with BMP7 
(33 or 100 µg/kg/day) or saline via a subcutaneously located osmotic minipumps at an environmental tem-
perature of 21°C or 28°C. A  Energy expenditure, fat and carbohydrate oxidation and activity levels measured 
during 5 consecutive days in the fourth week of treatment via fully automatic metabolic cages in mice housed 
at 28°C. Measurements were corrected for free fat mass (FFM). B  Food intake measured during the fourth 
week of treatment in mice housed at 28°C. C  Body weight (gram) development during treatment at 28°C. 
Values are means + SEM (n=9).
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SUPPLEMENTARY FIGURE 2- BMP7 does not affect weight development but increases bone mineral content 
at 21°C. 4-week-old C57Bl/6J mice were treated for 4 weeks with BMP7 (33 or 100 µg/kg/day) or saline via a 
subcutaneously located osmotic minipumps at an environmental temperature of 21°C or 28°C. A  Body 
weight development (gram) during treatment at 21°C B  Bone mineral content as measured via DEXA scan 
after 4 weeks of treatment at 21°C. 






SUPPLEMENTARY FIGURE 3 - BMP7 alters the M1/M2 
balance in WAT at 21°C, but not at thermoneutrality. 
4-week-old C57Bl/6J mice were treated for 4 weeks 
with BMP7 (33 or 100 µg/kg/day) or saline via a sub-
cutaneously located osmotic mini pump at an environ-
mental temperature of 21°C or 28°C. A-B  Expression 
of the M2 markers Mrc1 A  and Cd163 B  in gWAT 
measured by Q-RT-PCR of mice housed at 21°C (left) or 
28°C (right). C  Expression of the M1 marker Nos2 in 
gWAT measured by Q-RT-PCR of mice housed at 21°C 
(left) or 28°C (right). 
Values are means + SEM (n=9) and expression of genes was corrected 
for the housekeeping genes ß2-microglobulin and 36b4. *P<0.05 com-
pared to the control group. 





































SUPPLEMENTARY FIGURE 4 - BMP7 does not alter cytokine secretion by bone-marrow derived macrophages. 
Bone-marrow derived macro phages were isolated from untreated C57BL6/J mice, plated in a 24-well plate 
(106 cells/mL) and stimulated with BMP7 (8.3 nM) or vehicle for 24 hours or with BMP7 (8.3 nM) or vehicle for 
18 hours + 6 hours LPS (10 ng/mL). The concentration of IL-6 A , TNF B , NO2- C  and IL-12 D  in the supernatant 
was measured. 
Values are means + SEM (n=3).
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Soc1 CCGTGGGTCGCGAGAAC  AAGGAACTCAGGTAGTCACGGAGTA
Tnf GGCAGGTCTACTTTGGAGTCATTGC ACATTCGAGGCTCCAGTGAATTCGG
Ucp1 TCAGGATTGGCCTCTACGAC TGCATTCTGACCTTCACGAC
TABLE 1 - Primers used for quantitative real-time PCR analysis
Arg1 arginase 1
Atgl adipose triglyceride lipase
Ccl5 Chemokine (C-C motif) ligand 5
Hsl hormone-sensitive lipase 
Il10 interleukin-10 
Mrc1 mannose receptor 1 
Nos2 nitric oxide synthase 2 
Tnf tumor necrosis factor-α 
Ucp-1 uncoupling protein-1
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ABSTRACT
Metformin is the first-line drug for the treatment of type 2 diabetes. Besides its well-
characterized antihyperglycemic properties, metformin also lowers plasma VLDL 
 triglycerides (TGs). In this study, we investigated the underlying mechanisms in 
APOE*3-Leiden.CETP mice, a well-established model for human-like lipoprotein 
metabolism. We found that metformin markedly lowered plasma total cholesterol 
and TG levels, an effect mostly due to a decrease in VLDL-TG, whereas HDL was 
 slightly increased. Strikingly, metformin did not affect hepatic VLDL-TG production, 
VLDL particle composition, and hepatic lipid composition but selectively enhanced 
clearance of glycerol tri[3H] oleate-labeled VLDL-like emulsion particles into brown 
adipose tissue (BAT). BAT mass and lipid droplet content were reduced in metformin-
treated mice, pointing to increased BAT activation. In addition, both AMP-activated 
protein kinase 1 (AMPK1) expression and activity and HSL and mitochondrial 
 content were increased in BAT. Furthermore, therapeutic concentrations of metformin 
increased AMPK and HSL activities and promoted lipolysis in T37i differentiated 
brown adipocytes. Collectively, our results identify BAT as an important player in  
the TG-lowering effect of metformin by enhancing VLDL-TG uptake, intracellular  
TG lipolysis, and subsequent mitochondrial fatty acid oxidation. Targeting BAT might 
therefore be considered as a future therapeutic strategy for the treatment of dyslipi-
demia.




Metformin is one of the most widely used glucose-lowering agents for the treatment of type 
2 diabetes (1) and is now considered the first-line drug therapy for patients (2). This antidiabetic 
drug from the biguanides family is prescribed for its effective antihyperglycemic action, 
 mostly achieved through a potent reduction of hepatic glucose production secondary to 
 inhibition of gluconeogenesis (3). Interestingly, another important but often overlooked property 
of metformin relies on its beneficial. effect on the blood lipid profile, which is characterized 
by a significant reduction in circulating triglycerides (TGs) and VLDL cholesterol and 
increased HDL cholesterol levels (4). This metabolic feature might partly be involved in 
its cardioprotective effect observed in obese patients treated with the drug (5). Despite 
extensive efforts during the last years (6), the exact molecular mechanism (s) of action of 
 metformin still remains incompletely understood, especially the one by which the drug 
exerts its lipid-lowering action. In 2001, Zhou et al. (7) were the first to report that metformin 
activates hepatic AMPactivated protein kinase (AMPK), emphasizing the putative role of this 
energy-sensing kinase in the mechanism of action of the drug. 
AMPK is a well-conserved serine/threonine protein kinase that plays a crucial role in the 
regulation of catabolic/anabolic pathways by acting as a cellular energy and nutrient sensor 
(8,9). AMPK consists of a heterotrimeric complex containing a catalytic a subunit and two 
regulatory ß and γ subunits. Each subunit has several isoforms (1, 2; ß1, ß2; γ1, γ2, γ3) that 
are encoded by distinct genes, giving multiple heterotrimeric combinations with tissue- 
specific distribution (8,9). The ß subunit contains a threonine residue (Thr 172) whose 
 phosphorylation by upstream kinases, such as the liver kinase B (LKB1), is required for AMPK 
activation. The b subunit acts as a scaffold to which the two other subunits are bound and 
also allows AMPK to sense energy reserves in the form of glycogen (8,9). Binding of AMP 
and/or ADP to selective domains on the γ subunit leads to AMPK activation via a complex 
mechanism involving direct allosteric activation, phosphorylation on Thr172 by AMPK 
upstream kinases, and inhibition of dephosphorylation of this residue by specific protein 
phosphatases that remain to be identified (8,9). Interestingly, the mechanism by which 
metformin activates AMPK, involving specific inhibition of the mitochondrial respiratory 
chain complex 1 (10,11), was recently clarified (12,13), although the contribution of the LKB1/ 
AMPK axis in its hepatic effects still remains controversial (14–18). 
The objective of this study was to investigate the molecular mechanisms underlying the 
effects of metformin on lipoprotein metabolism by using APOE*3-Leiden. CETP (E3L.CETP) 
transgenic mice, a well-established model of human-like lipoprotein metabolism (19) that 
also responds to lipid-lowering pharmacological interventions (20–23). Collectively, our data 
show that treatment of E3L.CETP mice with metformin is able to recapitulate the lipid- 
lowering effect of the drug evidenced in humans, i.e., causing a reduction in plasma VLDL-TG 
associated with a parallel mild increase in HDL cholesterol. Remarkably, this effect is not 
mediated by apparent changes in hepatic VLDL-TG production but rather by a selective 
increase in VLDL-TG clearance by the brown adipose tissue (BAT). At the molecular level, we 
found an increase in AMPK1 activity and protein expression of both hormone-sensitive 
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lipase (HSL) and mitochondrial respiratory chain complexes, suggesting that metformin, on 
top of increasing VLDL-TG uptake, also promotes intracellular TG lipolysis and subsequent 
mitochondrial fatty acid (FA) oxidation in BAT. 
RESEARCH DESIGN AND METHODS
Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO). 
Ethics
All mouse experiments were performed in accordance with the Institute for Laboratory 
Animal Research Guide for the Care and Use of Laboratory Animals and have received 
approval from the university ethical review boards (Leiden University Medical Center). 
Animals, Diet, and Metformin Treatment 
Homozygous human CETP transgenic mice were crossbred with hemizygous APOE*3-Leiden 
(E3L) mice at our Institutional Animal Facility to obtain E3L.CETP mice, as previously 
described (19). In this study, 12-week-old E3L. CETP female mice, housed under standard 
 conditions in conventional cages with ad libitum access to food and water, were fed a 
Western-type diet containing 0.1% (weight for weight [w/w]) cholesterol (Hope Farms, 
Woerden, the Netherlands) for 4 weeks. Upon randomization according to body weight, 
plasma total cholesterol (TC), and TG levels, mice next received Western-type diet with or 
without 200 mg/kg body weight/day (0.2%, w/w) metformin for 4 weeks. Unless otherwise 
mentioned, experiments were performed after 4 h of fasting at 1:00 p.m. with food with-
drawn at 9:00 a.m. 
Plasma Lipid and Lipoprotein Analysis 
Plasma was obtained via tail vein bleeding and assayed for TC, TG, and phospholipid (PL) 
using the commercially available enzymatic kits 236691, 11488872, and 1001140 (Roche 
Molecular Biochemicals, Indianapolis, IN), respectively. Free FAs were measured using the 
NEFA-C kit from Wako Diagnostics (Instruchemie, Delfzijl, the Netherlands). The distribution 
of lipids over plasma lipoprotein fractions was determined using fast protein liquid chroma-
tography. Plasma was pooled per group, and 50 μL of each pool was injected onto a Superose 
6 PC 3.2/30 column (Akta System, Amersham Pharmacia Biotech, Piscataway, NJ) and eluted 
at a constant flow rate of 50 μL/min in 1 mmol/L EDTA in PBS, pH 7.4. Fractions of 50 μL were 
collected and assayed for TC and TG as described above. 
Hepatic VLDL-TG and VLDL-apoB Production 
Mice were fasted for 4 h prior to the start of the experiment. During the experiment, mice 
were sedated with 6.25 mg/kg acepromazine (Alfasan, Woerden, the Netherlands), 6.25 mg/kg 
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midazolam (Roche, Mijdrecht, the Netherlands), and 0.31 mg/kg fentanyl (Janssen-Cilag, 
Tilburg, the Netherlands). At t = 0 min, blood was taken via tail bleeding and mice were 
intravenously injected with 100 μL PBS containing 100 μCi Trans35S label (ICM Biomedicals, 
Irvine, CA) to measure de novo total apolipoprotein B (apoB) synthesis. After 30 min, the 
 animals received 500 mg tyloxapol (Triton WR-1339; Sigma- Aldrich) per kilogram body 
weight as a 10% (w/w) solution in sterile saline, to prevent systemic lipolysis of newly 
secreted hepatic VLDL-TG. Additional blood samples were taken at t = 15, 30, 60, and 90 min 
after tyloxapol injection and used for determination of plasma TG concentration. After 90 
min, the animals were killed and blood was collected by orbital bleeding for isolation of 
VLDL by density-gradient ultracentrifugation, as previously described (19–23). 35S-apoB was 
measured in the VLDL fraction, and VLDL-apoB production rate was calculated as dpm.h-1, as 
previously reported (19–23). 
In Vivo Clearance of VLDL-Like Emulsion Particles 
Mice were fasted overnight with food withdrawn at 6:00 p.m. During the experiment, mice 
were sedated as described above. At t = 0 min, blood was taken via tail bleeding and mice 
received a continuous intravenous infusion of glycerol tri[3H]oleate-labeled emulsion particles 
mixed with albumin-bound [14C]oleic acid (4.4 μCi [3H]TG and 1.2 μCi [14C]FA; both from GE 
Healthcare Life Sciences, Little Chalfont, U.K.) at a rate of 100 μL/h for 2.5 h, as previously 
described (24,25). Blood samples were taken using chilled paraoxoncoated capillaries by tail 
bleeding at 90 and 120 min of infusion to ensure that steady-state conditions had been 
reached. Subsequently, mice were killed and organs were quickly harvested and snap frozen 
in liquid nitrogen. Retention of radioactivity in the saponified tissues was measured per 
 milligram of tissue and corrected for the corresponding plasma-specific activities of [3H]FA 
and [14C]FA, as previously described (24). 
Hepatic Lipid Composition 
Liver lipids were extracted as previously described (20). In brief, small liver pieces were 
homogenized in ice-cold methanol. After centrifugation, lipids were extracted by addition of 
1,800 μL CH3OH:CHCl3 (1:3 volume for volume [v/v]) to 45 μL homogenate, followed by 
 vigorous vortexing and phase separation by centrifugation (14,000 rpm; 15 min at room 
temperature). The organic phase was dried and dissolved in 2% Triton X-100 in water. TG, TC, 
and PL concentrations were measured using commercial kits as described above. Liver lipids 
were expressed as nanomoles per milligram protein, which was determined using the BCA 
protein assay kit (Pierce, Rockford, IL). 
Histology 
Interscapular BAT was removed and fixed directly in 4% paraformaldehyde, dehydrated, and 
embedded in paraffin. Hematoxylin and eosin staining was performed using standard pro-
tocols. The area of intracellular lipid vacuoles in BAT was quantified using Image J (NIH).
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Cell Culture and Brown Adipocyte Differentiation 
T37i cells were cultured and differentiated as described previously (26). Cells were next 
treated with metformin or vehicle (PBS) for 8 h. Then, supernatant was collected for deter-
mination of glycerol (Instruchemie, Delfzijl, the Netherlands) and cells were harvested in 
ice-cold lysis buffer, as described below. 
Western Blot Analysis 
Snap-frozen liver and BAT samples (~50 mg) or T37i cells were lysed in ice-cold buffer 
 containing the following: 50 mmol/L HEPES (pH 7.6), 50 mmol/L NaF, 50 mmol/L KCl, 5 mmol/L 
NaPPi, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L dithiothreitol, 5 mmol/L ß-glycerophosphate, 
1 mmol/L sodium vanadate, 1% NP40, and protease inhibitor cocktail (Complete; Roche). 
Western blots were performed as previously described (13). All the primary antibodies used 
are listed in SUPPLEMENTARY TABLE 1. Bands were visualized by enhanced chemiluminescence 
and quantified using Image J (NIH). 
AMPK Assay
AMPK activity was assayed after immunoprecipitation with specific antibodies directed 
against 1- or 2-AMPK catalytic subunits (Kinasource, Dundee, Scotland), as previously 
described (14). 
RNA/DNA Purification and qRT-PCR 
RNA was extracted from snap-frozen liver or BAT samples (~25 mg) using Tripure RNA 
Isolation Reagent (Roche). Total RNA (1–2 μg) was reverse transcribed, and quantitative real-
time PCR was then performed with SYBR Green Core Kit on a MyIQ thermal cycler (Bio-Rad). 
mRNA expression was normalized to CypD mRNA content and expressed as fold change 
compared with control mice using the ΔΔCT method. Genomic DNA was extracted using 
the Qiagen Tissue and Blood Kit (Qiagen, Hilden, Germany). For mitochondrial DNA copy 
number, ND1 (mitochondrial) and LPL (nuclear) copy numbers were quantified by qRT-PCR. 
All the primer sequences are listed in SUPPLEMENTARY TABLE 1. 
Statistical Analysis 
All data are expressed as mean ± SEM. Statistical analysis was performed using SPSS 17.0 
software package for Windows (SPSS, Chicago, IL) with two-tailed unpaired Student t test. 
Differences between groups were considered statistically significant at P < 0.05. 
RESULTS
Metformin Reduces Plasma Cholesterol and TG Levels 
To investigate the effect of metformin on lipoprotein metabolism, E3L.CETP mice were first 
fed a cholesterolrich (0.1%) Western-type diet for 4 weeks and next treated with or without 
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metformin (200 mg/kg body weight/day) added to the diet for another 4 weeks. As com-
pared with the control group, metformin did not affect body weight and composition, food 
intake and plasma glucose, and insulin and FA levels throughout the intervention period 
(SUPPLEMENTARY FIGURE 1). However, metformin rapidly reduced both plasma TC (227 and 
236% at weeks 2 and 4, respectively; P < 0.05) and TGs (226 and 238% at weeks 2 and 4, 
respectively; P < 0.05) in a time-dependent manner (FIGURES 1A and C). Plasma lipoprotein 
profile analysis showed that this lipidlowering effect mostly resulted from a reduction of 
VLDL particles. In addition, a slight shift in plasma cholesterol profile, from VLDL-C to HDL-C 
(237 and +37%, respectively), was evidenced (FIGURES 1B and D).
FIGURE 1 - Effect of metformin on plasma cholesterol and TG levels and lipoprotein distribution. Blood 
 samples from 4 h–fasted control (black bars) and metformin-treated (open bars) mice were collected by tail 
bleeding using chilled paraoxon-coated capillaries at different time points. Plasma TC A  and TGs C  levels 
were determined. The plasma samples collected after 4 weeks of treatment were pooled groupwise and size 
fractionated by fast protein liquid chromatography. The individual fractions were analyzed for cholesterol B  
and TGs D . Data are means ± SEM (n = 9 per group). 
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Metformin Does Not Affect Hepatic VLDL-TG Production 
Plasma VLDL-TG levels are determined by the balance between VLDL-TG production by the 
liver and VLDL-TG clearance by peripheral organs. Therefore, we first assessed the effect of 
metformin on hepatic VLDL-TG and -apoB production by injecting Trans35S and tyloxapol in 
4 h–fasted control and metformin-treated E3L.CETP mice. Despite the significantly lower 
basal plasma TG levels (1.72 ± 0.26 vs. 2.65 ± 0.36 mmol/L, P < 0.05; data not shown), met-
formin did not affect the time-dependent accumulation of plasma TG after tyloxapol injection 
when compared with control E3L.CETP mice (FIGURE 2A). Therefore, the VLDL-TG production 
FIGURE 2 - Effect of metformin on hepatic VLDL-TG production. After 4 weeks of treatment, 4 h–fasted control 
(black squares/bars) and metformin-treated mice (open squares/bars) were injected with Trans35S label 
(t = –30 min) and tyloxapol (t = 0 min), and blood samples were drawn up to 90 min after tyloxapol injection. 
Plasma TG concentrations were determined and plotted as the increase in plasma TG as compared with 
 baseline A . The rate of TG production was calculated from the slopes of the curves from the individual mice 
( A , inset). After 120 min, mice were exsanguinated and the total VLDL fraction was isolated by ultracentrifu-
gation. The rate of newly synthesized VLDL-35S-apoB B , the TG-to–35S-apoB ratio C , as well as the amount of 
TGs, TC, and PLs per mg VLDL protein D  were measured. Data are means ± SEM (n = 5–8 per group).


















































































































0 30 60 90
Proefschrift_MB.indb   103 05-05-14   11:58
6
104 
rate, calculated from the slope of the curve, was not significantly different (FIGURE 2A, inserted 
panel), although a trend for a slight decrease can eventually be suggested. The rate of VLDL-
apoB production (FIGURE 2B), the ratio of TG-apoB (FIGURE 2C), as well as the composition of 
the VLDL particles secreted (FIGURE 2D) were not significantly altered, indicating that met-
formin did not affect the hepatic lipidation of VLDL particles. In line with these results, the 
TG, TC, and PL content in the liver from E3L.CETP mice did not significantly differ between 
the control and metformin groups, although hepatic TC content tended to be decreased in 
the metformin-treated group (221%, P = 0.07) (SUPPLEMENTARY FIGURE 2). Furthermore, in our 
experimental con ditions, metformin treatment did not affect hepatic AMPK activity, as 
FIGURE 3 - Effect of metformin on peripheral VLDL-TG clearance and BAT. Four hour–fasted control (black bars) 
and metformin-treated (open bars) mice were continuously infused with [3H]TG-labeled VLDL-like emulsion 
particles mixed with albumin-bound [14C]FA for 2.5 h. Blood samples were taken using chilled paraoxon-coated 
capillaries by tail bleeding at 90 and 120 min of infusion to ensure that steadystate conditions had been 
reached. Subsequently, mice were killed and organs were quickly harvested and snap frozen in liquid nitrogen. 
Plasma levels of TGs and FAs were determined in plasma, and uptake of the radioactively [3H]TG-labeled 
emulsion particles A  and albumin-bound [14C]FA B  was determined in the organs. In separate experiments, 
BAT from control and metformin-treated mice were collected and weighed C . Hematoxylin and eosin staining 
of BAT sections was performed, and representative pictures are shown D . Relative content of lipid vacuoles in 
BAT tissue sections (n = 3–4 per group) were quantified E . mRNA F  and protein G  expression of UCP1 were 
determined by qRT-PCR and Western blot, respectively. Data are means ± SEM (n = 7–8 per group). 
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FIGURE 4 - Effect of metformin on AMPK expression, activity, and downstream signaling in BAT. BAT from 
4 h–fasted mice was collected after 4 weeks of treatment with (open bars) or without metformin (control, 
black bars) and immediately snap frozen in liquid nitrogen. The protein expression of OCT1, AMPK1, and 
AMPK2 was determined by Western blot in BAT from control mice A . AMPK activity was measured by kinase 
assay after immunoprecipitation of either AMPK1 or -2 catalytic subunits with specific antibodies B . 
Adenine nucleotide concentrations in BAT were measured by high-performance liquid chromatography, and 
the AMP-to-ATP ratio was calculated C . The protein expression of BAT AMPK catalytic () and regulatory 
(ß and γ) subunits, ACC, and the phosphorylation states of Thr172- AMPK and Ser79-ACC were assessed by 
Western blot D , followed by densitometric quantification E-G . Tubulin expression was used as internal 
housekeeping protein. Data are means ± SEM (n = 8 per group). 
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assessed by phosphorylation of Thr172-AMPK and Ser79-acetyl-CoA carboxylase (ACC), the 
main downstream target of AMPK (SUPPLEMENTARY FIGURE 2). Finally, we found that hepatic 
expression of key genes involved in FA/TG uptake, synthesis, and oxidation were not affected, 
whereas Lrp1 and Scarp1, both involved in cholesterol uptake, were significantly downregu-
lated by metformin (SUPPLEMENTARY TABLE 1). In addition, the expression of Abca1, Lcat, and 
Pltp was also found to be significantly downregulated by metformin, suggesting that part 
of the HDL-enhancing effect of the drug could result from subtle changes in hepatic lipo-
protein metabolism. 
Metformin Promotes VLDL-TG Clearance by BAT and Influences BAT Mass and Composition 
As clearance of TG from plasma is the other major determinant of TG metabolism, the effect 
of metformin on whole-body lipid partitioning was investigated next. For this purpose, the 
tissue-specific retention of FA derived from both [3H]TG-labeled VLDL-like emulsion particles 
and albumin-bound [14C]FA was determined after continuous tracer infusion for 2.5 h. 
Strikingly, metformin did not affect the uptake of [3H]TG-derived FA by liver, heart, skeletal 
FIGURE 5 - Effect of metformin on expression of key lipolytic and mitochondrial proteins in BAT. BAT was 
 collected in control (black bars) and metformin-treated (open bars) mice, as described in FIGURE 4. The protein 
expression of HSL, ATGL, ADRP, eNOS, PGC-1, and CS and of various mitochondrial respiratory chain subunits 
(C1, NDUFB8; C2, SDHB; C3, UQCRC2; C4, MTCO1 and COX4l1; C5, ATP5A) was assessed by Western blot A , 
 followed by densitometric quantification B-E . Tubulin expression was used as internal housekeeping protein. 
The ratio of mitochondrial respiratory chain complex 2 to complex 1 was calculated F . Data are means ± SEM 
(n = 8 per group). 






























































































































Proefschrift_MB.indb   106 05-05-14   11:58
6
METFORMIN PROMOTES VLDL-TG CLEARANCE BY BAT
107 
muscle, and various WAT depots but markedly increased 3H retention in BAT (+58%, P < 0.05) 
(FIGURE 3A). The uptake of albumin-bound [14C]FA was not different for any of the organs 
 studied (FIGURE 3B), suggesting that metformin does not affect FA uptake per se but rather 
 promotes lipoprotein lipase (LPL)–mediated VLDL-TG hydrolysis in BAT. Interestingly, BAT 
mass (–29%) and intracellular lipid droplet content (–91%) were found to be reduced in 
 metformin-treated mice (FIGURES 3C–E), both pointing toward more active BAT (27). However, 
 neither UCP1 mRNA expression nor protein content was significantly affected (FIGURES 3F and G).
Metformin Increases AMPK Activity, Lipolytic Machinery, and Mitochondrial Content in BAT 
To further investigate the molecular mechanism by which metformin increased VLDL-TG 
clearance by BAT, we first showed that the organic cation transporter 1 (OCT1), which is 
 crucial for intracellular transport of metformin (28), was expressed in BAT at both transcript 
(data not shown) and protein levels (FIGURE 4A). We next determined the mRNA expression 
of genes involved in FA/lipoprotein uptake, FA metabolism, mitochondrial functions, and 
BAT differentiation but did not find any significant effect of metformin treatment in our 
FIGURE 6 - Effect of metformin on AMPK signaling and lipolysis in T37i brown adipocytes. T37i cells were 
 cultured and differentiated in brown adipocytes as described in RESEARCH DESIGN AND METHODS and next 
treated with increasing concentrations of metformin for 8 h. The protein expression and phosphorylation 
states of AMPK, ACC, and HSL on various residues were assessed by Western blot A  and the phospho- to-
total ratios were calculated after densitometric quantification B-F . Tubulin expression was used as internal 
housekeeping protein. The lipolysis rate was assessed by measuring the time-dependent accumulation of 
glycerol in the culture medium G  and expressed as μmol/h/mg protein. Data are means ± SEM (n = 3).
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FIGURE 7 - Proposed mechanism for the BAT-mediated TG-lowering effect of metformin. Metformin exerts a 
beneficial effect on circulating lipids by lowering plasma TG, through a selective increase in TG-derived FA 
uptake by BAT. In addition, metformin also improves intracellular lipolytic capacity by increasing HSL expres-
sion and activity, thereby enhancing FA release from TG stored in lipid droplets. We propose that metformin 
next promotes FA oxidation in BAT by multiple (path)ways. First, metformin activates AMPK, leading to the 
subsequent phosphorylation and inactivation of its downstream target ACC. This relieves the inhibition 
exerted by malonyl-CoA on CPT1, ultimately promoting mitochondrial FA transport and oxidation. Second, 
metformin increases the tissue mitochondrial content, an effect that might be due to AMPK-mediated stimu-
lation of mitochondrial biogenesis, as reflected by higher expression of eNOS and PGC-1. Finally, by changing 
the qualitative composition of the mitochondrial respiratory chain, metformin can enhance respiratory chain 
complex 2–mediated FA oxidation and UCP1-independent metabolic uncoupling of oxidative phosphorylation.
Metformin
Brown adipose tissue
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expe rimental condition (SUPPLEMENTARY TABLE 1). We confirmed that BAT mostly expressed 
AMPK1 (FIGURE 4A), as previously reported (29,30). Interestingly, we found that metformin 
selectively increased the activity of 1- (+19%, P < 0.05) but not of 2-containing AMPK 
 heterotrimers in BAT (FIGURE 4B) without affecting the whole-tissue energy state, as assessed 
by the AMP-ATP ratio (FIGURE 4C). This was associated with a significant increase in both Thr172 
phosphorylation (+21%, P < 0.05) and expression of the AMPK catalytic subunits (+21%, 
P < 0.05), whereas the phospho-to-total ratio was not affected (FIGURES 4D–F). However, a trend 
for increased phosphorylation of the AMPK downstream target ACC was evidenced (+22%, 
P = 0.07) (FIGURES 4D–F). The only AMPK subunit significantly increased by metformin was the 1 
isoform (+38%, P < 0.05), whereas the other subunits were not affected (FIGURE 4G), suggesting 
that the higher AMPK activity in BAT from metformin-treated mice was mostly due to an 
increase in AMPK1 content. We next examined whether some of the key players involved 
in the regulation of TG lipolysis and FA oxidation in BAT were affected by metformin. 
Interestingly, the protein expression of the lipolytic enzyme HSL, but not that of adipose 
TG lipase (ATGL) and adipose differentiation– related protein (ADRP), was significantly 
increased by metformin in BAT (+30%, P < 0.05) (FIGURES 5A and B). In addition, although the 
 mitochondrial DNA content was not affected (data not shown), we found a marked increase 
in protein expression of two of the main regulators of mitochondrial biogenesis, endothelial 
nitric oxide synthase (eNOS) and PGC-1 (+23 and +127%, respectively; P < 0.05), together 
with a significantly higher content of citrate synthase (CS) and of most of the mitochondrial 
electron transport chain complexes in BAT from metformin-treated E3L.CETP mice (FIGURES 
5A and C–E). Of note, the ratio of mitochondrial respiratory chain complex 2 to complex 1 
expression was also increased by metformin in BAT (+17%, P < 0.05) (FIGURE 5F). 
Metformin Induces AMPK Activation and Lipolysis in T37i Brown Adipocytes 
To investigate whether metformin can directly affect AMPK activity and lipid metabolism in 
BAT, we used T37i cells, a well-established in vitro model of differentiated brown adipocytes (26). 
Interestingly, we showed that therapeutic concentrations of metformin dose-dependently 
increased phosphorylation states of AMPK, ACC, and HSL (FIGURES 6A–F), as well as glycerol 
release into the medium, pointing toward enhanced intracellular lipolysis (FIGURE 6G). Taken 
together, our results show that metformin not only promotes VLDL-TG uptake by BAT but 
also enhances both intracellular lipolytic and mitochondrial FA ß-oxidation capacity in this 
tissue (FIGURE 7). 
DISCUSSION 
Metformin not only improves glycemic control in type 2 diabetic patients but also exerts 
beneficial effects on plasma lipid profiles (4) by a mechanism that has remained, so far, 
poorly understood. In the current study, we have therefore investigated the molecular 
mechanism(s) underlying this lipid-lowering property of metformin using E3L.CETP mice, a 
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well-characterized transgenic model displaying a human-like lipoprotein metabolism and 
human-like responses to lipid-modulating drugs when fed a Western-type diet (19–23). Our 
results show that chronic treatment of E3L.CETP mice with metformin recapitulates the 
effects on circulating lipoproteins observed in patients treated with the drug, i.e., reduction 
in plasma TG associated with significant reduction in VLDL (31). We next demonstrated that 
metformin does not affect hepatic VLDL-TG production but instead selectively promotes 
VLDL-TG clearance by BAT, an effect associated with elevated components of intracellular 
lipolytic and mitochondrial FA oxidation machinery in this highly active metabolic tissue. To 
the best of our knowledge, this study is the first one reporting that BAT is involved in the 
lipid-lowering effect of metformin, and therefore constitutes an important target tissue for 
the drug.
Plasma TG levels are determined by the balance between production of chylomicron-TG 
and VLDL-TG in intestine and liver, respectively, and their LPL-mediated TG clearance in 
peripheral tissues. In our study, all the experiments were performed in fasted mice, thereby 
excluding any significant contribution of intestine-derived chylomicrons to the change 
observed in circulating TG concentrations. Furthermore, metformin treatment did not affect 
the postprandial response to an oral lipid load (SUPPLEMENTARY FIGURE 3), suggesting that 
impaired intestinal TG absorption is not involved in the TG-lowering effect of the drug. 
Besides its central role in glucose homeostasis, the liver plays a key role in lipid metabolism, 
notably by regulating synthesis and secretion of apoB-containing VLDL-TG particles (32). 
Hepatic VLDLTG production is mostly driven by intracellular substrate availability resulting 
from both FA uptake from the circulation and the balance between de novo lipogenesis and 
mitochondrial FA ß-oxidation in the liver (33). In our study, we found that metformin did not 
significantly affect plasma FA levels; hepatic lipid content; AMPK activity; expression of 
genes involved in FA/TG uptake, synthesis, and oxidation; VLDL-TG and VLDL-apoB secretion 
rates; and composition of the excreted VLDL particles. Although we did not find an apparent 
contribution of the liver to the TG-reducing effect of metformin, we cannot completely 
exclude that some of its hepatic effects were lowered or masked due to our experimental 
conditions, e.g., fasting state, and the pharmacokinetic features of the drug. Of note, we 
found that expression of some genes involved in hepatic HDL uptake (Lrp1 and Scarb1) and 
remodeling (Abca1 and Pltp) was decreased by metformin, suggesting that part of the mild 
HDL-raising effect of the drug might be partly due to subtle changes in cholesterol metabo-
lism in the liver. Future studies are required for clarifying the exact underlying molecular 
mechanism. 
Plasma VLDL-TG clearance is driven by LPL-mediated lipolysis in the capillaries of periph-
eral tissues (34). The most striking result of our present study was that metformin induced a 
potent and selective increase in VLDLglycerol tri[3H]oleate-derived [3H]oleate retention in 
BAT without affecting VLDL-TG uptake by heart, muscle, and various white adipose tissues. 
Recently, Bartelt et al. (35) were the first to identify BAT as a major organ involved in plasma 
VLDL-TG clearance in rodents. In this elegant study confirming previous observations (36), 
they reported that BAT constitutes a quantitatively relevant lipid-clearing organ displaying 
very high rates of VLDL-TG uptake (35) by a mechanism that still remains to be fully charac-
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terized. In the current study, our observation that metformin promotes VLDL-[3H]TG– 
derived FA but not albumin-bound [14C]FA retention in BAT suggests that the TG-lowering 
effect of the drug is mediated by a tissue-specific increase in LPL-mediated VLDL-TG hydroly-
sis with subsequent retention of the liberated FA in BAT. At the molecular level, it remains 
to be clarified whether increases in endothelial LPL expression and/or subtle changes in 
apolipoproteins and angiopoietin-like proteins regulating local LPL activity (37) are involved 
in the BAT-specific VLDL-derived TG hydrolysis induced by metformin. 
Owing to its high mitochondrial and oxidative enzyme content, BAT has a marked ability 
to oxidize both glucose and FA, the latter being derived from either LPL-mediated hydrolysis 
of VLDL-TG or intracellular TG that is stored in lipid droplets. Once released, FAs are rapidly 
reesterified in TG or directed to mitochondria for oxidation or activation of UCP1, leading to 
dissipation of the proton gradient across the inner mitochondrial membrane and heat 
 production (38). At the molecular level, we found that metformin, both in vivo and in vitro, 
increased AMPK activity and Ser79-ACC phosphorylation, an effect that is expected to 
 promote mitochondrial FA transport and oxidation by relieving the inhibition of CPT1 by 
malonyl-CoA (9). AMPK activation is known to trigger mitochondrial biogenesis, at least in 
skeletal muscle (39) and liver (40). Interestingly, the expression of key proteins of the mito-
chondrial respiratory chain complexes and CS was increased by metformin in BAT, indicating 
enhanced mitochondrial content in this tissue. Mechanistically, the expression of PGC-1 
and eNOS, which are both recognized as important regulators of mitochondrial biogenesis 
(41,42), were found to be higher in BAT from metformin-treated mice, suggesting activation of 
the AMPK-PGC1-eNOS pathway by metformin in this tissue. Finally, we found that metformin 
affected the qualitative composition of the mitochondrial respiratory chain in BAT, leading to 
an increase in complex 2 relative to complex 1. This effect might also contribute to enhanced 
FA oxidation by promoting electron supply to the respiratory chain complex 2. Interestingly, 
modulating the ratio of FADH2 to NADH oxidation will also affect the stoichiometry of oxi-
dative phosphorylation and promote UCP1-independent metabolic uncoupling, with the 
yield of ATP synthesis being lowered by ~40% when FADH2 is oxidized as compared with 
NADH (43). Taken together, we propose that secondary to its tissue-specific increase in VLDL-
TG uptake, metformin promotes FA oxidation in BAT by enhancing both intracellular lipolytic 
capacity and mitochondrial oxidative machinery. It is important to underline that we do not 
exclude that another AMPKindependent mechanism(s) in BAT might also contribute to the 
TG-lowering effect of metformin in vivo.
The recent discovery of metabolically active BAT in adult humans (44–46) has caused a 
revival interest in this potential new therapeutic target for the treatment of obesity and 
metabolic disorders (47,48). Although the precise role of BAT in TG metabolism remains to 
be established, it has been recently shown that FA uptake and oxidation in BAT significantly 
contributes to energy expenditure in humans (49). Thus, it is tempting to speculate that 
part of the weight-lowering property of metformin might be secondary to enhanced lipid 
oxidation and energy dissipation in BAT. Further studies allowing imaging of lipid metabolism 
in BAT from metformin- treated patients, for instance using 18F-labeled FA incorporated into 
VLDL-TG coupled to position emission tomography scanning (50), would be crucial to 
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 specifically address this point. 
In summary, we show that metformin exerts a beneficial effect on circulating lipids by 
lowering plasma TG, through a selective BAT-mediated increase in VLDL-TG uptake/lipolysis 
(FIGURE 7). The current study is the first identifying BAT as a new important mechanistic play-
er in the lipid-lowering action of metformin, suggesting that targeting this tissue, on top of 
being interesting for body weight management, might also be of therapeutic importance in 
the treatment of dyslipidemia.
ACKNOWLEDGMENTS
The authors are grateful to Elsbet Pieterman, Chris van der Bent, Linda Switzar, and Amanda 
Pronk (Leiden University Medical Center) for their valuable technical assistance.
Proefschrift_MB.indb   112 05-05-14   11:58
6
METFORMIN PROMOTES VLDL-TG CLEARANCE BY BAT
113 
REFERENCES
1  Goodarzi MO, Bryer-Ash M. Metformin revisited: 
re-evaluation of its properties and role in the 
pharmacopoeia of modern antidiabetic agents. 
Diabetes Obes Metab 2005;7:654–665.
2  Nathan DM, Buse JB, Davidson MB, et al.; 
American Diabetes Association; European 
Association for the Study of Diabetes. Medical 
management of hyperglycaemia in type 2 
diabetes mellitus: a consensus algorithm for 
the initiation and adjustment of therapy:  
a consensus statement from the American 
Diabetes Association and the European 
Association for the Study of Diabetes. 
Diabetologia 2009;52:17–30.
3  Natali A, Ferrannini E. Effects of metformin and 
thiazolidinediones on suppression of hepatic 
glucose production and stimulation of glucose 
uptake in type 2 diabetes: a systematic review. 
Diabetologia 2006;49:434–441.
4  Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. 
Meta-analysis: metformin treatment in 
persons at risk for diabetes mellitus. Am J Med 
2008;121: 149–157.e2.
5  UK Prospective Diabetes Study (UKPDS) Group. 
Effect of intensive bloodglucose control with 
metformin on complications in overweight 
patients with type 2 diabetes (UKPDS 34). 
Lancet 1998a;352:854–865.
6  Viollet B, Guigas B, Sanz Garcia N, Leclerc J, 
Foretz M, Andreelli F. Cellular and molecular 
mechanisms of metformin: an overview.  
Clin Sci (Lond) 2012;122:253–270.
7  Zhou G, Myers R, Li Y, et al. Role of  
AMP-activated protein kinase in mechanism of 
metformin action. J Clin Invest 2001; 
108:1167–1174.
8  Carling D, Thornton C, Woods A, Sanders MJ. 
AMP-activated protein kinase: new regulation, 
new roles? Biochem J 2012;445:11–27.
9  Hardie DG, Ross FA, Hawley SA. AMPK: a 
nutrient and energy sensor that maintains 
energy homeostasis. Nat Rev Mol Cell Biol 
2012;13:251–262.
10  El-Mir MY, Nogueira V, Fontaine E, Avéret N, 
Rigoulet M, Leverve X. Dimethylbiguanide 
inhibits cell respiration via an indirect effect 
targeted on the respiratory chain complex I. 
J Biol Chem 2000;275:223–228.
11  Owen MR, Doran E, Halestrap AP. Evidence that 
metformin exerts its antidiabetic effects 
through inhibition of complex 1 of the 
mitochondrial respiratory chain. Biochem J 
2000;348:607–614.
12  Hawley SA, Ross FA, Chevtzoff C, et al. Use of 
cells expressing gamma subunit variants to 
identify diverse mechanisms of AMPK 
activation. Cell Metab 2010;11:554–565.
13  Stephenne X, Foretz M, Taleux N, et al. 
Metformin activates AMP-activated protein 
kinase in primary human hepatocytes by 
decreasing cellular energy status. Diabetologia 
2011;54:3101–3110.
14  Guigas B, Bertrand L, Taleux N, et al. 
5-Aminoimidazole-4-carboxamide-1-beta-D-
ribofuranoside and metformin inhibit hepatic 
glucose phosphorylation by an AMP-activated 
protein kinase-independent effect on 
glucokinase translocation. Diabetes 
2006;55:865–874.
15  Foretz M, Hébrard S, Leclerc J, et al. Metformin 
inhibits hepatic gluconeogenesis in mice 
independently of the LKB1/AMPK pathway via a 
decrease in hepatic energy state. J Clin Invest 
2010;120:2355–2369.
16  Shaw RJ, Lamia KA, Vasquez D, et al. The kinase 
LKB1 mediates glucose homeostasis in liver and 
therapeutic effects of metformin. Science 2005; 
310:1642–1646.
17  Kalender A, Selvaraj A, Kim SY, et al. Metformin, 
independent of AMPK, inhibits mTORC1 in a rag 
GTPase-dependent manner. Cell Metab 2010;11: 
390–401.
18  Miller RA, Chu Q, Xie J, Foretz M, Viollet B, 
Birnbaum MJ. Biguanides suppress hepatic 
glucagon signalling by decreasing production 
of cyclic AMP. Nature 2013;494:256–260.
Proefschrift_MB.indb   113 05-05-14   11:58
6
114 
19  Westerterp M, van der Hoogt CC, de Haan W,  
et al. Cholesteryl ester transfer protein 
decreases high-density lipoprotein and severely 
aggravates atherosclerosis in APOE*3-Leiden 
mice. Arterioscler Thromb Vasc Biol 
2006;26:2552–2559.
20  Bijland S, Pieterman EJ, Maas AC, et al. 
Fenofibrate increases very low density 
lipoprotein triglyceride production despite 
reducing plasma triglyceride levels in  
APOE*3-Leiden.CETP mice. J Biol Chem 2010; 
285: 25168–25175.
21  Bijland S, van den Berg SA, Voshol PJ, et al.  
CETP does not affect triglyceride production or 
clearance in APOE*3-Leiden mice. J Lipid Res 
2010;51:97–102.
22  de Haan W, van der Hoogt CC, Westerterp M,  
et al. Atorvastatin increases HDL cholesterol by 
reducing CETP expression in cholesterol-fed 
APOE*3-Leiden.CETP mice. Atherosclerosis 
2008;197:57–63
23  van der Hoorn JW, de Haan W, Berbée JF, et al. 
Niacin increases HDL by reducing hepatic 
expression and plasma levels of cholesteryl 
ester transfer protein in APOE*3Leiden.CETP 
mice. Arterioscler Thromb Vasc Biol 2008; 
28:2016–2022.
24  Coomans CP, Geerling JJ, Guigas B, et al. 
Circulating insulin stimulates fatty acid 
retention in white adipose tissue via KATP 
channel activation in the central nervous 
system only in insulin-sensitive mice.  
J Lipid Res 2011;52:1712–1722.
25  Teusink B, Voshol PJ, Dahlmans VE, et al. 
Contribution of fatty acids released from 
lipolysis of plasma triglycerides to total plasma 
fatty acid flux and tissue-specific fatty acid 
uptake. Diabetes 2003;52:614–620.
26  Zennaro MC, Le Menuet D, Viengchareun S, 
Walker F, Ricquier D, Lombès M. Hibernoma 
development in transgenic mice identifies 
brown adipose tissue as a novel target of 
aldosterone action. J Clin Invest 1998;  
101:1254–1260.
27  Ortega-Molina A, Efeyan A, Lopez-Guadamillas 
E, et al. Pten positively regulates brown adipose 
function, energy expenditure, and longevity. 
Cell Metab 2012;15:382–394.
28  Shu Y, Sheardown SA, Brown C, et al.  
Effect of genetic variation in the organic cation 
transporter 1 (OCT1) on metformin action.  
J Clin Invest 2007;117:1422–1431.
29  Pulinilkunnil T, He H, Kong D, et al. Adrenergic 
regulation of AMP-activated protein kinase in 
brown adipose tissue in vivo. J Biol Chem 
2011;286: 8798–8809.
30  Mulligan JD, Gonzalez AA, Stewart AM, Carey 
HV, Saupe KW. Upregulation of AMPK during 
cold exposure occurs via distinct mechanisms 
in brown and white adipose tissue of the 
mouse. J Physiol 2007;580:677–684.
31  Jonker JT, Wang Y, de Haan W, et al. Pioglitazone 
decreases plasma cholesteryl ester transfer 
protein mass, associated with a decrease in 
hepatic triglyceride content, in patients with 
type 2 diabetes. Diabetes Care 2010; 
33:1625–1628.
32  Xiao C, Hsieh J, Adeli K, Lewis GF. Gut-liver 
interaction in triglyceride-rich lipoprotein 
metabolism. Am J Physiol Endocrinol Metab 
2011;301:E429–E446.
33  Nielsen S, Karpe F. Determinants of  
VLDL-triglycerides production.  
Curr Opin Lipidol 2012;23:321–326.
34  Dallinga-Thie GM, Franssen R, Mooij HL, et al. 
The metabolism of triglyceride-rich 
lipoproteins revisited: new players, new insight. 
Atherosclerosis 2010;211:1–8.
35  Bartelt A, Bruns OT, Reimer R, et al. Brown 
adipose tissue activity controls triglyceride 
clearance. Nat Med 2011;17:200–205.
36  Hagberg CE, Falkevall A, Wang X, et al.  
Vascular endothelial growth factor B controls 
endothelial fatty acid uptake. Nature 
2010;464:917–921.
37  Davies BS, Beigneux AP, Fong LG, Young SG.  
New wrinkles in lipoprotein lipase biology.  
Curr Opin Lipidol 2012;23:35–42.
Proefschrift_MB.indb   114 05-05-14   11:58
6
METFORMIN PROMOTES VLDL-TG CLEARANCE BY BAT
115 
38  Festuccia WT, Blanchard PG, Deshaies Y.  
Control of brown adipose tissue glucose and 
lipid metabolism by PPARg. Front Endocrinol 
(Lausanne) 2011;2:84.
39  Zong H, Ren JM, Young LH, et al. AMP kinase is 
required for mitochondrial biogenesis in 
skeletal muscle in response to chronic energy 
deprivation. Proc Natl Acad Sci USA 
2002;99:15983–15987.
40  Guigas B, Taleux N, Foretz M, et al.  
AMP-activated protein kinase-independent 
inhibition of hepatic mitochondrial oxidative 
phosphorylation by AICA riboside. Biochem J 
2007;404:499–507.
41  Jornayvaz FR, Shulman GI. Regulation of 
mitochondrial biogenesis. Essays Biochem 
2010;47:69–84.
42  Lira VA, Brown DL, Lira AK, et al. Nitric oxide and 
AMPK cooperatively regulate PGC-1 in skeletal 
muscle cells. J Physiol 2010;588:3551–3566.
43  Leverve XM, Taleux N, Favier R, et al. Cellular 
energy metabolism and integrated oxidative 
phosphorylation. In Molecular System 
Bioenergetics: Energy for Life. Saks V, Ed. 
Weinheim, WILEY-VCH Verlag GmbH & Co., 
2007, p. 11–27.
44  Cypess AM, Lehman S, Williams G, et al. 
Identification and importance of brown 
adipose tissue in adult humans. N Engl J Med 
2009;360:1509–1517.
45  van Marken Lichtenbelt WD, Vanhommerig JW, 
Smulders NM, et al. Coldactivated brown 
adipose tissue in healthy men. N Engl J Med 
2009;360: 1500–1508.
46  Virtanen KA, Lidell ME, Orava J, et al. Functional 
brown adipose tissue in healthy adults.  
N Engl J Med 2009;360:1518–1525.
47  Ravussin E, Galgani JE. The implication of brown 
adipose tissue for humans. Annu Rev Nutr 
2011;31:33–47.
48  Seale P, Kajimura S, Spiegelman BM. 
Transcriptional control of brown adipocyte 
development and physiological function—of 
mice and men. Genes Dev 2009;23:788–797.
49  Ouellet V, Labbé SM, Blondin DP, et al.  
Brown adipose tissue oxidative metabolism 
contributes to energy expenditure during acute 
cold exposure in humans. J Clin Invest 
2012;122:545–552.
50  Labbé SM, Grenier-Larouche T, Croteau E, et al. 
Organ-specific dietary fatty acid uptake in 
humans using positron emission tomography 
coupled to computed tomography. Am J Physiol 
Endocrinol Metab 2011;300:E445–E453.




Primary antibody Residue Supplier Reference Dilution
ACC - Cell Signaling #3662 1:2000
ACC Ser79 Cell Signaling #3661 1:2000
ADRP - AbCam Ab108323 1:1000
AMPK - Cell Signaling #2532 1:1000
AMPK Thr172 Cell Signaling #2535 1:1000
AMPK1 - Kinasource AB-140 1:2500
AMPK2 - Kinasource AB-141 1:2500
ATGL - Cell Signaling #2439 1:1250
ATP5A (C5) - AbCam ab110413 1:1000
COX4l1 (C4) - Aviva Systems Biology ARP42784 1:500
CS - AbCam Ab96600 1:1000
HSL - Cell Signaling #4107 1:2000
HSL Ser563 Cell Signaling #4139 1:2000
HSL Ser565 Cell Signaling #4137 1:1000
HSL Ser660 Cell Signaling #4126 1:1000
MTCO1 (C4) - AbCam ab110413 1:1000
NDUFB8 (C1) - AbCam ab110413 1:1000
eNOS (NOS3) - Santa Cruz sc-654 1:1000
OCT1 - Santa Cruz sc-133866 1:500
PGC1 - AbCam ab54481 1:1000
UCP1 - Sigma U6382 1:2500
UQCRC2 (C3) - AbCam ab110413 1:1000
SDHB (C2) - AbCam ab110413 1:1000
Tubulin - Cell Signaling #2148 1:2000
Gene Accession number Forward primer Reverse primer
Abca1 NM_013454.3 CCCAGAGCAAAAAGCGACTC GGTCATCATCACTTTGGTCCTTG
Abcg5 NM_031884 TGTCCTACAGCGTCAGCAACC GGCCACTCTCGATGTACAAGG
Abcg8 NM_026180 TCCTGTGAGCTGGGCATCCGA CCCGCAGCCTGAGCTCCCTAT
Acaca NM_133360.2 CAGCTGGTGCAGAGGTACCG TCTACTCGCAGGTACTGCCG
Acacb NM_133904.2 GCGCCTACTATGAGGCCCAGCA ACAAACTCGGCTGGGGACGC
Acly NM_134037.2 TGTGGACGGCTTCATCGGCG ATGTCATCCCAGGGGTGACG
Acox1 NM_015729 GGGACCCACAAGCCTCTGCCA GTGCCGTCAGGCTTCACCTGG
Apoa1 NM_009692 TGCGGTCAAAGACAGCGGCA AGATTCAGGTTCAGCTGTTGGCCC
Apob NM_009693 CAGCTGCAAGTGTCCTCGTC GACACAGAGGGCTTTGCCAC
SUPPLEMENTARY TABLE 1 - Primary antibodies for Western blots
SUPPLEMENTARY TABLE 2 - Primer sequences for qRT-PCR
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Gene Accession number Forward primer Reverse primer
Atp5a1 NM_007505.2 CCAAGCAGGCTGTCGCTTACCG TCTCCAGCAGGCGGGAGTGT
Cd36 NM_001159558 GCAAAGAACAGCAGCAAAATC CAGTGAAGGCTCAAAGATGG
Cidea NM_007702 CTCGGCTGTCTCAATGTCAA CCGCATAGACCAGGAACTGT
Cidec NM_178373 CCATCAGAACAGCGCAAGAAG AGAGGGTTGCCTTCACGTTC
Cox7a1 NM_009944.3 AAAACCGTGTGGCAGAGAAG CCAGCCCAAGCAGTATAAGC
Cpt1a NM_013495 AGGAGACAAGAACCCCAACA AAGGAATGCAGGTCCACATC
Creb1 NM_133828 AGCTGCCACTCAGCCGGGTA TCGCCTGAGGCAGCTTGAACA
Cs NM_026444.3 GCTAAGTACTGGGAGCTCATCTAT GCCTAGAGTCAATGGCTCCG
Dgat1 NM_010046.2 CTAGTGAGCGTTCCCCTGCG GGGCATCGTAGTTGAGCACG
Dio2 NM_010050 CGCTCCAAGTCCACTCGCGG CGGCCCCATCAGCGGTCTTC
Fabp1 NM_017399.4 GCCACCATGAACTTCTCCGGCA GGTCCTCGGGCAGACCTATTGC
Fasn NM_007988 CACAGGCATCAATGTCAACC TTTGGGAAGTCCTCAGCAAC
Fdft1 NM_010191.2 CCAACTCAATGGGTCTGTTCCT TGGCTTAGCAAAGTCTTCCAACT
Fdps NM_134469.4 ATGGAGATGGGCGAGTTCTTC CCGACCTTTCCCGTCACA
Gpam NM_008149.3 TCATACCCGTGGGCATCTCG AATCCACTCGGACGTAGCCG
Gpihbp1 NM_026730 AGTGGACAGCCAGGGAGTGGC GCTCTCCCCGCTGTGAAGCAC
Hmgcr NM_008255 CTTGTGGAATGCCTTGTGATTG AGCCGAAGCAGCACATGAT
Hmgcs1 NM_145942.4 GGACTGGAAGCCTTTGGGGACG TGCCAGGACAGAAGCCAGGGA
Hmgcs2 NM_008256.4 CATCGCAGGAAGTATGCCCG GCTGTTTGGGTAGCAGCTCG
Idi1 NM_145360.2 TGGGAATACCCTTGGAAGAGGTTGA CCCCAGATACCATCAGATTGGGCCT
Lcat NM_008490.2 GGCAAGACCGAATCTGTTGAG ACCAGATTCTGCACCAGTGTGT
Ldlr NM_010700 GCATCAGCTTGGACAAGGTGT GGGAACAGCCACCATTGTTG
Lipe NM_010719 AGCCTCATGGACCCTCTTCT GCCTAGTGCCTTCTGGTCTG
Lpl NM_008509 CAGGGGGTCACCTGGTCGAAGT AGCTGGTCCACGTCTCCGAGT
Lrp1 NM_008512 GGAACTCCAGTCGCTGCAAC TAGCACAGGGATGTCCGCTC
Mttp NM_008642 GCCTGTGGCTTTGCCACCCA TCCACCACTGCCTTGAGCTTGC
ND1 NP_904328.1 CTACAACCATTTGCAGACGC GGAACTCATAGACTTAATGC
Ndufb8 NM_026061.2 GAGGCACGGAGAGCCTTCCA GGGAGCATCGGGTAGTCGCC
Nr1h3 NM_013839.4 CTGCACGCCTACGTCTCCAT AAGTACGGAGGCTCACCAGCT
Pltp NM_011125.2 GGCCGTCTCAGTGCTAAGTT CGAAGTTGATACCCTCAGGAA
Pnpla2 NM_001163689 TTCGCAATCTCTACCGCCTC TGGTTCAGTAGGCCATTCCTC
Plin2 NM_007408.3 CAGGATGGAGGAAAGACTGC CTTATCCACCACCCCTGAGA
Plin4 NM_020568.3 TGCCCCCTCATCTAAAGTGTC AGGCATCTTCACTGCTGGTC
Plin5 NM_001077348.1 TGTCCAGTGCTTACAACTCGG CAGGGCACAGGTAGTCACAC
Ppara NM_011144 CAACCCGCCTTTTGTCATAC CCTCTGCCTCTTTGTCTTCG
Pparg NM_011146 CCTGCGGAAGCCCTTTGGTGA AGCCTGGGCGGTCTCCACTG
Ppargc1a NM_008904.2 TGCTAGCGGTTCTCACAGAG AGTGCTAAGACCGCTGCATT
Ppargc1b NM_133249 CTTGCTTTTCCCAGATGAGG CCCTGTCCGTGAGGAACG
Prkaa1 NM_001013367 TGGTGGGAAAAATCCGCCGGG CGGCTTTCCTTTTCGTCCAACCTTC
Prkaa2 NM_178143 ACCGAGCTATGAAGCAGCTGGGTT CCTCTGCTCCACCACCTCATCATC
Scarb1 NM_016741 TCGCTTCACGGCCCCCGATA ACAGAGGCGCACCAAACCTGC
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Gene Accession number Forward primer Reverse primer
Scd1 NM_009127.4 GCTCTACACCTGCCTCTTCGGGAT TCCAGAGGCGATGAGCCCCG
Sdha NM_023281.1 GGGACAGGTGCTGAAGCATGTGAAT GCAATGCTCAGGGCACAGGCT
Sdhb NM_023374.3 CGACGGTCGGGGTCTCCTTGA CCTGAAACTGCAGGCCGACTC
Sqle NM_009270.3 TCGTTCGTGACGGACCCGGA ACTGTATCTCCAAGGCCCAGCTCC
Srebf1 NM_011480 GGCCGAGATGTGCGAACT TTGTTGATGAGCTGGAGCATGT
Srebf1 NM_011480 CTGGCTGAGGCGGGATGA TACGGGCCACAAGAAGTAGA
Tfam NM_009360 CTTCCTGGGTTCACCCGCAC ATGGGCACTATGGCTCCGTC
Ucp1 NM_009463 TCAGGATTGGCCTCTACGAC TGCATTCTGACCTTCACGAC
Vldlr NM_013703 TCTTGAGCAGTGTGGCCGTC TTGCAGTCAGGGTCTCCGTC




Fabp1 FABP1 1.00 ± 0.16 1.16 ± 0.14
Cd36 CD36 1.00 ± 0.13 0.89 ± 0.06
Lpl LPL 1.00 ± 0.07 0.83 ± 0.10
FA/TG synthesis
Srebf1 SREBP-1A 1.00 ± 0.14 0.84 ± 0.16
Srebf1 SREBP-1C 1.00 ± 0.06 0.94 ± 0.09
Nr1h3 LXR 1.00 ± 0.06 0.97 ± 0.04
Fasn FAS 1.00 ± 0.16 0.97 ± 0.25
Scd1 SCD1 1.00 ± 0.22 0.82 ± 0.16
Dgat1 DGAT1 1.00 ± 0.13 0.89 ± 0.10
FA oxidation
Pparagc1a PGC1 1.00 ± 0.10 0.72 ± 0.16
Ppara PPAR 1.00 ± 0.10 0.93 ± 0.06
Cpt1a CPT1 1.00 ± 0.05 0.94 ± 0.06
Acaca ACC1 1.00 ± 0.12 0.83 ± 0.14
Acacb ACC2 1.00 ± 0.22 1.07 ± 0.13
Acox1 ACOX1 1.00 ± 0.06 0.92 ± 0.09
Lipoprotein uptake
Ldlr LDLr 1.00 ± 0.10 0.96 ± 0.12
Lrp1 LRP1 1.00 ± 0.09 0.85 ± 0.07*
Scarb1 SRB1 1.00 ± 0.05 0.86 ± 0.05*
SUPPLEMENTARY TABLE 3 - Effect of metformin on hepatic expression of genes involved in FA/TG and 
 lipoprotein metabolism. Livers were isolated from 4 h-fasted mice treated with or without metformin for 
4 weeks. mRNA expression of the indicated genes were quantified by RT-PCR relative to CypD gene and 
expressed as fold difference compared with the control group. Data are means ± SEM (n=8). *, p<0.05.
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Apob ApoB 1.00 ± 0.05 0.88 ± 0.07
Mttp MTP 1.00 ± 0.10 0.95 ± 0.12
Cholesterol synthesis
Srbp2 SRBP2 1.00 ± 0.06 1.07 ± 0.11
Hmgcr HMG CoA-R 1.00 ± 0.15 1.13 ± 0.21
Hmgcs1 HMG CoA-S1 1.00 ± 0.10 1.04 ± 0.18
Hmgcs2 HMG CoA-S2 1.00 ± 0.06 0.99 ± 0.06
Sqle SQLE 1.00 ± 0.20 1.07 ± 0.21
Idi1 IDI1 1.00 ± 0.10 1.30 ± 0.10*
Fdps FDPS 1.00 ± 0.23 1.21 ± 0.17
Fdft1 FDFT1 1.00 ± 0.09 0.87 ± 0.14
Cholesterol excretion
Abcg5 ABCG5 1.00 ± 0.10 0.82 ± 0.09
Abcg8 ABCG8 1.00 ± 0.07 0.83 ± 0.12
HDL metabolism
Apoa1 ApoA1 1.00 ± 0.10 0.96 ± 0.15
Lipe HL 1.00 ± 0.30 0.70 ± 0.16
Pltp PLTP 1.00 ± 0.11 0.78 ± 0.10*
Abca1 ABCA1 1.00 ± 0.07 0.78 ± 0.09*
Lcat LCAT 1.00 ± 0.04 0.87 ± 0.06*
CETP CETP 1.00 ± 0.17 0.73 ± 0.20
SUPPLEMENTARY TABLE 4 - Effect of metformin on BAT expression of genes involved in tissue differentiation, 
lipoprotein/FA uptake, TG synthesis, FA oxidation and mitochondrial functions. Brown adipose tissues were 
isolated from 4 h-fasted mice treated with or without metformin for 4 weeks. mRNA expression of the 
 indicated genes were quantified by RT-PCR relative to CypD gene and expressed as fold difference compared 
with the control group. Data are means +/- SEM (n=7-8).




Prdm16 PRDM16 1.00 ± 0.27 1.14 ± 0.35
Cidea CIDEA 1.00 ± 0.20 1.09 ± 0.20
Dio2 DIO2 1.00 ± 0.16 1.00 ± 0.20
Essra ESSR 1.00 ± 0.36 1.03 ± 0.43
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CD36 CD36 1.00 ± 0.11 0.90 ± 0.12
Ldlr LDLr 1.00 ± 0.20 1.19 ± 0.29
Lrp1 LRP1 1.00 ± 0.09 1.34 ± 0.34
Vldlr VLDLr 1.00 ± 0.12 0.96 ± 0.11
Gpihbp1 GPIHBP1 1.00 ± 0.05 1.17 ± 0.13
Lpl LPL 1.00 ± 0.16 0.96 ± 0.22
FA/TG synthesis
Scd1 SCD1 1.00 ± 0.17 0.94 ± 0.26
Fasn FAS 1.00 ± 0.14 1.25 ± 0.22
Acly ACLY 1.00 ± 0.23 0.94 ± 0.18
Dgat1 DGAT1 1.00 ± 0.16 1.10 ± 0.13
Pck1 PEPCK 1.00 ± 0.18 1.18 ± 0.26
Gpam GPAT 1.00 ± 0.23 1.03 ± 0.31
FA oxidation
Ppara PPAR 1.00 ± 0.23 1.15 ± 0.25
Pparg PPARγ 1.00 ± 0.06 1.06 ± 0.08
Cpt1a CPT1 1.00 ± 0.20 0.98 ± 0.31
Prkaa1 AMPK1 1.00 ± 0.12 1.11 ± 0.14
Prkaa2 AMPK2 1.00 ± 0.20 1.09 ± 0.14
Acaca ACC1 1.00 ± 0.19 1.12 ± 0.19
Acacb ACC2 1.00 ± 0.19 1.25 ± 0.26
Lipid droplets
Cidea CIDEA 1.00 ± 0.20 1.09 ± 0.20
Cidec FSP27 1.00 ± 0.23 1.05 ± 0.28
Pnpla2 ATGL 1.00 ± 0.24 1.04 ± 0.36
Plin2 ADRP/Perilipin 2 1.00 ± 0.13 1.03 ± 0.16
Plin4 S3-12/Perilipin 4 1.00 ± 0.17 0.94 ± 0.19
Plin5 PAT-1/Perilipin 5 1.00 ± 0.23 1.04 ± 0.31
Mitochondria
Pparagc1a PGC1 1.00 ± 0.25 1.01 ± 0.21
Tfam Tfam 1.00 ± 0.13 0.96 ± 0.17
Cs CS 1.00 ± 0.19 0.96 ± 0.24
Ucp1 UCP1 1.00 ± 0.12 1.13 ± 0.05
Cox7a1 COX7 1.00 ± 0.11 1.05 ± 0.07
Atp5a1 ATP5A1 1.00 ± 0.09 0.99 ± 0.09
Ndufb8 NDUFB8 1.00 ± 0.13 0.98 ± 0.13
Sdha SDHA 1.00 ± 0.10 1.06 ± 0.21
Sdhb SDHB 1.00 ± 0.12 0.90 ± 0.10
Uqcrc2 UQCRC2 1.00 ± 0.08 1.04 ± 0.07
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SUPPLEMENTARY FIGURE 1 - Effect of metformin on body weight and composition, food intake and various 
plasma parameters. Body weight and composition A-B  and mean food intake C  were measured throughout 
the study in control (black bars) and metformin-treated (open bars) mice. Blood samples were collected as 
described in FIGURE 1 and plasma glucose D , insulin E  and free fatty acids (FFA; F  levels were determined.
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SUPPLEMENTARY FIGURE 3 - Effect of metformin on postprandial TG response. Overnightfasted control 
(closed squares) and metformin-treated (open squares) mice were given an intragastric bolus of 200 µl of 
olive oil. Blood samples were drawn at 0, 1, 2, 4, and 8 h. TG concentrations were determined in plasma and 
corrected for their respective values at time 0 A . The areas under the curse were calculated B . Data are 
means ± SEM (n=9-10/group).
SUPPLEMENTARY FIGURE 2 - Effect of metformin on hepatic lipid composition and AMPK signalling. Livers 
from 4 h-fasted mice were collected after 4 weeks of treatment with (open bars) or without metformin (con-
trol, black bars) and immediately snap-frozen in liquid nitrogen. Hepatic TG A , TC B  and PL C  content were 
measured after lipid extraction. The phosphorylation state of Thr172-AMPK and Ser79-ACC, and AMPK and 
ACC protein expression were assessed by Western blot D , followed by densitometric quantification E . 
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ACC2 acetyl-CoA carboxylase 2
ACSL1 long-chain-fatty-acid-CoA ligase 1
BAT brown adipose tissue




FASN fatty acid synthase
(F)FA (free) fatty acids 
HSL hormone-sensitive lipase 
LPL lipoprotein lipase
PL phospholipids
SCD-1  stearoyl-CoA desaturase
TC total cholesterol 
TG  triglyceride
UCP-1 uncoupling protein-1
SNS sympathetic nervous system
VLDL very-low density lipoprotein
(g,s)WAT (gonadal, subcutaneous) white adipose tissue
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ABSTRACT
The endocannabinoid system is an important player in energy metabolism by regu-
lating appetite, lipolysis and energy expenditure. Chronic blockade of the cannabinoid 
1 receptor (CB1R) leads to long-term maintained weight loss and reduction of dyslipi-
demia in experimental and human obesity. The molecular mechanism by which CB1R 
blockade reverses dyslipidemia in obesity has not been clarified yet. In this study, we 
show that systemic CB1R blockade by rimonabant in a diet-induced obese mouse 
model for human-like lipoprotein metabolism reversed obesity, increased energy 
expenditure and lowered plasma VLDL-triglycerides (TG). Mechanistic studies showed 
that rimonabant selectively increased VLDL-TG clearance by brown adipose tissue 
(BAT) accompanied by decreased lipid droplet size in BAT. Of note, the mechanism 
involved peripheral activation of BAT since the effects were still present at thermo-
neutral temperature at which sympathetic output towards BAT is negligible and 
could be fully recapitulated by using the strictly peripheral CB1R antagonist AM6545. 
In support, we demonstrate that the CB1R is highly expressed in BAT and that in vitro 
blockade of the CB1R in cultured brown adipocytes increased UCP-1 content and 
 lipolysis. Our data indicate that selective targeting of the peripheral CB1R in BAT has 
therapeutic potential in attenuating dyslipidemia and obesity.




The endocannabinoid system regulates a broad range of physiological functions (1) and 
 consists of G-protein coupled cannabinoid receptors, its endogenous lipid ligands (endocanna-
binoids) and the enzymes involved in the biosynthesis and degradation of endocanna-
binoids (2,3). The cannabinoid type 1 receptor (CB1R) is expressed at high levels in the brain 
but also at functionally relevant concentrations in various peripheral tissues (1). In contrast, 
the cannabinoid type 2 receptor is mainly expressed on immune cells (4). CB1R knockout 
mice display reduced adiposity and are resistant to diet-induced obesity (5). Moreover, over-
weight and obese humans exhibit an overactive endocannabinoid system (6,7), suggesting 
a role of the endocannabinoid system in energy metabolism.
Chronic systemic blockade of the CB1R with the inverse agonist rimonabant leads to 
long-term maintained weight loss and reduction of dyslipidemia in obese rodents (8,9) and 
humans (10-13). Rimonabant was considered one of the most promising therapeutic drugs 
to treat obesity, until the appearance of central psychiatric side effects resulted in its removal 
from the market in 2008. Nevertheless, several lines of evidence indicate that the effect of 
CB1R blockade is not restricted to a central mode of action, especially since the CB1R has 
been shown to be present in peripheral tissues including the liver (14), skeletal muscle (15) 
and adipocytes (16). More specifically, Tam et al (17) recently showed that the strictly peripheral 
CB1R antagonist AM6545 induced weight loss and diminished hepatic steatosis in a mouse 
model. Thus, it seems plausible that psychiatric side effects can be avoided by strict peripheral 
blockade of the CB1R, while retaining the beneficial anti-obesity and lipid-lowering effects. 
Despite clear evidence that pharmacological CB1R antagonism improves dyslipidemia, 
the exact mechanisms and the peripheral tissues involved have not yet been elucidated. 
Recently, brown adipose tissue (BAT) emerged as an important player in triglyceride (TG) 
clearance (18). In contrast to white adipose tissue (WAT), which stores excess TG as fat, BAT 
dissipates energy into heat, a process mediated by the mitochondrial uncoupling protein-1 
(UCP-1) (19). The best known trigger for activation of BAT is cold, which increases sympa-
thetic outflow from the hypothalamic temperature centre towards BAT, leading to release of 
noradrenalin and increased thermogenesis (19). Metabolically active BAT stores exist in adult 
humans (20-22), and BAT volume and activity are lower in obese subjects (22). In addition, 
BAT volume and activity are lower in South Asians, a population prone to develop type 2 
 diabetes mellitus and cardiovascular disease (23). Together, these findings have increased 
interest in the therapeutic potential of BAT to combat obesity and related disorders, such as 
dyslipidemia. 
In this study, we aimed at elucidating the molecular mechanism by which CB1R blockade 
attenuates dyslipidemia in diet-induced obesity by using a mouse model for human-like 
lipoprotein metabolism. 
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Homozygous human cholesteryl ester transfer protein (CETP) transgenic mice were crossbred 
with hemizygous APOE*3-Leiden (E3L) mice at our Institutional Animal Facility to obtain E3L.
CETP mice, as previously described (24). We chose to perform our studies in this specific 
mouse model, since these mice are a well-established model for human-like lipoprotein 
metabolism and respond to lipid-lowering pharmacological interventions (24-26). In all the 
studies described below, 10 week-old E3L.CETP male mice were housed under standard 
 conditions in conventional cages in a 12:12 h light: dark cycle with ad libitum access to food 
and water, and were fed a high-fat diet (HFD; Research diets, New Brunswick, USA, 60% lard 
fat) for 12 weeks to induce obesity. From the 7th week onwards, the drinking water was 
 supplied with 10% fructose. All mouse experiments were performed in accordance with the 
Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals 
and have received approval from the Departmental Ethical Review Board (Leiden University 
Medical Center, Leiden, The Netherlands).
Pharmacological intervention
After 12 weeks of HFD, diet-induced obese (DIO) mice were randomised according to 
their body weight and plasma total cholesterol (TC) and triglyceride (TG) levels into four 
groups. Subsequently, mice were housed at either 21°C (subthermoneutral) or 28°C (thermo-
neutral), and received 60% HFD with or without 10 mg/kg body weight/day (0.00885%, 
w/w)  rimonabant (Axon Medchem, Groningen, the Netherlands) or AM6545 (Sigma-Aldrich, 
St. Louis, USA) for 4 weeks.
Body weight and food intake
In all experiments, mice were housed individually during the 4 week treatment period. Food 
intake was recorded daily by weighing the food that was left in the cage or was recorded 
automatically in metabolic cages (see below). Body weight was measured twice a week.
Indirect calorimetry and physical activity
Indirect calorimetry was performed in fully automatic metabolic cages (LabMaster System, 
TSE Systems, Bad Homburg, Germany) during the fourth week of treatment. After 20 h 
 acclimatization, oxygen uptake (V˙ O2), carbon dioxide production (V˙ CO2) and caloric intake 
were measured for 5 consecutive days. Carbohydrate (CHO) and fat oxidation rates were 
 calculated from V˙ O2 and V˙ CO2 as described previously (27). Total energy expenditure (EE) 
was calculated from V˙ O2 and V˙ CO2 using the Weir equation (28). Physical activity was 
measured using infrared sensor frames.
Dual-energy X-ray absorptiometry (DEXA) scan
After 4 weeks treatment, body composition was measured by DEXA using the Norland 
pDEXA Sabre X-ray Bone Densitometer. Mice were anaesthetized intraperitoneally with a 
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combination of 6.25 mg⁄kg acepromazine (Alfasan), 6.25 mg⁄kg midazolam (Roche) and 
0.31  mg⁄kg fentanyl (Janssen-Cilag). The total body of the mice was scanned, yet the heads 
were excluded from the analyses.
Plasma parameters
Blood was collected from the tail vein of 4-6 hour fasted mice into chilled capillaries 
that were coated with paraoxon (Sigma, St. Louis, MO) to prevent ongoing lipolysis (29). 
Capillaries were placed on ice and centrifuged, and plasma was assayed for TG, TC, and 
 phospholipids (PL) using commercially available enzymatic kits from Roche Diagnostics 
(Mannheim, Germany for TG and TC) and Instruchemie (Delfzijl, the Netherlands for PL). Free 




To determine lipid distribution over plasma lipoproteins, pooled plasma was used for fast 
performance liquid chromatography (FPLC). Plasma was injected onto a Superose 6 column 
(ÄKTA System, Amersham Pharmacia Biotech, Piscataway, NJ) and eluted at a constant flow 
rate of 50 µL/min with PBS pH 7.4. TG and TC were measured as described above in collected 
fractions of 50 µL.
In vivo clearance of labeled VLDL-like emulsion particles
VLDL-like TG-rich emulsion particles (80 nm) labeled with glycerol tri[3H]oleate (triolein, TO) 
were prepared and characterized as described previously (30). To study the in vivo clearance 
of the VLDL-like particles, mice were fasted for 4 h and injected (t = 0) via the tail vein with 
200 µL of emulsion particles (1.0 mg TG per mouse). Blood samples were taken from the tail 
vein at 2, 10, 20 and 30 min after injection to determine the serum decay of [3H]TO. Plasma 
volumes were calculated as 0.04706 × body weight (g) as determined from 125I-BSA 
 clearance studies as described previously (31). After taking the last blood sample, mice were 
cervically dislocated and perfused with ice-cold PBS via the heart to remove blood from 
the organs. Subsequently, the liver, heart, spleen, hindlimb muscle, gonadal WAT (gWAT), 
subcutaneous WAT (sWAT) and brown adipose tissue (BAT) were collected. Organs were 
 dissolved overnight at 60°C in Tissue Solubilizer (Amersham Biosciences, Rosendaal, The 
Netherlands), and 3H activity was quantified. Uptake of [3H]TO-derived radioactivity by the 
organs was expressed per gram wet tissue weight.
In vivo hepatic VLDL-TG and VLDL-apoB production
To measure VLDL production in vivo, mice were fasted for 4 h and anesthetized by intra-
peritoneal injection of 6.25 mg⁄kg acepromazine (Alfasan), 6.25 mg⁄kg midazolam (Roche) 
and 0.31 mg⁄kg fentanyl (Janssen-Cilag). Mice were injected intravenously with Tran[35S] 
label (150 µCi/mouse) (MP Biomedicals, Eindhoven, The Netherlands) to label newly 
 produced apolipoprotein B (apoB). After 30 min, at t=0 min, Triton WR-1339 (Sigma-Aldrich) 
was injected intravenously (0.5 mg/g body weight, 10% solution in PBS) to block serum 
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VLDL-TG clearance. Blood samples were drawn before (t = 0) and at 15, 30, 60, and 90 min 
after injection of Triton WR-1339 and used for determination of plasma TG concentration as 
described above. After 90 min, mice were exsanguinated via the retro-orbital plexus. VLDL 
was isolated from serum after density gradient ultracentrifugation at d<1.006 g/mL by 
 aspiration (32) and examined for incorporated 35S-activity.
RNA isolation and qRT-PCR analysis
Total RNA was isolated with the Nucleospin® RNA II Kit (Macherey-Nagel) according to the 
manufacturer’s instructions. 1 µg of total RNA was reverse-transcribed with iScript cDNA 
synthesis kit (Bio-Rad), and the obtained cDNA was purified with Nucleospin Extract II kit 
(Macherey-Nagel). Real-time PCR was carried out on the IQ5 PCR machine (Bio-Rad) using 
the Sensimix SYBR Green RT-PCR mix (Quantace). Melt curve analysis was included to assure 
a single PCR product was formed. Expression levels were normalized using glyceraldehyde-
3-phosphate dehydrogenase (Gapdh), ß2-microglobulin and 36b4 as housekeeping genes. 
Primer sequences are listed in TABLE 1. 
Histology
Interscapular BAT, liver and sWAT were removed and fixed directly in 4% paraformaldehyde, 
dehydrated and embedded in paraffin. For UCP-1 staining in BAT, sections (5 µm) were 
dewaxed in xylene, rehydrated in ethanol and treated with 3% H2O2 (Sigma) in absolute 
methanol for 30 min. Next, sections were immersed in 10 mmol/L citrate buffer (pH 6.0), 
boiled for 10 min and cooled down at room temperature. Slides were blocked during 60 min 
with normal goat serum (1:75 in PBS) and incubated overnight at 4°C with rabbit monoclonal 
anti-UCP-1 antibodies (Abcam) diluted 1:400 in normal goat serum (1:75). Next, sections 














TABLE 1 - List of primer sequences for RT-PCR
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were incubated for 60 min with biotinylated goat -rabbit secondary antibodies (Vector 
Labs) diluted 1:600 in normal goat serum (1:75). Immunostaining was amplified using Vector 
Laboratories Elite ABC kit (Vector Labs) and the immunoperoxidase complex was visualized 
with Nova Red (Vector Labs). Counterstaining was performed with Mayer’s hematoxylin 
(1:4). Haematoxylin and Eosin stainings of liver and sWAT sections were done using standard 
protocols. Intracellular lipid content in BAT was quantified by use of ImageJ (version 1.47).
Liver lipid extraction
Lipids were extracted from livers consistent with a modified protocol from Bligh and Dyer 
(33). Small liver samples (approx. 50 mg) were homogenized in 10 µL of ice-cold methanol 
per mg tissue. Lipids were extracted into an organic phase by adding 1800 µL of CH3OH: 
CHCl3 (3:1, vol/vol) to 45 µL of homogenate and subsequent centrifugation. The lower, organic 
phase was dried and suspended in 2% Triton X-100. Hepatic TG and TC concentrations were 
measured using commercial kits, as explained (see: Plasma parameters). Liver lipids were 
expressed per milligram of protein, which was determined using the BCA protein assay kit 
(Thermo Scientific, Rockford, IL, USA).
In vitro experiments with brown adipocytes
The murine brown preadipocyte cell line T37i (34) was cultured in HAM’S-F12 medium 
(Gibco-Invitrogen) supplemented with 10% fetal calf serum, 2 mM HEPES, 100 U/mL penicillin 
and 100 µg/mL streptomycin (Gibco-Invitrogen). For experiments, T37i cells were seeded in 
6-wells plates and grown towards confluence. Two days after reaching confluence, cells 
were differentiated using normal culture medium supplemented with 2 nM triiodothyronine 
(T3) (Sigma) and 112 ng/mL bovine insulin (Sigma). The differentiation medium was replaced 
every 2 or 3 days. After 9 days of differentiation, cells were stimulated for 8 h with rimonabant 
(Axon Medchem) at 0.1 µM or 1 µM or with vehicle (DMSO). Then, 500 µL of supernatant was 
collected and snap-frozen in liquid nitrogen. Cells were washed twice with ice-cold PBS and 
cells were harvested in ice-cold lysis buffer as described below.
Protein isolation and Western Blot
T37i cells or snap-frozen tissue samples were lysed in ice-cold buffer containing 50 mM 
Hepes (pH 7.6), 50 mM NaF, 50 mM KCl, 5 mM NaPPi, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 5 mM 
ß-glycerophosphate, 1 mM sodium vanadate, 1% NP40 and protease inhibitors using cocktail 
tablets (Roche). Homogenates were centrifuged at 13,000 rpm for 15 min at 4°C and the 
 protein content of the supernatant was determined using the BCA Protein Assay Kit from 
Thermo Scientific. Proteins (20 µg) were separated by 10% SDS-PAGE followed by transfer 
to a polyvinylidene fluoride transfer membrane (Merck, Amsterdam, The Netherlands). 
Membranes were blocked for 1 h at room temperature in Tris-buffered saline tween-20 buffer 
with 5% non-fat dry milk followed by an overnight incubation with specific primary 
 antibodies. Primary antibodies specific for cannabinoid type 1 receptor (CB1R), E2-F, AMPK, 
P-AMPK, ACC, P-ACC and tubulin were purchased from Cell Signaling (Leiden, The Nether-
lands). A primary antibody specific for uncoupling protein 1 (UCP1) was purchased from 
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Sigma-Aldrich. All antibodies were diluted 1:1000. Blots were incubated with horseradish 
 peroxidase-conjugated secondary antibodies for 1 h at room temperature. Bands were 
 visualized with SuperSignal West Pico Chemiluminescent Substrate (Pierce) and quantified 
using ImageJ (version 1.47).
Statistical analysis
All data are expressed as mean ± SEM. Statistical analysis using the unpaired two-tailed 
Student’s test was performed with the SPSS 20.0 software package for Windows (SPSS, 
Chicago, United States) to determine differences between vehicle- and compound-treated 
groups. A P-value < 0.05 was considered statistically significant.
RESULTS
Systemic CB1R blockade by rimonabant in DIO mice reduces obesity and dyslipidemia and 
increases energy expenditure. To investigate the effect of systemic CB1R blockade on body 
composition and energy  balance, E3L.CETP transgenic mice were fed a HFD for 12 weeks to 
render them obese (mean body weight: 53.2 ± 0.9 g) and treated with rimonabant or vehicle 
for 4 weeks. Rimonabant elicited a profound decrease in body mass (-25%, P<0.001; FIGURE 
1A) which was not due to a decrease in lean mass but rather to a massive decrease in fat 
mass (-32%, P<0.001; FIGURE 1B). Rimonabant decreased caloric intake transiently (i.e. until 
day 6) (FIGURE 1C), in accordance with previous observations (35, 36), while it persistently 
induced weight loss throughout the treatment period (i.e. 4 weeks). Furthermore, rimona-
bant markedly diminished plasma TG levels (-59%, P<0.05) and TC levels (-40%, P<0.01) 
(FIGURE 1D), which is in line with previous human studies (10-12). Rimonabant tended to 
reduce plasma phospholipid (PL) levels (-31%, P=0.05) and had no effect on plasma free fatty 
acid (FFA) levels. Lipoprotein profiling showed that the marked decrease in plasma TG mostly 
resulted from a reduction in VLDL-TG (AUC -62%) (FIGURE 1E). The persistent reduction in 
body weight despite the transient decrease in food intake following rimonabant treatment 
suggests increased energy expenditure. Indeed, rimonabant increased substrate utilization 
reflected by increased fat oxidation (+18%, P<0.05; FIGURE 1F), carbohydrate (CHO) oxidation 
(+18%, P<0.05; FIGURE 1G), and consequently total energy expenditure (+17%, P<0.05; FIGURE 
1H), as measured via  indirect calorimetry, without increasing locomotor activity (FIGURE 1I). 
 
Systemic CB1R blockade by rimonabant attenuates dyslipidemia by activating brown adipose 
tissue. Plasma VLDL-TG levels are determined by the balance between hepatic VLDL-TG 
 production and VLDL-TG clearance by lipoprotein lipase (LPL)-expressing peripheral organs. 
Therefore, to gain insight into the mechanism by which systemic CB1R antagonism reduces 
plasma VLDL-TG, we first assessed the effect of rimonabant on VLDL production. DIO mice 
were treated with rimonabant or vehicle for 4 weeks and then sequentially injected with 
Trans35S and Triton WR1339 resulting in linear accumulation of VLDL in which newly synthe-
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FIGURE 1 - Systemic CB1R blockade by rimonabant in DIO mice reduces obesity and dyslipidemia and 
increases energy expenditure. Male E3L.CETP mice were fed a HFD for 12 weeks to induce DIO and were then 
treated with rimonabant or vehicle for 4 weeks while housed at 21°C. A  Body weight change (g) during the 
treatment period. B  Lean and fat mass (g) as measured via DEXA-scan after 4 weeks of treatment. C  Mean 
daily food intake (g) during the treatment period. D  Plasma triglyceride (TG), total cholesterol (TC), phospholipid 
(PL), and free fatty acid (FFA) levels in 4-hour fasted mice after 4 weeks of treatment. E  TG distribution over 
lipoproteins after separation from pooled plasma (n=9) by FPLC. F  Fat oxidation, G ) carbohydrate (CHO) 
 oxidation, H  energy expenditure (EE), and I  activity levels as measured during 5 consecutive days in the fourth 
week of treatment via fully automatic metabolic cages. F-H  Measurements were corrected for lean mass. 
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sized apolipoproteins are radiolabeled. Rimonabant did not affect the time-dependent 
 accumulation of plasma TG following Triton injection (FIGURE 2A). Therefore, the VLDL-TG 
 production rate, as determined from the slope of the curve, was not significantly different. 
In addition, the rate of VLDL-apoB production did not change (FIGURE 2B). In line with these 
observations, hepatic expression of lipogenic genes such as fatty acid synthase (Fasn) and 
stearoyl-CoA desaturase (Scd1) was unchanged (FIGURE 2C). All together, these data demon-
strate that global CB1R antagonism does not diminish dyslipidemia by lowering hepatic 
VLDL-TG production.
To investigate whether rimonabant increases VLDL-TG clearance, we determined the 
kinetics of i.v. injected [3H]TO-labeled TG-rich VLDL-like emulsion particles, which have been 
previously shown to mimic the metabolic behavior of TG-rich lipoproteins (30), and studied 
the plasma clearance and organ distribution of [3H]TO-derived fatty acids (FA) in mice 
 treated with rimonabant or vehicle for 4 weeks. Rimonabant accelerated clearance of [3H]TO 
from plasma (t½ =3.9 ± 0.6 vs. 6.4 ± 0.4 min, P<0.05) (FIGURE 2D), as explained by increased 
uptake of [3H]TO-derived activity by energy-dissipating BAT (+53%, P<0.05; FIGURE 2E). Of 
note, rimonabant decreased the uptake of [3H]TO by the energy-storing sWAT depot (-42%, 
P<0.05). 
To further investigate the molecular mechanism by which systemic CB1R blockade 
increased FA uptake by BAT, the mRNA expression of genes involved in both BAT differentiation, 
BAT activity, TG lipolysis and FA uptake were determined. Rimonabant did not affect expression 
of genes involved in BAT differentiation (Pgc1, Prdm16) and intracellular lipolysis (Hsl, Atgl) 
(data not shown). However, as shown in FIGURE 2F, rimonabant increased expression of 
Lpl (+30%, P<0.05) and Cd36 (+24%, P<0.05) that drive extracellular VLDL-TG lipolysis and 
subsequent uptake of FA by BAT (18). In addition, rimonabant increased expression of Ucp1, 
which encodes the uncoupling protein that mediates thermogenesis (+49%, P<0.05). 
Furthermore, histology showed a more intense immunohistochemical staining of UCP-1 in 
BAT (FIGURE 2G) as well as a decrease in intracellular lipid droplet size, reflected by a decrease 
in relative lipid area (-39%, P<0.001; FIGURE 2H), both pointing to more active BAT (37). Thus, 
these data provide strong evidence that systemic CB1R antagonism diminishes dyslipidemia 
and increases energy expenditure, by promoting VLDL-TG uptake and subsequent combustion 
by BAT. 
Systemic CB1R blockade by rimonabant diminishes TG storage in WAT and liver. To investi-
gate whether the increased flux of TG towards BAT reduces (ectopic) TG accumulation, we 
 analyzed WAT and the liver in more detail. Indeed, from the VLDL-TG clearance experiment it 
appeared that retention of [3H]TO-derived activity by the energy storing sWAT depot was 
diminished after rimonabant treatment (-42%, P<0.05; FIGURE 2E). In line with this, the cell 
size of white adipocytes was decreased in this depot as evident after H&E staining (SUPPL. 
FIGURE 1A). In addition, rimonabant diminished expression of the lipogenic genes Fasn (-58%, 
P<0.05) and Scd1 (-54%, P<0.05), while it increased expression of the lipolytic enzyme hormone 
sensitive lipase (Hsl) (+126%, P<0.05) in WAT (SUPPL. FIGURE 1B), suggesting net FA efflux from 
WAT. In liver, rimonabant markedly decreased liver weight (SUPPL. FIGURE 2A), which was 
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FIGURE 2 - Systemic CB1R blockade by rimonabant in DIO mice attenuates dyslipidemia by activating brown 
adipose tissue. Male E3L.CETP mice were fed a HFD for 12 weeks to induce DIO and were then treated with 
rimonabant or vehicle for 4 weeks while housed at 21°C A  After 4 weeks of treatment, 4-hour fasted mice were 
injected intravenously with Tran[35S] and TritonWR1339 and blood samples were drawn at the indicated time 
points. TG concentrations were determined and plotted as the increase in plasma TG relative to t=0. B  ApoB 
production rate, as measured by counting 35S-activity in the VLDL fraction isolated after 90 min. C  Expression of 
Fasn and Scd1 in liver as measured by qRT-PCR. D  After 4 weeks of treatment, 4-hour fasted mice were injected 
intravenously with [3H]TO-labeled VLDL-like emulsion particles, blood was collected at the indicated time points 
and radioactivity was measured in plasma. E  Uptake of [3H]TO-derived radioactivity by various organs was 
determined, and expressed as percentage of the injected dose per gram wet tissue weight. F  Expression of 
Lpl, Cd36, and Ucp1 in BAT as measured by qRT-PCR. G  Representative pictures of immunohistochemical UCP-1 
stainings of BAT in vehicle (top) and rimonabant (bottom) treated mice. Pictures were taken at 100x magnifi-
cation (scale bar 100 µm). H  Percentual lipid content in BAT tissue sections as quantified by use of ImageJ. 
Values are means ± SEM (n=9) and expression of genes was corrected for the housekeeping genes ß2-microglobulin and 36b4. *P<0.05, ***P<0.001 
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FIGURE 3 - The anti-obesity and lipid-lowering effects of systemic CB1R blockade by rimonabant in DIO mice 
are not abrogated at thermoneutrality. Male E3L.CETP mice were fed a HFD for 12 weeks to induce DIO and 
were then treated with rimonabant or vehicle for 4 weeks while housed at 28°C A . Body weight change (g) 
during the treatment period. B  Lean and fat mass (g) as measured via DEXA-scan after 4 weeks of treatment. 
C  Mean daily food intake (g) during the treatment period. D  Plasma triglyceride (TG) levels in 4-hour fasted 
mice after 4 weeks of treatment. E  TG distribution over lipoproteins after separation from pooled plasma 
(n=9 per group) by FPLC. F  Energy expenditure (EE) as measured during 5 consecutive days in the fourth 
week of treatment via fully automatic metabolic cages, corrected for lean mass. G  Expression of Lpl, Cd36, 
and Ucp1 in BAT as measured by qRT-PCR H  Representative pictures of immunohistochemical UCP-1 stainings 
of BAT in vehicle (left) and rimonabant (right) treated animals. Pictures were taken at 100x magnification 
(scale bar 100 µm). 
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accompanied by a reduction in liver TG content (-45%, P<0.01) (SUPPL. FIGURE 2B) and smaller 
intracellular lipid vacuoles (SUPPL. FIGURE 2C). Furthermore, rimonabant caused a (likely 
 compensatory) downregulation of hepatic expression of genes involved in lipid oxidation, 
such as acyl-CoA synthetase long-chain family member 1 (Acsl1) and acetyl-CoA carboxylase 
2 (Acc2) (SUPPL. FIGURE 2D), while genes involved in lipogenesis were not affected (FIGURE 2C). 
Thus, these data suggest that systemic CB1R blockade reduces storage of TG in WAT and 
liver, which may, at least in part, be a consequence of increased FA demand and flux towards 
BAT.
The anti-obesity and lipid-lowering effects of systemic CB1R blockade by rimonabant are 
not abrogated at thermoneutrality. BAT is densely innervated by the sympathetic nervous 
system (SNS) (19). Therefore, one of the mechanisms by which systemic CB1R blockade may 
lead to BAT activation could involve central CB1R blockade resulting in increased sympathetic 
outflow towards BAT. To investigate whether rimonabant acts centrally by increasing sym-
pathetic nervous system (SNS) activation towards BAT, we next evaluated the effects of 
rimonabant in DIO mice that were housed at thermoneutral temperature (28°C). At thermo-
neutrality, rimonabant still markedly reduced obesity (FIGURE 3A-B) without affecting lean 
mass. This was accompanied by a transient decrease in food intake (i.e. until day 6) (FIGURE 3C). 
Importantly, at thermoneutrality rimonabant still lowered plasma TG (-70%, P<0.05; FIGURE 
3D), which was mainly due to a reduction in VLDL-TG (AUC -52%; FIGURE 3E). Furthermore, 
rimonabant still increased whole-body fat and carbohydrate oxidation (SUPPL. FIGURE 3A-B), 
resulting in increased total energy expenditure (+21%, P<0.05; FIGURE 3F), accompanied by 
increased markers of BAT activation both on mRNA (FIGURE 3G) and histological levels (FIGURE 
3H). Thus, these data suggest that the reduction in dyslipidemia, increase in energy expen-
diture and activation of BAT by systemic CB1R blockade occurs at least in part independent of 
SNS activation of BAT.
In vitro CB1R blockade by rimonabant induces activation of brown adipocytes and stimula-
tion of AMPK phosphorylation. To explore the possibility that direct blockade of a CB1R in 
BAT may be responsible for the anti-obesity and lipid-lowering effect induced by systemic 
CB1R blockade, we first investigated whether the CB1R is expressed on BAT. Indeed, western 
blots on protein from tissues derived from untreated mice showed that the CB1R is highly 
expressed in BAT (FIGURE 4A), even when compared to the expression in hypothalamus 
and liver. Furthermore, in vitro treatment of T37i brown adipocytes with rimonabant 
 dose-dependently increased glycerol release (FIGURE 4B), pointing to increased intracellular 
lipolysis, and upregulated UCP-1  protein (FIGURE 4C). AMP-activated protein kinase (AMPK) 
serves as an intracellular energy sensor and activation of AMPK by means of phosphory-
lation results in enhanced fatty acid and glucose oxidation in a variety of tissues (38). Of 
note, CB1R blockade has been shown to increase AMPK phosphorylation in both liver cells 
(39) and white adipocytes (40). In line with this, we found that in vitro treatment of cultured 
T37i brown adipocytes with rimonabant induced AMPK phosphorylation (FIGURE 4D) as well as 
phosphorylation of ACC (FIGURE 4E), the downstream effector of AMPK. 
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FIGURE 4 - Rimonabant directly stimulates BAT activity in T37i brown adipocytes in vitro. A  CB1R protein 
expression was measured via western blot in BAT, hypothalamus and liver derived from diet-induced obese 
E3L.CETP transgenic mice with elongation factor 2 (EF-2) as housekeeping protein. B-F  T37i brown adipo-
cytes were treated with rimonabant (0, 0.1 or 1 µM) for 8 hours and B  glycerol release was measured in the 
supernatant, and protein content of (C) UCP-1, (D) p-AMPK/AMPK E  p-ACC/ACC and F  Pgc1 was measured 
via western blot. Tubulin was used as housekeeping protein. 





































































































Altogether, these data indicate that direct blockade of the CB1R on brown adipocytes 
directly stimulates their activity with respect to intracellular lipolysis and UCP-1 protein 
 content, accompanied by enhanced phosphorylation of AMPK and ACC.
Strictly peripheral CB1R blockade by AM6545 reduces obesity and dyslipidemia and increases 
energy expenditure in DIO mice. To investigate whether peripheral CB1R blockade is suffi-
cient to induce weight loss and reverse dyslipidemia in vivo, we treated DIO mice for four 
weeks with vehicle or AM6545, a peripherally restricted CB1R antagonist that has been 
 previously shown not to elicit central side effects (17). AM6545 markedly reduced body 
weight (-19%, P<0.001; FIGURE 5A) and fat mass (-23%, P<0.01; FIGURE 5B), without altering lean 
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FIGURE 5 - Strictly peripheral CB1R blockade by AM6545 reduces obesity and dyslipidemia and increases 
 energy expenditure in DIO mice. Male E3L.CETP mice were fed a HFD for 12 weeks to induce DIO and were then 
treated with AM6545 or vehicle for 4 weeks while housed at 21°C. A  Body weight change (g) during the 
 treatment period. B  Lean and fat mass (g) as measured via DEXA-scan after 4 weeks of treatment. C  Mean 
daily food intake (g) during the treatment period. D  Plasma triglyceride (TG) levels in 4-hour fasted mice after 
4 weeks of treatment. E  TG distribution over lipoproteins after separation from pooled plasma (n=9 per group) 
by FPLC. F-H  energy expenditure, fat oxidation and carbohydrate (CHO) oxidation as measured during 
5 consecutive days in the fourth week of treatment via fully automatic metabolic cages, corrected for lean mass. 
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FIGURE 6 - Strictly peripheral CB1R blockade by AM6545 attenuates dyslipidemia in DIO mice by activating 
brown adipose tissue. Male E3L.CETP mice were fed a HFD for 12 weeks to induce DIO and were then treated 
with AM6545 or vehicle for 4 weeks while housed at 21°C. A  After 4 weeks of treatment, 4-hour fasted mice 
were injected intravenously with Tran[35S] and TritonWR1339 and blood samples were drawn at the indicated 
time points. TG concentrations were determined and plotted as the increase in plasma TG relative to t=0. B  
ApoB production rate, as measured by counting [35S]-activity in the VLDL fraction after 90 min. C  Expression 
of Fasn and Scd1 in liver as measured by qRT-PCR. D  After 4 weeks of treatment, 4-hour fasted mice were 
injected intravenously with [3H]TO-labeled VLDL-like emulsion particles. Blood was collected at the indicated 
time points and radioactivity was measured in plasma. E  Uptake of [3H]TO-derived radioactivity by various 
organs, and expression per gram wet tissue weight. F  Expression of Lpl, Cd36, and Ucp1 in BAT as measured 
by qRT-PCR. (G) Representative pictures of immunohistochemical UCP-1 stainings of BAT in vehicle (left) and 
rimonabant (right) treated animals. Pictures were taken at 100x magnification (scale bar 100 µm). 
Values are means ± SEM (n=9) and expression of genes was corrected for the housekeeping genes ß2-microglobulin and 36b4. *P<0.05, **P<0.01, 
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mass. AM6545 did not induce the initial transient decrease in food intake as seen with 
rimonabant, although a slight decrease was evident later during the treatment period 
(FIGURE 5C). However, total caloric intake was not affected. Furthermore, AM6545 substantially 
decreased plasma TG levels (-49%, P<0.05; FIGURE 5D), which mostly resulted from a reduction 
in VLDL-TG (AUC -73%; FIGURE 5E). In addition, AM6545 increased total energy expenditure 
(FIGURE 5F), which was due to an increase in both fat and carbohydrate oxidation (FIGURE 
5G-H). Thus, these data demonstrate that peripheral CB1R blockade is sufficient to diminish 
obesity and dyslipidemia in DIO.
Strictly peripheral CB1R blockade by AM6545 attenuates dyslipidemia by activating brown 
adipose tissue. To investigate whether peripheral CB1R blockade also diminished dyslipi-
demia by increasing FA uptake by BAT, we again assessed VLDL-TG production and clearance. 
Just like rimonabant, AM6545 did not affect the production rates of VLDL-TG and VLDL-apoB 
(FIGURE 6A-B) or hepatic expression of lipogenic genes (FIGURE 6C). Instead, AM6545 also 
 accelerated clearance of [3H]TO-labeled VLDL-like emulsion particles from plasma (FIGURE 
6D), accompanied by a marked increase of 3H retention by BAT (+235%, P<0.01; FIGURE 6E), and 
a decrease in 3H uptake by sWAT (-51%, P<0.01). In BAT, AM6545 increased expression of Lpl 
(+67%,P<0.05), Cd36 (+59%, P<0.05) and Ucp1 (+32%, P<0.05; FIGURE 6F) and decreased lipid 
content (FIGURE 6G), all pointing to increased BAT activity. AM6545 also decreased white 
 adipocyte size (SUPPL. FIGURE 4A) and liver weight (-24%, P<0.001; SUPPL. FIGURE 4B) accompa-
nied by a reduction in liver TG content (-17%, P<0.05) (SUPPL. FIGURE 4C) and lipid vacuole size 
(SUPPL. FIGURE 4D). Thus, peripheral CB1R blockade is sufficient to diminish dyslipidemia, 
and probably also obesity, by promoting VLDL-TG uptake and subsequent combustion of 
engulfed FA by BAT.
DISCUSSION
Systemic CB1R blockade by the inverse CB1R agonist rimonabant alleviates the excess body 
weight and dyslipidemia that are associated with obesity, both in mice and in humans 
(8-12). In this study, we demonstrate that systemic CB1R blockade reverses DIO and reduces 
plasma VLDL-TG by selectively increasing VLDL-TG clearance by metabolically active BAT 
 followed by combustion. Of note, the mechanism involves peripheral activation of BAT since 
the effects were still present at thermoneutrality and could be recapitulated by using the 
strictly peripheral (17) CB1R antagonist AM6545. Accordingly, cultured brown adipocytes 
could be activated by blockade of the CB1R with rimonabant. 
Systemic CB1R blockade by rimonabant resulted in massive activation of BAT, as evi-
denced by reduced lipid content and increased UCP-1 expression, accompanied by increased 
energy expenditure, which is in accordance with previous studies (36,41). Of note, by per-
forming kinetic studies with radioactively labeled VLDL-TG we provided clear evidence that 
the TG-lowering effect of rimonabant is due to increased uptake of TG-derived FAs by BAT. 
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Since metabolically active BAT has been shown to be present and active in human adults 
(20-23), it is tempting to speculate that the body weight-reducing and TG-lowering effects 
of rimonabant previously found in obese subjects might be due to activation of BAT, 
although the precise role of BAT in TG metabolism in humans remains to be established. 
Previous studies suggested central CB1R blockade as the main mechanism by which 
rimonabant induces BAT activation, resulting in increased sympathetic outflow towards BAT 
and increased energy expenditure (36,41). For instance, Bajzer and colleagues (36) reported 
that denervation of BAT in mice blunted the effect of rimonabant on insulin-mediated 
 glucose uptake. However, in their study, the increase in energy expenditure and the reduction 
in body weight and fat mass were not blunted by BAT denervation, suggesting that a 
peripheral mechanism is at least in part involved in these beneficial effects. Indeed, we 
found that treatment of DIO mice with the strictly peripheral CB1R antagonist AM6545 still 
resulted in increased energy expenditure accompanied by increased uptake of TG-derived 
FAs by BAT as well as significant weight loss and reduction in dyslipidemia. Furthermore, we 
showed that the CB1R is highly expressed in BAT, and rimonabant increased the activity of 
brown adipocytes, further supporting the possibility of a peripheral mode of action of CB1R 
blockade in BAT. 
We found that systemic blockade of the CB1R by rimonabant did not affect VLDL-TG 
 production following either systemic or selective peripheral CB1R blockade. In contrast, a 
study by Tam and colleagues (17) reported that blocking the peripheral CB1R by AM6545 
treatment resulted in a marked increase in the production of VLDL-TG in both DIO C57Bl/6 
and leptin-deficient ob/ob mice. This might be explained by differences in study set-up, 
since Tam and colleagues measured VLDL-TG production after 1 week of treatment while in 
the present study VLDL-TG production was measured after 4 weeks. Likely, CB1R blockade 
transiently increases VLDL-TG production, leading to a fast initial reduction in hepatic 
 steatosis as was also observed in their study. The subsequent normalization in VLDL production 
that we found in our study after 4 weeks of treatment may then be the consequence of 
a lower supply of FFAs towards the liver for incorporation into VLDL-TG, since these are 
 efficiently cleared by BAT.
While we provide clear evidence that the TG-lowering effect of CB1R blockade is due to 
peripheral activation of BAT, the mechanism by which CB1R blockade lowers body weight 
and fat mass is less clear and no consistent mechanism has been reported up to date. 
Although BAT activation has been repeatedly shown to decrease body weight and fat mass 
(18,42,43), we cannot exclude that CB1R blockade on peripheral tissues other than BAT may 
contribute to the weight-reducing effect. For instance, the CB1R has been shown to be 
 present on white adipocytes (16) and treatment of mice with rimonabant and AM6545 
increased lipolysis (17,44,45). Accordingly, we also found that rimonabant increased mRNA 
expression of Hsl in subcutaneous WAT. Furthermore, the weight-reducing effect of global 
CB1R blockade is also at least in part due to an initial transient decrease in food intake 
induced by rimonabant. The greater efficacy of rimonabant over AM6545 in reducing body 
weight is then likely explained by the fact that AM6545 did not affect total caloric intake 
over the treatment period, as has been shown before (17). Thus, future studies are needed to 
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elucidate the specific contribution of BAT in the weight-reducing effect of (peripheral) CB1R 
blockade. 
The intracellular mechanism by which CB1R blockade is linked to BAT thermogenesis 
likely involves phosphorylation of AMP-activated kinase (AMPK), a key evolutionary conserved 
cellular energy sensor that regulates metabolism (37). We show that CB1R blockade resulted 
in increased AMPK phosphorylation in brown adipocytes, which is in accordance with previous 
studies performed in hepatocytes (39) and white adipocytes (40). Thus, AMPK might be a 
central player by which CB1R blockade results in BAT activation. Future studies should be 
directed at investigating these pathways in more detail. 
Together, our study shows that CB1R blockade diminishes dyslipidemia by inducing BAT-
mediated VLDL-TG uptake and BAT thermogenesis via a peripheral mode of action. Our data 
suggest that blockade of the peripheral CB1R in BAT may be a promising therapy to combat 
obesity and to lower cardiovascular risk without inducing centrally mediated side effects.
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SUPPLEMENTARY APPENDIX
SUPPLEMENTARY FIGURE 1 - Effect of systemic CB1R blockade by rimonabant on subcutaneous WAT. Male E3L.
CETP mice were fed a HFD for 12 weeks to induce diet-induced obesity and were then treated with rimonabant 
or vehicle for 4 weeks while being housed at an environmental temperature of 21°C. A  Representative pictures 
of H&E stainings of sWAT in vehicle (left) and rimonabant (right) treated animals. Sections were enlarged 
100x (scale bar 100 µm). B  Expression of Fasn, Scd1, and Hsl in sWAT as measured by qRT-PCR. 
Values are means ± SEM (n=9) and expression of genes was corrected for the housekeeping genes ß2-microglobulin and 36b4. *P<0.05 compared 
to the control group.
SUPPLEMENTARY FIGURE 2 - Effect of systemic CB1R blockade by rimonabant on hepatic steatosis. Male E3L.
CETP mice were fed a HFD for 12 weeks to induce diet-induced obesity and were then treated with rimonabant 
or vehicle for 4 weeks while being housed at an environmental temperature of 21°C. A  Liver weight (g). B  
Liver content of triglycerides (TG), total cholesterol (TC) and phospholipids (PL). C  Representative pictures of 
H&E stainings of livers from vehicle (left) and rimonabant (right) treated animals. Pictures were taken at 100x 
magnification (scale bar 100 µm). D  Expression of Acsl1 and Acc2 in liver as measured by qRT-PCR. 
Values are means ± SEM (n=9) and expression of genes was corrected for the housekeeping genes ß2-microglobulin and 36b4. *P<0.05 , **P<0.01 
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SUPPLEMENTARY FIGURE 3 - Systemic CB1R blockade increases fat and carbohydrate oxidation at thermo-
neutrality. Male E3L.CETP mice were fed a HFD for 12 weeks to induce diet-induced obesity and were then 
treated with rimonabant or vehicle for 4 weeks while being housed at an environmental temperature of 28°C. 
A-B  Fat and carbohydrate (CH) oxidation as measured during 5 consecutive days in the fourth week of treat-
ment via fully automatic metabolic cages, corrected for lean body mass. 




























































































SUPPLEMENTARY FIGURE 4 - Effect of strictly peripheral CB1R blockade by AM6545 on lipid storage in sWAT 
and liver. Male E3L.CETP mice were fed a HFD for 12 weeks to induce diet-induced obesity and were then treated 
with AM6545 or vehicle for 4 weeks while being housed at an environmental temperature of 21°C. A  
Representative pictures of H&E stainings of sWAT in vehicle (left) and AM6545 (right) treated animals. Pictures 
were taken at 100x magnification (scale bar 100 µm). B  Liver weight (g). C  Liver content of triglycerides (TG), 
total  cholesterol (TC) and phospholipids (PL). D  Representative pictures of H&E stainings of liver in vehicle 
(left) and AM6545 (right) treated animals. Pictures were taken at 100x magnification (scale bar 100 µm). 
Sections were enlarged 100x (scale bar 100 µm). 
Values are means ± SEM (n=9). *P<0.05 , ***P<0.001 compared to the control group.
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ABSTRACT
The melanocortin system is an important regulator of energy balance and MC4R 
 deficiency is the most common monogenic cause of obesity. We investigated whether 
the relationship between melanocortin system activity and energy expenditure is 
mediated by brown adipose tissue (BAT) activity. Therefore, female APOE*3-Leiden.
CETP transgenic mice were fed a Western-type diet for 4 weeks and infused intra-
cerebroventricularly with the MC3/4R antagonist SHU9119 or vehicle for 2 weeks. 
SHU9119 increased food intake (+30%), body fat (+50%) and decreased energy 
expenditure by reduction in fat oxidation (-42%). In addition, SHU9119 impaired 
 plasma clearance of VLDL-TG, which was solely explained by reduced TG uptake by 
BAT. In line with this, SHU9119 decreased uncoupling protein-1 protein levels in BAT 
(-60%) and induced large intracellular lipid droplets, indicative of severely disturbed 
BAT activity. Finally, SHU9119-treated mice pair-fed to the vehicle-treated group still 
exhibited these effects, indicating that MC4R inhibition impairs BAT activity indepen-
dent of food intake. We conclude that inhibition of central MC3/4R signaling impairs 
BAT function, which is accompanied by reduced energy expenditure thereby promoting 
adiposity. We anticipate that activation of MC4R is a promising strategy to combat 
obesity by increasing BAT activity.




The hypothalamus is important in the regulation of energy balance. Activation of pro- 
opiomelanocortin neurons, e.g. by insulin or leptin, induces secretion of -melanocyte-
stimulating hormone, which in turn stimulates melanocortin -3 and -4 receptors (MC3R/
MC4R) within the paraventricular nucleus to cause a negative energy balance (1). Accordingly, 
activation of central MC4R in rodent models results in anorexia and weight loss (2), whereas 
blockade or targeted gene disruption induces hyperphagia and obesity, even on regular 
chow diet (3,4). Loss-of-function mutations in MC4R are the most common monogenic form 
of obesity in humans and are associated with severe obesity in childhood (5). In addition, 
recent meta-analyses of genome-wide association studies identified common variants near 
MC4R to influence fat mass, obesity and obesity risk (6,7). These observations support an 
essential role for the melanocortin system in the regulation of energy homeostasis across 
mammalian species. 
In addition to the effects of the melanocortin system on food intake, this system also 
affects energy balance via other pathways. This notion is supported by the observation that 
pharmacological inhibition of central MC4R by intracerebroventricular (i.c.v.) administration 
of the synthetic MC3/4R antagonist SHU9119 still increases body fat in pair-fed rats (8). 
Moreover, the peripheral effects of the central melanocortin system involves alterations in 
the activity of the sympathetic nervous system (SNS), as i.c.v. administration of the MC3/4R 
agonist MTII dose-dependently increases renal sympathetic activity in mice (9). Furthermore, 
ablation of neurons that produce agouti-related protein (AgRP), the endogenous antagonist 
for MC4R, in mice changes autonomic output into metabolic organs, accompanied by 
a changed respiratory exchange ratio (RER) indicating altered nutrient combustion (10). 
Additionally, chronic i.c.v. SHU9119 treatment in rats increases the RER (8), indicative of 
reduced lipid utilization. Interestingly, variants near and in the MC4R gene in humans are not 
only associated with an increased RER (8), but also with reduced total energy expenditure 
(EE) (11,12), underscoring the importance of the melanocortin system in the regulation of EE.
A recently discovered and highly important contributor to EE is brown adipose tissue 
(BAT). BAT contributes to EE by combusting high amounts of TG into heat, a process mediated 
by uncoupling protein-1 (UCP-1) (13). Interestingly, MC4R expressing neurons project onto 
BAT (14), indicating that BAT may mediate the association between MC4R signaling and EE. 
Therefore, the aim of this study was to evaluate the role of the melanocortin system in BAT 
activity. For this purpose, we inhibited melanocortin receptor signaling using the MC3/4R 
antagonist SHU9119 in APOE*3-Leiden.CETP transgenic mice.
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Female APOE*3-Leiden.CETP mice on a C57Bl/6J background (15) were bred at our institutional 
animal facility and housed under standard conditions with a 12-12 h light-dark cycle with ad 
libitum access to food and water unless stated otherwise. From 12-22 weeks after birth, they 
were fed a Western-type diet containing 15% (w/w) cacao butter and 0.1% cholesterol (AB 
Diets, Woerden, The Netherlands) for the duration of the study. After 4 weeks of run-in diet, 
mice were randomized into groups that received i.c.v. administration of artificial cerebrospinal 
fluid (vehicle) or SHU9119 (5 nmol/day; Bachem, Bubendorf, Germany) in vehicle during 
14-17 days. Since SHU9119 induces hyperphagia (3), the effect of SHU9119 on BAT activity 
independent of food intake was also investigated by using an extra treated group that 
was pair-fed to the vehicle-treated group. All animal experiments were approved by the institu-
tional ethics committee on animal care and experimentation at Leiden University Medical 
Center.
Surgical procedure
For continuous i.c.v. administration of SHU9119 vs. vehicle, mice were sedated using a mixture 
of dexmedetomidine (0.5 mg/kg), midazolam (5 mg/kg) and fentanyl (0.05 mg/kg), and 
 cannulas (Brain Infusion Kit 3, ALZET Cupertino, CA, USA) were stereotactically placed in the 
left lateral ventricle of the brain (coordinates: -0.45 mm anteroposterior, -1.00 mm lateral 
and 2.50 mm dorsoventral from bregma). Osmotic mini-pumps (Model 1004, Alzet, CA) 
attached to the cannula via a catheter were implanted subcutaneously on the back slightly 
posterior to the scapulae. The skin was sutured and the sedation was antagonized with 
a mixture of antiparnezol (2.5 mg/kg), flumanezil (0.5 mg/kg) and naloxon (1.2 mg/kg). 
Buprenorphine (0.9 µg) was used as pain killer. After the surgery, mice were housed individually 
and food intake and body weight were monitored on a daily basis. By filling the catheters 
with vehicle, mice were allowed to recover for four days before actually receiving the 
assigned treatment for 17 days (collection of organs or VLDL production) or 14 days (indirect 
calorimetry and VLDL clearance).
Body composition
After 17 days of treatment, body composition (lean mass and fat mass) was determined in 
conscious mice using an EchoMRI-100 (EchoMRI, Houston, Texas). 
Indirect calorimetry
During the first 5 days of treatment, oxygen uptake (V˙ O2), carbon dioxide production (V˙ CO2) 
and physical activity were measured in fully automatic metabolic cages (LabMaster System, 
TSE Systems, Bad Homburg, Germany). The average RER, EE, carbohydrate and fat oxidation 
rates were calculated as described previously (16). 
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Liver lipid staining and content
Liver samples were perfused with PBS, collected, snap frozen and stored at -80°C. Sections 
of 10 µm were cut, fixed in 4% paraformaldehyde and stained with Oil-red-O and Mayer’s 
hematoxylin. Lipids were extracted according to a modified protocol from Bligh and Dyer 
(17). In short, small liver pieces were homogenized in ice-cold methanol (10 µL/mg tissue). 
1.8 mL of CH3OH: CHCl3 (3:1, vol/vol) was added to 45 µL of homogenate. After vigorous 
 mixing and centrifugation, the supernatant was dried and suspended in 2% Triton X-100. 
Concentrations of hepatic TG, total cholesterol (TC) and phospholipids (PL) were measured 
using commercially available enzymatic kits for TG (11488872, Roche Diagnostics, Germany), 
TC (11489232, Roche Diagnostics, Mannheim, Germany) and PL (3009, Instruchemie, Delfzijl, 
the Netherlands). Liver lipids were expressed per milligram of protein, which was deter-
mined using the BCA protein assay kit (Thermo Scientific, Rockford, IL, USA).
VLDL production
After 17 days of treatment, after 4 h of fasting (from 8.00 h to 12.00 h), the VLDL production 
rate was assessed. Mice were sedated using a mixture of ventranquil (6.25 mg/kg), dormicum 
(6.25 mg/kg), and fentanyl (0.31 mg/kg). Subsequently, mice were injected intravenously (i.v.) 
with 100 µL PBS containing 150 µCi Tran35S label to measure de novo apoB synthesis and 
blood samples were taken via tail bleeding (t=0). 30 min after injection of the Tran35S label, 
the mice received an i.v. injection of 500 mg of tyloxapol (Triton WR-1339, Sigma Aldrich, 
Germany) per kg body weight as 10% (w/w) solution in PBS, to block VLDL-TG clearance by 
lipoprotein lipase (LPL)-mediated TG hydrolysis. Additional blood samples were taken at 
t=15, 30, 60 and 90 min after tyloxapol injection and used for determination of plasma TG 
concentration. After 120 min, the mice were exsanguinated via the retro-orbital plexus. 
VLDL was isolated from serum after density gradient ultracentrifugation and counted for 
incorporated 35S-activity. VLDL particle size was determined using a Zetasizer (Malvern 
Instruments, Malvern, UK) and VLDL lipid composition was determined as described above. 
BAT histology and UCP-1 analysis
After 17 days of SHU9119 treatment, a part of interscapular BAT was fixed in 4% paraformal-
dehyde in PBS (pH 7.4) for 24 h, dehydrated and embedded in paraffin. 10 µm sections were 
cut, rehydrated and stained with Mayer’s hematoxylin and eosin. Another part of BAT was 
snap frozen and stored at -80°C. These BAT samples were homogenized in RIPA buffer, 
 centrifuged and protein concentration was determined using the BCA protein assay kit 
(Thermo Scientific, Rockford, IL, USA). Samples were diluted and denatured for 5 min at 95°C 
after adding Laemmli Sample Buffer (1:1, vol/vol; Serva, Heidelberg, Germany). Proteins within 
homogenates (1 µg protein) were separated on a 10% SDS-page gel and subsequently 
 transferred onto blotting membrane. The blotting membranes were then washed with 
PBS+0.1% Tween (PBS+T), blocked with 5% milk powder in PBS+T and incubated O/N at 4°C 
with the first antibody (anti-UCP-1 rabbit polyclonal; 1:5,000; Ab U6382, Sigma Aldrich, 
Germany). After washing (PBS-T) the second antibody (anti-rabbit IgG HRP conjugate; 
1:5,000; Promega, Madison, WI, USA) was added. After another wash with PBS-T and PBS, 
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SuperSignal Western Blot Enhancer (Thermo Scientific, Rockford, IL, USA) was added to the 
blotting membranes after which they were analyzed with Bio-Rad Quantity One.
VLDL clearance experiment
Glycerol tri[3H]oleate ([3H]TO) and [14C]cholesteryl oleate ([14C]CO) double-labeled VLDL-like 
emulsion particles (80 nm) were prepared as previously described (18). After 14 days of i.c.v. 
SHU9119 or vehicle treatment, mice were fasted for 4 h (from 8.00 h to 12.00 h) and injected 
i.v. with the radiolabeled emulsion particles (1.0 mg TG in 200 µL PBS) via the tail vein. 
At time points t=2, 5, 10 and 15 min after injection, blood was taken from the tail vein to 
determine the serum decay of both radiolabels. Immediately after the last blood withdrawal, 
mice were euthanized by cervical dislocation and perfused with ice-cold PBS for 5 min. 
Organs were harvested, weighed, and the uptake of 3H and 14C radioactivity was determined.
Statistical analysis
Differences between groups were determined using independent sample T-tests for normally 
distributed data and Mann-Whitney U tests for non-normal distributed data. Serum decay 
in the VLDL clearance experiment was analyzed using repeated measurements ANOVA 
with a Tukey’s Post-Hoc test. Probability values less than 0.05 were considered statistically 
significant. Data are presented as means ± SEM.
RESULTS
SHU9119 increases body weight and fat mass independent of food intake
APOE*3-Leiden.CETP mice were treated i.c.v. with SHU9119 or vehicle for 17 days. In ad libitum 
fed mice, throughout the treatment period, SHU9119 consistently increased food intake (on 
average 4.04±0.21 vs. 3.18±0.13 g/day, p<0.01) (FIGURE 1A), concomitantly with an increased 
body weight gain (after 17 days: 6.68±0.58 vs. 0.70±0.14 g, p<0.001). Obviously, SHU9119 also 
increased body weight in pair-fed mice when compared to vehicle-treated mice (4.14±0.45 
vs. 0.70±0.14 g, p<0.01) (FIGURE 1B) indicating that the SHU9119-induced weight gain is inde-
pendent of food intake. Determination of body composition using EchoMRI revealed that 
SHU9119 increased body weight under both ad libitum feeding and pair-fed conditions due 
to a selective increase in fat mass (10.6±1.2 and 9.6±1.0 vs. 4.9±1.1 g, p<0.05) (FIGURE 1C). The 
SHU9119-induced increase in body weight and fat mass was accompanied by an increase in 
gonadal white adipose tissue (gWAT) weight, both in ad libitum feeding conditions (+124%; 
1.32±0.13 vs. 0.59±0.12 g, p<0.001) and pair-fed conditions (+124%; 1.32±0.16 vs. 0.59±0.12 g, 
p<0.01) (FIGURE 1D).
SHU9119 reduces whole body fat oxidation independent of food intake
Since SHU9119 induced fat accumulation independent of food intake, we reasoned that 
SHU9119 likely affected EE. Therefore, we next assessed the effect of SHU9119 on energy 
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metabolism. Fully automated metabolic cages were used during the first 5 days of treatment 
in order to prevent a potential confounding effect of differences in body weight. Indeed, in 
ad libitum fed mice, SHU9119 decreased EE (-10%; 23.7±0.3 vs. 26.4±0.2 cal/h/g fat-free mass 
[FFM], p<0.05) (FIGURE 2A) and increased RER (0.92±0.01 vs. 0.88±0.00 p<0.01) (FIGURE 2B). 
These effects were not caused by an effect on carbohydrate oxidation (FIGURE 2C) but rather 
by a large reduction in fat oxidation (-43%; 5.1±1.0 vs. 8.9±0.3 cal/h/g FFM, p<0.001) (FIGURE 
2D). SHU9119 also reduced activity of the animals (-46%; 67±6 vs. 123±5 A.U., p<0.05; not 
shown). Strikingly, the effects of SHU9119 in pair-fed mice, as compared to the control group, 
were essentially similar as in ad libitum fed mice with respect to EE (23.9±0.1 cal/h/g FFM; 
p<0.01), RER (0.91±0.01; p<0.01), fatty acid oxidation (5.3±0.5 cal/h/g FFM; p<0.001) and activity 
(75±3 A.U.; p<0.05). Apparently, SHU9119 reduced EE, mainly because of reduced fat oxidation 
and independent of food intake.
FIGURE 1 - SHU9119 increases body weight and fat mass independent of food intake. APOE*3-Leiden.CETP 
mice were treated intracerebroventricularly with vehicle (n=21) or SHU9119 (5 nmol/day) while being fed ad 
libitum (n=21) or being pair-fed (pf) to the vehicle-treated group (n=22). Food intake A  and body weight gain 
B  were monitored on a daily basis. After 17 days of treatment, lean and fat mass were measured in a random 
selection of the mice (n=3-4 per group) using EchoMRI C . Part of the mice were used for the collection of 
organs, and weight of gonadal white adipose tissue was determined (n=10-11 per group) D . 
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SHU9119 induces hepatic steatosis, and this is due to increased food intake 
Since the liver is an important player in TG storage and secretion, we evaluated the effect of 
SHU9119 on liver weight and TG content as well as on hepatic VLDL-TG secretion. SHU9119 
induced hepatomegaly as evidenced by increased liver weight (+85%; 2.17±0.11 vs. 1.17±0.06 g, 
p<0.001) (FIGURE 3A) and aggravated hepatic steatosis, as shown by a selective increase in 
liver TG (+57%; 689±33 vs. 439±37 nmol/mg protein, p<0.001) (FIGURE 3B) and neutral lipid 
staining (FIGURE 3C). However, the effects of SHU9119 on the liver were fully attributed to the 
induction of hyperphagia, as hepatomegaly and hepatic steatosis were not induced under 
pair-fed conditions (FIGURES 3A-C). SHU9119 did not affect the VLDL-TG production rate in 
mice that were either fed ad libitum (3.39±0.14 mmol/L/h) or pair-fed (3.61±0.37 mmol/L/h) 
as compared to control mice (3.59±0.29 mmol/L/h) (FIGURES 3D, E). The VLDL-apoB production 
rate was slightly decreased in SHU9119-treated mice, but not in pair-fed SHU9119-treated 
FIGURE 2 - SHU9119 lowers energy expenditure by reducing fat oxidation independent of food intake. 
APOE*3-Leiden.CETP mice were treated intracerebroventricularly with vehicle (n=9) or SHU9119 (5 nmol/day) 
while being fed ad libitum (n=6) or being pair-fed (pf) to the vehicle-treated group (n=9). During the first 
5 days of treatment, mice were housed in fully automated metabolic cages. Energy expenditure A , respiratory 
exchange ratio B , carbohydrate oxidation C  and fat oxidation D  were calculated from O2 uptake and CO2 
excretion. 
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FIGURE 3 - SHU9119 induces hepatomegaly and steatosis only in ad libitum fed mice. APOE*3-Leiden.CETP 
mice were treated intracerebroventricularly with vehicle (n=21) or SHU9119 (5 nmol/day) while being fed ad 
libitum (n=21) or being pair-fed (pf) to the vehicle-treated group (n=20). After 17 days of treatment, part of the 
mice were sacrificed (n=10-11 per group) to collect organs and determine liver weight A , and to determine 
liver content of triglycerides (TG), total cholesterol (TC) and phospholipids (PL) B . Frozen liver samples were 
sectioned and stained with a neutral lipid staining (Oil-red-O) and hematoxylin, and representative pictures 
are shown C . The remaining mice (n=8-10 per group) were 4 h fasted, consecutively injected with Trans35S 
label and tyloxapol, and blood samples were drawn up to 90 min after tyloxapol injection. Plasma TG concen-
tration was determined and plotted as the increase in plasma TG relative to t=0 D . The rate of TG production 
was calculated from the slopes of the curves from the individual mice E . After 120 min, the total VLDL fraction 
was isolated by ultracentrifugation and the rate of newly synthesized VLDL-ApoB was determined F . The 
VLDL fractions were assayed for particle size G  and lipid content H . 
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FIGURE 4 - SHU9119 causes malfunction of brown adipose tissue. APOE*3-Leiden.CETP mice were treated 
intracerebroventricularly with vehicle (n=21) or SHU9119 (5 nmol/day) while being fed ad libitum (n=21) or being 
pair-fed (pf) to the vehicle-treated group (n=22). After 17 days of treatment, part of the mice were sacrificed 
(n=10-11 per group) to collect organs and determine interscapular brown adipose tissue weight (iBAT) A  and 
morphology B , and to determine UCP-1 protein content C . In a second experiment, after 14 days of i.c.v. treat-
ment with vehicle (n=8) or SHU9119 (5 nmol/day) while being fed ad libitum (n=5) or being pf to the vehicle-
treated group (n=9), mice were 4h fasted and consecutively injected with 3H]TO and [14C]CO-labeled VLDL-like 
emulsion particles. Plasma [3H]TO D  and [14C]CO E  were determined at the indicated time points and plotted 
relative to the dosage at t=2 min. At 15 min after injection, organs were isolated and uptake of the 3H-activity 
F  and 14C-activity G  was determined. 
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mice (FIGURE 3F). In line with these observations, SHU9119 did not affect VLDL particle size 
(FIGURE 3G), VLDL composition (FIGURE 3H), or hepatic expression of the genes Apob, Mttp, 
Dgat2 involved in VLDL synthesis (not shown). Taken together, SHU9119 induced hepatic 
 steatosis secondary to its induction of hyperphagia and without affecting VLDL-TG secretion.
SHU9119 induces brown adipose tissue dysfunction independent of food intake
Since BAT strongly contributes to fat oxidation and total energy expenditure, we subse-
quently determined the effect of SHU9119 treatment on BAT function. SHU9119 treatment 
increased BAT weight in ad libitum fed mice (+50%; 0.15±0.01 vs. 0.10±0.01 g, p<0.01) and 
tended to increase BAT weight in pair-fed animals (+24%; 0.13±0.01 g, p=0.06) (FIGURE 4A). 
Surprisingly, SHU9119 dramatically increased intracellular lipid droplet size in BAT in both 
ad libitum fed and pair-fed mice (FIGURE 4B), along with largely reduced UCP-1 protein levels 
in BAT (-61%; p<0.001 and -61%, p<0.001) (FIGURE 4C). These data imply that SHU9119 decreases 
BAT activity independent of food intake, which may result in a decreased capacity of BAT to 
take up VLDL-TG for subsequent combustion as well as decreased burning of intracellulary 
stored TG.
Therefore, we next determined the effect of SHU9119 on the kinetics of i.v. injected [3H]
TO and [14C]CO double-labeled VLDL-like emulsion particles after 14 days of treatment. 
SHU9119 impaired the plasma decay of [3H]TO (FIGURE 4D) and [14C]CO (FIGURE 4E) under 
ad libitum fed conditions, and that of [14C]CO under pair-fed conditions (FIGURE 4E). At 15 min 
after injection, the distribution of radiolabels over the organs was assessed. In control mice, 
[3H]TO uptake by BAT (31.6±8.0%/g) was much higher than the uptake by liver (~4-fold), 
muscle (~25-fold) and WAT (~25-fold). Interestingly, SHU9119 tended to selectively decrease 
the uptake of [3H]TO by BAT in the ad libitum fed group, and significantly did so in mice 
 pair-fed to the control group (-57%; 13.7±1.9% of injected dose/g; p<0.05) (FIGURE 4F). In the 
control group, as compared to the 3H-label, the uptake of the 14C-label was much lower in 
BAT (~10-fold), muscle (~4-fold), heart (~3-fold) and WAT (~3-fold), while the uptake of 
14C-label was higher in liver (~3-fold). This pattern is compatible with selective delipidation 
of the VLDL-like emulsion particles in plasma by the LPL-expressing tissues (i.e. uptake of 3H 
activity), with subsequent uptake of the core remnant by the liver (i.e. uptake of 14C activity). 
SHU9119 treatment tended to reduce the uptake of [14C]CO in the liver of both ad libitum 
fed mice(-20%; 20.8±3.6 %/g; p=0.11) and pair-fed mice (-11%; 23.1±1.5 %/g; p=0.25) as compared 
to the control group (26.1±2.1 %/g), whereas it decreased the uptake of [14C]CO by BAT (ad 
libitum fed: -39%; p=0.24 ; pair-fed: -57%; p<0.01) (FIGURE 4G).
DISCUSSION
The melanocortin system is an important regulator of energy balance and MC4R deficiency 
is the most common monogenic cause of obesity. BAT recently emerged as an important 
player in energy expenditure by combusting high amounts of TG towards heat. In addition, 
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MC4R expressing neurons project onto BAT (14). Hence, the association between MC4R and 
energy expenditure may be mediated by BAT. In the current study we aimed to evaluate the 
direct effect of the melanocortin system on BAT activity. For this purpose, we inhibited the 
central melanocortin system using the MC3/4R synthetic antagonist SHU9119 in APOE*3-
Leiden,CETP mice. We found that i.c.v. administration of SHU9119 decreased EE and BAT 
activity, concomitant with selectively impaired uptake of TG from plasma by BAT, independent 
of food intake. 
Both in ad libitum as well in pair-fed conditions, SHU9119 treatment increased body 
weight and WAT mass. These data are in line with those of Nogueiras et al. (8), who attributed 
weight gain and adiposity upon SHU9119 treatment to an increase in both lipid uptake as 
well as TG synthesis for storage in WAT. We also showed that in ad libitum fed conditions, 
SHU9119 induced ectopic lipid deposition in the liver, manifested by hepatomegaly and 
hepatic steatosis. Hepatic steatosis did not develop in pair-fed mice, indicating that this 
effect is a direct consequence of SHU9119-induced hyperphagia. Similar effects on the liver 
are observed after 4 days of i.c.v. SHU9119 treatment in rats (19) and in MC4R deficient mice, 
which in addition develop steatohepatitis when fed a high-fat diet and have therefore been 
proposed as a novel mouse model for non-alcoholic steatohepatitis (NASH) (20). Although 
hepatic steatosis could promote the secretion of hepatic lipid as VLDL (21), SHU9119 did not 
increase the production, size or composition of newly synthesized VLDL. Our data corroborate 
those of Stafford et al.(22) who showed that a single i.c.v. injection of 15 µg SHU9119 does 
not affect VLDL-TG production in rats. 
Because SHU9119 was able to increase body adiposity independent of a change in food 
intake, we reasoned that SHU9119 reduces EE. Indeed, studies with metabolic cages 
 confirmed that inhibition of the central melanocortin system reduced EE. SHU9119 treat-
ment attenuated locomotor activity to some extent, which may have contributed to this 
decreased EE. More specifically, SHU9119 selectively reduced fat oxidation, whereas carbohy-
drate oxidation remained unaffected. This reduction in fat oxidation and total EE occurred 
independently of food intake and before changes in body weight were observed, indicative 
of a causal relation between reduced energy expenditure and the induction of obesity. 
Likewise, a previous study has shown that 7 days of i.c.v. injections with SHU9119 in rats 
increased the RER and thereby decreased fat utilization independent of food intake (8). As 
locomotor activity was not affected in that study, reduced fat oxidation may be dominant 
over the effect of decreased locomotor activity in the decrease in EE. In addition, MC4R-
deficient humans also display an increase in RER (8). Taken together, we suggest that, in 
general, inhibition of the melanocortin system results in a shift towards decreased meta-
bolic use of lipids leading to elevated fat deposition in WAT.
Since BAT is a highly active metabolic tissue involved in EE and regulation of weight gain, 
we next proposed that the reduction in fat oxidation could be largely attributed to 
decreased activity of BAT. Indeed, in both ad libitum and pair-fed conditions, analysis of BAT 
revealed that SHU9119 largely increased intracellular lipid stores and decreased the protein 
level of the UCP-1, both indicative of reduced BAT activity (23). These data corroborate previous 
findings showing that chronic i.c.v. treatment of ad libitum fed rats with SHU9119 lowered 























FIGURE 5 - Proposed model of the effect of SHU9119 on peripheral triglyceride metabolism. Under physiological 
conditions MC3/4R signalling is required for basal combustion of VLDL-derived triglycerides (TG) in brown 
adipose tissue (BAT), preventing storage of excess TG in WAT A . Inhibition of central MC3/4R signaling by 
SHU9119 reduces BAT activity, thereby reducing the uptake and combustion of VLDL-TG by BAT. As a consequence, 
excess TG is stored in WAT, independent of SHU9119-induced hyperphagia B .
BAT temperature during the night (24). Moreover, 7 daily i.c.v. injections of AgRP, the endoge-
nous antagonist for MC4R, decreased UCP-1 gene expression in pair-fed rats (25), while acute 
i.c.v. injections of GLP-1, which indirectly stimulates MC4R, increased BAT thermogenesis by 
increasing activity of the sympathetic fibers towards BAT (26). These data can explain previous 
observations that MC4R deficient mice are unable to increase UCP-1 levels in BAT upon a 
high fat diet or cold stimulus (14). Since the activity of BAT is dependent on output from the 
SNS from the hypothalamus (27,28), it is likely that inhibition of the melanocortin system 
reduces sympathetic output to BAT.
Recently, Bartelt et al. (13) identified BAT as a major organ involved in plasma VLDL-TG 
clearance, with 24 hours of cold induction resulting in normalisation of plasma TG levels in 
hypertriglyceridemic mice. In a first experiment, we did observe a large increase in plasma 
TG levels upon 17 days of SHU9119 treatment under ad libitum conditions (SUPPLEMENTAL 
FIGURE 1A), which would be consistent with reduced uptake of TG by BAT. However, in a sub-
sequent study the SHU9119-induced increase in plasma TG only reached significance under 
pair-fed conditions (SUPPLEMENTAL FIGURE 1B). Likewise, i.c.v. infusion of the MC4R synthetic 
antagonist HS104 also failed to increase plasma TG levels in pair-fed rats (29). It should be 
noted that MC4R deficient mice have only modestly increased plasma TG levels compared 
to control mice (+30%) (30), implying that partial inhibition of MC4R by SHU9119 may be 
insufficient to significantly increase plasma TG levels. In heterozygous MC4R-deficient subjects, 
plasma TG levels are increased (1.7 vs. 1.3 mmol/L) (31), indicating that the melanocortin 
 system does play a role in the regulation of plasma VLDL-TG levels in humans.
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Recently, Perez-Tilve et al. (32) demonstrated that inhibition of the central melanocortin 
neurons by either ghrelin or SHU9119 in wild-type mice increased circulating cholesterol, 
related to a decreased hepatic expression of SR-BI involved in the selective hepatic uptake of 
HDL-cholesteryl esters. In our study in APOE*3-Leiden.CETP mice with a human-like lipoprotein 
metabolism, SHU9119 did not increase total cholesterol (SUPPLEMENTAL FIGURE 1) despite 
decreased hepatic SR-BI expression (SUPPLEMENTAL FIGURE 2). This is likely due to the expression 
of human CETP that provides an alternative route for the clearance of HDL-cholesterol, as 
CETP expression in SR-BI-deficient mice also precludes an increase in HDL-cholesterol (33). 
Likewise, humans with heterozygous MC4R deficiency also do not have increased HDL-
cholesterol levels (31), pointing to a species-dependent effect of MC4R function on HDL-
cholesterol levels.
In conclusion, inhibition of central MC3/4R signaling by SHU9119 reduces BAT activity 
thereby reducing the uptake and combustion of VLDL-TG by BAT. As a consequence, excess 
lipids are stored in WAT (FIGURE 5). We anticipate that MC4R agonists that are currently in 
develop ment to combat obesity, increase energy expenditure through activation of BAT.
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SUPPLEMENTARY FIGURE 1 - Effect of SHU9119 on plasma lipid levels. A  In a first experiment, APOE*3-Leiden.
CETP mice were treated intracerebroventricularly with vehicle (n=10) or SHU9119 (5 nmol/day) (n=7). After 
17 days of treatment, blood was drawn after a 4 h fast (from 8.00 h to 12.00 h) via tail vein bleeding in paraoxon-
coated capillary tubes to prevent ex vivo lipolysis and assayed for triglycerides (TG), total cholesterol (TC) 
and phospholipids (PL) using commercially available enzymatic kits for TG (11488872, Roche Diagnostics, 
Germany), TC (11489232, Roche Diagnostics, Mannheim, Germany) and PL (3009, Instruchemie, Delfzijl, the 
Netherlands). B  In a second experiment, mice were treated i.c.v. with vehicle (n=21) or SHU9119 (5 nmol/day) 
while being fed ad libitum (n=21) or being pair-fed (pf) to the vehicle-treated group (n=22). Plasma lipids were 
determined after 4 h of fasting. 
Values are means ± SEM. *p<0.05, **p<0.01 compared to control.
SUPPLEMENTARY FIGURE 2 - Effect of SHU9119 on hepatic SR-BI protein levels. APOE*3-Leiden.CETP mice were 
treated intracerebroventricularly with vehicle (n=21) or SHU9119 (5 nmol/day) while being fed ad libitum 
(n=21) or being pair-fed (pf) to the vehicle-treated group (n=20). After 17 days of treatment, part of the mouse 
groups were sacrificed (n=10-11 per group) to collect organs and determine hepatic SR-BI protein levels. 
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ABSTRACT
Brown adipose tissue (BAT) combusts high amounts of fatty acids into heat, thereby 
lowering plasma triglyceride levels and reducing obesity. However, the precise role  
of BAT in plasma cholesterol metabolism and atherosclerosis development remains 
unclear. Here we show that BAT activation by the ß3-adrenergic receptor agonist 
CL316243 in dyslipidemic APOE*3-Leiden.CETP mice, a well-established model for 
human-like lipoprotein metabolism, increases energy expenditure, lowers body fat 
and plasma triglyceride levels, and attenuates plasma cholesterol levels and the 
development of atherosclerosis. Mechanistically, we show that BAT activation 
enhanced the selective uptake of fatty acids from glycerol tri[3H]oleate-labeled  
VLDL-like emulsion particles into BAT. Importantly, the cholesterol and atherosclerosis 
lowering effects of BAT activation were dependent on a functional hepatic apoE-LDLR 
clearance pathway, as BAT activation in Apoe-/- and Ldlr-/- mice, while lowering 
 triglyceride levels, did not attenuate hypercholesterolemia and atherosclerosis.  
We demonstrate that activation of BAT is a powerful therapeutic tool to improve 
 dyslipidemia and protect from atherosclerosis.




Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the 
Western world, and are mainly caused by atherosclerosis for which dyslipidemia is a main 
risk factor. As current treatment strategies of atherogenic dyslipidemia prevent only 30% of 
all cardiovascular events (1), novel treatment strategies are highly warranted.
Brown adipose tissue (BAT) is a highly active metabolic tissue being present and active 
in adults (2,3). Brown adipocytes are mainly present in fat pads, but also lie scattered in 
 certain white adipose tissue (WAT) depots. The development of these so-called peripheral, 
inducible brown adipocytes or ‘beige cells’ can be stimulated by prolonged cold exposure or 
pharmacological adrenergic stimulation, a process called ‘browning’ (4,5). Both brown and 
beige adipocytes are characterized by a large number of mitochondria and numerous small 
lipid droplets and both cell types are functionally thermogenic (6). Physiologically, BAT is 
activated by cold exposure via sympathetic neurons that release noradrenalin (7). The 
noradrenalin-stimulated activation of brown adipocytes can be pharmacologically mimicked 
by selective ß3-adrenergic receptor (ß3-AR) treatment (8,9). Activation of the ß3-AR rapidly 
induces intracellular lipolysis of TG from lipid droplets, releasing fatty acids (FA). FA are 
directed towards mitochondria where they either allosterically activate the uncoupling 
 protein-1 (UCP1) in the inner membrane of the mitochondrion (10), or undergo oxidation. 
The intracellular TG stores of the brown adipocyte are replenished mainly by uptake of FA 
derived from TG-rich lipoproteins in the plasma (11).
The magnitude of the plasma TG clearance capacity of BAT became clear only recently. 
We showed that activation of BAT in mice via cold or metformin potently reduces plasma TG 
levels and obesity (12,13). Therefore, activation of BAT is now considered a promising new 
therapeutic avenue to combat hypertriglyceridemia and obesity (14,15). However, increased 
turnover of plasma lipoproteins may also lead to adverse side effects when pro-atherogenic 
cholesterol-rich remnants that arise from TG turnover accumulate in plasma. In that vein, 
BAT activation by cold exposure has been described to aggravate hypercholesterolemia and 
atherosclerosis development in Apoe-⁄- and Ldlr-⁄- mice (16). We reasoned that the enhanced 
clearance of plasma TG upon BAT activation requires efficient clearance of cholesterol-
enriched lipoprotein remnants by the liver, a pathway that is considered to be crucially 
dependent on a functional apoE-LDLR axis. Here, we investigate the effects of ß3-AR-mediated 
BAT activation on cholesterol metabolism and atherosclerosis development in APOE*3-
Leiden.CETP (E3L.CETP), a well-established model for human-like lipoprotein metabolism 
that unlike Apoe-⁄- and Ldlr-⁄- mice responds well to the lipid-lowering and anti-atherogenic 
effects of statins, fibrates and niacin (17-19). 
We show that pharmacological activation of BAT in E3L.CETP mice enhances lipolytic 
 conversion of TG-rich lipoproteins in BAT, resulting in a pronounced reduction in plasma 
 cholesterol and TG levels and ultimately marked attenuation of atherosclerosis development. 
In addition, we show that Apoe-⁄- and Ldlr-⁄- mice do not respond to the plasma cholesterol-
lowering activity of BAT and are not protected from atherosclerosis development, under-
lining the importance of the apoE-LDLR axis for the anti-atherogenic potential of BAT.
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RESULTS
Activation of BAT augments fatty acid combustion and uptake under atherogenic conditions
We first assessed the effect of BAT activation on energy expenditure and lipid storage in 
E3L.CETP mice fed an atherogenic Western-type diet (WTD) for 10 weeks while treated 
with the selective ß3-AR agonist CL316243 (3x 20 µg/mouse/week; subcutaneous) or vehicle 
(PBS). ß3-AR agonism tended to reduce body mass (up to -8%; P=0.05; FIGURE 1A) and 
 markedly reduced total fat mass gain (up to -81%; P<0.001; FIGURE 1B), without affecting lean 
mass (FIGURE 1C). Accordingly, in the ß3-AR agonist-treated mice the weight of the individual 
WAT pads was lower (ranging from -25 to -52%; P<0.05; FIGURE S1A), and the lipid droplets 
within white adipocytes were smaller (-48%; P<0.001; FIGURES S1B-C).
The ß3-AR-mediated reduction in body fat gain was likely the consequence of increased 
 adaptive thermogenesis as energy expenditure was markedly increased on the day of treat-
ment (+17%; P<0.001; FIGURE 1D) without differences in activity levels (FIGURE 1E) or food intake 
(not shown). The increase in energy expenditure was confined to an increased fat oxidation 
(+67%; P<0.001; FIGURE 1F) rather than carbohydrate oxidation (FIGURE 1G), and  consequently, 
ß3-AR agonism reduced the respiratory exchange ratio (-3.5%; P<0.001; FIGURE 1H). The enhanced 
energy expenditure was accompanied by a marked activation of interscapular BAT (iBAT) as 
 evidenced by reduced intracellular lipid vacuole size in iBAT (-87%; P<0.05; FIGURES S2A-B), 
reduced BAT pads weight (approx. -25%; FIGURE S1A), and increased expression of UCP1 (+43%; 
P<0.01; FIGURES S2C-D). In addition, ß3-AR agonism increased browning of WAT (FIGURES S3A-B). 
BAT activation markedly reduced plasma TG levels throughout the treatment period (-54%; 
P<0.001; FIGURE 2A), caused by a reduction in VLDL-TG (FIGURE 2B). To confirm that this reduction 
was caused by enhanced uptake of TG-derived FA by BAT, we determined the effect of BAT 
activation on the serum decay and organ uptake of glycerol tri[3H]oleate (triolein, TO)-labeled 
VLDL-mimicking emulsion particles (20). Indeed, ß3-AR agonism markedly accelerated the 
serum clearance of [3H]TO (FIGURE 2C; t½= 1.7±0.2 vs. 3.6±0.8 min; P<0.05) by selectively 
increasing the uptake of [3H]TO-derived activity by the various BAT depots (approx. +120%; 
P<0.05; FIGURE 2D). Interestingly, the uptake of [3H]oleate by WAT fat depots was also 
increased (approx. +120%; P<0.01), indicating enhanced uptake by beige adipocytes within 
WAT. Taken together, these data show that also under atherogenic conditions ß3-AR agonism 
activates BAT E3L.CETP mice, resulting in increased uptake and combustion of VLDL-TG-
derived FA and a consequent decrease in plasma TG levels.
Activation of BAT reduces cholesterol-rich remnant lipoproteins levels
Since disturbed cholesterol metabolism rather than disturbed triglyceride metabolism is 
the main determinant for atherosclerosis development (21), we next investigated the effect 
of BAT activation on cholesterol metabolism in E3L.CETP mice. BAT activation consistently 
reduced plasma total cholesterol (TC) levels throughout the treatment period (approx. -23%; 
P<0.05; FIGURE 2E) which was due to a reduction of plasma (V)LDL-cholesterol ((V)LDL-C) 
 levels (approx. -27%; P<0.05; FIGURE 2F). Lipoprotein fractionation using fast performance 
 liquid chromatography (FPLC) confirmed the improved cholesterol profile (FIGURE 2G).
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FIGURE 1 - 3-AR agonism reduces body fat mass and increases energy expenditure. Western-type diet-fed 
E3L.CETP mice were treated with the ß3-AR agonist CL316243 or vehicle and body weight A , gain of total body 
fat mass B  and lean mass C  were determined at the indicated time points. During the ninth week of treat-
ment, mice were housed in fully automated metabolic cages and energy expenditure D , physical activity E , 
fat oxidation F  and carbohydrate oxidation G  were determined. In addition, respiratory exchange ratio was 
determined H . Data are shown as the first 12 hours directly after the injection with CL316243 or vehicle (‘Day 
of treatment’) and the same 12-hours period 24 hours later (‘Day after treatment’).
Values are means ± S.E.M. (n=13-19 per group). **P<0.01, ***P<0.001
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FIGURE 2 - Activation of BAT improves both TG and cholesterol metabolism. Western-type diet-fed E3L.CETP 
mice were treated with the ß3-AR agonist CL316243 or vehicle and fasting plasma TG levels A  were measured 
at the indicated time points. The distribution of TG over lipoproteins was determined after 10 weeks of 
 treatment on pooled plasma samples per group B . CL316243- and vehicle-treated mice were injected with 
[3H]TO-labeled VLDL-like emulsion particles and clearance from plasma C  and organ and tissue uptake 
15 min after injection D  were determined. Fasting plasma total cholesterol E  and (V)LDL-cholesterol ((V)LDL-C; 
F ) were assessed at the indicated times during the study. The distribution of total cholesterol over lipoproteins 
was determined after 10 weeks of treatment on pooled plasma samples per group G .
Values are means ± S.E.M. (n=13-19 per group). *P<0.05, **P<0.01, ***P<0.001
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Activation of BAT reduces atherosclerosis development by improving the plasma cholesterol 
profile
Next, we studied whether the decreased (V)LDL levels were accompanied by reduced athero-
sclerosis development. To this end, we determined atherosclerotic lesion area as well as severity 
and composition of the lesions in the root of the aortic arch after 10 weeks of BAT activation. 
Indeed, sustained BAT activation by ß3-AR agonism markedly reduced  atherosclerotic lesion 
area throughout the aortic root (FIGURES 3A-B), resulting in 43% lower mean athero sclerotic 
lesion area (FIGURE 3C). BAT activation clearly reduced the severity of the lesions, as indicated by 
more mild lesions (i.e. type I-III; +64%; P<0.05) and less severe lesions (i.e. type IV-V; -66%; 
P<0.05) (FIGURE 3D) without significantly affecting atherosclerotic lesion compo sition (i.e. 
 collagen, vascular smooth muscle cell and macrophage content of the lesions; FIGURES 3E-G) or 
the lesion stability index (i.e. ratio collagen/macrophage area; FIGURE 3H).
To evaluate the contribution of TG versus TC lowering to the reduction in atherosclerosis, 
univariate regression analyses were performed. To linearize data for analysis, the atheroscle-
rotic lesion area was square root (SQRT)-transformed (19) and plotted against the exposure 
(i.e. AUC of plasma lipid for the complete treatment period) of TG, and TC. The SQRT of the 
lesion area did not correlate with plasma TG exposure (ß=0.028; R2=0.086; P=0.10; FIGURE 3I), 
but did correlate with plasma TC exposure (ß=0.054; R2=0.333; P<0.001; FIGURE 3J). Additional 
univariate regression analyses showed that the (V)LDL-C exposure specifically predicts the 
SQRT of the lesion area (ß=0.055; R2=0.358; P<0.001; FIGURE 3K). These analyses thus strongly 
indicate that a reduction in plasma (V)LDL-C is the main contributor to the anti-atherogenic 
effect of ß3-AR-mediated activation of BAT.
The anti-atherogenic potential of BAT activation crucially depends on functional hepatic 
lipoprotein clearance
As BAT activation by cold in Apoe-⁄- and Ldlr-⁄- mice has been described to aggravate atheroscle-
rosis development (16), we evaluated the role of apoE, the main clearance ligand for TG-rich 
lipoprotein remnants, in the (V)LDL-C-reducing effect of BAT activation. In order to control 
for increases in food intake as described in these mouse models during cold adaption (16), 
as well as to match dietary cholesterol intake we studied the effect of ß3-AR-mediated 
BAT activation in WTD-pair-fed Apoe-⁄- mice. Similar as in E3L.CETP mice, activation of BAT 
FIGURE 3 - Activation of BAT reduces atherosclerotic lesion development and severity via improving the 
plasma cholesterol profile. Slides of the valve area of the aortic root of ß3-AR agonist CL316243- and vehicle-
treated E3L.CETP mice were stained with hematoxylin-phloxine-saffron and representative pictures are shown 
A . Lesion area as a function of distance was determined in four consecutive sections per mouse starting from 
the appearance of open aortic valve leaflets B . The mean atherosclerotic lesion area was determined from the 
four cross sections from B C  and lesions were categorized according to lesion severity D . The smooth muscle 
cell E , collagen F  and macrophage G  content of the lesions were determined and the  stability index (collagen/
macrophage content of the lesions; H ) was calculated. The square root (SQRT) of the atherosclerotic lesion area 
from B was plotted against the plasma total TG I , total cholesterol J  and (V)LDL-cholesterol ((V)LDL-C; K) 
exposure during the 10 week treatment period. Linear regression analyses were  performed.
Values are means ± S.E.M. (n=13-19 per group). *P<0.05, **P<0.01
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reduced body weight, WAT pad size and plasma TG levels (FIGURES 4A and S4A-C). However, 
activation of BAT did neither reduce plasma TC and (V)LDL-C levels (FIGURES 4B and S4D) nor 
did it reduce atherosclerosis development (FIGURES 4C-D) or alter plaque composition (data 
not shown) in Apoe-⁄- mice. Accordingly, the SQRT of the lesion area did not correlate with 
either total plasma TG exposure or plasma TC exposure during the study (FIGURES 4E-F).
As the (V)LDL-C-reducing effect of BAT activation thus crucially depends on apoE-mediated 
clearance, we next investigated the role of the LDLR, the main hepatic clearance receptor 
for apoE-containing lipoprotein remnants. Similar as in E3L.CETP mice, activation of BAT 
FIGURE 4 - Activation of BAT in Apoe-⁄- and 
Ldlr-⁄- mice reduces plasma TG, but not TC 
and atherosclerosis. Western-type diet-fed 
Apoe-⁄- mice were treated with the ß3-AR 
agonist CL316243 or vehicle and fasting 
 plasma TG A  and total cholesterol B  levels 
were measured at the indicated time points. 
Slides of the valve area of the aortic root of 
CL316243- or vehicle-treated Apoe-⁄- mice 
were stained with hematoxylin-phloxine-
saffron (HPS) and representative pictures 
are shown C . Mean atherosclerotic lesion 
area was determined from four consecutive 
cross sections per mouse starting from the 
appearance of open aortic valve leaflets D . 
The square root (SQRT) of the atherosclerotic 
lesion area from D in Apoe-⁄- mice was plot-
ted against the  plasma total TG E  and total 
cholesterol F  exposure during the 12-week 
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Western-type diet-fed Ldlr-⁄- mice were 
treated with the ß3-AR agonist CL316243 or 
vehicle and fasting  plasma TG G  and total 
cholesterol H  levels were measured at the 
indicated time points. Slides of the valve area 
of the aortic root of CL316243- or vehicle-
treated Ldlr-⁄- mice were stained with HPS 
and representative pictures are shown I . 
Mean atherosclerotic lesion area was deter-
mined from four consecutive cross sections 
per mouse starting from the appearance of 
open aortic valve leaflets J . The square root 
(SQRT) of the atherosclerotic lesion area 
from J in Ldlr-⁄- mice was plotted against the 
plasma total TG K  and total cholesterol L  
exposure during the 12-week treatment 
 period. Linear regression analyses were 
performed.




















































































reduced body weight, WAT pad size and plasma TG levels in WTD-pair-fed Ldlr-⁄- mice (FIGURES 
4G and S5A-C). However, activation of BAT in Ldlr-⁄- mice did neither reduce plasma TC and (V)
LDL-C levels (FIGURES 4H and S5D), nor reduce atherosclerosis development (FIGURES 4I-J) or 
alter plaque composition (data not shown), nor did the SQRT of the lesion area correlate 
with the total plasma TG and TC exposure during the study (FIGURES 4K-L). Taken together, 
these findings indicate that activation of BAT reduces plasma (V)LDL-C and subsequently 
reduces atherosclerosis development through enhanced LDLR-mediated hepatic clearance 
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Since its rediscovery in human adults in 2009 (2,3,22), BAT has been considered a promising 
therapeutic target for obesity and associated metabolic disorders. The anti-obesity potential 
of BAT has been irrefutably proven in murine studies (23,24) and shown in human studies 
(2,25,26). However, the effect of BAT activation on cholesterol metabolism and atherosclerosis 
development remained controversial if not elusive. The present study demonstrates that 
activation of BAT potently improves plasma cholesterol metabolism via a mechanism 
involving local lipolysis of TG-rich lipoproteins in BAT followed by increased clearance of 
apoE-containing lipoprotein remnants via the LDLR pathway. As a result, BAT activation 
reduces atherosclerotic lesion size and severity.
We observed that BAT activation decreased atherosclerosis development in E3L.CETP 
mice that possess a functional apoE-LDLR clearance pathway, but not in Apoe-⁄- and Ldlr-⁄- 
mice, both of which have an abrogated apoE-LDLR clearance pathway. This indicates that a 
crucial event in the anti-atherogenic property of BAT is the concomitant ability of the liver to 
clear apoE-enriched lipoprotein remnants, generated by BAT-mediated lipolysis of TG-rich 
lipoproteins, via the LDLR. E3L.CETP mice express a naturally occurring mutant form of 
human apoE3 that slows down remnant clearance, but does not abrogate the interaction 
with the LDLR (27). This results in an attenuated hepatic remnant clearance that is sufficient 
to induce dyslipidemia and atherosclerosis when feeding a WTD, but, importantly, the 
hepatic remnant clearance route is still functional and can be modulated. Accordingly, 
E3L.CETP mice respond to cholesterol-lowering drugs such as statins (18), fibrates (17) and 
niacin (19) in a similar manner as humans, whereas Apoe-⁄- and Ldlr-⁄- mice do not. According 
to this view, it is not surprising that Dong et al. (16) recently observed that BAT activation by 
cold in Apoe-⁄- and Ldlr-⁄- mice actually increased plasma (V)LDL-C levels and atherosclerosis. 
Likely, in these hyperlipidemic mouse models prolonged BAT activation results in lipoprotein 
remnant levels in plasma exceeding the hepatic clearance capacity.
Our work sets the foundation for future studies that may investigate the anti-atherogenic 
potential of BAT in humans. As the discovery that functional BAT is present and active in 
human adults was made only in the last decade (2,3), recent studies have focused on the 
physiological relevance of BAT for humans. That BAT is likely involved in energy metabolism 
and obesity development in humans appeared from studies that showed that BAT activity is 
inversely correlated to obesity (28) and that cold acclimation recruits BAT (29) and lowers fat 
mass (26). In addition, South Asians, who have a high susceptibility to metabolic disorders, 
have decreased energy expenditure associated with decreased BAT volume and activity (30). 
Importantly, BAT activation by means of cold acclimation also improved cholesterol meta-
bolism in human patients with hypercholesterolemia (31), underscoring the potential of 
BAT activation as an anti-atherogenic treatment in humans. Future prospective studies are 
 evidently needed to verify the anti-atherogenic properties of BAT activation in human subjects. 
Though the ß3-AR is abundantly present on rodent BAT, it is still uncertain whether this 
isoform also controls BAT activity in humans. Although differentiated brown adipocytes 
from human multipotent adipose-derived stem cells could be activated by the ß3-AR agonist 
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CL316243 (32), treatment of humans with ß3-AR agonists showed no or only minor improve-
ment of metabolic parameters (33,34). This may be due to low bioavailability of the agonist 
or low ß3-AR expression in human BAT, as plasma concentration of the agonist and reduction 
in fat mass and resting metabolic rate were in fact positively correlated. Alternatively, the 
ß1-AR and/or ß2-AR may be involved in human BAT function, as blockade of these receptors 
by propranolol decreased 18F-fluorodeoxyglucose uptake by BAT as visualized by PET-CT 
scans (35), though the thermogenic responses remain unaffected (36). Collectively, this 
may suggest that 18F-fluorodeoxyglucose uptake is regulated by ß1- or ß2-ARs, whereas 
mitochondrial uncoupling itself is regulated by ß3-ARs. Future studies should thus be directed 
at investigating the precise role of ß-ARs in human BAT function.
The long-term objective of this work is to set out novel therapeutic targets to activate 
BAT beyond ß-AR stimulation. Promising targets include the cannabinoid 1 receptor (CB1R) 
on BAT (Boon and Rensen, unpublished), irisin (37) and the fibroblast growth factor FGF21 (37), 
which massively activate BAT and induce browning in mice, and lowers plasma cholesterol 
in both mice and humans (37-39).
In conclusion, our data demonstrate that activation of BAT lowers plasma cholesterol 
levels and protects against atherosclerosis development, a scenario that is dependent on 
the apoE-LDLR clearance pathway for lipoprotein remnants. Future research should focus 
on elucidating whether BAT activation is a valuable strategy to combat obesity and athero-
sclerosis in humans. We expect that BAT activation, resulting in accelerated generation of 
lipoprotein remnants, should preferentially be combined with strategies that increase 
hepatic LDLR expression, including statins and/or PCSK9 blockers, fully unraveling the thera-
peutic potential of BAT for atherosclerosis prevention and treatment.
EXPERIMENTAL PROCEDURES
Animals, diet and ß3-AR agonist treatment
Female E3L were crossbred with mice expressing human cholesteryl ester transfer protein 
(CETP) under control of its natural flanking regions to generate heterozygous E3L.CETP mice 
(18). Female E3L.CETP mice were 10-12 weeks of age and housed under standard conditions 
with a 12-hours light/dark cycle, free access to food and water and 22°C room temperature. 
Mice were fed a Western-type diet (WTD) supplemented with 0.1% cholesterol and treated 
with the ß3-AR agonist CL316243 (Tocris Bioscience Bristol, United Kingdom; 3x 20 µg/
mouse/week; subcutaneous) or vehicle (PBS). Food intake and body weight as well as total 
body fat and lean mass by Echo-MRI were monitored during the studies. Male Apoe-⁄- and 
Ldlr-⁄- mice (Jackson Laboratory, Bar Harbor, ME) were fed a WTD supplemented with 0.2% 
cholesterol with or without CL316243 (0.001% w/w). As CL316243 treatment of Apoe-⁄- 
and Ldlr-⁄- mice increased food intake, these mice were pair-fed to their respective controls 
after onset of effect. All animal experiments were approved by the Institutional Ethics 
Committees on Animal Care and Experimentation.




Indirect calorimetry was performed in fully automatic metabolic cages (LabMaster System, 
TSE Systems, Bad Homburg, Germany) during the ninth week of treatment. After 1 day 
of acclimatization, O2 consumption, CO2 production and caloric intake were measured for 
3 consecutive days. Carbohydrate and fat oxidation rates were calculated from O2 consumption 
and CO2 production as described previously (40). Total energy expenditure (EE) was calcu-
lated from the sum of carbohydrate and fat oxidation. Physical activity was monitored using 
infrared sensor frames. The first 12 h directly after injection with CL316243 or vehicle (‘Day 
of treatment’) were analysed and compared to the same 12-h period 24 h later (‘Day after 
treatment’).
In vivo serum decay and organ uptake of VLDL-like emulsion particles 
VLDL-like TG-rich emulsion particles (80 nm) labeled with glycerol tri[3H]-oleate (triolein, TO) 
were prepared and characterized as described previously (20). After 4 weeks of treatment 
with the ß3-AR agonist CL316243 mice were fasted for 4 h, and injected (t=0) via the tail vein 
with the emulsion particles (1.0 mg TG/mouse in 200 µl PBS). Blood samples were taken 
from the tail vein at 2, 5, 10 and 15 min after injection to determine the serum decay of [3H]
TO. Plasma volumes were calculated as 0.04706 x body weight (g) as described (41). After 
15 min, mice were sacrificed by cervical dislocation and perfused with ice-cold heparin solution 
(0.1% v/v in PBS) via the heart to remove blood from the organs and tissues. Subsequently, 
organs and tissues were isolated, dissolved overnight at 56°C in Tissue Solubilizer (Amersham 
Biosciences, Rosendaal, The Netherlands), and quantified for 3H-activity. Uptake of [3H]
TO-derived radioactivity by the organs and tissues was expressed per gram wet tissue 
weight.
Plasma parameters and lipoprotein profiles
Blood was collected from the tail vein of 4-h fasted mice into EDTA- (E3L.CETP) or lithium-
heparin-coated tubes (Apoe-⁄- and Ldlr-⁄- mice). Tubes were placed on ice, centrifuged, and 
plasma was isolated and assayed for TG and TC using commercially available enzymatic kits 
from Roche Diagnostics (Mannheim, Germany). Plasma HDL-C levels were determined by 
precipitating apoB-containing lipoproteins from plasma by addition of 20% polyethylene 
glycol (PEG) in 200 mM glycine buffer with pH 10, and TC was measured in the supernatant 
as described above. Plasma (V)LDL-C levels were calculated by extraction of HDL-C from TC 
levels. The distribution of triglycerides and cholesterol over lipoproteins was determined in 
pooled plasma by fast performance liquid chromatography on a Superose 6 column (GE 
Healthcare, Piscataway, NJ).
Sacrification and Histology of BAT and WAT
At the end of the study mice were anesthetized by intraperitoneal injection of acepromazine 
(6.25 mg/kg; Alfasan, Woerden, The Netherlands), midazolam (0.25 mg/kg; Roche, Mijdrecht, 
The Netherlands) and fentanyl (0.31 mg/kg; Janssen-Cilag, Tilburg, The Netherlands), bled 
and killed by cervical dislocation or transcardial blood withdrawal. The blood circulation was 
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perfused with ice-cold heparin solution (0.1% v/v in PBS) and organs and tissues were 
weighed and collected for further analyses. Epididymal WAT and interscapular BAT were 
removed and fixated in phosphate-buffered 4% formaldehyde and embedded in paraffin. 
Hematoxylin-eosin (HE) staining was performed using standard protocols. Intracellular lipid 
droplet size in WAT and percentage of lipid-droplet-positive area in BAT were quantified 
using Image J software (version 1.47).
For UCP1 staining, 5 µm sections were deparafinnated in xylene, rehydrated in ethanol 
and treated with 3% H2O2 (Sigma-Aldrich, Zwijndrecht, The Netherlands) in absolute methanol 
for 30 min to block endogenous peroxidase activity. Sections were immersed in citrate buffer 
(10 mM, pH 6) and boiled for 10 min. Slides were blocked with 1.3% normal goat serum (in 
PBS) and incubated overnight at 4°C with rabbit monoclonal anti-UCP1 antibody (Abcam, 
Cambridge, United Kingdom; 1:400 in 1.3% normal goat serum). Subsequently, sections were 
incubated for 60 min with biotinylated goat -rabbit secondary antibody (Vector Labs, 
Burlingame, CA) diluted in 1.3% normal goat serum. Immunostaining was amplified using 
Vector Laboratories Elite ABC kit (Vector Labs) and the immunoperoxidase complex was 
visulalized with Nova Red (Vector Labs). Counterstaining was performed with Mayer’s 
hematoxylin (1:4). Expression of UCP1 was quantified using Image J software (version 1.47).
Atherosclerosis quantification
Hearts were collected and fixated in phosphate-buffered 4% formaldehyde, embedded in 
paraffin and perpendicular to the axis of the aorta cross-sectioned (5 µm) throughout 
the aortic root area starting from the appearance of open aortic valve leaflets. Per mouse 
4 sections with 50 µm intervals were used for atherosclerosis measurements. Sections 
were stained with hematoxylin-phloxine-saffron for histological analysis. Lesions were 
 categorized for lesion severity according to the guidelines of the American Heart Association 
adapted for mice (42). Various types of lesions were discerned: mild lesions (types 1-3) and 
severe lesions (types 4-5). Lesion area was determined using Image J Software (version 1.47). 
Lesion composition with respect to smooth muscle cell and collagen content was deter-
mined as described previously (42). Rat monoclonal anti-MAC-3 antibody (BD Pharmingen, 
San Diego, CA) was used to quantify macrophage area. The stability index was calculated by 
dividing the collagen by the macrophage area.
Statistical analyses
Statistical analyses were assessed using the unpaired two-tailed Student’s t-test. Univariate 
regression analyses were performed to test for significant correlations between atherosclerotic 
lesion area and plasma lipid exposures during the study. Multiple regression analysis was 
performed to predict the contribution of plasma TG and TC exposures during the study 
to the atherosclerotic lesion area. The square root (SQRT) of the lesion area was taken to 
 linearize the relationship with the plasma lipid exposures. Data are presented as mean 
± S.E.M., unless indicated otherwise. A probability level (P) of 0.05 was considered significant. 
SPSS 20.0 for Windows (SPSS, Chicago, IL) was used for statistical analyses.
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FIGURE S1 - ß3-AR agonism reduces adiposity and lipid droplet size in white adipose tissue. E3L.CETP mice 
were fed a Western-type diet and treated with the ß3-AR agonist CL316243 or vehicle for 10 weeks. After 
sacrifi cation at week 10, the weight of various organs was determined A . Epididymal white adipose tissue 
(epiWAT) was stained with hematoxylin-eosin (HE) and representative pictures are shown B . Lipid droplet 
size of white adipocytes was determined using Image J software C . visWAT, visceral WAT; scWAT, subcutaneous 
WAT; intBAT, interscapular brown adipose tissue; subBAT, subscapular BAT; PVAT, perivascular adipose tissue. 
Values are means ± S.E.M. (panel A-B: n=13-19 per group; panel D: n=8 per group). *P<0.05, **P<0.01, ***P<0.001.








FIGURE S3 - ß3-AR agonism increases browning of white adipose tissue. E3L.CETP mice were fed a Western-
type diet and treated with vehicle or the ß3-AR agonist CL316243 for 10 weeks. Epidydimal WAT was stained 



































































FIGURE S2 - ß3-AR agonism markedly increases brown adipose tissue activity. E3L.CETP mice were fed a 
Western-type diet and treated with vehicle or the ß3-AR agonist CL316243 during 10 weeks. Interscapular BAT 
was stained with HE and representative pictures are shown A . Lipid droplet-positive area was quantified 
using Image J software B . In addition, representative pictures are shown of UCP1-stained interscapular BAT 
C . The UCP1 expression was quantified using Image J software D . 
Values are means ± S.E.M. (panel B: n=3 per group; panel D: n=7-8 per group). *P<0.05, **P<0.01.
B
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FIGURE S4 - BAT activation in Apoe-⁄- mice reduces fat mass and plasma triglycerides, but not total cholesterol. 
Apoe-⁄- mice were fed a Western-type diet and treated with vehicle or the ß3-AR agonist CL316243, pair-fed to 
the vehicle-treated group, during 12 weeks. Body weight was determined after 6 and 12 weeks of treatment A . 
Organ weight was determined after sacrification at week 12 B . The distribution of triglycerides C  and 
 cholesterol D  over lipoproteins was determined at week 12 in fasted plasma samples that were pooled per group. 
Values are means ± S.E.M. (n=9-10 per group). *P<0.05, ***P<0.001.
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FIGURE S5 - BAT activation in Ldlr-⁄- mice reduces fat mass and plasma triglycerides, but not total cholesterol. 
Ldlr-⁄- mice were fed a Western-type diet and treated with vehicle or the ß3-AR agonist CL316243, pair-fed to 
the vehicle-treated group, during 12 weeks. Body weight was determined after 6 and 12 weeks of treatment 
A . Organ weight was determined after sacrification at week 12 B . The distribution of triglycerides C  and 
cholesterol D  over lipoproteins was determined at week 12 in fasted plasma samples that were pooled per group. 
Values are means ± S.E.M. (n=8-11 per group). **P<0.01, ***P<0.001.
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SHORT-TERM HIGH-FAT DIET 
 INCREASES MACROPHAGE MARKERS 
IN SKELETAL MUSCLE ACCOMPANIED 
BY IMPAIRED INSULIN SIGNALING 
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CETP cholesteryl ester transfer protein 
hsCRP high sensitive C-reactive protein 
(F)FA (free) fatty acid 
GLUT-4 glucose transporter 4
GYS1 glycogen synthase 1
HFD high-fat diet
HFHC high-fat high calorie
INSR insulin receptor
IR insulin resistance 
RT-MLPA dual color reverse transcriptase multiplex ligation-dependent probe amplification 
SLC2A4 solute carrier family 2
TBC1D1 TBC1 domain family member 1
TBC1D4 TBC1 domain family member 4
TG triglyceride
(s)WAT (subcutaneous) white adipose tissue
Proefschrift_MB.indb   192 05-05-14   11:59
10
MACROPHAGE MARKERS IN SKELETAL MUSCLE
193 
ABSTRACT
Recent studies have demonstrated elevated macrophage markers in skeletal muscle 
of obese subjects, that inversely related to insulin sensitivity. The aim of the present 
study was to investigate whether short-term high-fat high calorie (HFHC) diet 
already increases macrophage markers and affects glucose metabolism in skeletal 
muscle of healthy lean subjects. To this end, 24 healthy lean young male subjects 
received a 5-day HFHC diet. Before and after the diet, muscle and subcutaneous 
white adipose tissue (sWAT) biopsies were taken and mRNA expression levels of 
 relevant genes,  plasma glucose, insulin, C-peptide and cholesteryl ester transfer protein 
(CETP) levels were measured. 5 days of HFHC diet markedly increased mRNA expres-
sion of the  general macrophage markers CD68 (3.7-fold, P<0.01) and CD14 (3.2-fold, 
P<0.01), as well as the M1 macrophage marker MARCO (11.2-fold, P<0.05) in muscle. 
This was accompanied by downregulation of TBC1D1, SLC2A4 and GYS1 mRNA expres-
sion, all involved in uptake and storage of glucose, and elevation of plasma glucose 
(+4%, P<0.001) and insulin (+55%, P<0.001) levels together with HOMA-IR (+48%, 
P<0.001), suggesting development of insulin resistance. Furthermore, plasma CETP 
levels, a marker of liver macrophage content, were increased (+21%, P<0.001) while 
macrophage content in sWAT remained unchanged. Short-term HFHC diet increases 
expression of macrophage markers in skeletal muscle, but not sWAT, of healthy male 
subjects accompanied by reduced markers of insulin signalling and development  
of insulin resistance. Therefore, recruitment of macrophages into muscle may be an 
early event in development of insulin resistance in the course of obesity. 




Skeletal muscle is the primary site of dietary glucose disposal in vivo. Insulin stimulates 
 glucose uptake into muscle through an elaborate signaling cascade eventually resulting in 
mobilization of glucose transporter 4 (GLUT-4) channels to the plasma membrane that 
mediate glucose uptake (1). High-fat diet (HFD) feeding impairs whole-body insulin sensitivity 
and substrate homeostasis in both mice and humans (2,3). Skeletal muscle insulin resistance 
(IR) is the major contributor to development of whole-body IR (4) but the exact underlying 
molecular mechanism remains to be elucidated, although various hypotheses have been 
proposed.
First, lipid accumulation inside muscle cells and the formation of subsequent lipid 
metabolites (e.g. diacylglycerols, ceramides and acylcarnitines) contribute to muscle IR by 
interfering with the insulin signaling cascade (5). 
Second, fatty acids (FAs) trigger activation of inflammatory signals in myocytes, and also 
in innate immune cells such as macrophages, leading to the release of pro-inflammatory 
cytokines that result in low-grade systemic inflammation (6,7). In vitro studies support this 
concept, showing that FAs promote release of pro-inflammatory cytokines by macrophages 
that, in turn, induce IR in skeletal muscle cells (8). Of note, cytokines can directly influence 
insulin actions on muscle. For example, the pro-inflammatory cytokine TNF caused IR and 
impaired glucose uptake in primary human myocytes (9).
A third mechanism underlying the development of muscle IR in response to HFD may 
involve recruitment of macrophages into the muscle tissue itself. Hong et al (10) showed 
that HFD increased the number of M1-activated (CD11c+) macrophages in skeletal muscle in 
mice. Of note, this was corrected by transgenic overexpression of the anti-inflammatory 
cytokine IL-10 in skeletal muscle, which also improved whole-body insulin sensitivity. 
In humans, Varma et al (8) showed that the skeletal muscle from obese subjects contained 
2.5-fold higher CD68+ macrophage numbers in skeletal muscle compared to lean subjects. 
Strikingly, their study showed that macrophage content in muscle was strongly associated 
with BMI and inversely related to insulin sensitivity. 
Taken together, these data suggest that HFD results in recruitment of pro-inflammatory 
macrophages in muscle which contribute to the development of muscle IR by releasing pro-
inflammatory cytokines. However, the timing at which macrophages are recruited into skel-
etal muscle in the time course of HFD-induced obesity and the possible involvement of other, 
adaptive, immune cell types is currently unknown and may either be an early event or a late 
consequence when chronic low-grade inflammation has already developed. To investigate 
this issue, we subjected healthy, male lean subjects for 5 days to a high-fat high calorie 
(HFHC) diet and studied expression of markers for macrophages, T cells, pattern recognition 
receptors, as well as markers for glucose metabolism, in skeletal muscle biopsies before and 
after the diet. Furthermore, to investigate whether short-term HFD results in influx of macro-
phages in other tissues besides muscle, we investigated expression of macrophage markers 
in subcutaneous white adipose tissue (sWAT) biopsies as well as plasma cholesteryl ester 
transfer protein (CETP) levels as a marker of the liver macrophage content (11).
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METHODS AND MATERIALS 
Study participants 
24 Dutch, lean (BMI < 25 kg/m2) and healthy males of Caucasian (n=12) and South Asian 
(n=12) ethnicity between 19 and 25 years of age and with a positive family history of type 2 
diabetes were enrolled via local advertisements. All subjects underwent a medical screening 
including their medical history, a physical examination, blood chemistry tests and an oral 
glucose tolerance test to exclude individuals with type 2 diabetes according to the 
American Diabetes Association (ADA) 2010 criteria. Other exclusion criteria were rigorous 
exercise, smoking and recent body weight change. The present study was approved by the 
Medical Ethical Committee of the Leiden University Medical Centre and performed in 
accordance with the principles of the revised Declaration of Helsinki. All volunteers gave 
written informed consent before participation.
Study design
Subjects were studied before and after a 5-day HFHC diet, consisting of the subject’s regular 
diet, supplemented with 375 ml of cream per day (=1275 kcal/day extra containing 94% fat). 
They were instructed not to alter life style habits, and not to perform physical activity in 
the last 48 hours prior to the study days. Furthermore, subjects were asked to keep a food 
diary before and during the HFHC diet to estimate normal dietary intake, and to check for 
compliance and compensation behavior respectively. Diaries were entered and analyzed 
using a specialized internet application (http://www.dieetinzicht.nl, Dutch). Magnetic 
 resonance (MR) studies were performed shortly before and on the fifth day of the HFHC 
diet. In addition, one day before and one day after the diet anthropometric measurements 
were performed and muscle and subcutaneous white adipose tissue biopsies were obtained 
from all subjects in fasted condition.
MR studies
Hepatic triglyceride content was assessed by proton MR-spectroscopy (1H-MRS; Gyroscan 
ACS-NT15; Philips, The Netherlands) in postprandial state (five hours after the last meal), as 
previously described (12). Vertebra Th12 was used as a marker to ascertain the same position 
of the 8-ml-voxel at both study days. A spectrum with water suppression as internal stand-
ard was obtained, and 64 averages were collected without water suppression. The spectra 
were fitted using Java-base MR user interface software ( jMRUI version 2.2) (12). The percent-
age of hepatic triglyceride (TG) signals was calculated as: (signal amplitude hepatic TG/ sig-
nal amplitude water) x 100.
Anthropometric measurements
Anthropometric measurements were performed after an overnight fast. Body composition 
(fat and lean body mass) was assessed by bioelectrical impedance analysis (BIA; Bodystat® 
1500, Bodystat Ltd., Douglas, UK). 
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Skeletal muscle biopsies 
Muscle biopsies from the m. vastus lateralis (approx. 75-100 mg) were collected one day 
before and one day after the diet intervention in fasted condition under localized anesthesia, 
using a modified Bergström needle, as previously described (13). Muscle samples were snap-
frozen in liquid nitrogen and stored at -80°C until further analysis.
White adipose tissue biopsies
Subcutaneous fat biopsies were obtained from the umbilical region in fasted condition 
under localized anesthesia, using a syringe with needle while applying suction. Fat samples 
were immediately submersed into a medium (DMEM/F12 + Glutamax) until further analysis. 
Of note, analysis was done in a subset of subjects (n=8) due to limited availability of tissue 
in lean subjects.
Laboratory analysis
Fasting serum glucose, total cholesterol, HDL-cholesterol and triglycerides (TG) were 
 measured on a Modular P800 analyzer (Roche, Almere, The Netherlands). LDL-cholesterol 
was calculated according to Friedewald’s formula (14). Serum insulin and C-peptide levels 
were analyzed on an Immulite 2500 (Siemens, The Netherlands). The HOMA-IR index was 
calculated using the formula: fasting insulin (pmol/L) x fasting glucose (mmol/L)/22.5. 
Plasma free fatty acid (FFA) concentrations were determined by a colorimetric method 
(Wako Chemicals, Germany). ELISA kits were used to measure serum levels of high-sensitive 
C-reactive protein (hsCRP) (Meso Scale Discovery, Gaithersburg, USA), adiponectin (Cayman 
Chemical, Ann Arbor, USA) and CETP concentration (ALPCO Diagnostics, Salem, USA) according 
to the manufacturers’ instructions. 
RNA isolation 
Total RNA was isolated from skeletal muscle biopsies (approx. 25-30 mg) using the phenol-
chloroform extraction method (Tripure RNA Isolation reagent, Roche, Germany) and treated 
with a DNAse kit (TURBO DNAse, Life Technologies, The Netherlands) according to the manu-
facturer’s instruction. Amount of RNA was determined by NanoDrop.
cDNA synthesis and real-time PCR
For RT-PCR, first-strand cDNA was synthesized from 1 µg total RNA using a Superscript first 
strand synthesis kit (Invitrogen, The Netherlands). Real-time PCR was carried out on the IQ5 
PCR machine (Bio-Rad) using the Sensimix SYBRGreen RT-PCR mix (Quantace). Melt curve 
analysis was included to assure a single PCR product was formed. Expression levels were 
normalized to ribosomal protein S18 (RPS18). Primer sequences are listed in SUPPLEMENTARY 
TABLE 1.
dcRT-MLPA assay 
A dual-color reverse transcriptase multiplex ligation-dependent probe amplification (dcRT-
MLPA) assay was performed as described previously (15). Briefly, for each target-specific 
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sequence, a specific RT primer was designed located immediately downstream of the left 
and right hand half-probe target sequence. Following reverse transcription, left and right 
hand half-probes were hybridized to the cDNA at 60°C overnight. Annealed half-probes 
were ligated and subsequently amplified by PCR (33 cycles of 30 s at 95°C, 30 s at 58°C and 
60 s at 72°C, followed by 1 cycle of 20 min at 72°C). PCR amplification products were 
1:10 diluted in HiDi formamide-containing 400HD ROX size standard and analyzed on an 
Applied Biosystems 3730 capillary sequencer in GeneScan mode (Applied Biosystems).
Trace data were analyzed using the GeneMapper software package (Applied Biosystems). 
The areas of each assigned peak (in arbitrary units) were exported for further analysis in 
Microsoft Excel spreadsheet software. Data were normalized to beta-2-microglobulin (B2M) 
and signals below the threshold value for noise cutoff in GeneMapper (log2 transformed 
peak area 7.64) were assigned the threshold value for noise cutoff
Immunohistochemical stainings
Formalin-fixed-paraffin-embedded subcutaneous adipose tissue sections were used for 
immunohistochemistry of CD68. Antigens were retrieved using citrate buffer. The primary 
antibody was mouse-anti-human CD68 (1:800 dilution, clone KP1, from Dako, Glostrup, 
Denmark). Staining and counterstaining was done with Nova Red (Vector labs, Brunschwig 
Chemie, Amsterdam, The Netherlands) and haematoxylin, respectively. Crown-like struc-
tures (CLS) were counted according to the criterion that a CLS consisted of three or more 
CD68 positive cells surrounding an adipocyte. 
Statistical analysis
The data of South Asian and Caucasian subjects were pooled for all analyses since no signifi-
cant differences were observed between ethnicities for baseline values or diet effects. Data 
are presented as mean ± SEM. Paired T-tests were applied to assess mean differences before 
and after the diet intervention. Significance level was set at P<0.05. Statistical analyses were 
performed using SPSS for Windows version 20.0 (IBM, USA).
RESULTS 
Clinical characteristics
Clinical characteristics are shown in TABLE 1. Mean age was 22.1±0.4 years and mean BMI was 
21.5±0.4 kg/cm2. Five days of HFHC diet resulted in a small but significant increase in body 
weight (+0.7%, P<0.01) and BMI (+0.9%, P<0.01), while waist circumference and percentage 
of fat mass remained unchanged. Although plasma FFA, serum TG and total cholesterol 
 levels did not change significantly upon the HFHC diet, HDL-C and LDL-C did increase (both 
+9%, P<0.01). Furthermore, the HFHC diet significantly increased fasting glucose (+4%), insulin 
(+55%) and C-peptide (+29%) levels, as well as the HOMA-IR index (+ 48%) (all P<0.001). 
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HFHC diet and markers of glucose uptake/metabolism and muscle inflammation 
The HFHC diet did not affect mRNA expression of the insulin receptor (INSR) and its down-
stream signaling target TBC1D4 (encoding AS160) in muscle biopsies (FIG 1A). However, a 
diminished expression of TBC1D1 (-23%, P<0.05), SLC2A4 encoding GLUT-4 (-34%, P<0.001) 
and GYS-1 (-35%, P<0.001), all involved in uptake and storage of glucose, was evident. 
Using the dcRT-MLPA assay, we measured mRNA expression of a large panel of inflam-
matory genes, including markers for innate and adaptive immune cells, pattern recognition 
receptors and cytokines in muscle biopsies before and after the HFHC diet (TABLE 2). Of note, 
the HFHC diet significantly upregulated the expression of CD14 (+118%, P<0.05), a general 
macrophage marker, and the expression of MARCO (+415%, P<0.05), a scavenger receptor 
that is mainly present on pro-inflammatory M1 macrophages (16). In line with this, expression 
of the anti-inflammatory cytokine IL10 tended to be downregulated (-27%, P=0.10). 
Furthermore, expression of the general T-cell marker CD3 was undetectable in the muscle 
biopsies, pointing to absence or very low presence of T-cells. Expression of CD4, a T-helper 
cell marker that is also expressed by innate immune cells such as monocytes and macro-
Before HFHC diet  
(n= 24)
After HFHC diet  
(n=24)
Age (years) 22.1 ± 0.4
Length (m) 1.79 ± 0.01
Weight (kg) 69.1 ± 1.9 69.6 ± 1.9**
BMI (kg/cm2) 21.5 ± 0.4 21.7 ± 0.4**
Waist (cm) 80.1 ± 1.5 80.8 ± 1.7
Fat mass (%) 13.2 ± 0.7 13.0 ± 0.7
Total cholesterol (mmol/L) 4.16 ± 0.19 4.51 ± 0.17
HDL-C (mmol/L) 1.22 ± 0.05 1.33 ± 0.04**
LDL-C (mmol/L) 2.51 ± 0.17 2.74 ± 0.15**
Triglycerides (mmol/L) 0.96 ± 0.08 0.97 ± 0.08
FFA (mmol/L) 0.49 ± 0.03 0.48 ± 0.03
Glucose (mmol/L) 5.17 ± 0.06 5.37 ± 0.06***
Insulin (pmol/L) 4.53 ± 1.00 7.02 ± 1.16***
C-peptide (nmol/L) 0.49 ± 0.03 0.63 ± 0.04***
HOMA-IR 1.62 ± 0.26 2.39 ± 0.32***
hsCRP (µg/mL) 0.94 ± 0.23 1.16 ± 0.24
Adiponectin (µg/mL) 6.27 ± 0.63 6.58 ± 0.50
Hepatic TG content (%) 1.57 ± 0.27 3.43 ± 0.49***
CETP mass (µg/mL) 1.69 ± 0.09 2.02 ± 0.10***
TABLE 1 - Anthropometrics and metabolic characteristics before and after a 5-day HFHC diet in healthy, 
young male subjects
Data are presented as mean ± SEM. ** P<0.01, *** P<0.001 vs. before diet. HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein 
cholesterol; FFA, free fatty acid; hsCRP, high-sensitive C-reactive protein; TG, triglyceride; CETP, cholesteryl ester transfer protein.
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(fold change vs baseline) P-value 
Immune cell subset markers
CD14 1.00 ± 0.16 2.18 ± 0.23 0.04*
CD163 1.00 ± 0.10 0.84 ± 0.15 0.31
NCAM1 1.00 ± 0.14 1.15 ± 0.13 0.37
CD19 1.00 ± 0.12 1.09 ± 0.16 0.61
BLR1 1.00 ± 0.15 0.84 ± 0.14 0.42
FCGR1A# 1.00 ± 0.00 1.68 ± 0.26 0.13
T cell subsets
CD3E# 1.00 ± 0.00 1.01 ± 0.01 0.33
CD4 1.00 ± 0.09 1.48 ± 0.15 0.04*
CD8A 1.00 ± 0.14 0.89 ± 0.15 0.61
IL7-R 1.00 ± 0.06 0.93 ± 0.10 0.53
CCR7 1.00 ± 0.08  0.87 ± 0.11 0.26
Th1 response
CXCL10 1.00 ± 0.10 0.98 ± 0.11 0.88
IFNG 1.00 ± 0.27 1.62 ± 0.28 0.28
IL-2 1.00 ± 0.17 1.06 ± 0.17 0.84
IL-1B 1.00 ± 0.13 0.93 ± 0.15 0.78
TNF 1.00 ± 0.08 1.09 ± 0.10 0.52
Th2 response
IL-4# 1.00 ± 0.29  0.79 ± 0.24 0.56
IL-4d2 1.00 ± 0.35 0.79 ± 0.35 0.65
IL-5 1.00 ± 0.24 1.04 ± 0.24 1.00
IL-6 1.00 ± 0.11 1.08 ± 0.14 0.70
IL-9# 1.00 ± 0.00 1.17 ± 0.10 0.16
IL-10 1.00 ± 0.17 0.73 ± 0.19 0.13
IL-13 1.00 ± 0.45 1.94 ± 0.28 0.26
Treg markers
CCL4 1.00 ± 0.16 1.11 ± 0.15 0.80
CTLA4 1.00 ± 0.13 0.88 ± 0.13 0.38
LAG3 1.00 ± 0.29 0.43 ± 0.42 0.08
TGF-B1 1.00 ± 0.13 1.12 ± 0.11 0.42
Key MF1 and MF2 cytokines
IL-12A 1.00 ± 0.32 0.89 ± 0.46 0.82
IL-12B 1.00 ± 0.39 1.10 ± 0.36 0.85
IL-23A 1.00 ± 0.08 0.81 ± 0.13 0.22
CCL2# 1.00 ± 0.44 1.78 ± 0.40 0.37
CCL5 1.00 ± 0.09 0.90 ± 0.10 0.51
TABLE 2 - Expression of adaptive and innate immune markers in muscle biopsies before and after a 5-day 
HFHC diet in healthy male subjects





(fold change vs baseline) P-value 
CCL19 1.00 ± 0.11 1.07 ± 0.13 0.66
CCL22 1.00 ± 0.08 0.85 ± 0.06 0.16
CXCL13# 1.00 ± 0.40 0.97 ± 0.38 0.96
Scavenger receptors
MARCO 1.00 ± 0.23 5.15 ± 0.37 0.04*
Pattern recognition receptors
TLR1# 1.00 ± 0.00 1.55 ± 0.36 0.33
TLR2# 1.00 ± 0.51 0.17 ± 0.00 0.11
TLR3  1.00 ± 0.11 1.07 ± 0.14 0.68
TLR4  1.00 ± 0.29 1.20 ± 0.33 0.67
TLR5 1.00 ± 0.57 0.46 ± 0.65 0.33
TLR6 1.00 ± 0.37 1.28 ± 0.32 0.64
TLR7 1.00 ± 0.12 0.96 ± 0.15 0.83
TLR8 1.00 ± 0.10 0.96 ± 0.17 0.85
TLR9 1.00 ± 0.11 0.79 ± 0.14 0.21
TLR10## 1.00 ± 0.00 2.36 ± 0.59 0.33
NOD1 1.00 ± 0.24 1.06 ± 0.15 0.83
NOD2# 1.00 ± 0.00 1.33 ± 0.26 0.33
MRC1 1.00 ± 0.23 1.63 ± 0.18 0.06
MRC2 1.00 ± 0.05 0.91 ± 0.11 0.48
CD209 1.00 ± 0.14 1.02 ± 0.16 0.94
CLEC7A 1.00 ± 0.17 1.23 ± 0.19 0.38
Inflammasome components
NLRP1# 1.00 ± 0.51 0.21 ± 0.00 0.13
NLRP2 1.00 ± 0.10 1.00 ± 0.15 0.99
NLRP3# 1.00 ± 0.42 0.85 ± 0.32 0.77
NLRP4 1.00 ± 0.16 0.86 ± 0.22 0.56
NLRP7 1.00 ± 0.37 0.88 ± 0.35 0.78
NLRC4 1.00 ± 0.05 0.89 ± 0.10 0.37
Data are presented as mean ± SEM and expressed relative to baseline. *P<0.05 vs. before diet. # Low expression of gene.
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FIGURE 1 - Effect of short-term HFHC diet on expression of insulin signaling and macrophage markers in 
muscle in healthy male subjects. mRNA expression levels of genes related to glucose uptake/metabolism A
and macrophage markers B  were measured in skeletal muscle biopsies of healthy male subjects (n=24) 
obtained before (white bars) and after (black bars) a 5-day HFHC diet. Expression levels are normalized to the 
housekeeping gene S18 and expressed as fold change compared to baseline as mean ± SEM. *P<0.05, **P<0.01 
and ***P<0.001 vs. before diet. 
HFHC, high-fat high calorie. INSR, insulin receptor. TBC1D4, TBC1 domain family member 4. TBC1D1, TBC1 domain family member 1. SLC2A4 solute 













































phages (17), was detectable and increased upon the HFHC diet (+48%, P<0.05). Given the 
absence of CD3 in the muscle biopsies, the increase in CD4 expression probably reflects 
increased expression by innate immune cells. Other inflammatory markers remained unaf-
fected. 
Thus, these data suggested that upon a short-term HFHC diet, especially markers of 
innate immunity were upregulated in muscle. We confirmed these findings by performing 
RT-PCR analyses on several macrophage markers in the muscle biopsies (FIG 1B). More 
 specifically, the HFHC diet upregulated the general macrophage markers CD68 (3.7-fold, 
P<0.01) and CD14 (3.2-fold, P<0.01), as well as the M1 marker MARCO (11.2-fold, P<0.05). Hence, 
short-term HFHC diet resulted in increased expression of pro-inflammatory M1 macrophages 
in muscle. 
HFHC diet and markers of inflammation in other tissues 
Since HFD-induced obesity is often associated with influx of pro-inflammatory macrophages 
and appearance of crown-like structures (CLS) in WAT (18), we next investigated whether 
markers of macrophage infiltration were also evident in WAT after 5 days of HFHC diet 
in healthy lean subjects. Due to the very small amount of tissue, we could only perform 
immuno histological staining of CD68 in subcutaneous WAT taken before and after the diet 
intervention in a subset of subjects. At baseline, solitary macrophages were identified 
 sporadically in the WAT biopsies, while no CLS were observed. After the HFHC diet, influx of 
solitary macrophages increased in only a few subjects as did the appearance of CLS in WAT 
(SUPPLEMENTARY FIGURE 1A-B), however, these effects were not statistically significant. Further-
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more, plasma adiponectin, an adipocyte-derived hormone that is suggested to play a role in 
suppression of the development of obesity and IR (19), did not change upon the dietary 
intervention (TABLE 1). 
The HFHC diet increased the liver triglyceride (TG) content (+118%, P<0.001; TABLE 1). For 
obvious reasons we could not obtain liver biopsies from our healthy subjects to measure 
macrophage content. However, we have recently shown that plasma CETP levels highly 
 correlate with levels of general macrophage markers in liver biopsies (Wang and Rensen et 
al, unpublished) and therefore, we measured plasma CETP levels as a marker of liver macro-
phage content. Intriguingly, plasma CETP levels increased upon the HFHC diet (+21%, 
P<0.001; TABLE 1), suggesting influx of macrophages into the liver. Furthermore, after the 
HFHC diet plasma CRP levels tended to increase (+24%, P=0.06; TABLE 1), pointing to low-
grade systemic inflammation. 
DISCUSSION 
Recent studies have detected elevated numbers of macrophage markers in skeletal muscle 
during chronic HFD feeding and obesity, but the timing at which these macrophages are 
recruited and their role in the development of muscle and whole-body IR is unknown. The 
present study demonstrates that only 5 days of HFHC diet resulted in a marked increase in 
expression of macrophage markers in muscle of healthy lean male subjects. Moreover, 
this was accompanied by downregulation of genes involved in glucose metabolism and 
 elevation of fasting plasma glucose and insulin levels and HOMA-IR index. Of note, plasma 
CETP levels, which were previously shown by our group to correlate with liver macrophage 
content, increased while macrophage content in the subcutaneous WAT depot remained 
unchanged. 
As in other organs, resident macrophages are present in human skeletal muscle (8) 
where they contribute to regeneration and revascularization in case of damage (20). In 
accordance with these data, we found that the general macrophage markers CD14 and 
CD68 were significantly expressed in skeletal muscle of healthy lean men. Of note, the 
homeostatic functions of muscle macrophages are exerted only when the macrophages 
are in their M2 (anti-inflammatory) phenotypic polarization stage (21,22). In response to 
 different stimuli, such as circulating FA, macrophages are polarized towards an M1-like 
(inflammatory) phenotype, leading to release of pro-inflammatory cytokines which can 
induce IR in myocytes (8). Indeed, previous mouse and human studies have repeatedly 
observed increased numbers of activated M1 (CD11c+) macrophages in skeletal muscle 
 tissue in the context of obesity and IR (23-26). Intriguingly, our data demonstrate that the 
increased expression of M1 macrophages in skeletal muscle occurs already after short-term 
HFD and even in healthy young subjects, supporting the concept that recruitment of M1 
macrophages into skeletal muscle is an early event in the time course of HFD-induced obesity. 
What would be the trigger of the extensive increase in macrophage markers in muscle 
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and does this mainly reflect activation of resident macrophages or increased influx from 
blood-derived monocytes? We speculate that both mechanisms are involved. The fact that 
the expression of general macrophage markers (CD68 and CD14) was increased, is most 
 easily explained by an increased influx of these cells into muscle, rather than by upregula-
tion of the expression of these genes in resident macrophages. The trigger that stimulated 
this influx is likely the high load of saturated FAs ingested with the HFHC diet. Saturated FAs 
can signal via Toll-like receptors (TLRs), particularly TLR-4 that is present on both macrophages 
and myocytes (27). Activation of TLR-4 stimulates the transcription and release of various 
chemokines and pro-inflammatory cytokines, such as MCP-1 or tumor necrosis factor- 
(TNF-), which attract other macrophages and may also directly impair insulin signaling in 
skeletal muscle (5; 28,29). In the present study, we did not find effects of the HFHC diet on 
gene expression of Toll-like receptors or pro-inflammatory cytokines such as TNF- in skeletal 
muscle. However, we cannot exclude that either local release of pro-inflammatory cytokines 
or activation of TLR-4-driven signaling pathways might have occurred in this tissue. 
Intriguingly, while we found that expression of macrophage markers was markedly 
increased in skeletal muscle upon the HFHC diet, no significant increase could be identified in 
the subcutaneous WAT depot. This might be in part due to the fact that visceral adipose tissue 
(VAT) seems to be more closely associated with the inflammatory state than subcutaneous 
adipose tissue (30). Furthermore, muscle cells might be more prone to release macrophage 
attractant factors in the presence of pro-inflammatory stimuli compared to adipocytes. 
Indeed, a recent study demonstrated that the presence of both macrophages and the 
 saturated FA palmitate exerted a synergistic effect on MCP-1 release by muscle cells, resulting 
in greater attraction of macrophages (8). To our knowledge, such a positive feedback-loop 
has not been demonstrated for adipocytes. 
Besides a large increase in macrophage markers in muscle upon the HFHC diet, the 
increased plasma CETP levels suggests increased hepatic macrophage content as well. Our 
group has recently shown that the hepatic macrophage is the main producer of plasma 
CETP (Wang et al., unpublished), meaning that an increase in plasma CETP levels reflects an 
increase in hepatic macrophages. Interestingly, various studies have shown that pro-inflam-
matory cytokines also impaired insulin signaling in hepatocytes (31). Thus, it is tempting 
to speculate that dietary saturated FAs may have resulted in influx of pro-inflammatory M1 
macrophages in the liver, leading to release of pro-inflammatory cytokines and subsequent 
impairment of hepatic insulin signaling. This mechanism may also explain the previously 
found reduced suppression of endogenous glucose production in response to 5 days of 
HFHC diet (32). 
A potential limitation of the current study could be that we determined immune cell 
markers via MLPA-assay and RT-PCR instead of performing fluorescence-activated cell sorting 
(FACS) analyses, a method by which true cell counts are determined. However, performing 
FACS analyses would require relatively large amounts of muscle tissues, the collection of 
which was not feasible in the current study. 
In conclusion, we show that 5 days of HFHC diet resulted in a marked increase in gene 
expression of M1 macrophage markers in skeletal muscle of healthy lean male subjects, a 
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feature associated with apparent impairment in whole-body insulin sensitivity and glucose 
homeostasis. Future studies should be directed at unraveling the precise contribution of 
muscle macrophages in the development of peripheral IR, with the ultimate goal to develop 
novel therapeutic targets that decrease inflammation-induced IR without interfering with 
all innate immune functions. 
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SUPPLEMENTARY FIGURE 1 - Effect of short-term HFHC diet on macrophage content in subcutaneous white 
adipose  tissue in healthy male subjects. The number of solitary macrophages and CLS were counted following 
a CD68 (macrophage) staining in sWAT biopsies of healthy male subjects (n=8) obtained before (open dots) 
and after (closed dots) a 5-day HFHC diet. Counts represent absolute numbers. 
HFHC, high-fat high calorie. CLS, crown-like structure. sWAT, subcutaneous white adipose tissue.
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ABSTRACT
To test the hypothesis that the increased risk of type 2 diabetes mellitus and coronary 
artery disease in South Asian subjects could be caused by the presence of endothelial 
dysfunction in early life. Westudied markers of endothelial dysfunction in umbilical 
cord blood of South Asian neonates and compared these with that of Caucasian 
 control subjects. FromSouth Asian (n=57) and Caucasian (n=21) neonates, cord blood 
was collected and levels of glucose, insulin, lipids, and markers of endothelial dys-
function (E-selectin, intercellular adhesion molecule 1, vascular cell adhesion molecule 1) 
and inflammation (C-reactive protein) were measured. Plasma E-selectin levels were 
signi ficantly higher in South Asian neonates (46.7 versus 33.5 ng/mL, P<.001), and 
 levels of intercellular adhesion molecule 1 and vascular cell adhesion molecule 1 did 
not differ. Furthermore, South Asian neonates had hyperinsulinemia (P=.043), dys-
lipidemia (with significantly higher triglyceride and lower high-density lipoprotein 
cholesterol levels), and higher C-reactive protein levels (75.7 versus 43.8 ng/mL, 
P=.009). In conclusion, South Asian newborns are characterized by elevated 
E-selectin levels in line with the hypothesis that endothelial dysfunction is present 
early in life. In addition, hyperinsulinemia, dyslipidemia, and inflammation are present. 
Because many pathogenic variables for coronary artery disease and type 2 diabetes are 
already present at birth in South Asian patients, the question arises whether rigorous 
childhood lifestyle intervention could be beneficial. (J Pediatr 2012;160:844-8).




South Asian people originate from the Indian subcontinent (India, Pakistan, Bangladesh, 
Sri Lanka, and Nepal) and represent one-fifth of the world’s population.1 They are at higher 
risk of coronary artery disease (CAD) and its subsequent morbidity and mortality than 
Caucasian individuals.2,3 Several studies show that CAD in South Asian patients is not only 
much more prevalent compared with white European patients, but also starts at an earlier 
age.4-6 Conventional coronary risk factors, including smoking, hypercholesterolemia, and 
hypertension, do not explain their increased CAD risk compared with Caucasian subjects.2 
Although type 2 diabetes mellitus and insulin resistance are significantly more prevalent in 
South Asian patients, this appears to contribute only to some of the excess risk.7 Thus, residual 
risk is present, suggesting that additional factors may play a role. An ethnic suscepti bility for 
endothelial dysfunction in the South Asian population has been hypothesized, because 
endothelial dysfunction plays a key role in the initiation of atherosclerosis.8,9 
Although endothelial dysfunction contributes to atherosclerosis in large arteries, it has 
been suggested that in the capillary and arteriolar endothelium, it may contribute to the 
development of type 2 diabetes mellitus.10-12 Indeed, Meigs and coworkers10 found that 
endothelial dysfunction, as measured with elevated levels of the biomarker E-selectin in 
blood, predicted the occurrence of type 2 diabetes mellitus in adult women, and intercellular 
adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), which are 
other and less sensitive markers of endothelial dysfunction, did not. These results were still 
found after correction for several known risk factors, such as body mass index (BMI), family 
history of diabetes mellitus, smoking, and subclinical inflammation. 
We hypothesized that in South Asian subjects, both the residual risk for CAD and the 
high prevalence of type 2 diabetes mellitus could be caused by the presence of a susceptibility 
to endothelial dysfunction. We examined the presence of E-selectin, ICAM-1, and VCAM-1 in 
umbilical cord plasma of South Asian neonates and Caucasian control subjects.
METHODS
Umbilical venous cord blood was collected from South Asian neonates living in the 
Netherlands (n=21), from South Asian neonates living in Surinam (n=36), and from 
Caucasian neonates living in the Netherlands (n=21). In total, 78 neonates, all born between 
Jan 1, 2006, and Jan 1, 2009, were examined in two hospitals in Paramaribo, Surinam,13 and 
in one hospital in The Hague, the Netherlands, after their mothers had given informed 
 consent and approval had been obtained by the local ethics committee. Live-born singleton 
babies with 4 South Asian grandparents or 4 Caucasian grandparents were included. 
Pregnancies complicated by pre-eclampsia were excluded. Gestational age was based on 
last menstrual period or ultrasound scanning (before 12 weeks). Birth weights were taken 
from the medical records and information about the mother of the neonate (maternal 
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 disease including diabetes mellitus, hypertension, hyperthyroidism, and hypothyroidism; 
gestational age; parity; usage of medication; and age). For both the mother and father of the 
baby, a questionnaire was used to gather information on family history of diabetes mellitus, 
hypertension, and coronary events. Family history was marked as “positive” when one of the 
family members (grandparents, parents, brothers/sisters) had been diagnosed with the 
 disease. Furthermore, the health status of the father was assessed. 
Immediately after delivery, 20 mL of cord blood was collected from the umbilical vein 
with standard protocols. Within 1 hour, the cord blood was centrifuged. Plasma insulin and 
glucose levels were measured immediately, and a portion of the plasma was frozen and 
stored at 80 C. The stored samples from Surinam and the Netherlands were transported 
in special media to the Leiden University Medical Center (Leiden, The Netherlands), 
where markers of endothelial dysfunction (E-selectin, ICAM-1, and VCAM-1) and C-reactive 
protein (CRP) were measured (Meso Scale Discovery, Gaithersburg, Maryland). Furthermore, 
cholesterol and triglyceride levels were determined by using commercially available kits 
(Roche Diagnostics Cholesterol reagent and Triglyceride reagent, respectively; Roche 
Diagnostics, Almere, The Netherlands). High-density lipoprotein cholesterol levels were 
determined by precipitating the apoB-containing lipoproteins as described previously.14 
Non-high-density lipoprotein cholesterol levels were calculated by subtracting the high-
density lipoprotein cholesterol levels from the total cholesterol levels. 
Statistical Analysis 
All data were analyzed with SPSS software version 17.0 (SPSS, Chicago, Illinois). Mean 
 differences in gestational age, birth weight, APGAR scores, and levels of E-selectin, ICAM-1, 
VCAM-1, CRP, and glucose were compared between South Asian neonates and Caucasian 
neonates by using independent t tests. Birth weight and levels of E-selectin, CRP, and 
 glucose were skewed and required log transformation to satisfy assumptions of normality. 
Maternal age and insulin levels were not normally distributed, even after log transfor-
mation. Differences in maternal age and insulin measures therefore were compared with 
the non-parametric Mann- Whitney test. Differences in the prevalence of chronic diseases 
in the mothers, smoking, alcohol and drug use, and sex of the neonates were tested with 
the χ2 test. Outliers were detected with the Grubb’s test. In the case of CRP, two significant 
outliers (one in each group) were detected, which were subsequently excluded.
RESULTS
The South Asian neonates living in Surinam and the Netherlands were clustered in one 
group (“South Asians,” n=57) because no significant differences were observed for sex, birth 
weight, maternal age, and plasma E-selectin levels. The characteristics of the South Asian 
and Caucasian groups are given in (TABLE 1). South Asian mothers were significantly younger 
than Caucasian mothers. Pre-pregnancy BMI did not differ between South Asian mothers 
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and Caucasian mothers, with mean values of 23.6 and 23.7, respectively (P=.93). Infants were 
equally exposed to maternal chronic disease, such as asthma, diabetes mellitus, hypothyroidism, 
hyperthyroidism, and hypertension. More specifically, 6 of the South Asian women (10.7%) 
had some form of diabetes mellitus (type 1, type 2, or gestational diabetes) during pregnancy, 
compared with two women in the Caucasian group (9.5%), which was not significantly 
 different (data not shown). Furthermore, 6 of the South Asian women had pre-existent or 
pregnancyinduced hypertension, compared with 3 women in the Caucasian group (P=.116). 
Although maternal smoking and drug use did not differ between the groups, Caucasian 
mothers drank alcohol more often during pregnancy. Birth weight was approximately 400 g 
lower for South Asian babies (P=.002), and gestational age was 2 days longer for South Asian 
neonates, which was not significantly different (P=.437). Apgar scores after 5 minutes did not 
differ. Furthermore, there was no difference in sex of the neonate in the groups: 48% of South 
Asian babies were female, compared with 49% of Caucasian babies (P=.947). 
Caucasian (n=21) South Asian (n=57) P value
Mothers  
Age, years†  33 .9 (3.6)  31 .1 (4.7) .012
Pre-pregnancy BMI  23 .7 (5.0)  23 .6 (4.7)  .93
Chronic disease‡  24% (5)  24% (5)  .811
Smoking‡  5% (1)  7% (4)  .800
Alcohol use‡  30% (6)  2% (1)  .000
Drug use‡  0% (0)  2% (1)  .555
Neonates
Gestational age, days  273 .8 (9.7)  275 .9 (10.8)  .437
Birth weight, g*  3516 (525)  3113 (489)  .002
Apgar score 5 min†  9 .8  9 .6  .485




TABLE 1 - Characteristics of mothers and neonates
Caucasian (n=21) South Asian (n=57)
Vaginal delivery  52% (11)  45% (28)
Cesarean delivery  14% (3)  44% (27)
Vacuum extraction  19% (4)  8% (5)
Assisted delivery (forceps)  0% (0)  3% (2)
Induced labor  14% (3)  0% (0)
Data represent percentage (absolute number).
TABLE 2 - Mode of delivery
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Mode of delivery is summarized in (TABLE 2). Cesarean delivery was more common in South 
Asian women, and vacuum extraction was more common in Caucasian women. 
In (TABLE 3), the health status of the father and the family history of both the mother and 
father of the neonates is shown. Although most measurements did not differ, South Asian 
fathers had a positive family history for diabetes mellitus more often (P=.04). 
As shown in (TABLE 4), CRP levels were significantly higher in South Asian neonates 
 compared with Caucasian neonates (75.7 versus 43.8 ng/mL; P=.009). Glucose levels did not 
significantly differ between South Asian babies and Caucasian babies (not significant, 
P  =  .116). Mean insulin levels, however, were found to be 16.6 mmol/L in South Asian babies 
and 6.9 mmol/L in Caucasian neonates (P=.043). Furthermore, South Asian neonates had sig-
nificantly higher triglyceride levels (0.38 versus 0.27 mmol/L; P=.009). Total cholesterol levels 
did not differ in the groups (1.57 versus 1.60 mmol/L; P=.717). South Asian babies had signifi-
cantly higher non high-density lipoprotein cholesterol levels (0.66 versus 0.53 mmol/L; 
Caucasian South Asian P value
Fathers
Chronic disease (n=21 & n=57)  14% (3)  13% (8)  .872
Positive family history diabetes (n=19 & n=54)  32% (6)  59% (32)  .038
Positive family history hypertension (n=18 & n=52)  50% (9)  60% (31)  .477
Positive family history coronary event (n=19 & n=49)  16% (3)  35% (17)  .125
Mothers
Positive family history diabetes (n=20 & n=57)  45% (9)  67% (38)  .087
Positive family history hypertension (n=20 & n=58)  50% (10)  60% (35)  .419
Positive family history coronary event (n= 8 & n=56)  22% (4)  32% (18)  .423
Data represent percentage (absolute number).
TABLE 3 - Family history
Caucasian (n=21) South Asian (n=57) Delta P value
CRP, ng/mL*  43 .8 (26.1)  75 .7 (48.3) +73%  .009
Glucose, mM*  4 .7 (1.15)  5 .7 (2.40) .120
Insulin, mM†  6 .9 (10.2)  16 .6 (29.6) +141%  .043
Triglycerides, mM*  0 .27 (0.09)  0 .38 (0.19) +41%  .009
Total cholesterol, mM  1 .60 (0.38)  1 .57 (0.37)  .717
Non-HDL-cholesterol, mM  0 .53 (0.22)  0 .66 (0.27) +25%  .040
HDL-cholesterol, mM  1 .08 (0.24)  0 .91 (0.17) -16%  .001
Data represent mean (SD).
HDL, high-density lipoprotein.
* After log transformation.
† Non-parametric test.
TABLE 4 - Metabolic parameters
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P=.040) and lower high-density lipoprotein cholesterol levels (0.91 versus 1.08; P=.001) com-
pared with Caucasian neonates. 
E-selectin levels were significantly higher in cord blood of South Asian neonates 
 compared with that of Caucasian newborns (46.7 versus 33.5 ng/mL, P<.001). Levels of ICAM-1 
and VCAM-1 did not differ significantly in the groups (FIGURE). A multivariate analysis was 
 performed with E-selectin levels as dependent variable and ethnicity, maternal age, birth 
weight, insulin levels, and CRP levels as co-variates. In this analysis, ethnicity significantly 
 contributed to explain the variety of E-selectin. After correction for the aforementioned 
 co-variates, the estimated E-selectin levels were found to be 42.5 and 34.5 ng/mL for South 
Asian and Caucasian neonates, respectively (P=.047). 
Although the mode of delivery differed in the ethnic groups, stratification of the data 
showed that they did not influence E-selectin and other cord blood measures. Furthermore, 
no correlation was found between maternal pre-pregnancy BMI and cord plasma E-selectin 






FIGURE - Markers of endothelial dysfunction in cord 
blood of Caucasian and South Asian neonates. Data 
represent mean SD. A , Plasma ICAM-1 and B , VCAM-1 
levels do not differ between Caucasian (n=21) and 
South Asian (n=57) neonates. C , Plasma E-selectin 
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DISCUSSION
The link between endothelial dysfunction and type 2 diabetes mellitus has been described 
by Meigs and co-workers,10 who found that elevated levels of the biomarker E-selectin (but 
not ICAM-1 and VCAM-1) in serum predicts the occurrence of type 2 diabetes mellitus in 
adult women. We found a very similar pattern in South Asian newborns immediately after 
birth; E-selectin levels were elevated, but ICAM-1 and VCAM-1 levels were not.
Earlier research supports our finding of the presence of susceptibility for endothelial 
dysfunction in the South Asian population. In healthy South Asian men, impaired brachial 
artery response to reactive hyperemia has been demonstrated. This was independent of 
both conventional risk factors and markers of insulin resistance, supporting the presence 
of endothelial dysfunction.15 Our study, however, supports the hypothesis that endothelial 
dysfunction in South Asians is present as early as at birth. 
A recent study performed by Whincup et al16 showed that type 2 diabetes mellitus 
 precursors are already present in apparently healthy South Asian children 9 to 10 years of 
age. These children were found to have higher levels of hemoglobin A1c, insulin, triglycerides, 
and CRP and lower levels of high-density lipoprotein cholesterol compared with Caucasian 
children. In our study, we showed that South Asian newborns are not only characterized by 
elevated E-selectin levels, but also by hyperinsulinemia, inflammation, and dyslipidemia 
(elevated triglyceride levels, elevated non-high-density lipoprotein cholesterol levels, and 
decreased high-density lipoprotein cholesterol levels). 
Thus, in South Asian patients, many potential pathogenic variables for CAD and type 2 
diabetes mellitus are already present as early as at birth. Apparently, at least some of the 
risk factors responsible for the ethnic differences in CAD and type 2 diabetes mellitus are 
operating well before adult life, potentially offering opportunities for early prevention. 
There are some potential limitations to our study. First, cord blood E-selectin levels were 
used as a marker of endothelial dysfunction. It is not known whether E-selectin levels in the 
cord blood purely reflect neonatal E-selectin levels or whether they could also be partly 
derived from maternal origin. Unfortunately, in our study, levels of maternal E-selectin were 
not measured. However, an earlier study by Krauss et al17 showed that, in both normal and 
pre-eclamptic pregnancies, cord blood levels of E-selectin, ICAM-1, and VCAM-1 did not 
 correlate with maternal levels, despite mothers with pre-eclampsia having significantly 
 elevated levels of these factors. This suggests that these endothelial adhesion molecules 
are differently regulated in the fetus and, very likely, originate from the fetus. Second, the 
sample size of both groups was relatively small. However, the elevation of metabolic variables 
and E-selectin levels in South Asian newborns were found to be significantly different com-
pared with that in the control group. The South Asian neonates included in our study were 
from both Surinam and the Netherlands. Place of birth was not associated with sex, birth 
weight, maternal age, or plasma E-selectin levels. Moreover, the South Asian neonates living 
in the Netherlands all had grandparents who originally descended from Surinam. Lastly, this 
study is a cross-sectional study and is thus not able to show whether the presence of 
endothelial dysfunction in South Asian neonates indeed leads to the generation of CAD and 
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type 2 diabetes mellitus later in life. However, because endothelial dysfunction is considered 
a risk factor for the development of atherosclerosis,8 its contribution to the development of 
CAD is highly plausible. Moreover, in light of the fastemerging field of non-traditional risk 
factors and biomarkers for cardiovascular disease18 in South Asian children, E-selectin might 
be a biomarker for future cardiovascular disease. Furthermore, because of the cross-sectional 
design of our study, it is not possible to draw conclusions about whether the endothelial 
dysfunction found in the South Asian neonates has an ethnic or genetic origin. Future 
 studies, for example studies in which the effect of intrauterine conditions on endothelial 
function in South Asians is studied, could clarify this. 
Potentially, many pathogenic variables for CAD and type 2 diabetes mellitus are already 
present right after birth in South Asians, so the question arises whether rigorous childhood 
lifestyle intervention could be beneficial in these vulnerable children.
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SOUTH ASIANS EXHIBIT DISTURBED 
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ABSTRACT
South Asians have an exceptionally high risk of developing cardiovascular disease (CVD) 
compared to white Caucasians. A possible contributing factor might be dysfunction  
of high density lipoprotein (HDL). This study aimed to compare HDL function in neo-
nates, adolescents and adults of both ethnicities. HDL functionality with respect  
to cholesterol efflux, anti-oxidation and anti-inflammation was determined using 
fasting plasma samples from South Asian and white Caucasian neonates (n=14 
each), adolescent, healthy men (n=12 each, 18-25y), and adult, overweight men (n=12 
each, 40-50y). Adolescents were subjected to a 5-day high fat high calorie diet (HCD) 
and adults to an 8-day very low calorie diet (LCD). In neonates, anti-inflammatory 
capacity was reduced in South Asian neonates (22.9±0.7 vs. 35.9±1.9%, p<0.00001) 
while cholesterol efflux and anti-oxidative capacity of HDL were comparable 
between groups. In adolescents, all three measures of HDL functionality were 
 comparable between groups. Cholesterol efflux capacity increased in response to 
the HCD in South Asians (+6.3±2.9%, p=0.073) and Caucasians (+11.8±3.4%, p=0.002). 
In adults, anti-oxidative capacity was lower in South Asians before LCD (18.1±2.6  
vs. 24.2±2.2%, p=0.077) and after LCD (16.4±2.4 vs. 27.6±2.7%, p=0.003). Anti-
inflammatory capacity was negatively affected by the diet only in South Asians 
(-12.2±4.3%, p=0.005). Cholesterol efflux capacity was significantly reduced after  
the LCD in both South Asians (-10.3±2.4%, p<0.001) and Caucasians (-13.7±1.9%, 
p<0.0001). In conclusion, South Asians exhibit disturbed function of HDL compared 
to Caucasians, which may contribute to their excess risk of CVD.




The burden and mortality of cardiovascular disease (CVD) are significantly increased among 
both native and migrant South Asians compared to people of white Caucasian descent. 
The age-standardized mortality rate from CVD is around 50% higher for South Asians (1-4). 
In addition, CVD is more aggressive and has higher mortality rates at younger ages in South 
Asians (1,2,5-7). The underlying mechanism of this excess risk is still poorly understood. 
Traditional risk factors such as smoking, hypertension, and type 2 diabetes (T2D) seem to 
account for only part of the excess risk in South Asians (3,8-11). Thus, additional factors must 
be involved. One of these factors may be dysfunction of high density lipoprotein (HDL).
Numerous clinical and epidemiological studies have consistently shown a strong inverse 
association between the level of HDL-cholesterol and cardiovascular risk (12-17). The cardio-
vascular protective effects of HDL have been attributed to several anti-atherogenic functional 
properties, including: HDL (i) prevents LDL oxidation, (ii) is anti-inflammatory, and (iii) stimu-
lates cholesterol efflux from foam cells (18-22). Of note, recent evidence suggests that HDL 
functionality might be affected independent of changes in plasma HDL-cholesterol level 
(23,24). In trials that aimed at raising HDL-cholesterol levels with niacin or dalcetrapib on 
top of LDL lowering, no decrease in the occurrence of cardiovascular endpoints was 
observed compared to treatment with LDL lowering only (25,26). This suggests that simply 
raising HDL-cholesterol levels is not sufficient to lower CVD risk and that HDL functionality 
may thus be more importantly linked to CVD than plasma HDL-cholesterol concentrations. 
Indeed, previous studies showed that HDL is dysfunctional in patients with coronary athero-
sclerosis, in men with cardiovascular risk factors, and in patients with an acute phase 
response after surgery (27-30).
HDL functionality can not only be influenced by the cardiovascular health status, but 
also by dietary intervention. A 3-week high-fiber-low-fat diet and exercise intervention 
 converted HDL from pro- to anti-inflammatory (29). Furthermore, data from our study group 
demonstrated a decrease in cholesterol efflux capacity of HDL after very low calorie diet 
(LCD)-induced weight loss (31). 
Interestingly, multiple studies have repeatedly found lower HDL-cholesterol levels in South 
Asians compared to white Caucasians, even in South Asian neonates (32-39). In addition, 
South Asians seem to have relatively more small HDL particles, which are associated with 
decreased cardiac protection compared to normal sized HDL particles (40-42). Remarkably, 
though, little is known about HDL functionality in South Asians. Therefore, this study aimed 
to compare HDL function in South Asian and white Caucasian subjects. In particular, we 
were interested in the following questions: (i) is HDL function impaired in middle-aged 
overweight South Asians compared to matched Caucasians?, (ii) if so, is this dysfunction 
already present in young healthy subjects and/or even at birth?, and (iii) is the effect of 
short-term dietary intervention on HDL function different between South Asians and 
Caucasians? To answer these questions, we determined three functions of HDL, namely its 
ability to induce cholesterol efflux and its anti-oxidative and anti-inflammatory properties, 
in neonates, in young healthy men (adolescents) and in middle-aged overweight men 
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(adults). The adolescents and adults were subjected to a 5-day high-fat-high-calorie diet 
(HCD) and an 8-day LCD respectively. 
METHODS
Subjects
Neonates. Umbilical venous cord blood was collected from 28 neonates (14 South Asian and 
14 Caucasian neonates) as described previously (32). All neonates were born between Jan 1, 
2006, and Jan 1, 2009, and were examined after their mothers had given informed consent 
and approval had been obtained by the local ethics committee. Live-born singleton babies 
with 4 South Asian grandparents or 4 Caucasian grandparents were included. Pregnancies 
complicated by pre-eclampsia were excluded. Gestational age was based on last menstrual 
period or ultrasound scanning (before 12 weeks). Birth weights were taken from the medical 
records. Immediately after delivery, 20 mL of cord blood was collected from the umbilical 
vein according to standard protocols. South Asian and Caucasian neonates were matched 
for HDL-cholesterol level.
Adolescents and adults. 24 young healthy Dutch males (adolescents; age 18-25y, BMI <25 
kg/m2) and 24 middle-aged overweight Dutch males (adults; age 40-50y, BMI 25-30 kg/m2) 
were enrolled via local advertisements. Subjects were of South Asian (n=12 for each group) 
or Caucasian (n=12 for each group) origin. They underwent a medical screening including 
their medical history, a physical examination, blood chemistry tests and an oral glucose 
 tolerance test (OGTT) to exclude individuals with T2D. Other exclusion criteria were CVD, any 
significant chronic disease, use of medication known to influence lipid metabolism, rigorous 
exercise, smoking and recent body weight change. The study was approved by the Medical 
Ethical Committee of the Leiden University Medical Centre and performed in accordance 
with the principles of the revised Declaration of Helsinki. Written informed consent was 
obtained from all subjects prior to participation.
Dietary interventions adolescents and adults
The adolescents were subjected to a 5-day HCD, consisting of the subject’s regular diet, 
 supplemented with 375 mL of cream per day (1275 kcal/day, 94% fat), yielding to approx. 3775 
kcal/day and 54% of fat. The adults received an 8-day LCD, consisting of three sachets of 
Modifast per day (approx. 450 kcal/day, 50 g protein, 50-60 g carbohydrates, 7 g lipids and 
15 g dietary fibers). Subjects were instructed not to alter life style habits, and not to perform 
physical activity in the last 48 h before the study days. One day before and one day after the 
dietary interventions blood samples were obtained from all subjects after a 10h overnight fast.
Laboratory analyses
Fasting plasma total cholesterol, triglycerides and glucose were measured on a Modular 
P800 analyzer (Roche, Almere, The Netherlands) using commercially available enzymatic 
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kits from Roche Molecular Biochemicals (total cholesterol, triglycerides) and Instruchemie, 
Delfzijl, The Netherlands (glucose). HDL-cholesterol levels were determined after precipitating 
the apoB-containing lipoproteins as described previously (43). LDL-cholesterol was calculated 
according to Friedewald’s formula (44). Serum insulin levels were analyzed using a commer-
cially available chemiluminescence immunometric assay on an Immulite 2500 analyzer 
(Siemens Healthcare Medical Diagnostics, Germany).
HDL function measurements
ApoB-containing lipoproteins were precipitated by adding 100 µL 36% polyethylene glycol 
(PEG 6000, Sigma, St. Louis, MO, USA) in 10 mM HEPES (pH = 8.0) to 200 µL plasma. 
Subsequently, samples were incubated for 30 min on ice and centrifuged for 30 min at 
2200 g (45). The HDL-containing supernatant was collected, kept on ice, and used within the 
same week for HDL function assays.
Cholesterol efflux capacity. To determine HDL-mediated cholesterol efflux, THP-1 human 
monocytes (ATCC via LGC Promochem, Teddington, UK) were differentiated into macrophages 
in the presence of 100 nM phorbol myristate acetate (46). Differentiated THP-1 macrophages 
were then loaded with 50 µg/mL acetylated LDL and 1 µCi/mL [3H]cholesterol (Perkin Elmer, 
Boston, MA, USA) for 24 h. Next, macrophages were equilibrated for 18 h in RPMI 1640 medium 
containing 2% bovine serum albumin (46). Thereafter, 2% apoB-depleted plasma was added 
to the macrophages. After 5 h, effluxed radioactivity was determined by liquid scintillation 
counting (Packard 1600CA Tri-Carb, Packard, Meriden, CT, USA). Then the plates were washed 
two times with PBS and cells were lysed with 0.1 M NaOH (30 min incubation at room 
 temperature). Subsequently, the radioactivity within the cells was counted. Efflux per well 
is expressed as the percentage of radioactivity released into the medium related to the total 
initial dose of radioactivity. To correct for nonspecific efflux, we subtracted values obtained 
from control cells without added apoB-depleted plasma.
Anti-oxidative capacity. The anti-oxidative properties of HDL were assessed by measuring 
the capacity of HDL from the respective groups to inhibit the oxidation of native LDL using a 
previously published method (45). LDL was isolated from plasma of a fasted healthy male 
donor by density gradient ultracentrifugation (1.019 < d < 1.063 g/mL) (47). LDL (100 mg/dL 
cholesterol) was then oxidized with 5 mM 2,2′-azobis(2-methylpropionamidine) dihydro-
chloride (AAPH) for 24 h at 37°C either in the presence of 10% apoB-depleted plasma or an 
equal volume of precipitation reagent in PBS as a control. Protein was precipitated with 10% 
trichloroacetic acid. Then, the accumulation of thiobarbituric acid reactive substances 
(TBARS) as a measure of oxidative modification was determined by incubating the samples 
for 10 min at 99°C and measuring the fluorescence at 485 nm excitation and 545 nm emission 
using 1,1,3,3-tetramethoxypropane as a standard as published previously (47). The anti- 
oxidative capacity of HDL was expressed as the amount of TBARS accumulating in the 
 samples relative to control LDL oxidized in the absence of HDL.
Anti-inflammatory capacity. Anti-inflammatory properties of HDL were assessed using 
human umbilical vein endothelial cells (HUVECs, provided by the Endothelial Cell Core 
Facility of the UMCG) isolated and cultured as described previously (48). HUVECs were 
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 pre-incubated with 2% apoB-depleted plasma or an equal volume of precipitation reagent 
in PBS as a control for 1 h. Then, 10 ng/mL tumor necrosis factor  (TNF-; R&D systems, 
Abingdon, UK) was added. After an additional incubation for 8 h, total RNA was isolated 
using Trizol (Invitrogen, Carlsbad, CA, USA) and quantified with a NanoDrop ND-100 UV-Vis 
spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). One µg of total RNA 
was reversed transcriped into cDNA (Invitrogen). Real-time quantitative PCR was performed 
on an ABI-Prism 7700 (Applied Biosystems) sequence detector (49). Vascular cell adhesion 
molecule-1 (VCAM-1) mRNA expression was calculated relative to the expression of the 
housekeeping gene cyclophilin. 
Statistical analysis
Data are presented as mean ± SEM when normally distributed or as median (IQR) when not 
normally distributed. A mixed effects model was applied to assess mean differences before 
and after the intervention within and between groups, and to determine differences in 
diet effect. Groups and intervention were modeled as fixed effects and the subject specific 
deviances from the group mean were modeled as random effects. Nonparametric tests 
(Wilcoxon signed-rank test within group, Mann-Whitney between groups) were performed 
when appropriate. Significance level was set at p<0.05. Statistical analyses were performed 
using SPSS for Windows version 20.0 (IBM, USA).
RESULTS
Clinical characteristics
Clinical characteristics are shown in TABLE 1.
Neonates. Mean gestational age was 278 ± 2 days. Birth weight tended to be lower in 
South Asian neonates (p=0.078). Glucose levels were comparable between groups, but insulin 
levels were significantly higher in South Asian neonates (p=0.044). No significant differences 
were observed in lipid levels.
Adolescents. Mean age was 22.1 ± 0.4 years. BMI did not differ between groups (at baseline 
20.9 ± 0.6 (South Asians) vs. 22.2 ± 0.6 kg/m2 (Caucasians), p=0.11). Fasting glucose, insulin, 
triglyceride, HDL-cholesterol and phospholipid levels were comparable at baseline, while 
total cholesterol levels were significantly higher and LDL-cholesterol tended (p=0.055) to 
be higher in South Asians. After the HCD, anthropometric parameters were unchanged. 
Fasting glucose and insulin levels were significantly increased only in South Asians. The HCD 
induced a significant increase in total cholesterol, HDL-cholesterol and LDL-cholesterol 
 levels in Caucasians. In South Asians only HDL-cholesterol showed a tendency to increase 
(p=0.060). Phospholipids increased significantly to a similar degree in both groups. 
Adults. Mean age was 44.6 ± 0.8 years. BMI did not differ between groups (at baseline 
28.4 ± 0.4 (South Asians) vs. 28.1 ± 0.5 kg/m2 (Caucasians), p=0.65). Fasting glucose and lipid 
levels were comparable between groups, whereas insulin levels were significantly higher in 
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South Asians (p=0.002). After the LCD, anthropometric parameters were significantly 
reduced in both groups. The mean reduction in body weight was 4.0±0.2 kg, of which 
approximately 50% was fat mass. Furthermore, caloric restriction induced a comparable, 
 significant decrease in fasting plasma glucose, insulin, triglyceride, total cholesterol and 
phospholipid levels. HDL-cholesterol and LDL-cholesterol levels were not affected by the diet. 
Of note, HDL-cholesterol levels were significantly lower in adult South Asians vs. adolescent 
South Asians (p=0.027). Furthermore, HDL-cholesterol was significantly lower at neonatal 
age compared to adolescent age for both South Asian (p=0.001 and p=0.040) and Caucasian 
(p=0.005 and p=0.017) subjects.
HDL functionality
The functionalities of HDL in Caucasians and South Asians with respect to inducing cholesterol 
efflux and anti-oxidative and anti-inflammatory action are depicted in FIGURE 1.
Cholesterol efflux capacity is affected by dietary intervention. The ability of HDL to elicit 
 cholesterol efflux from macrophages did not differ between groups for all ages, both at 
 baseline and after the dietary interventions. However, the HCD led to a significant increase in 
TABLE 1 - Clinical and metabolic characteristics in South Asian and Caucasian neonates, and in adolescent 
healthy and adult overweight South Asian and Caucasian men before and after a 5-day HCD and 8-day LCD, 
respectively.
Neonates Group 18 – 25 years Group 40 – 50 years


















(Gestational) age (days or years) 277 ± 3 279 ± 2 22.1 ± 0.6 22.2 ± 0.7 44.3 ± 1.1 44.9 ± 0.9
length (m) 1.84 ± 0.01 1.74 ± 0.02** 1.81 ± 0.02 1.75 ± 0.01**
weight (g or kg) 3474 ± 133 3148 ± 118 75.1 ± 1.8 75.6 ± 1.8 63.2 ± 2.3** 63.7 ± 2.3† ** 92.6 ± 2.5 88.2 ± 2.5†† 86.7 ± 1.4 83.2 ± 1.6†† ‡
body mass index (kg/m2) 22.2 ± 0.6 22.4 ± 0.6 20.9 ± 0.6 21.0 ± 0.6† 28.1 ± 0.5 26.8 ± 0.5†† 28.4 ± 0.4 27.3 ± 0.4††
waist (cm) 81.3 ± 2.2 82.0 ± 2.3 78.9 ± 2.2 79.5 ± 2.6 103 ± 1.8 100 ± 1.6†† 101 ± 1.6 98 ± 1.5††
Fasting plasma and serum levels
glucose (mmol/L) 4.7 ± 0.4 4.7 ± 0.3 5.1 ± 0.1 5.2 ± 0.1 5.3 ± 0.1 5.5 ± 0.1†† * 5.3 ± 0.2 4.5 ± 0.2†† 5.3 ± 0.1 4.5 ± 0.1††
insulin (mU/L) 4.4 (3.9) 7.9 (6.7)* 4.8 (4.5) 7.0 (6.6) 7.1 (4.2) 10.6 (4.9)†† ** ‡‡ 8.9 (3.3) 3.7 (4.9)†† 11.7 (2.8)** 4.8 (5.8)††
triglycerides (mmol/L) 0.29 (0.13) 0.29 (0.33) 0.79 (0.26) 0.75 (0.67) 0.98 (0.75) 1.08 (0.70) 1.29 (2.48) 0.89 (0.18)†† 1.78 (2.91) 0.91 (0.25)††
total cholesterol (mmol/L) 1.48 ± 0.09 1.55 ± 0.09 3.75 ± 0.19 4.25 ± 0.22†† 4.60 ± 0.30* 4.79 ± 0.24 5.56 ± 0.24 4.72 ± 0.33†† 5.74 ± 0.28 5.13 ± 0.26††
HDL-cholesterol (mmol/L) 0.98 ± 0.04 0.94 ± 0.04 1.18 ± 0.05 1.31 ± 0.06† 1.26 ± 0.08 1.36 ± 0.07 1.09 ± 0.08 0.99 ± 0.06 1.00 ± 0.07 0.95 ± 0.05
LDL-cholesterol (mmol/L) 0.37 ± 0.07 0.43 ± 0.07 2.21 ± 0.21 2.55 ± 0.22†† 2.83 ± 0.24 2.95 ± 0.20 3.54 ± 0.28 3.42 ± 0.37 3.58 ± 0.25 3.77 ± 0.24
Data are presented as mean ± SEM or median (IQR). HCD, 5-day high fat high calorie diet.  
LCD, 8-day very low calorie diet. † p<0.05, †† p<0.005 within group vs. before diet.  
* p<0.05, ** p<0.005 vs. Caucasians. ‡ p<0.05, ‡‡ p<0.005 diet effect vs. Caucasians.
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cholesterol efflux ability in Caucasian adolescents (+11.8 ± 3.4%, p=0.002), while in South Asian 
adolescents there was a tendency towards an increase (+6.3 ± 2.9%, p=0.073). On the other 
hand, the LCD in the adult group resulted in a significantly lower cholesterol efflux capacity for 
both ethnicities (South Asians: -10.3 ± 2.4% (p<0.001) vs. Caucasians: -13.7 ± 1.9% (p<0.0001)). 
Cholesterol efflux capacity was comparable throughout different ages for both ethnic groups.
Anti-oxidative capacity is impaired in adult South Asians. The ability of HDL to prevent 
oxidation of LDL was comparable between groups at neonatal and adolescent age. However, 
this ability was markedly impaired in adult South-Asian subjects compared to Caucasians 
(before LCD: 18.1 ± 2.6 vs. 24.2 ± 2.2%, p=0.077; after LCD: 16.4 ± 2.4 vs. 27.6 ± 2.7%, p=0.003). 
Anti-oxidative capacity was not affected by dietary intervention. Of note, anti-oxidative 
capacity was significantly lower in adult South Asians compared to adolescent South Asians 
(p<0.005), while for Caucasian subjects anti-oxidative capacity was comparable between 
both age groups (p=0.160). Furthermore, anti-oxidative capacity was markedly lower at 
 neonatal age compared to adolescent and adult age for both South Asian (vs. adolescents: 
p=0.00004, vs. adults: p=0.048) and Caucasian (vs. adolescents: p=0.000008; vs. adults: 
p=0.00007) subjects.
Neonates Group 18 – 25 years Group 40 – 50 years


















(Gestational) age (days or years) 277 ± 3 279 ± 2 22.1 ± 0.6 22.2 ± 0.7 44.3 ± 1.1 44.9 ± 0.9
length (m) 1.84 ± 0.01 1.74 ± 0.02** 1.81 ± 0.02 1.75 ± 0.01**
weight (g or kg) 3474 ± 133 3148 ± 118 75.1 ± 1.8 75.6 ± 1.8 63.2 ± 2.3** 63.7 ± 2.3† ** 92.6 ± 2.5 88.2 ± 2.5†† 86.7 ± 1.4 83.2 ± 1.6†† ‡
body mass index (kg/m2) 22.2 ± 0.6 22.4 ± 0.6 20.9 ± 0.6 21.0 ± 0.6† 28.1 ± 0.5 26.8 ± 0.5†† 28.4 ± 0.4 27.3 ± 0.4††
waist (cm) 81.3 ± 2.2 82.0 ± 2.3 78.9 ± 2.2 79.5 ± 2.6 103 ± 1.8 100 ± 1.6†† 101 ± 1.6 98 ± 1.5††
Fasting plasma and serum levels
glucose (mmol/L) 4.7 ± 0.4 4.7 ± 0.3 5.1 ± 0.1 5.2 ± 0.1 5.3 ± 0.1 5.5 ± 0.1†† * 5.3 ± 0.2 4.5 ± 0.2†† 5.3 ± 0.1 4.5 ± 0.1††
insulin (mU/L) 4.4 (3.9) 7.9 (6.7)* 4.8 (4.5) 7.0 (6.6) 7.1 (4.2) 10.6 (4.9)†† ** ‡‡ 8.9 (3.3) 3.7 (4.9)†† 11.7 (2.8)** 4.8 (5.8)††
triglycerides (mmol/L) 0.29 (0.13) 0.29 (0.33) 0.79 (0.26) 0.75 (0.67) 0.98 (0.75) 1.08 (0.70) 1.29 (2.48) 0.89 (0.18)†† 1.78 (2.91) 0.91 (0.25)††
total cholesterol (mmol/L) 1.48 ± 0.09 1.55 ± 0.09 3.75 ± 0.19 4.25 ± 0.22†† 4.60 ± 0.30* 4.79 ± 0.24 5.56 ± 0.24 4.72 ± 0.33†† 5.74 ± 0.28 5.13 ± 0.26††
HDL-cholesterol (mmol/L) 0.98 ± 0.04 0.94 ± 0.04 1.18 ± 0.05 1.31 ± 0.06† 1.26 ± 0.08 1.36 ± 0.07 1.09 ± 0.08 0.99 ± 0.06 1.00 ± 0.07 0.95 ± 0.05
LDL-cholesterol (mmol/L) 0.37 ± 0.07 0.43 ± 0.07 2.21 ± 0.21 2.55 ± 0.22†† 2.83 ± 0.24 2.95 ± 0.20 3.54 ± 0.28 3.42 ± 0.37 3.58 ± 0.25 3.77 ± 0.24
Data are presented as mean ± SEM or median (IQR). HCD, 5-day high fat high calorie diet.  
LCD, 8-day very low calorie diet. † p<0.05, †† p<0.005 within group vs. before diet.  
* p<0.05, ** p<0.005 vs. Caucasians. ‡ p<0.05, ‡‡ p<0.005 diet effect vs. Caucasians.
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FIGURE 1 - HDL functionality in Caucasian (solid black) and South Asian (striped black) neonates, and in 
 adolescent healthy and adult overweight Caucasian and South Asian men before (solid black and striped black, 
respectively) and after (solid white and striped white, respectively) a 5-day HCD and 8-day LCD, respectively. 
HDL function was determined as A  D  G ) induction of cholesterol efflux from cholesterol-laden THP-1 cells, 
B  E  H ) protection against oxidation of LDL, and C  F  I ) protection of HUVECs against TNF-induced 
inflammation as determined by VCAM-1 expression. Assays were performed as detailed in methods. 
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Anti-inflammatory capacity is impaired in South Asian neonates and is negatively affected 
by an 8-day LCD in South Asian adults only. The anti-inflammatory capacity of HDL was 
 significantly lower in South Asian neonates (22.9 ± 0.7 vs. 35.9 ± 1.9%, p<0.00001), a difference 
that disappeared at adolescent and adult age, at least at baseline. A 5-day HCD had no 
impact on anti-inflammatory capacity. Remarkably, though, anti-inflammatory capacity was 
negatively affected by an 8-day LCD in adult South Asians only (-12.2 ± 4.3% (p=0.005) vs. 
+0.2 ± 4.2% (p=0.984)), resulting in a significantly lower anti-inflammatory capacity compared 
to adult Caucasians after the diet (23.0 ± 1.6% vs. 29.8 ± 2.3%, p=0.024). Anti-inflammatory 
capacity was significantly higher in Caucasian neonates compared to Caucasian adults 
(p=0.044). No other significant differences were observed for anti-inflammatory capacity at 
different ages.
Cholesterol efflux capacity positively correlates with HDL-cholesterol and phospholipid levels
Linear regression analysis showed a clear positive correlation between cholesterol efflux 
capacity and HDL-cholesterol levels for all ages at baseline (neonates: R2=0.451, β=0.672, 
p<0.0001; adolescents: R2=0.286, β=0.534, p=0.009; adults: R2=0.201, β=0.448, p=0.032; 
FIGURE 2). The same was true for cholesterol efflux capacity and HDL-phospholipid levels 
(neonates: R2=0.277, β=0.527, p=0.004; adolescents: R2=0.293, β=0.541, p=0.008; adults: 
R2=0.176, β=0.419, p=0.047). In addition, cholesterol efflux capacity was positively correlated 
with HDL-cholesterol after the diet (adolescents: R2=0.456, β=0.676, p=0.0004; adults: 
R2=0.307, β=0.554, p=0.006) and for diet effect (delta HDL-cholesterol; adolescents: 
R2=0.395, β=0.629, p=0.001; adults: R2=0.240, β=0.489, p=0.018). Of note, correlations were 
pooled for South Asians and Caucasians. Similar correlations were observed per group, 
although these did not always reach statistical significance, probably due to a limited number 
of subjects.
FIGURE 2 - Correlations of cholesterol efflux capacity with HDL-cholesterol. Cholesterol efflux capacity in 
relation to HDL-cholesterol levels in South Asian and Caucasian neonates A , and in adolescent healthy B  
and adult overweight C  South Asian and Caucasian men, respectively. Correlations were determined by 
 linear regression analysis. Caucasian subjects are depicted in open circles and South Asian subjects in closed 
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Anti-oxidative and anti-inflammatory capacity did not correlate with HDL-cholesterol 
levels nor with phospholipid levels for all ages (data not shown). As expected, HDL-
cholesterol and HDL-phospholipid levels were positively correlated for all ages and all 
 conditions (data not shown). 
DISCUSSION
South Asians have an exceptionally high risk to develop CVD compared to Caucasians. 
A possible contributing factor might be dysfunctionality of HDL, which has been shown to 
be associated with cardiovascular disease in human studies. Interestingly, the current study 
showed that the ability of HDL to prevent oxidation of LDL was impaired in adult over-
weight South Asian males compared to matched Caucasians. At younger ages, the anti- 
oxidative function of HDL was still comparable between both ethnicities. In contrast, the 
anti-inflammatory capacity of HDL was markedly lower in South Asian neonates, a difference 
that was not present at adolescent and adult age. However, short-term caloric restriction 
at adult age significantly impaired anti-inflammatory capacity in South Asians only. Finally, 
the ability of HDL to induce cholesterol efflux was similar between South Asians and 
Caucasians, albeit that in both ethnic groups cholesterol efflux was increased after a 5-day 
HCD and reduced after an 8-day LCD. 
HDL functionality between ethnic groups
Several recent studies have reported lower HDL-cholesterol levels in South Asians as 
 compared to Caucasians (33-39), even already at birth (32). Surprisingly, little is known about 
HDL functionality in South Asians. To date only one cross-sectional, uncontrolled pilot study 
assessed the anti-oxidative capacity of HDL in 28 South Asian immigrants in the USA (50). 
They found dysfunctional HDL, as measured by a cell-free assay, in 50% of the participants, 
which was significantly correlated with carotid intima media thickness, a surrogate marker 
of atherosclerosis. However, no Caucasian control group was included, so no statements 
could be made on the ethnic implication of this percentage. In the present study, HDL-
cholesterol levels were comparable between South Asians and Caucasians for all ages. For 
the neonates this was due to the fact that we matched the groups on HDL-C levels. For the 
adolescents and adults, this is probably due to lack of power to detect differences on HDL 
levels. However, despite equal HDL-cholesterol levels, we still observed several differences 
in HDL functionality between both ethnicities, suggesting that the HDL-cholesterol level 
was not a confounder in the current set-up. Recent evidence indeed suggests that HDL 
functionality might be affected independent of changes in plasma HDL-cholesterol levels 
and may be more important than plasma HDL-cholesterol concentrations with respect to 
prediction of the cardioprotective effect of HDL (23,24).
The oxidative modification of LDL is an important step in the initiation and progression 
of atherosclerosis as it results in enhanced uptake of LDL by macrophages and subsequent 
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foam cell formation. HDL is able to prevent the oxidation of LDL and hence its subsequent 
atherogenic actions by various mechanisms (22,51). In the present study, we observed that 
the ability of HDL to prevent oxidation of LDL was markedly lower in adult South Asian adult 
men compared to matched Caucasian men. Therefore, the reduced anti-oxidative capacity 
of HDL in South Asians may be involved in the increased risk of CVD in this ethnic group. 
Interestingly, the anti-oxidative capacity of HDL was only impaired in adult overweight 
South Asians and not at adolescent and neonatal age, suggesting that the ability of HDL to 
protect against LDL oxidation deteriorates with age. Indeed, for South Asians anti-oxidative 
capacity was significantly lower in adult compared to adolescent subjects (p=0.002), while 
for Caucasians this capacity was comparable between both age groups (p=0.160). On the 
underlying mechanism behind this deterioration we can only speculate, but this might be 
due to exogenous factors such as insulin resistance (IR) and T2D, which are also known to 
be considerably more prevalent in people of South Asian origin, especially at higher age. 
Indeed, it has been shown that IR and T2D are associated with a decrease in HDL-cholesterol 
levels, altered HDL composition and impaired HDL function (20). Elevated levels of free fatty 
acids and disturbed insulin action may contribute to low HDL-cholesterol in T2D by modifying 
lipolysis, apolipoprotein A-I production, as well as the activities of ATP-binding cassette 
transporter A1 (ABCA1) and lipid transfer (20). In the current study plasma insulin levels were 
significantly higher in the South Asian adults, pointing to IR. Interestingly, Mulder et al (45) 
showed that the anti-oxidative capacity of HDL from T2D patients is inversely related to skin 
autofluorescence, a non-invasive marker of tissue advanced glycation end products (AGEs), 
suggesting that impaired anti-oxidative capacity of HDL may contribute to tissue accumu-
lation of AGEs and thereby to the development of long term diabetic complications. Thus, IR 
may affect the ability of HDL to prevent oxidation of LDL or, vice versa, HDL dysfunction may 
also be involved in the increased risk of T2D and diabetes-related complication in South 
Asians. 
Another interesting finding is that anti-oxidative capacity of HDL was significantly 
impaired at neonatal age compared to adolescent and adult age for both South Asian and 
Caucasian subjects. This is in line with a study of Sreckovic et al (52) who compared fetal to 
maternal HDL functionality and found lower anti-oxidative capacity of fetal HDL, as measured 
by Cu2+-induced oxidation. This was likely the consequence of a 7-fold lower HDL-associated 
PON1 protein content and activity in the fetal than in the maternal circulation, as PON1 is an 
HDL-associated enzyme that inhibits LDL and HDL oxidation. The underlying reason for the 
lower anti-oxidative function of HDL is unknown, but it is one of the reasons why neonates 
are more prone to oxidative stress than are young children and adults (53). 
HDL has several anti-inflammatory effects, such as the ability to inhibit cytokine-
induced expression of adhesion molecules on endothelial cells, and to control the adaptive 
immune system (51,54). Since suppression of immunity in neonates is important during 
pregnancy to prevent miscarriage, this may explain why we found higher anti-inflammatory 
capacity of HDL in neonates as compared to adults. Furthermore, the anti-inflammatory 
capacity of HDL was significantly lower in South Asian neonates (-36%). Interestingly, we 
previously found higher levels of the adhesion molecule E-selectin in cord blood of the same 
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cohort of South Asian neonates as compared to Caucasians (32). This is a marker of endothelial 
activation which may thus be the consequence of the lower anti-inflammatory capacity of 
HDL. We did not find a difference in anti-inflammatory capacity of HDL at adolescent and 
adult age, thus the opposite direction of effect as compared to anti-oxidative function. This 
could suggest that during development the lower anti-inflammatory functions in South 
Asians recovers. However, a basis for atherosclerosis and the concomitant risk of CVD is then 
probably already formed. 
Finally, cholesterol efflux capacity did not differ between groups for all ages. The ability 
of HDL to stimulate cholesterol efflux involves transport of cholesterol from peripheral cells, 
particularly foam cells within atherosclerotic plaques, to the liver for final excretion into bile 
and faeces, i.e. the reverse cholesterol transport pathway (51,54). This ability of HDL therefore 
might reverse or prevent the formation of macrophage foam cells and is thus an important 
atheroprotective property, however, deterioration of this function is likely not involved in the 
high CVD risk of the South Asian population. 
Response of HDL functionality to short-term dietary intervention
HDL functionality was also assessed in response to short-term dietary intervention in order 
to investigate ethnic differences upon dietary stimuli. Previous studies have demonstrated 
that HDL-cholesterol levels can be influenced by dietary intervention, with an increase 
in response to short-term high fat diets (55-57), and a reduction after low fat diets (29). 
Moreover, a 3-week high-fiber-low-fat diet and exercise intervention converted HDL from 
pro- to anti-inflammatory (29). Furthermore, data from our study group demonstrated a 
decrease in cholesterol efflux capacity of HDL after weight loss (31).
In the present study, a 5-day HCD increased HDL-cholesterol, whereas an 8-day LCD did 
not affect HDL-cholesterol levels and decreased HDL-phospholipids. Cholesterol efflux ability 
was enhanced in response to a 5-day HCD, and reduced after an 8-day LCD, which might be 
explained by the increase in HDL-cholesterol and phospholipid levels and decrease in phos-
pholipids, respectively. Indeed, in both the adolescent group and adult group cholesterol 
efflux capacity was positively correlated with HDL-cholesterol and phospholipid levels 
(FIGURE 2). 
Interestingly, anti-inflammatory capacity was significantly impaired after an 8-day LCD 
only in South Asians. Hence, instead of being beneficial, caloric restriction appears to be 
 detrimental to South Asians with respect to anti-inflammatory function of HDL. Possibly, 
this worsening of HDL anti-inflammatory capacity may only be present in the calorie-
restricted state, returning to normal or even improving after weight loss and re-introduction 
of a normal diet. Indeed, our group previously assessed the short- and long-term effects of a 
4-month LCD on low-grade inflammation in obese patients with T2D, and demonstrated 
that the beneficial effects on chronic inflammation became apparent only when patients 
were on a eucaloric diet, suggesting that severe caloric restriction at first increased cytokine 
production by adipose tissue macrophages and that the beneficial effects of weight loss 
became apparent only in the eucaloric state (58). Hence, perhaps the initial response to 
caloric restriction is worse in South Asians compared to Caucasians, but may normalize later 
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on. This may, at least in part, be due to the fact that South Asians have higher release of 
 pro-inflammatory cytokines, such as interleukin-6 and tumor necrosis factor- (TNF-), 
by adipocytes, which may aggravate in case of caloric restriction (59,60). As mentioned 
above, one of the anti-inflammatory properties of HDL includes the ability to inhibit 
cytokine-induced adhesion molecule expression by the endothelium (61). Although the exact 
mechanism remains elusive, it has been postulated that HDL inhibits TNF--induced acti va-
tion of the sphingosine kinase signal transduction pathway in endothelial cells, resulting in a 
decrease in sphingosine 1-phosphate production and adhesion protein expression. This also 
leads to reduced TNF--mediated activation of extracellular signal-regulated kinases and 
nuclear factor κβ (NF- κβ) cascade activity and ultimately to inhibition of endothelial 
inflammation (61). All and all, further research is needed to elucidate why South Asians 
respond differently compared to Caucasians to caloric restriction concerning HDL anti-
inflammatory functionality
This study is not without limitations. The sample sizes are relatively small, which might 
limit generalization potential. On the other hand, subjects were their own controls (with 
respect to diet intervention), which increases power to detect relevant differences. 
Strengths of this study are the assessment of several HDL functions, in comparison to 
Caucasians, at three different age categories, and in response to dietary intervention.
In conclusion, we showed that adult, overweight South Asians have impaired anti-oxidative 
capacity of HDL, which is not yet present at a young age and, therefore, likely the consequence 
of environmental factors. Furthermore, anti-inflammatory capacity was reduced in South 
Asian neonates, and was significantly impaired in response to short-term caloric restriction 
in South Asian adults. These impairments in HDL functionality may contribute to the excess 
risk of CVD, and possibly of T2D, in people of South Asian origin. Therefore, future studies 
should be directed at developing treatment strategies that improve HDL functionality, 
and at investigating whether these strategies will lower cardiovascular risk in South Asian 
subjects.
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ABSTRACT
South Asians have an exceptionally high risk of developing type 2 diabetes mellitus 
(T2DM) compared to white Caucasians. Though the underlying cause is still poorly 
understood, it is assumed that an ethnic susceptibility towards a disturbed energy 
metabolism might be present. Brown adipose tissue (BAT) has emerged as an impor-
tant player in energy metabolism by combusting fatty acids and glucose towards 
heat. We, therefore, hypothesized that a low total BAT activity might underlie the 
 susceptibility for T2DM in South Asians. BAT volume and activity were measured in 
healthy lean adolescents (mean age 24•1±0•8 years) from South Asian (n=12) and 
white Caucasian (n=12) origin, matched for BMI, using cold-induced 18F-FDG-PET-CT-
scans. Furthermore, resting energy expenditure (REE), non-shivering thermogenesis 
(NST) and serum parameters were assessed. Thermoneutral REE was lower in South 
Asian compared to white Caucasian adolescents (-32%, P=0•001). Upon cold exposure, 
the shiver temperature of South Asians was higher (+2•0°C, P=0•007). Furthermore, 
cold exposure significantly increased NST in white Caucasians (+20%, P<0•0001), but 
not in South Asians. Though the SUVmax and SUVmean of 18F-FDG in BAT did not 
differ, total BAT volume was markedly lower in South Asians (-34%, P=0•04). Taken 
the subjects together, BAT volume correlated positively with basal REE (ß=0.44; 
P=0•04). In conclusion, healthy South Asian adolescents have lower REE, NST, as well 
as lower BAT volume compared to matched white Caucasians. This might underlie 
their high susceptibility to develop metabolic disturbances, such as obesity and 
T2DM. Future studies should focus on developing novel strategies to increase BAT 
volume and activity.




South Asian individuals originate from the Indian subcontinent and constitute a fifth of the 
world’s population. The risk of development of type 2 diabetes and its related complications 
is very high in native and migrant south Asians compared with people of white Caucasian 
descent, and prevalence is increasing.1 Moreover, type 2 diabetes occurs at a younger age 
and lower BMI in south Asians than Caucasians,2,3 and the risk of complications related to 
diabetes is increased in this group.4,5 The underlying cause of this excess risk is incompletely 
understood, but might involve a common disadvantageous metabolic phenotype, consisting 
of central obesity, insulin resistance, and dyslipidaemia.6,7 A common assumption is that 
ethnic susceptibility towards a disturbed energy homoeostasis (eg, reduced oxidation of 
glucose and fatty acids by mitochondria) underlies this phenotype.8
Recently, brown adipose tissue (BAT) has been identified to have a role in energy 
homoeostasis in humans.9–12 In contrast to white adipose tissue, BAT burns triglycerides 
and  glucose to generate heat through a process called mitochondrial uncoupling.13 A main 
 stimulator for BAT activation is cold and repeated cold exposure leads to recruitment of BAT 
in healthy humans.14 BAT volume and activity—as assessed after exposure to cold by use of 
18F-fluorodeoxyglucose (18F-FDG) PET CT scans—are inversely related to BMI and percentage 
of body fat in adult humans, suggesting an inverse association between BAT and obesity.11,15,16 
Besides a clear role for BAT in triglyceride metabolism,17 this tissue is also thought to 
 contribute to glucose homoeostasis, especially in resting conditions when glucose use by 
skeletal muscle is minimal.18 Notably, BAT seems to contribute to non-shivering thermo-
genesis12,16 and fully activated BAT in humans has been estimated to contribute up to 
15–20% of total energy expenditure.13 
Because BAT is involved in total energy expenditure and clearance of serum triglycerides 
and glucose, thereby protecting against metabolic disturbances, we postulated that a low 
BAT volume or activity might underlie the disadvantageous metabolic phenotype and 
 susceptibility to type 2 diabetes in south Asians. Therefore, we investigated resting energy 
expenditure and BAT volume and activity in young healthy lean south Asian men and 
matched white Caucasians (hereafter referred to as Caucasians), by use of a ventilated hood 
technique and cold-induced 18F-FDG PET CT scans. In addition, we examined the effect of 
cold exposure on non-shivering thermogenesis, thermoregulation, and plasma lipid levels.
METHODS
Study design and participants
We enrolled Dutch south Asian participants (ie, individuals with two south Asian parents 
born in the Netherlands) and matched Dutch Caucasian participants at The Rijnland 
Hospital in Leiderdorp in the Netherlands. We recruited eligible healthy men aged 18–28 
years with a lean body type (BMI <25 kg/m2) via local advertisements. Participants under-
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went medical screening to obtain their medical history and a physical examination, blood 
chemistry tests, and an oral glucose tolerance test to exclude individuals with type 2 dia-
betes according to the American Diabetes Association 2010 criteria. Other exclusion criteria 
were rigorous exercise (>10 h of exercise per week), smoking, and recent bodyweight change 
(>3 kg weight gain or loss within 3 months before enrolment). Participants were matched for 
BMI with a pairwise approach. The study was approved by the Medical Ethical Committee of 
the Leiden University Medical Center and undertaken in accordance with the principles of 
the revised Declaration of Helsinki. All volunteers provided written informed consent.
Procedures
We assessed participants in the morning after a 10 h overnight fast and after 24 h without 
exercise. Participants wore standardised clothing, consisting of a T shirt and boxer shorts. 
We determined body composition by means of dual-energy x-ray absorptiometry (iDXA, GE 
Healthcare, UK). We inserted a cannula in the left antecubital vein for blood sampling and 
injection of 18F-FDG. The appendix contains further details on study techniques.
To activate BAT, we applied two water perfused cooling mattresses (Blanketrol III, 
Cincinnati Sub-Zero Products, Cincinnati, OH, USA).16 During the procedure participants 
stayed in a clinical examination room. The protocol started with a baseline period of 1 h in 
thermoneutral condition, after which participants were exposed to mild cold. Because the 
onset temperature of shivering is very variable and dependent on the individual (eg, 
because of differences in body composition),13 we used an individualised cooling protocol 
to ensure maximum non-shivering thermogenesis, and thus a maximum level of BAT 
 acti vity, for each participant. Cooling started at 32°C and temperature was gradually 
decreased until shivering occurred. Temperature was then raised by 3–4°C and the cooling 
Caucasians (n=12) South Asians (n=12) P value*
Age, years  24 ·6 (2·8)  23 ·6 (2·8)  0·39
Height, m  1 ·85 (0·04)  1 ·74 (0·06) <0·0001
Weight, kg  75 ·1 (7·2)  65 ·0 (8·5)  0·0051
BMI, kg/m2  22 ·0 (1·6)  21 ·5 (2·0)  0·50
Waist circumference, cm  84 (5·1)  83 (7·7)  0·80
Hip circumference, cm  96  (3·5)  89 (5·7)  0·0041
Waist-to-hip ratio  0 ·88 (0·04)  0 ·93 (0·04)  0·0047
Fat mass, %  18 ·3% (5·0)  23 ·9% (5·0)  0·0123
Fat mass, kg  13 ·9 (4·3)  15 ·8 (4·6)  0·31
Lean body mass, %  77 ·6% (4·8)  72 ·1% (4·7)  0·0107
Lean body mass, kg  58 ·5 (6·0)  46 ·8 (5·1) <0·0001
Bone mineral content, %  4 ·1% (0·2)  4 ·0% (0·4)  0·49
Bone mineral mass, kg  3 ·1 (0·3)  2 ·6 (0·3)  0·0008
Data are mean (SD). *Unpaired t test.
TABLE 1 - Characteristics of study participants
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Caucasians (n=12) South Asians (n=12) Between-group difference 
in cooling effect
Thermoneutral Cold-induced Within-group change 
(95% CI); P value
Thermoneutral Cold-induced Within-group change 
(95% CI); P value
Difference (95% CI) P value*
Systolic blood pressure, 
mm Hg
135 (11) 143 (13) 6% (–1 to 13); 
P=0·082
126 (18) 125 (13)‡ 0% (–6 to 6); 
P=0·759
8
 (–3 to – 20) 
0·141
Diastolic blood pressure, 
mm Hg
77 (6) 84 (6) 10% (3 to 16); 
P=0·0051
73 (9) 79 (8) 9% (3 to 16); 
P=0·0093
1 




64 (10)  57 (10) –9% (–16 to –2);
 P=0·0172
62 (8) 54 (8) –12% (–19 to –5); 
 P=0·0027
2 




 4 ·17 (0·26)  4 ·32 (0·29) 4% (–1 to 9); 
P=0·213
 4 ·30 (0·42)  4 ·26 (0·58) –1% (–7 to 5); 
 P=0·698
 0 ·20 




 0 ·78 (0·58–0·96)  0 ·92 (0·69–1·32) 27% (6 to 48); 
P=0·0142
 0 ·77 (0·57-0·82)  0 ·90 (0·76–0·96) 34% (13 to 56); 
P=0·0029
 –0 ·05 
 (–0·29 to –0·18)
0·624
Free fatty acid concentration, 
mmol/L
 0 ·66 (0·30)  0 ·99 (0·29) 50% (34 to 66); 
P<0·0001
 0 ·88 (0·39)  0 ·97 (0·37) 10% (–2 to 23); 
P=0·099
 0 ·24 
 (0·08 to –0·39)
0·0046
Free fatty acid concentration, 
mmol/L per kgfatmass
 0 ·052 (0·035)  0 ·078 (0·034) 50% (34 to 66); 
P<0·0001
 0 ·069 (0·037)  0 ·075 (0·035) 10% (–2 to 23); 
P=0·099
 0 ·020 
 (0·010 to –0·030)
0·0046
Data are mean (SD) or median (IQR), unless otherwise stated. All P values are based on a mixed model.  
*P value for cooling effect in the south Asian group vs Caucasian group.  
‡P=0·0046 for cold-induced value in the south Asian group vs the Caucasian group.
TABLE 2 - Cardiovascular parameters and fasting serum levels in thermoneutral and cold-induced conditions
TABLE 3- Indirect calorimetry in thermoneutral and cold-induced conditions
Caucasians (n=12) South Asians (n=12) Between-group difference 
in cooling effect
Thermoneutral Cold-induced Within-group change 
(95% CI); P value
Thermoneutral Cold-induced Within-group change 
(95% CI); P value
Difference (95% CI) P value*
Resting energy expenditure,
kcal per day
1689 (193) 2027 (471) 20% (9 to 31);
P=0·0011
1297 (123)† 1462 (127)‡ 13% (–1% to 27%); 
P=0·072
 171




 0 ·063 (0·024)  0 ·092 (0·040) 46% (24 to 70);
P<0·0001
 0 ·049 (0·009)  0 ·062 (0·014)§ 26% (–7% to 46%); 
P=0·072
 0 ·016 




 0 ·151 (0·057)  0 ·141 (0·037) –6% (–23 to 12);
 P=0·277
 0 ·114 (0·014)¶  0 ·111 (0·036) –0·3% (–25% to 24%); 
 P=0·804
 –0 ·011
 (–0·046 to –0·025)
0·538
Respiratory quotient  0 ·85 (0·06)  0 ·82 (0·04) –4% (–6 to –1);
 P=0·0303
 0 ·84 (0·02)  0 ·82 (0·04) –2% (–6% to 1%);
 P=0·128
 –0 ·01
 (–0·05 to –0·03)
0·577
Data are mean (SD), unless otherwise stated. All P values are based on a mixed model. 
*P value for cooling effects in the south Asian group vs Caucasians. 
†P=0·0008 for thermoneutral value in the South Asian group vs Caucasian group. 
‡P<0·0001 for cold-induced value in the South Asian group vs Caucasian group. 
§P=0·0058 for cold-induced value in the South Asian group vs Caucasian group. 
¶P=0·0285 for thermoneutral value in the South Asian group vs Caucasian group.
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Caucasians (n=12) South Asians (n=12) Between-group difference 
in cooling effect
Thermoneutral Cold-induced Within-group change 
(95% CI); P value
Thermoneutral Cold-induced Within-group change 
(95% CI); P value
Difference (95% CI) P value*
Systolic blood pressure, 
mm Hg
135 (11) 143 (13) 6% (–1 to 13); 
P=0·082
126 (18) 125 (13)‡ 0% (–6 to 6); 
P=0·759
8
 (–3 to – 20) 
0·141
Diastolic blood pressure, 
mm Hg
77 (6) 84 (6) 10% (3 to 16); 
P=0·0051
73 (9) 79 (8) 9% (3 to 16); 
P=0·0093
1 




64 (10)  57 (10) –9% (–16 to –2);
 P=0·0172
62 (8) 54 (8) –12% (–19 to –5); 
 P=0·0027
2 




 4 ·17 (0·26)  4 ·32 (0·29) 4% (–1 to 9); 
P=0·213
 4 ·30 (0·42)  4 ·26 (0·58) –1% (–7 to 5); 
 P=0·698
 0 ·20 




 0 ·78 (0·58–0·96)  0 ·92 (0·69–1·32) 27% (6 to 48); 
P=0·0142
 0 ·77 (0·57-0·82)  0 ·90 (0·76–0·96) 34% (13 to 56); 
P=0·0029
 –0 ·05 
 (–0·29 to –0·18)
0·624
Free fatty acid concentration, 
mmol/L
 0 ·66 (0·30)  0 ·99 (0·29) 50% (34 to 66); 
P<0·0001
 0 ·88 (0·39)  0 ·97 (0·37) 10% (–2 to 23); 
P=0·099
 0 ·24 
 (0·08 to –0·39)
0·0046
Free fatty acid concentration, 
mmol/L per kgfatmass
 0 ·052 (0·035)  0 ·078 (0·034) 50% (34 to 66); 
P<0·0001
 0 ·069 (0·037)  0 ·075 (0·035) 10% (–2 to 23); 
P=0·099
 0 ·020 
 (0·010 to –0·030)
0·0046
Data are mean (SD) or median (IQR), unless otherwise stated. All P values are based on a mixed model.  
*P value for cooling effect in the south Asian group vs Caucasian group.  
‡P=0·0046 for cold-induced value in the south Asian group vs the Caucasian group.
Caucasians (n=12) South Asians (n=12) Between-group difference 
in cooling effect
Thermoneutral Cold-induced Within-group change 
(95% CI); P value
Thermoneutral Cold-induced Within-group change 
(95% CI); P value
Difference (95% CI) P value*
Resting energy expenditure,
kcal per day
1689 (193) 2027 (471) 20% (9 to 31);
P=0·0011
1297 (123)† 1462 (127)‡ 13% (–1% to 27%); 
P=0·072
 171




 0 ·063 (0·024)  0 ·092 (0·040) 46% (24 to 70);
P<0·0001
 0 ·049 (0·009)  0 ·062 (0·014)§ 26% (–7% to 46%); 
P=0·072
 0 ·016 




 0 ·151 (0·057)  0 ·141 (0·037) –6% (–23 to 12);
 P=0·277
 0 ·114 (0·014)¶  0 ·111 (0·036) –0·3% (–25% to 24%); 
 P=0·804
 –0 ·011
 (–0·046 to –0·025)
0·538
Respiratory quotient  0 ·85 (0·06)  0 ·82 (0·04) –4% (–6 to –1);
 P=0·0303
 0 ·84 (0·02)  0 ·82 (0·04) –2% (–6% to 1%);
 P=0·128
 –0 ·01
 (–0·05 to –0·03)
0·577
Data are mean (SD), unless otherwise stated. All P values are based on a mixed model. 
*P value for cooling effects in the south Asian group vs Caucasians. 
†P=0·0008 for thermoneutral value in the South Asian group vs Caucasian group. 
‡P<0·0001 for cold-induced value in the South Asian group vs Caucasian group. 
§P=0·0058 for cold-induced value in the South Asian group vs Caucasian group. 
¶P=0·0285 for thermoneutral value in the South Asian group vs Caucasian group.
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Caucasians (n=12) South Asians (n=12) Between-group difference 
in cooling effect
Thermoneutral Cold-induced P value† Thermoneutral Cold-induced P value† Difference (95% CI) P value*
Shiver temperature …  8 ·9 (1·5) … …  10 ·9 (1·8) … … 0·0067
Cooling temperature …  19 ·8 (2·5) … …  18 ·7 (2·2) … … 0·271
Core temperature  36 ·8 (0·2)  36 ·6 (0·3)  0 ·130  36 ·6 (0·3)  36 ·8 (0·2)  0· 128 –0·4 (–0·7 to –0·0) 0·0339
Skin temperature  33 ·1 (0·5)  28 ·6 (1·0)  <0 ·0001  33 ·4 (0·7)  28 ·8 (1·0)  <0 ·0001 0·1 (–0·7 to –0·8) 0·836
Proximal skin temperature  34 ·4 (0·4)  30 ·8 (1·0)  <0 ·0001  34 ·4 (0·4)  31 ·0 (1·1)  <0 ·0001 –0·2 (–1·0 to –0·5) 0·535
Distal skin temperature  31 ·8 (0·9)  26 ·3 (1·4)  <0 ·0001  32 ·5 (1·3)  26 ·6 (1·5)  <0 ·0001 0·4 (–0·7 to –1·5) 0·482
Core mean skin temperature gradient  3 ·6 (0·4)  7 ·9 (0·9)  <0 ·0001  3 ·2 (1·0)  8 ·1 (1·1)  <0 ·0001 –0·5 (–1·4 to –0·6) 0·643
Core distal skin temperature gradient  4 ·8 (0·7)  10 ·0 (1·4)  <0 ·0001  4 ·1 (1·5)  10 ·2 (1·5)  <0 ·0001 –0·8 (–2·2 to –0·6) 0·236
Data are mean (SD) in degrees centigrade.  
*P value for between-group difference in cooling effects, or difference in shiver temperature and cooling  
temperature based on an unpaired t test. 
†P value for withingroup change from thermoneutral to cold-induced condition.  
All P values are based on a mixed model, except for shiver temperature and cooling temperature (unpaired t test).
TABLE 4 - Thermoregulation in thermoneutral and cold-induced conditions
period of 2 h was started (defined as tcold=0 min). If shivering occurred, the temperature was 
raised by 1°C until shivering stopped. We detected shivering visually or it was reported by 
participants. After 1 h of cooling (tcold=60 min), we injected 2 MBq/kg 18F-FDG intravenously. 
To exclude artefacts of muscle activity, participants were instructed to lie still. We collected 
venous blood when participants were thermoneutral and when they were in a cold-induced 
 condition (tcold=110 min) and did indirect calorimetry with a ventilated hood (Oxycon Pro, 
CareFusion, Germany) in thermoneutral condition and tcold of 80–110 min. After 2 h of 
 cooling (tcold=120 min) we did 18F-FDG PET CT imaging to quantify BAT volume an activity. 
Imaging was done with a PET CT scanner (Gemini TF PET CT, Philips, Netherlands) as 
described previously (appendix).11 Imaging started with a low-dose CT scan (effective dose 
2 mSv), immediately followed by a PET scan. We used the CT scan for attenuation correction 
and localisation of the 18F-FDG uptake sites. Both image sets were reconstructed in trans axial, 
coronal, and sagittal images with a slice thickness of 4 mm. PET CT images were interpreted 
by a nuclear medicine physician (LPAB) and a researcher (MRB or RADL), who were masked to 
patient group, with dedicated software (Hermes Hybrid Viewer, Hermes Medical Solutions, 
Sweden). We quantified BAT activity and detectable volume in the region of interest by auto-
contouring the BAT areas with a set threshold (standardised uptake value [SUV] of 2·0 g/mL).
To register temperature changes, we measured core body temperature in the small 
intestine at 1 min intervals with an ingestible telemetric capsule (Jonah, BMedical, 
Australia). Measurement of core temperature did not work in two participants (one in each 
group). We also measured skin temperature at 1 min intervals by wireless iButtons (Maxim, 
USA) placed at different positions on the skin.19 
We report total detectable BAT volume in mL and BAT activity in terms of SUV (the ratio 
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of activity in kBq/mL within the region of interest and the injected activity [kBq] per body-
weight [g]). We established maximum SUV (SUVmax) in g/mL and the average SUV (SUVmean) 
in g/mL within the volume of interest. We assessed energy expenditure, respiratory quotient, 
and rates of substrate oxidation every 1 min as described previously.20,21 We measured skin 
temperatures according to the 14 point International Organization for Standardization meth-
od (appendix).19 
We used enzymatic kits to measure serum triglyceride concentrations (Roche Diagnostics, 
Netherlands), serum glucose concentrations (Instruchemie, Delfzijl, Netherlands) and free 
fatty acid concentrations (Wako Chemicals, Germany). 
Statistical analysis 
Normally distributed data are shown as mean (SD) and non-normally distributed data are 
shown as median (IQR). We applied a mixed-effects model to assess mean differences 
before and after cold exposure within and between groups, and to determine differences 
in the effect of cold exposure. We modelled groups and interventions as fixed effects and 
modelled participant-specific deviances from the group mean as random effects. We used 
unpaired t tests to compare baseline characteristics and BAT parameters between groups. 
We used non-parametric tests (Wilcoxon signed-rank test for within-group analyses and 
Mann-Whitney tests for between-group analyses) when appropriate. We used ANCOVA to 
correct parameters for lean body mass. Linear regression analyses were done to identify 
 correlations between variables. The significance level was set at p<0·05. We did not adjust 
for multiple testing. All statistical analyses were done with SPSS for Windows version 20.0. 
This study is registered with the Netherlands Trial Register, number 2473.
Caucasians (n=12) South Asians (n=12) Between-group difference 
in cooling effect
Thermoneutral Cold-induced P value† Thermoneutral Cold-induced P value† Difference (95% CI) P value*
Shiver temperature …  8 ·9 (1·5) … …  10 ·9 (1·8) … … 0·0067
Cooling temperature …  19 ·8 (2·5) … …  18 ·7 (2·2) … … 0·271
Core temperature  36 ·8 (0·2)  36 ·6 (0·3)  0 ·130  36 ·6 (0·3)  36 ·8 (0·2)  0· 128 –0·4 (–0·7 to –0·0) 0·0339
Skin temperature  33 ·1 (0·5)  28 ·6 (1·0)  <0 ·0001  33 ·4 (0·7)  28 ·8 (1·0)  <0 ·0001 0·1 (–0·7 to –0·8) 0·836
Proximal skin temperature  34 ·4 (0·4)  30 ·8 (1·0)  <0 ·0001  34 ·4 (0·4)  31 ·0 (1·1)  <0 ·0001 –0·2 (–1·0 to –0·5) 0·535
Distal skin temperature  31 ·8 (0·9)  26 ·3 (1·4)  <0 ·0001  32 ·5 (1·3)  26 ·6 (1·5)  <0 ·0001 0·4 (–0·7 to –1·5) 0·482
Core mean skin temperature gradient  3 ·6 (0·4)  7 ·9 (0·9)  <0 ·0001  3 ·2 (1·0)  8 ·1 (1·1)  <0 ·0001 –0·5 (–1·4 to –0·6) 0·643
Core distal skin temperature gradient  4 ·8 (0·7)  10 ·0 (1·4)  <0 ·0001  4 ·1 (1·5)  10 ·2 (1·5)  <0 ·0001 –0·8 (–2·2 to –0·6) 0·236
Data are mean (SD) in degrees centigrade.  
*P value for between-group difference in cooling effects, or difference in shiver temperature and cooling  
temperature based on an unpaired t test. 
†P value for withingroup change from thermoneutral to cold-induced condition.  
All P values are based on a mixed model, except for shiver temperature and cooling temperature (unpaired t test).
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FIGURE 1 - Brown adipose tissue activity as assessed by 18F-fluorodeoxyglucose PET CT scans in three repre-
sentative healthy young south Asian men A  and matched Caucasians B . Black areas show uptake of 
18F-fluorode oxyglucose in brown adipose tissue, and other glucose-consuming tissues such as brain and 






Between March 1, 2013, and June 1, 2013, we enrolled 12 South Asian participants and 
12 Caucasian participants. Mean age and BMI values did not differ between groups, but south 
Asian participants were shorter and lighter than were Caucasian participants (TABLE 1). The 
percentage of fat mass was higher in south Asians than Caucasians and, consequently, the 
percentage of lean body mass was lower. Additionally, the waist-to-hip ratio was higher in 
south Asians than Caucasians. One Caucasian participant developed hyperventilation after 
18F-FDG administration, and was excluded from all cold-induced and BAT comparisons. 
Cold exposure increased diastolic blood pressure and decreased heart rate in both 
groups (TABLE 2). Cold exposure did not seem to affect systolic blood pressure, but systolic 
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FIGURE 2 - Brown adipose tissue activity and vol-
ume in healthy young south Asian men and matched 
Caucasians, assessed by 18F-fluorodeoxyglucose PET 
CT scans. Error bars show SD. A  Maximum stand-
ardised uptake value (SUVmax). B  Mean standard-
ised uptake value (SUVmean). C  Total detectable 























































blood pressure during cold exposure was significantly lower in south Asian participants 
than in Caucasian participants (TABLE 2). 
Fasting thermoneutral glucose and lipid concentrations did not differ between groups 
(TABLE 2). Cooling did not affect serum glucose concentrations, but increased serum trigly-
ceride concentrations in both groups. Of note, a significant cold-induced increase in serum 
free fatty acid concentrations was present in Caucasian participants, but not in south Asian 
participants. The ethnic difference in cold-induced free fatty acid release was even more 
 pronounced after dividing serum free fatty acid levels by total fat mass, which is the main 
source of serum free fatty acid (TABLE 2). 
Before cooling, resting energy expenditure was 32% lower in south Asians than it was in 
Caucasians (TABLE 3). This difference persisted after correction for lean body mass with 
ANCOVA (intercept 177 kcal per day [SD 173] vs 290 kcal per day [215]; P=0·0316; appendix). 
During cold exposure, non-shivering thermogenesis increased significantly in Caucasians 
(by 20%; 1689 kcal per day [SD 193] vs 2027 kcal per day [471]; p<0·0001), but not in south 
Asians (by 13%; 1297 kcal per day [123] kcal per day vs 1462 [127]; P=0·09) (appendix). 
Furthermore, cold exposure significantly increased lipid oxidation only in Caucasians, 
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whereas glucose oxidation was not affected in either group (TABLE 3). In line with this 
 fin ding, cold exposure significantly decreased respiratory quotient in Caucasians only 
(TABLE 3). Despite an increased fat mass percentage, the temperature at which shivering 
started was higher in south Asians than it was in Caucasians (TABLE 4). Due to individual 
fine-tuning of the environmental temperature during non-shivering thermogenesis, mean 
environmental cooling temperature did not differ between groups during the second half 
of cooling (TABLE 4). Core temperature was not affected by cold exposure. Mean overall, 
 proximal, and distal skin temperatures decreased substantially to much the same extent in 
both groups (TABLE 4). Consequently, core distal and core mean skin temperature gradients 
were signi ficantly higher during cooling, suggesting an insulative response in south Asian 
and Caucasian participants. 
In 22 (96%) of 23 assessable participants, active BAT was detected by 18F-FDG uptake in 
the classic regions for this tissue (FIGURE 1).15 The only participant who did not have cold-
induced BAT activity was Caucasian and also had the lowest resting energy expenditure in 
that group. SUVmax and SUVmean in the volume of interest with metabolically active BAT did 
not differ between south Asian and Caucasian participants (FIGURE 2). Notably, detectable 
BAT volume was substantially lower in south Asians (188 mL [SD 81]) than it was in 
Caucasians (287 mL [169]; difference –34%, P=0·04), as shown in a representative sample of 
patients in FIGURE 1. Linear regression analysis showed a clear positive correlation between 
SUVmax and BAT volume (FIGURE 3). Furthermore, thermoneutral serum free fatty acid 
 concentration correlated with BAT volume in Caucasian participants (R2=0·49, ß=0·70, 
P=0·02), but not in south Asian participants (R2=0·0009, ß=0·03, P=0·97). Thermoneutral 
resting energy expenditure did not correlate with BAT volume in individual groups. However, 
A B
FIGURE 3 - Correlations with brown adipose tissue. BAT volume in relation to SUVmax A  and thermoneutral 
resting energy expenditure B . Correlations were determined with linear regression analysis. BAT=brown 
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with pooling of all participants, there was a weak but significant positive association 
between thermoneutral resting energy expenditure and BAT volume (R2=0·19, ß=0·44, 
P=0·038;  FIGURE 3), strongly suggesting that BAT is involved in total energy metabolism.
DISCUSSION
In our study, healthy, young, lean south Asian participants had lower resting energy expen-
ditures than did equivalent Caucasians. Notably, the detectable volume of metabolically 
active BAT, which has previously been shown to significantly contribute to energy meta-
bolism,11,15 was substantially lower in south Asian participants than Caucasians. These findings 
were corroborated by an increased shiver temperature and lower cold-induced non-shivering 
thermogenesis in south Asians compared with Caucasians. 
We detected BAT in 96% of assessable participants, which corresponds to the proportions 
noted in previous studies (Panel).11,23 Moreover, as reported previously,13,23 cold exposure in 
Caucasian participants resulted in increased serum free fatty acid concentrations, lipid 
 oxidation, systolic blood pressure, and non-shivering thermogenesis (which aims to prevent 
a drop in core body temperature). In south Asians, all of these responses were less pronounced. 
Our previous study14 suggested that BAT, and not muscle, is responsible for nonshivering 
thermogenesis via mitochondrial uncoupling. Lean participants with detectable BAT activity 
have significantly higher non-shivering thermogenesis than those without detectable 
activity.12 Therefore, less BAT volume might underlie the smaller increase in nonshivering 
thermogenesis in south Asians; however, we did not identify a correlation between BAT 
 volume and non-shivering thermogenesis, which has been shown previously,12,16,24 albeit 
not consistently.11,25 
Because cold-induced increases in lipolysis and systolic blood pressure are mediated by 
sympathetic activation, the lower response in south Asians might be attributable to a lower 
cold-induced sympathetic activation. We cannot rule out the possibility that this change 
was attributable to the fact that south Asians were initially cooled from a somewhat higher 
initial shiver temperature, resulting in less sympathetic outflow. However, SUVmax and 
SUVmean did not differ between groups, suggesting that BAT could be equally stimulated in 
all individuals by cold exposure. Thus, signs of lower sympathetic activation were only 
 present in the white adipose tissue depot and the vasculature, and not in BAT. This finding 
can be explained because sympathetic outflow neurons towards various organs derive from 
different brain regions.26 A lower sympathetic response in south Asians might, at least in 
part, underlie their lower resting energy expenditure, because the reduced liberation of free 
fatty acids from white adipose tissue in plasma could have lowered the availability of free 
fatty acids for combustion by BAT, resulting in lower fat oxidation. Future studies would be 
needed to investigate a potentially different (organspecific) sympathetic response in south 
Asians and the potential link with resting energy expenditure. 
South Asians had a significantly increased shivering temperature on cold exposure, 
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despite their overall increased total percentage of fat mass compared with Caucasians. 
Conversely, obese participants have lower shivering temperatures than do lean participants 
because of increased insulation.16 An impaired capacity of BAT to contribute to total heat 
 production might underlie the accelerated action of the muscles to produce heat by shivering 
in south Asians. This assumption is supported by a study of Ouellet and colleagues10 in which 
participants with high BAT volumes had reduced rates of shivering during cooling. However, 
we cannot exclude the possibility that the increased shivering temperature in south Asians 
could, at least in part, be influenced by their small body size and lower lean body mass. 
It could be argued that low energy metabolism in south Asians is not be solely attributable 
to decreased BAT volume but also because of diminished oxidative metabolism in muscle. 
We obtained muscle biopsies from the same participants as in this study before and after 
a short-term high-fat diet challenge, and did not observe differences in skeletal muscle 
insulin signalling or expression of genes involved in oxidative phosphorylation and mito-
chondrial biogenesis.27 Furthermore, food intake and levels of physical activity did not differ 
between south Asians and Caucasians. Thus, the lower resting energy expenditure which 
we found in south Asians is probably not a consequence of a lower food intake or lower 
 levels of physical activity. 
The question remains as to what mechanisms underlie the decreased BAT volume in 
south Asians. Because this decrease is noted in healthy young adults without differences in 
the degree of 18F-FDG uptake, as shown by equivalent SUVmax and SUVmean values, a defect 
could have arisen in BAT differentiation. However, 18F-FDG uptake only represents glucose 
uptake by the tissue and not metabolism itself. Therefore, a potential dysfunction in oxidative 
metabolism in the tissue cannot be excluded and should be investigated further, for example 
with an 11C-acetate tracer as described previously10 or by study of BAT biopsies. The under-
lying cause of lower BAT volume in south Asians might be genetic (ie, blunted expression of 
signalling molecules involved in BAT differentiation), environmental (ie, clothing or heating), 
or a combination of the two. 
Our study had limitations. Although our group size was in line with several landmark 
BAT studies9,11 and provided sufficient power to identify differences in detectable BAT 
 volume between south Asians and Caucasians, the study may have been underpowered for 
some correlations. Strengths of our study included large number of measurements we did 
alongside 18F-FDG PET CT scans, such as indirect calorimetry and temperature records, and 
the use of a personalised cooling protocol with water-perfused cooling mattresses, which 
results in maximal BAT activity and detectable BAT volume in non-shivering conditions.13 
This personalised cooling protocol might explain why in a recent study by Admiraal and 
 colleagues,22 in which all participants were cooled in an air-cooled chamber with a stable 
temperature of 17°C, no difference in BAT volume could be identified in south Asian 
 compared with Caucasian participants. Because water has a higher heat transfer coefficient 
than air, water cooling results in more rapid cooling of participants and, possibly, an 
increased ability to detect BAT. Median BAT volume in Caucasian patients in the Admiraal 
study22 was only 16 mL compared with 287 mL in our study. Thus, the less-intense cooling 
protocol in that study might have underestimated BAT volumes in their study participants. 
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Moreover, exposure of all participants to a stable room temperature of 17°C might have led 
to underestimation of BAT volume in Caucasian participants compared with south Asian 
participants, because Caucasians begin (according to our study) to shiver at lower tempe-
ratures. A possible drawback of the use of a personalised cooling protocol is that differences 
in environmental temperature could induce differences in BAT activity, because a strong 
 positive association exists between environmental temperature and thermogenesis.28 
However, we do not believe such differences arose in our study because SUVmax and 
SUVmean did not differ between the groups, suggesting equal BAT activation. 
This study has important clinical implications. Until now, little was known about the 
underlying mechanisms of the disadvantageous metabolic phenotype and the consequently 
high risk of type 2 diabetes in south Asians. Therefore, treatment options and, more impor-
tantly, preventive strategies are unfocused and of limited efficacy in south Asians. Increasing 
the volume or activity of BAT, resulting in increased clearance of glucose and fatty acids and 
increased total energy expenditure, might be of great therapeutic potential in this group. 
We recently showed that BAT can be recruited in humans following 10 days of cold inter-
vention.14 Future studies should be directed towards the efficacy of this strategy, as well 
as other options, such as medication, to increase BAT volume or activity. These strategies 
might ultimately be useful for improving the metabolic phenotype in south Asians with 
type 2 diabetes or at high risk of developing the disease.
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ABSTRACT
Brown adipose tissue (BAT) has emerged as a novel player in energy homeostasis in 
humans and is considered a potential new target for combating  obesity and related 
diseases. The current ‘gold standard’ for quantification of BAT volume and activity is 
cold-induced 18F-FDG uptake in BAT. However, use of this  technique is limited by cost 
and radiation exposure. Given the fact that BAT is a thermogenic tissue, mainly located 
in the supraclavicular region, the aim of the current study was to investigate whether 
cold-induced supraclavicular skin temperature and core body temperature may be 
alternative markers of BAT activation in humans. BAT volume and activity were 
measured in 24 healthy lean adolescent males (mean age 24.1 ± 0.8 years), using 
cold-induced 18F-FDG uptake with PET-CT. Core body temperature was measured 
continuously in the small intestine with use of an ingestible telemetric capsule and 
skin temperature was measured by eighteen wireless iButtons attached to the skin 
following ISO-defined locations. Proximal and distal (hand/feet) skin temperatures 
markedly decreased upon cold exposure, while supraclavicular skin temperature 
 significantly increased (35.2±0.1 vs. 35.5±0.1°C, p=0.001). Furthermore, cold-induced 
supraclavicular skin temperature positively correlated with both total (R2=0.28, 
P=0.010) and clavicular BAT volume (R2=0.20, P=0.030) and clavicular SUVmax 
(R2=0.27, P=0.010), while core body temperature did not. In conclusion, supraclavicular 
skin temperature as measured by iButtonsmay have predicitive value for BAT detec-
tion in adult humans. This is highly desirable considering the increasing interest in 
pharmacological interventions to stimulate BAT in human subjects.




Brown adipose tissue (BAT) is a highly metabolically active tissue involved in facultative 
thermogenesis in mice (reviewed in [1]) and humans [2–5]. Cold-induced 18F-fluorodeoxy-
glucose (FDG) positron emission tomography-computed tomography (PET-CT) studies in 
humans have shown that BAT is mainly present in the neck area and along the great vessels 
[6]. At these strategic locations, the produced heat can immediately be dispersed throughout 
the body. In addition, brown-like adipocytes, so-called ‘beige’ adipocytes, are present within 
white adipose tissue and these may contribute to total energy expenditure and thermogenesis 
as well, albeit to a lesser extent as the ‘classical’ brown adipocytes [7]. In order to execute 
their function, brown adipocytes contain a wealth of mitochondria that express uncoupling 
protein 1 (UCP-1), which uncouples respiration from adenosine triphosphate (ATP) synthesis, 
leading to heat production [1]. As a substrate, brown adipocytes oxidize triglyceride-derived 
fatty acids and glucose. In line with this, in mice, BAT is importantly involved in plasma 
 triglyceride clearance [8] and contributes to glucose homeostasis [9]. Furthermore, in 
humans, BAT activation by means of cold induction results in elevation of plasma free fatty 
acids (FFA) levels and a steep increase in fat oxidation [10]. 
It has been estimated that fully activated BAT in humans can contribute to up to 15-20% 
of total energy expenditure [11]. The fact that obese individuals have lower BAT volume and 
activity supports the metabolic importance of BAT [6,12,13]. Of note, we recently showed that 
the South Asian population, which is highly susceptible of developing a disadvantageous 
metabolic phenotype along with type 2 diabetes, has markedly lower BAT volume along with 
lower resting energy expenditure and non-shivering thermogenesis, further supporting a role 
of BAT in whole-body metabolism [14]. Therefore, stimulation of BAT is currently considered 
a potential preventive and therapeutic target in the combat against obesity and related 
 diseases, such as dyslipidemia and type 2 diabetes. In fact, the modest decrease in body 
weight as evoked by the anti-diabetic drug metformin may be due to activation of BAT [15].
The current ‘gold standard’ for determination of BAT volume and BAT activity in human 
subjects is cold-induced 18F-FDG uptake as assessed with PET-CT, for which subjects are 
cooled for approximately 2 hours at a temperature just above their shivering temperature 
[4,12,13,16], followed by infusion of 18F-FDG and performance of a PET-CT scan. 18F-FDG is 
an analogue of glucose that is taken up by glucose transporters. Once taken up, 18F-FDG 
is phosphorylated but is no substrate for further metabolism and becomes trapped in 
 metabolically active, glucose-using tissues, amongst which BAT, allowing the assessment of 
glucose uptake by tissues by PET-CT. 18F-FDG uptake by activated BAT regions on the PET-CT 
scan can be quantified, resulting in measures for BAT volume as well as for maximal 18F-FDG 
uptake (maximal standardized uptake value, ‘SUVmax’) and mean 18F-FDG uptake (mean 
standardized uptake value, ‘SUVmean’), which may be considered measures for the level of 
BAT activation.
Interestingly, in mice, in which most BAT is present in the interscapular region, ‘inter-
scapular temperature’ is commonly used as a measure for BAT activity [17], as well as core 
body temperature [18]. For instance, activation of BAT by the cannabinoid 1 receptor inverse 
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agonist rimonabant resulted in a transient but steep increase in interscapular temperature 
as recorded by implantable temperature probes [17]. Since in humans a large part of BAT 
is located in the supraclavicular region, recording cold-induced skin temperature in this 
 specific area may be an attractive alternative for measuring BAT activity instead of the 
18F-FDG scans which are relatively expensive and pose a radiation burden on study subjects. 
Therefore, the aim of the current study was to investigate whether cold-induced supra-
clavicular skin temperature as measured with wireless temperature sensors and core body 
temperature as measured in the small intestine with an ingestible telemetric temperature 




24 Dutch healthy, lean (BMI < 25 kg/m2) males of white Caucasian (n=12) and South Asian 
(n=12) origin between 18 and 28 years of age were enrolled via local advertisements as 
described previously [14]. Subjects underwent a medical screening including their medical 
history, a physical examination, blood chemistry tests and an oral glucose tolerance test to 
exclude individuals with type 2 diabetes according to the American Diabetes Association 
2010 criteria. Other exclusion criteria were rigorous exercise, smoking and recent body 
weight change. The present study was approved by the Medical Ethical Committee of 
the Leiden University Medical Center and performed in accordance with the principles of 
the revised Declaration of Helsinki. All volunteers gave written informed consent before 
 participation.
Study design
The study was conducted in The Rijnland Hospital, Leiderdorp (The Netherlands). Subjects 
were studied in the morning after a 10-hour overnight fast and subjects were not allowed 
to exercise 24 hours prior to the study. Subjects wore standardized clothing, consisting of a 
T-shirt and boxer short. Upon arrival, subjects ingested a telemetric capsule to measure core 
body temperature, and eighteen wireless iButtons were attached to the skin to measure 
skin temperature (see below). A cannula was inserted in the left antecubital vein for 18F-FDG 
injection.
Cooling protocol. To activate BAT an individualized cooling protocol was applied, using 
two water perfused cooling mattresses (Blanketrol® III, Cincinatti Sub-Zero (CSZ) Products, 
Inc), as described previously [14]. Importantly, the cooling mattresses covered the anterior 
and posterior sides of the body of the subject, from the caudal part of the chin and upper 
side of the neck, respectively, until the ankles or lower legs, depending on the height of 
the subject. Thus, the clavicular region of the subject was fully covered in each subject. The 
protocol started with a baseline period of one hour in thermoneutral condition, after which 
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subjects were exposed to mild cold. Cooling started at 32°C and temperature was gradually 
decreased until shivering occurred. Temperature was then raised with 3-4°C and the cooling 
period of two hours was started (tcold=0min). At the end of the first hour (tcold=60min) 
of cooling 18F-FDG was injected intravenously (2 MBq/kg). Both in thermoneutral and cold-
induced condition (tcold=110min) indirect calorimetry was performed with a ventilated hood
(Oxycon Pro™, CareFusion, Germany) (tcold=80-110min). After the second hour (tcold=120min)
of cooling 18F-FDG-PET-CT imaging was performed to quantify BAT.
18F-FDG-PET-CT-scan. Imaging was performed on a PET-CT-scanner (Gemini TF PET-CT, 
Philips, The Netherlands) as described previously [14]. Blind to subject characteristics, both a 
nuclear medicine physician and two researchers analyzed the PET-CT images using dedicated 
software (Hermes Hybrid Viewer™, Hermes Medical Solutions AB, Sweden). BAT activity and 
detectable BAT volume were quantified in the region of interest (as assessed by CT) by auto-
contouring the BAT areas with a set threshold (SUV of 2.0 g/mL).
Temperature registration. Core body temperature was measured continuously in the 
small intestine with the use of an ingestible telemetric capsule (Jonah™, BMedical, 
Australia) that recorded core body temperature at 1-minute intervals. Skin temperature was 
measured at 1-minute intervals by wireless iButtons (iButton®, Maxim, USA) [19]. An iButton 
contains a semiconductor temperature sensor, a computer chip with a real time clock and 
memory, and a battery. In total eighteen iButtons were attached to the skin with adhesive 
tape at the following ISO-defined locations: forehead, supraclavicular (left and right), 
 clavicular (left and right), subclavicular (left and right), sternal (left and right) (see FIGURE 1A), 
supra umbilicular, anterior thigh (left and right), lateral thigh (left and right), flat of the 
hand (left and right) and bow of the foot (left and right). 
Calculations
Total detectable BAT volume: In every slice, BAT size (measured in square centimetres) was 
quantified in the anatomical regions of interest (ROIs) using the auto contouring and region 
growing tool of the Hybrid Viewer. Detectable BAT volume (measured in millilitres) was 
 calculated by summing up the ROIs from the individual slices, establishing a volume of 
interest (VOI). Since the localization of BAT differs between individuals (e.g. some have more 
BAT in the clavicular region, some more in the paravertebral region), both total detectable 
BAT volume and BAT volume in the clavicular region were quantified (FIGURE 1B).
BAT activity: Within every region of interest, the Hybrid Viewer provided two measures of 
18F-FDG uptake, the maximal and mean standardized uptake value (SUVmax and SUVmean, 
respectively). The standardized uptake value (SUV) is defined as the ratio of activity [kBq per 
mL] within the region of interest (ROI) and the injected activity [kBq] per bodyweight [g] 
and is expressed in g/mL. For SUVmax, the highest value in the VOI was taken. For SUVmean 
the mean value within the VOI was determined. 
Skin temperature measurements: Distal skin temperature was calculated as the average 
temperature of hands and feet and proximal skin temperature as the weighted average 
temperature of claviculae, anterior thigh and umbilicus (Tprox=0·383*Tavg_thighs + 
0·293*Tavg_clav + 0·324*Tavg_umbilicus) according to the equation of Van Marken Lichten-
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belt et al [19], based on the formulas by Kräuchi et al [20] and Hardy et al [21]. Mean skin 
temperature was calculated as the average of distal and proximal skin temperature. Core 
mean skin temperature gradient was calculated as the difference between core and mean 
skin temperature, and core distal skin temperature gradient as the difference between core 
and distal skin temperature. For thermoneutral skin temperature, the mean temperature of 
the second half of the thermoneutral period was calculated for each iButton. Cold-induced 
skin temperature was calculated as the mean skin temperature during the twenty minutes 
following 18F-FDG administration, i.e., at the beginning of the second hour of cooling. 
Statistical analysis
Data are presented as mean ± SEM. Paired t-tests were used to assess mean differences 
before and after cold exposure. To identify correlations between variables, linear regression 
analyses were performed. Significance level was set at P<0.05. Statistical analyses were 
 performed using SPSS for Windows version 20.0 (IBM, USA).
RESULTS
Clinical characteristics
Clinical characteristics are shown in TABLE 1. Part of these data have recently been published 
for white Caucasians and South Asians separately [14]. However, analysis of covariance 
showed that there was no interaction between ethnicity and BAT volume with supraclavicular 
temperature as dependent factor (p=0.36) and that there was no difference in the intercept 
between South Asian and white Caucasian subjects (p=0.33). We, therefore, pooled the data 
for both ethnicities. One subject developed hyperventilation following 18F-FDG administration, 
FIGURE 1 - Location of iButtons and clavicular and paravertebral brown adipose tissue. In the clavicular and 
sternal region, iButtons were symmetrically attached at the supraclavicular, clavicular, subclavicular and 
 sternal region A . Clavicular and paravertebral brown adipose tissue regions in young, healthy male subjects 
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Healthy male subjects (n=24)
Thermoneutral Cold-induced
age (years) 24.1 ± 0.6
body mass index (kg/m2) 21.7 ± 0.4
systolic blood pressure (mmHg) 119 ± 2 134 ± 4**
diastolic blood pressure (mmHg) 66 ± 1 82 ± 2**
heart rate (bpm) 60 ± 2 57 ± 2
SUVmax (g/mL) 15 ± 1.0
SUVmean (g/mL) 4.1 ± 0.1
Total BAT volume (mL) 235 ± 29
Clavicular SUVmax (g/mL) 14 ± 1
Clavicular SUVmean (g/mL) 4.6 ± 1
Clavicular BAT volume (mL) 84 ± 1
Resting energy expenditure (kcal/day) 1493 ± 52 1732 ± 91**
Data are presented as mean ± SEM. ** p<0.005 vs. thermoneutral condition. 
TABLE 1 - Clinical characteristics in young, healthy, male subjects 
Healthy male subjects (n=24)
Thermoneutral Cold-induced
shiver temp 9.9 ± 0.4
core body temp 36.7 ± 0.1 36.7 ± 0.1
mean skin temp 33.3 ± 0.1 28.7 ± 0.2**
mean proximal skin temp 34.4 ± 0.1 30.9 ± 0.2**
supraclavicular skin temp 35.2 ± 0.1 35.5 ± 0.1**
clavicular skin temp 34.4 ± 0.1 34.2 ± 0.2
subclavicular skin temp 34.4 ± 0.1 33.6 ± 0.2**
mean distal skin temp 32.3 ± 0.2 26.5 ± 0.3**
forehead skin temp 33.7 ± 0.1 33.2 ± 0.1**
distal proximal skin temp gradient -2.2 ± 0.2 -4.4 ± 0.3**
core mean skin temp gradient 3.3 ± 0.1 8.0 ± 0.2**
core distal skin temp gradient 4.4 ± 0.3 10.1 ±0.3**
core proximal skin temp gradient 2.3 ± 0.1 5.9 ± 0.2**
Data are presented as mean ± SEM. Units are in degrees Celsius. **p<0.005 vs. thermoneutral condition. 
Temp, temperature.
TABLE 2 - Thermoregulation in thermoneutral and cold-induced condition in young, healthy, male subjects
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and was therefore excluded from all cold-induced and BAT measurements. Mean age was 
24.1 ± 0.6 years and mean BMI was 21.7 ± 0.4 kg/cm2. Systolic and diastolic blood pressure 
were significantly increased in response to cold (119 ± 2 vs. 134 ± 4 mmHg, p=0.00002; 66 ± 1 
vs. 82 ± 2 mmHg, p=0.000000), while heart rate was not affected. 
In all subjects active BAT was detected, as evidenced by 18F-FDG uptake in the classical BAT 
regions, though one subject exhibited only 1.5 mL of detectable BAT. Mean total BAT  volume 
was 235 ± 29 mL. Mean SUVmax was 15 ± 1 g/mL, and mean SUVmean was 4.1 ± 0.1 g/mL for total 
BAT volume. In the clavicular region, mean BAT volume was 84 ± 11 mL. Mean SUVmax in this 
region was 14 ± 1 g/mL, while mean SUVmean was 4.6 ± 0.1 g/mL. Cold stimu lation resulted in 
an increase in energy expenditure, i.e. nonshivering thermogenesis, by 16% (16 ± 4%, p=0.001).
FIGURE 2 - Correlations between cold-induced supraclavicular skin temperature and 18F-FDG uptake by brown 
adipose tissue in young, healthy male subjects. Total SUVmax in relation to total BAT volume A . Cold-
induced supraclavicular skin temperature in relation to total BAT volume B  and total SUVmax C ). Clavicular 
SUVmax in relation to clavicular BAT volume D . Cold-induced supraclavicular skin temperature in relation to 
clavicular BAT volume E  and clavicular SUVmax F . Correlations were determined by linear regression analysis. 
Open circles represent South Asian subjects, black circles white Caucasian subjects. BAT, brown adipose 
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FIGURE 4 - Correlations between cold-induced core body temperature and 18F-FDG uptake by brown adipose 
tissue in young, healthy male subjects. Cold-induced core body temperature in relation to total BAT volume 
A  and total SUVmax B . Correlations were determined by linear regression analysis. Open circles represent 
South Asian subjects, black circles white Caucasian subjects. BAT, brown adipose tissue. SUV, standard uptake 
value.
FIGURE 3 - Correlations between cold-induced clavicular and subclavicular skin temperature and 18F-FDG 
uptake by brown adipose tissue in young, healthy male subjects. Cold-induced clavicular and subclavicular 
skin temperature in relation to total BAT volume ( A  and B , respectively) and clavicular BAT volume ( D  and 
E , respectively). Correlations were determined by linear regression analysis. Open circles represent South 
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Thermoregulation
Thermoregulation is shown in TABLE 2. Mean inlet water temperature of the cooling matresses 
at which shivering started was 9.9 ± 0.4 °C. Mean core body temperature was not affected 
by cold exposure. Mean total, proximal and distal skin temperature markedly decreased on 
cold stimulation. Consequently, core distal and core mean skin temperature gradients were 
significantly higher during cooling, indicating an insulative response. With respect to the 
clavicular region, supraclavicular skin temperature was significantly increased upon cold 
exposure (35.2 ± 0.1 vs. 35.5 ± 0.1 °C, p=0.001). Clavicular skin temperature was not affected 
and subclavicular skin temperature was significantly reduced. 
Correlations thermoregulation and 18F-FDG uptake by BAT
Linear regression analysis showed a clear positive correlation between SUVmax and total BAT 
volume (R2=0.64, P<0.0001) (FIGURE 2A; this figure is modified from a previous publication 
[14]). Furthermore, a positive correlation was found between cold-induced supraclavicular 
skin temperature and total BAT volume (R2=0.28, P=0.010) (FIGURE 2B) and SUVmax (R2=0.32, 
P=0.005) (FIGURE 2C). With respect to BAT that was located in the clavicular region only, again 
a clear positive correlation was found between SUVmax and BAT volume (R2=0.52, P<0.0001) 
(FIGURE 2D). Furthermore, cold-induced supraclavicular skin temperature correlated positively 
with clavicular BAT volume (R2=0.20, P=0.030) (FIGURE 2E) and clavicular SUVmax (R2=0.27, 
P=0.010) (FIGURE 2F). No correlations were found between cold-induced clavicular and sub-
clavicular skin temperature and total and clavicular BAT volume (FIGURE 3). Furthermore, both 
total BAT volume and SUVmax did not correlate with cold-induced core body temperature 
(R2=0.04, P=0.410, FIGURE 4A; R2=0.004, P=0.790, FIGURE 4B; respectively). Finally, no correlations 
were found between delta (i.e. the change in temperature upon cooling) supraclavicular, 
 clavicular and subclavicular skin temperature and total and clavicular BAT volume, respectively 
(data not shown).
DISCUSSION
BAT has emerged as a novel player in energy homeostasis in humans and is currently 
 considered a potential new target for obesity and related diseases. The current ‘gold standard’ 
for quantification of BAT volume and activity in humans is the cold-induced 18F-FDG uptake 
measured with PET-CT, which is, however, limited by cost and radiation exposure. Therefore, 
a less expensive and less burdensome alternative to determine BAT in human research is 
highly desirable. In the present study, we demonstrated that, while mean proximal and distal 
skin temperatures were markedly decreased upon cold exposure as expected, supraclavicular 
skin temperature was significantly increased. Furthermore, cold-induced supraclavicular 
skin temperature was positively correlated with both total and clavicular BAT volume and 
SUVmax, suggesting that cold-induced supraclavicular skin temperature may have predictive 
value for BAT detection in humans. BAT is a thermogenic tissue with special importance in 
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neonates who are sensitive to develop hypothermia due to their large body surface area [1]. 
In this study, we detected BAT in 100% of the subjects with a corresponding thermogenic 
response, as indicated by a mean increase in energy expenditure of 16%. The strategic 
 location of BAT, mainly in the interscapular region in neonates and in the neck area and 
along the great vessels in adults, results in efficient spreading of the produced heat 
throughout the body. Hence, an increase in temperature of the skin that overlies BAT, i.e. the 
supraclavicular region, upon BAT activation may be expected. Heat production by BAT is 
the direct result of uncoupling of ATP synthesis by the uncoupling protein UCP-1. The main 
 stimulus for activation of this intracellular  cascade is sympathetic activation with subse-
quent release of catecholamines, i.e. following cold induction [1]. Next to heat production, 
sym pathetic activation may also result in alterations in BAT blood flow [2], aimed at spreading 
the heat throughout the body to maintain core body temperature and away from BAT. 
In addition, sympathetic activation induces peripheral cutaneous vasoconstriction [22], also 
facilitating maintenance of core body  temperature. In the present study, blood pressure and 
core distal and core mean skin temperature gradients were significantly increased during 
cooling, suggesting cold-induced activation of the sympathetic nervous system.
We found that supraclavicular skin temperature significantly increased upon cold 
 exposure. This is in line with a recent study in healthy human volunteers in which short-
term (5 minutes) cooling of the hand resulted in a highly localized increase in supraclavicular 
skin temperature as measured by infrared thermal imaging [23]. However, in that study, 
changes in skin surface temperature had not been directly correlated with direct measure-
ments of BAT activity. Rather, PET-CT images from a comparable group of age- and sex 
matched subjects were used. In the current study, we combined skin temperature measure-
ments with 18F-FDG PET-CT scans in the same subjects and found that cold-induced supra-
clavicular skin temperature significantly correlated with clavicular BAT volume and clavicular 
SUVmax though the R2 was modest (up to 0.27 for clavicular SUVmax). Moreover, a comparable 
correlation was found with total BAT volume and SUVmax in the total BAT region. Thus, 
 supraclavicular skin temperature may not only be indicative for activated BAT present in 
the clavicular region, but also for the total amount of BAT. Interestingly, Yoneshiro et al [5] 
previously showed that supraclavicular skin temperature as measured by means of small 
disc-type temperature data loggers was only decreased in subjects without detectable BAT 
during cold while in subjects with detectable BAT it remained equal. This difference may be 
attributable due to a difference in thermogenesis between BAT positive and BAT negative 
subjects. Our results are furthermore in accordance with a previous mouse study in which 
changes in BAT temperature as determined by  thermal imaging highly correlated with 
increases in 18F-FDG uptake within BAT [24]. Of note, we used iButtons to measure skin 
 temperature instead of thermal imaging. iButtons have been shown to be a reliable, safe, 
cheap and extensively researched technique in both cold and warm conditions [19]. 
The rise in supraclavicular skin temperature may not solely be due to thermogenesis by 
activated BAT, but also due to short-term changes in BAT blood flow, as has been shown in 
rats [25] as well as in humans [2]. In line with this, cold acclimation in mice leads to 
increased mitochondrial density and increased sympathetic nerve fiber density together 
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with increased angiogenesis [26]. The physiological role of this increased blood flow is likely 
to spread the heat throughout the body to maintain core body temperature. Thus, the 
increased supraclavicular skin temperature is likely the consequence of a combination of 
increased BAT thermogenesis as well as increased BAT blood flow. However, since the under-
lying mechanism (i.e. increased sympathetic activation towards BAT) is the same, both provide 
a good measure of BAT activation and may thus be measured at the skin surface. 
In our study, clavicular and subclavicular skin temperature did not correlate with BAT 
 volume. This is likely explained by the fact that most of the clavicular BAT pool is located in the 
supraclavicular region ([23], and see FIGURE 1). Furthermore, core body temperature did not 
 correlate with total BAT volume nor with total SUVmax. In mice, core body temperature is 
 commonly used as a measure for BAT activity [17], and core body temperature may  transiently 
rise by as much as 1.5°C following BAT activation. However, as is evident from the current study 
as well as from a previous study [12], in human subjects core body temperature does not rise 
following BAT activation due to cold exposure but rather stays equal, likely as a consequence 
of BAT activation preventing a drop in core body temperature. The lack of a rise in core body 
temperature could be due to the fact that the relative amount of BAT in humans is lower as 
compared to mice. Accordingly, in mice housed at 5°C nutrient oxidation in BAT can account 
for over 60% of the total energy expenditure [27,28], as compared to 15-20% in humans [11], 
resulting in tremendous heat production and a subsequent rise in core body temperature. Thus, 
in humans, cold-induced core body temperature is likely no good measure of BAT volume.
A potential limitation of the current study is our cooling protocol. We used a personalized 
cooling protocol in which water-perfused cooling mattresses were used to cool subjects 
just above their shiver temperature. Though this cooling protocol results in maximal BAT 
activation under non-shivering conditions [11], the cooling mattresses do not cover all parts 
of the body, such as the head and feet. Furthermore, since the supraclavicular region is 
located at the upper region of the mattresses, we cannot exclude that this region may have 
been influenced by warmer airflows. However, temperature of the forehead, which was not 
cooled, significantly decreased upon the cooling protocol making influence of warmer 
 airflows less likely. Furthermore, an extra bed sheet covered the upper cooling mattress in 
order to create a cold compartment. Lastly, in the study by Symonds et al [23], short-term 
cooling of a hand or foot also resulted in a rise in supraclavicular skin temperature, supporting 
the concept that a cold stimulus induces rapid BAT activation accompanied by supraclavicular 
heat production. Furthermore, an extra bed sheet covered the upper cooling mattress in 
order to create a cold compartment. Lastly, in the study by Symonds et al [23], short-term 
cooling of a hand or foot also resulted in a rise in supraclavicular skin temperature, supporting 
the concept that a cold stimulus induces rapid BAT activation accompanied by supraclavicular 
heat production. A strength of our study is that changes in supraclavicular skin temperature 
were correlated with measures of BAT activity as measured by 18F-FDG uptake in BAT. 
Furthermore, we measured BAT volume and SUVmax in both the total detectable BAT region 
and the clavicular region, in order to prevent confounding by localization.
In conclusion, supraclavicular skin temperature as measured by iButtons is a potential 
novel non-invasive tool that may have predictive value for BAT detection in adult humans. 
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This is highly desirable, since there is increasing interest in pharmacological interventions 
to stimulate BAT in human subjects given its role in energy homeostasis. Therefore, supra-
clavicular skin temperature may be a non-invasive method to monitor BAT activity in 
response to treatments. 
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The current ‘diabesity’ epidemic in Western society demands novel preventive and curative 
strategies to combat both obesity and its related morbidities, such as type 2 diabetes, cardio-
vascular disease (CVD) and cancer. The recent discovery of functional brown adipose tissue 
(BAT) in adult humans meant the beginning of an exciting new area in metabolic research. 
Potentially, everybody has its own tool to increase energy expenditure, and we now need to 
discover the right triggers to benefit from this tool. To enhance the understanding of BAT 
physiology, in this thesis we investigated the involvement of BAT in whole-body lipid meta-
bolism as well as the role of the central melanocortin system in BAT function using well-
established mouse models and ex vivo engineered radioactively labeled lipoprotein-mimicking 
particles. Furthermore, to identify novel targets that may activate BAT, we investigated the 
effect of several compounds (e.g. BMP7, metformin, a cannabinoid 1 receptor blocker and 
a ß3 adrenergic receptor agonist) on brown adipocyte activity in vitro and on BAT activity 
in vivo, as well as their effects on energy expenditure, lipid metabolism and atherosclerosis. 
In the last part of the thesis, we investigated the involvement of BAT in metabolism in 
humans by studying South Asians, a population with an unusually high risk to develop obesity, 
type 2 diabetes and CVD compared to white Caucasians. In addition, we studied additional 
factors that may contribute to their high CVD risk, such as endothelial dysfunction, inflam-
mation and dysfunctional HDL. Lastly, in search for a non-invasive estimate of BAT activity, 
we studied whether supraclavicular skin temperature may be a novel tool to measure BAT 
volume and activity in humans.
From this thesis, various new insights on BAT have arisen which will be discussed and 
interpreted in this final chapter. In addition, possible clinical implications derived from this 
thesis and future directions of BAT in treating disease will be addressed.
SUBSTRATE UTILIZATION BY BROWN ADIPOSE TISSUE 
AND CONSEQUENCES FOR FUNCTIONAL IMAGING 
Glucose uptake by brown adipose tissue 
The presence of functional BAT in adult humans has been irrefutably proven in 2009, when 
cold-induced 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography-computed 
tomography (PET-CT) scans showed high FDG uptake in regions that were histologically 
identified as being BAT (1-3). Importantly, BAT activity correlated positively with thermoneutral 
as well as cold-induced resting energy expenditure (REE) and lean subjects had more 
BAT compared to obese subjects, suggesting that BAT contributes substantially to energy 
metabolism in adult humans (2). The 18F-FDG PET-CT scan, which is currently the gold standard 
to determine BAT volume and activity in humans, relies on the visualization and quantification 
of FDG, a glucose analogue that is taken up by metabolically active tissues without being 
metabolized. However, it may be questioned whether a glucose tracer is indeed the best 
method to visualize BAT and quantify BAT activity. First, it should be realized that metaboli-
cally active tissues such as the brain and heart show a high, but to some extent variable 
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uptake of FDG between individuals, which may affect the relative amount of radiolabel that 
can be taken up by BAT. Moreover, murine studies have repeatedly shown that the main fuel 
for BAT thermogenesis are fatty acids (FA) while glucose utilization for thermogenesis by 
BAT is considered low (~5-15%) (4). As described in CHAPTER 1, glucose is suggested to be 
mainly used for de novo lipogenesis in BAT. In addition, glucose is converted into lactate via 
anaerobic glycolysis to yield cytosolic ATP during thermogenesis (4). FA are likely also the 
dominant fuel for BAT in humans, as we found in CHAPTER 11 that non-shivering thermogenesis 
(NST) following a personalized cooling protocol was exclusively due to an increase in FA 
 oxidation (up to +46% in Caucasian subjects), while glucose oxidation was unaltered. 
Thus, this suggests that a tracer that monitors FA uptake by BAT, such as 18F-fluoro-
thiaheptadecanoic acid (18F-FTHA), may be more reliable to estimate BAT activity with 
respect to combustion of FA as compared to 18F-FDG. 
Fatty acid uptake and combustion by brown adipose tissue 
Ouellet et al (5) recently showed that two hours of cold exposure enhanced FTHA uptake 
by BAT as compared to muscle and WAT, though plasma triglyceride (TG) levels remained 
unaltered, which was likely due to the short time period of cold exposure. However, a draw-
back of use of a FA tracer as compared to a glucose tracer is that the uptake is rather non-
specific since it is also largely taken up by other organs such as liver and intestine (FIGURE 1). 
This may lower availability for uptake by BAT and thereby hamper its use as a tool to estimate 
BAT volume. Thus, the FA tracer needs to be optimized more before it can be used on a large 
scale. 
Another important point of consideration is the mode of FA uptake by BAT. 18F-FTHA traces 
the uptake of plasma free FA by BAT. However, as described in CHAPTER 2, a substantial part 
of FA taken up by BAT are derived from the TG-rich lipoproteins (TRLs) chylomicrons and 
very-low-density lipoproteins (VLDL) (6). In line with this, in CHAPTER 4, by performing kinetic 
studies using glycerol tri[3H]oleate and [14C]cholesteryl oleate double-labeled TRL-like emul-
FIGURE 1 - Tissue glucose and fatty acid uptake. 
Postero-anterior projection of whole-body 18F-FDG 
and 18F-FTHA uptake during cold exposure.
Adapted from: Ouellet et al., JCI 2012
FDG FTHA
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sion particles, we concluded that BAT delipidates TRL to selectively take up TG-derived FA 
released from the core of VLDL-mimicking particles. Just as in muscle and WAT, this process 
is likely dependent on lipoprotein lipase (LPL) that lipolyses the TG-rich particle to yield FA 
that are subsequently taken up by brown adipocytes via the FA transporter CD36 (7). Indeed, 
BAT activation has repeatedly been shown to massively increase LPL activity as well as CD36 
expression (8,9). Additional evidence that the LPL/CD36 route is required for TRL-derived FA 
uptake by BAT emerged from a studies showing that inhibition of local LPL activity in BAT 
through injection of tetrahydrolipstatin abolished the uptake of [3H]oleate and that CD36-/- 
mice show cold intolerance due to inability of BAT to take up FA (8). It is likely that human 
BAT also utilizes FA from circulating lipoproteins, though this has not been investigated yet. 
Therefore, an interesting topic for future studies in human subjects would be to synthesize 
TRL-mimicking particles in which TG with radioactively labeled FA are incorporated, followed 
by visualization and quantification of uptake of the radiolabeled FA in BAT by PET-scan. This 
is likely a more specific way to visualize and quantify FA uptake by BAT, as it is restricted to 
LPL-mediated FA uptake. In addition, if TRL-derived FA are indeed the main substrate for 
human BAT, use of radiolabeled FA incorporated in TG will likely result in higher BAT uptake 
as compared to the 18F-FTHA label which will enhance the sensitivity to estimate BAT volume 
and activity.
Measuring brown adipose tissue oxidative metabolism 
In addition to a tracer that monitors uptake of substrates (i.e. glucose or fatty acid) by the 
tissue, a tracer that determines the metabolic capacity of BAT may also be used. Ouellet et al 
(5) determined oxidative metabolism in human BAT indirectly using 11C-acetate PET imaging. 
11C-acetate is rapidly taken up by BAT and other tissues (i.e. myocardium, muscle) and 
metabolized to 11CO2 and H2O after intravenous injection. The rate of clearance of 11C-acetate 
from the tissue reflects oxidative metabolism, with higher oxidative metabolism resulting 
in faster clearance from the tissue. Indeed, based on 11C-acetate tissue kinetics, cold exposure 
markedly increased oxidative metabolism in BAT in all subjects (n=6). In a recent study, 
 oxygen consumption was measured in BAT during cold exposure by means of dynamic 
 oxygen (15O) PET imaging, a possibly very adequate marker for BAT metabolism (10). 
Unfortunately, due to the limits of radiation exposure, both studies were unable to include 
the 18F-FDG tracer in their study as it would be interesting to investigate whether oxygen 
consumption correlates with glucose uptake by BAT. 
Measuring brown adipose tissue sympathetic activation 
A tracer that has been shown to nicely correlate with 18F-FDG uptake by BAT and further-
more identified the same anatomic regions as active BAT, is 123I-metaiodobenzylguanidine 
(123I-MIBG), an analog of noradrenalin, which thus monitors the sympathetic innervation of 
BAT (11). This tracer has not widely been used yet in the context of BAT studies, but may be a 
valuable tool, especially when used in combination with 18F-FDG, to investigate whether 
compounds may enhance BAT activity by increasing sympathetic activation towards BAT, 
i.e. exert central effects. 
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Measuring brown adipose tissue heat production 
The eventual product of BAT thermogenesis is heat. Therefore, methods could also be 
designed to determine BAT volume and activity by measuring the amount of heat produced 
by BAT. Indeed, in mice, in which most BAT is present in the interscapular region, ‘interscapular 
temperature’ is commonly used as a measure for BAT activity (12), as well as core body 
 temperature (13). Since in humans a large part of BAT is located in the supraclavicular region 
(FIGURE 2) (1), recording cold-induced skin temperature in this specific area may be an attractive 
alternative for measuring BAT volume and/or activity instead of using radioactive tracers 
that are relatively expensive and pose a radiation burden on study subjects. Therefore, in 
CHAPTER 12, we performed a dedicated study in which we exposed healthy male subjects to a 
personalized cooling protocol and measured BAT volume and activity (by means of PET scan 
with 18F-FDG) and supraclavicular skin temperature, in addition to core temperature.
Interestingly, we found that cold-induced supraclavicular skin temperature was positively 
correlated with both total and clavicular BAT volume and SUVmax, the latter being a measure 
of BAT activity. Curiously, we did not find a correlation between delta (i.e. the change in 
 temperature upon cooling) supraclavicular skin temperature and total and clavicular BAT 
volume, which could be expected. However, we determined BAT volume and activity on the 
basis of FDG uptake. As mentioned above, glucose uptake may not be the optimal marker of 
BAT volume and activity. Therefore, it would be interesting to investigate the correlation 
between cold-induced delta skin temperature and BAT metabolism with use of a tracer that 
monitors BAT metabolism, such as 11C-acetate. Anyhow, from CHAPTER 12 it is evident that 
cold-induced supraclavicular skin temperature per se, rather than delta skin temperature, 
may be a qualitative marker of BAT activation in humans. 
In the same study, core body temperature did not rise following BAT activation due to 
cold exposure but rather stayed equal, which is in accordance with a previous study (2). 
Likely heat produced by the activated BAT is just sufficient to prevent a drop in core body 
temperature. In mice, activation of BAT does generally result in a rise in core body temperature 
(13,14). The lack of a rise in core body temperature in humans could be due to the fact that 
FIGURE 2 - Location of clavicular and paravertebral 
brown adipose tissue. Clavicular and paravertebral 
brown adipose tissue regions in young, healthy male 
subjects as assessed by PET-CT scan with 18F-FDG. 
Modified from Boon et al., unpublished.
Clavicular BAT
Paravertebral BAT
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the relative amount of BAT in humans is lower as compared to mice. Accordingly, in mice 
housed at 5°C, nutrient oxidation in BAT can account for over 60% of the total energy 
expenditure (15,16) as compared to 15-20% in humans (17,18) resulting in tremendous heat 
production and a subsequent rise in core body temperature. Thus, in contrast to mice, cold-
induced core body temperature is likely not a reliable measure of BAT volume in humans.
In summary, BAT volume and activity in humans may be determined by use of a variety 
of radioactive tracers, followed by visualization and quantification by PET scan. Though the 
18F-FDG PET scan is currently the gold standard for BAT visualization in humans, tracers that 
monitor (TG-derived) FA uptake or BAT metabolism may be superior compared to 18F-FDG, as 
glucose uptake by BAT is relatively low and (TG-derived) FA is the main substrate to be used 
for BAT thermogenesis. Furthermore, monitoring heat production by BAT may be a promising 
and noninvasive method to determine BAT volume and activity. Future studies should be 
directed at investigating and comparing these methods by performing prospective studies 
using adequate tracers and cooling methods. 
BROWN ADIPOSE TISSUE AS A NOVEL TARGET TO 
COMBAT OBESITY AND RELATED DISEASES
Brown adipose tissue contributes to energy expenditure in humans 
When considering BAT as a novel therapeutic tool to enhance energy expenditure thereby 
lowering obesity and related diseases in humans, it is highly relevant to assess the actual 
contribution of human BAT to total daily energy expenditure. Several assumptions can be 
made based on the results of this thesis and from previous studies. In CHAPTER 11, we found 
that healthy white Caucasian male subjects who were exposed to a personalized cooling 
protocol of approx. 2.5 h increased their REE with a mean increase of 20%, but up to a maxi-
mum increase of as much as 79%. As subjects did not shiver during the cooling protocol, the 
increase in REE upon cold exposure may equal NST, which is thought to exclusively arise 
from thermogenesis in BAT rather than uncoupling by muscle (19). This mean increase in 
NST of 20% is in line with previous studies (5,20-22). As REE accounts for 60-75% to the total 
daily energy expenditure (17), the contribution of BAT to total daily energy expenditure as 
calculated from our study could therefore be up to ~ 13% when the tissue is maximally 
 stimulated by cold. As this will result in a sustained negative energy balance, this may thus 
significantly influence energy balance and body weight on the long term. 
Additional evidence for the contribution of BAT in human energy expenditure appears 
from association and intervention studies by the research group of Masayuki Saito. They 
found that cold induction enhanced NST by 20% in BAT-positive subjects, while NST 
was enhanced by only 3% in BAT-negative subjects (23). Furthermore, BMI and body fat 
content were significantly lower in BAT-positive subjects (24). Intriguingly, these parameters 
increased with age in the BAT-negative group, while they remained unchanged from the 
twenties to fourties in the BAT-positive group (24). Importantly, a recent study by Yoneshiro 
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et al (25) recently inevitably showed that prolonged BAT activation by means of cold 
 acclimation (2 h cold exposure at 17°C for 6 weeks) and capsinoids resulted in enhanced NST 
with concomitant decrease in body fat mass, which reached significance for cold exposure.
BAT has the potential to contribute even more to total daily energy expenditure when its 
mass and activity are enhanced due to catecholamine excess. This appears from patients 
with pheochromocytomas that are neuroendocrine tumors secreting excessive amounts of 
noradrenalin, an important stimulator of BAT activation and differentiation (CHAPTER 2) (4). 
18F-FDG-PET-CT-scans in patients with such tumors show an increased mass and activity of 
BAT (23,26), accompanied by increased energy expenditure up to two-fold in a recent case 
report (Sondergaard et al., unpublished). Thus, when further stimulated due to endogenous 
or exogenous factors, BAT has the potential to even more substantially contribute to total 
daily energy expenditure.
All together, these data unequivocally demonstrate that BAT contributes to NST in 
humans and that BAT activation is a promising novel therapeutic modality to combat 
 obesity. Therefore, identification of novel therapeutic targets that may activate BAT is highly 
warranted. In this thesis, we have investigated the potential of several targets and com-
pounds to activate BAT in mouse models, of which two (i.e. cannabinoid 1 receptor blockade 
and metformin) will be further discussed below. 
Cannabinoid 1 receptor blockade as a tool to activate BAT 
As described in CHAPTER 2, the cannabinoid 1 receptor (CB1R) inverse agonist rimonabant has 
been shown to induce long-term maintained weight loss and reduction of dyslipidemia in 
obese patients and was, therefore, regarded as one of the most promising therapeutic drugs 
to treat obesity (27-30). In CHAPTER 7, we showed that BAT likely plays a profound role in 
these beneficial effects. Systemic CB1R blockade by rimonabant led to massive BAT activation 
in diet-induced obese mice, resulting in increased energy expenditure and increased VLDL-
TG clearance, caused by a increased uptake of VLDL-TG selectively by BAT. Since VLDL-TG 
 production was not affected, we concluded that the TG-lowering effect of rimonabant was 
the consequence of increased BAT activity. BAT activation likely contributes to the anti- 
obesity and lipid lowering effects of rimonabant in humans as well, as a recent study 
showed that treatment of obese women with rimonabant for 12 weeks enhanced FA 
oxidation (31). This effect on energy expenditure was independent of the weight loss 
induced by the compound, as this was not found in the control group that lost equal 
amounts of weight through a hypocaloric diet. 
Unfortunately, it is unlikely that rimonabant will be introduced on the market as a novel 
BAT activating drug, as central psychiatric side effects caused its removal from the market in 
2008. However, several lines of evidence indicate that the effect of CB1R blockade was not 
restricted to a central mode of action, as the CB1R is also present on cells from peripheral 
 tissues including hepatocytes (32), white adipocytes (33) and muscle cells (34). Therefore, 
strictly peripheral CB1R blockers have been developed and the results derived from these 
compounds in pre-clinical studies are promising. For instance, Tam et al (35) showed 
that the peripheral CB1R blocker AM6545 diminished obesity in diet-induced obese mice 
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and improved glucose metabolism, though the weight-reducing effect of the compound 
was somewhat less effective compared to rimonabant that also reduces food intake. 
Interestingly, in CHAPTER 7, we found that AM6545 is a very potent BAT activator in vivo, 
resulting in increased energy expenditure and TG-derived FA uptake by BAT. This suggests 
that the BAT activating effect of CB1R blockade is, at least in part, mediated via a direct 
peripheral mechanism. Indeed, we found that at thermoneutrality, in which sympathetic 
input towards BAT is largely diminished (4), rimonabant still activates BAT. Furthermore, 
we showed that the CB1R is highly expressed in BAT and that in vitro blockade of the CB1R 
in cultured brown adipocytes increases UCP-1 protein content and TG lipolysis, pointing 
to enhanced activity. Of note, CB1R blockade enhanced AMP-activated kinase (AMPK) 
phosphorylation in brown adipocytes, which has also been found in hepatocytes (36) and 
white adipocytes (37). It remains to be determined whether this is due to a direct effect of 
the compound on AMPK phosphorylation, or due to a secondary mechanism, i.e. following 
cAMP activation (38,39). Anyhow, AMPK may be a central player by which CB1R blockade 
results in BAT activation as well as by which it exerts its positive effects in other metabolic 
tissues. The possible role of AMPK in BAT function will be discussed further below. 
Our data thus evidence that targeting the peripheral CB1R on BAT may be a promising 
method to increase energy expenditure and TG clearance by BAT. However, whether the 
CB1R is also present in human BAT and whether its blockade will enhance BAT activity in 
humans remains to be investigated. Furthermore, to the best of our knowledge, human 
trials aimed at investigating the metabolic effects of strictly peripheral CB1R blockers have 
not been conducted so far. Whether these blockers will be of benefit in humans should thus 
be investigated first.
Metformin as a tool to activate BAT 
As discussed above, CB1R blockade may activate BAT, at least partly, via activating AMPK. 
Interestingly, the AMPK activator metformin is one of the most widely used glucose- 
lowering agents for the treatment of type 2 diabetes (CHAPTER 2) (40,41). In addition, 
metformin markedly reduces plasma TG levels in patients (42), of which the underlying 
mechanism(s) was unknown. In CHAPTER 6, we used APOE*3-Leiden (E3L).CETP transgenic 
mice, a well-established model for human-like lipoprotein metabolism (43,44), to unravel 
this mechanism. Metformin appeared to lower plasma TG due to activation of BAT, accom-
panied by increased uptake of TG-derived FA by BAT. The involvement of BAT in the 
TG-lowering effect of metformin in humans has not been studied yet. Several studies 
reported that metformin induces weight loss in obese diabetic patients (45-47). This may 
point to enhanced energy expenditure, possibly due to BAT activation. In fact, the weight 
loss induced by metformin is more pronounced in obese diabetic children (48-50), who also 
have more BAT than adults. Furthermore, in type 2 diabetes patients metformin decreases 
the respiratory exchange ratio without affecting energy expenditure, which is suggestive of 
increased fat oxidation, possibly due to BAT activation (51). 
Our results in mice clearly showed that metformin directly activates BAT. Treatment of 
cultured brown adipocytes in vitro with metformin results in massive AMPK phosphorylation, 
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an effect that has previously been found for hepatocytes (52) and muscle cells (53,54). This was 
accompanied by massive intracellular lipolysis as evidenced by enhanced phosphorylation 
of hormone sensitive lipase (HSL) (CHAPTER 1) and glycerol release. In addition, metformin 
increases mitochondrial biogenesis in BAT in mice. This is likely a direct consequence of 
increased phosphorylation of AMPK, as activated AMPK is a potent inducer of mitochondrial 
biogenesis (55). Though we did not study central effects of metformin in our study, we 
cannot exclude that such effects may, at least in part, play a role. A recent study in rats has 
shown that metformin is able to cross the blood-brain barrier to reach the hypothalamus 
and change expression of orexigenic peptides (56), though we did not find effects on food 
intake in our study. Possibly, metformin may also enhance sympathetic outflow towards BAT 
from the hypothalamus, thereby increasing the activity of BAT. It would be interesting to 
investigate this aspect in more detail, for example by performing PET scans using 123I-MIBG 
that monitors sympathetic outflow towards BAT. 
AMPK: a central player in BAT activation? 
The studies described in CHAPTER 6 and CHAPTER 7 demonstrate that both metformin and 
CB1R blockade by rimonabant enhance phosphorylation of AMPK in BAT. AMPK is a well- 
conserved energy sensing kinase that plays a crucial role in the regulation of catabolic 
versus anabolic pathways in cells (57,58). AMPK consists of a heterotrimeric complex con-
taining a catalytic  subunit and two regulatory ß and γ subunits. The 1 subunit contains a 
threonine residue (Thr172) whose phosphorylation by upstream kinases, such as the liver 
kinase B (LKB1), is required for AMPK activation. In addition, a decrease in cellular energy 
status (leading to high intracellular AMP and ADP levels) results in binding of AMP and/or 
ADP to the ß subunit and activation of AMPK (57,58). AMPK subsequently phosphorylates 
various downstream targets, resulting in inhibition of energy (ATP)-consuming processes 
(i.e. synthesis of glycogen, protein, and fatty acids) and stimulation of ATP-generating path-
ways (i.e. fatty acid oxidation) in order to restore energy balance (58).
The mechanism by which metformin activates AMPK in BAT is likely through phospho-
rylation of Thr172 within the 1 subunit. This is supported by our finding that metformin 
enhances Thr172 phosphorylation in BAT at equal AMP/ADP ratio (CHAPTER 6), and is consistent 
with previous observations in hepatocytes by others (59). Rimonabant may activate AMPK 
in BAT by activation of LKB1, which has been previously shown to occur in hepatocytes in 
vitro (36). 
Apart from our pioneering studies, reports on the role of AMPK in BAT are so far limited. 
This is in sharp contrast to the extensive knowledge on the role of AMPK in liver, where 
activation leads to a reduction in lipogenesis and cholesterol synthesis and a simultaneous 
increase in FA oxidation resulting in decreased hepatic steatosis (60,61). AMPK protein 
amount and activity are two to threefold higher in BAT than in liver and chronic cold expo-
sure of mice leads to a substantial increase in AMPK activity in BAT (62), while denervation 
reduces AMPK activity (63). These studies suggest a role for AMPK in BAT thermogenesis. 
Whole body AMPK1-/- mice exhibit completely normal cold-induced thermogenesis, which 
is surprising at first glance, but this may be due to a compensatory upregulation of the 
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AMPK2 subunit in BAT (64). Thus, future studies are needed to unravel the necessity of 
AMPK in BAT function, for instance by studying BAT thermogenesis also in AMPK2-/- mice. 
The intracellular pathways that are regulated by AMPK in BAT and that link AMPK with 
thermogenesis are not completely elucidated as yet. However, we found several intracellular 
mediators that were upregulated or phosphorylated upon metformin treatment in our 
in vitro and in vivo studies (CHAPTER 6) and literature exists on the intracellular pathways 
induced by AMPK in other cell types. Taken these data together, we speculate that AMPK 
activation, e.g. by metformin or CB1R blockade, increases phosphorylation of ATGL and HSL 
resulting in net increased lipolysis and breakdown/shrinking of intracellular lipid droplets 
and release of glycerol from the cells. The increased intracellular lipolysis results in release 
of FA and allosteric activation of UCP-1 in the inner membrane of the mitochondrion 
(CHAPTER 1) (4). Furthermore, we found that metformin enhances the phosphorylation of 
acetyl-CoA carboxylase (ACC). ACC was the first identified target of AMPK. ACC synthesizes 
malonyl-CoA from acetyl-CoA, and is, therefore, a key enzyme in the lipogenic pathway (65). 
Phosphorylation of ACC results in its inactivation; thereby the inhibition exerted by its 
product malonyl-CoA on CPT1 will be relieved, ultimately promoting mitochondrial FA 
transport and oxidation (58). Furthermore, we found that metformin enhances the phos-
phorylation of PGC-1 and eNOS, both of which are important regulators of mitochondrial 
biogenesis (66) and UCP-1 expression. The role of AMPK in eNOS phosphorylation is well-
established in endothelial cells, resulting in enhanced NO production and vasodilation (67). 
Furthermore, NO itself may also enhance Pgc1 phosphorylation as has been shown in 
various cell types (68). Furthermore, AMPK has also been shown to directly enhance Pgc1 
phosphorylation in muscle cells independent of NO (69).
In summary, as depicted in FIGURE 3, we postulate that AMPK is a cellular energy sensor 
that may enhance BAT thermogenesis by 1) increasing intracellular lipolysis and release of 
FA, thereby activating UCP1, 2) enhancing oxidation of FA by mitochondria, and 3) enhancing 
mitochondrial biogenesis. Taken together, this results in reduction of intracellular lipid 
droplet size and enhanced need for FA uptake from the plasma. The latter may also be 
mediated by AMPK, as AMPK has been shown to enhance LPL activity in muscle (70) as well 
as expression of the FA transporters CD36 and FAT (71), resulting in enhanced LPL-mediated 
FA uptake by BAT (CHAPTER 6). This eventually results in lowering of plasma TG levels. It is 
interesting to note that, in contrast to other cell types such as hepatocytes and white adipo-
cytes, AMPK in brown adipocytes does not merely stimulate generation of energy in the 
form of ATP, but rather induces dissipation of energy towards heat by promoting uncoupling. 
Thus, it may be questioned whether the term ‘energy saver’ for AMPK truly applies to BAT. 
Anyway, enhancing AMPK activation in BAT may thus be a very potent therapeutic strategy 
to increase energy expenditure, thereby lowering plasma lipid levels and diminishing obesity. 
It should be noted that the insight on the role of AMPK in BAT is still far from complete and 
assumptions are partly derived from the role of AMPK as found in other organs. Therefore, 
to gain more insight in the intracellular pathways in BAT evoked by AMPK, dedicated studies 
with AMPK modulators in BAT or brown adipocytes should be performed. Furthermore, the 
role of AMPK in regulating BAT activity in humans remains to be determined. 
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Effects of activation of BAT on other metabolic organs 
As is evident from CHAPTER 4 and previous literature (8), sympathetic activation of BAT results 
in increased uptake of FA towards BAT, a large part being derived from TRLs. However, this 
inevitably implies that FA are channeled away from other metabolic organs. Indeed, cold 
exposure enhances both hepatic VLDL-TG production (72) as well as WAT lipolysis (73) in 
mice. In line with this, in CHAPTER 11, we found a marked increase in plasma free FA levels in 
white Caucasian subjects after only approx. 2.5 h cold exposure, which suggests a marked 
increase in WAT lipolysis. The effects of cold exposure on hepatic VLDL-TG production in 
humans remain to be investigated. 
We thus propose a model in which BAT activation results in enhanced uptake of 
TG-derived FA from VLDL in plasma. To fuel the increased need for FA by BAT, the liver 
enhances its VLDL-TG secretion in plasma, which in itself is fueled by an enhanced FA flux 
FIGURE 3 - Proposed effects of AMPK activation in the brown adipocyte. AMPK activation enhances the intra-
cellular lipolytic capacity by increasing ATGL and HSL phosphorylation and activation, thereby enhancing FA 
release from TG stored in lipid droplets for oxidation. In addition, AMPK promotes FA oxidation in BAT by 
multiple (path)ways. First, AMPK phosphorylates and inactivates its downstream target ACC. This relieves the 
inhibition exerted by malonyl-CoA on CPT1, ultimately promoting mitochondrial FA transport and oxidation. 
Second, AMPK increases mitochondrial biogenesis, likely through phosphorylation of eNOS and Pgc1. Third, 
AMPK may enhance activation of LPL and translocation of CD36/FAT, resulting in enhanced FA uptake by the 
brown adipocyte for subsequent storage by the lipid droplet and ultimately combustion. 
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FIGURE 4 - Effects of BAT activation on FA fluxes. Activation of BAT results in combustion of FA to generate 
heat. Hepatic VLDL-TG production will be increased to fuel the enhanced FA demand by BAT. Lipolysis in WAT 
will also increase, resulting in release of FA that are transported to the liver to fuel the increased synthesis of 
VLDL-TG. In addition, FA may also be directly taken up as free FA from the plasma by BAT. The consequence of 
these processes is reduction of TG storage in WAT (i.e. obesity) and liver (i.e. hepatosteatosis). These processes 
may, at least in part, be modulated by enhanced sympathetic outflow towards the target organs. 
Modified from Geerling and Boon et al. (75).
derived from increased lipolysis by WAT (74). Thus, via this mechanism, shown in FIGURE 4, 
prolonged BAT activation will result in enhanced lipid fluxes from WAT and liver and conse-
quently weight loss and diminished hepatic steatosis. Indeed, several compounds that were 
investigated in this thesis in CHAPTER 5, CHAPTER 7 and CHAPTER 9 (i.e. BMP7, rimonabant, and 
CL316243, respectively) resulted in both BAT activation and lowering of fat mass. In addition, 
BMP7 and rimonabant also massively lowered hepatic steatosis. Upon BAT activation, the 
sympathetic nervous system may, at least in part, mediate the enhanced lipid fluxes from 
WAT and liver towards BAT as activation of the sympathetic nervous system has been 
shown to enhance hepatic VLDL-TG production and WAT lipolysis (74). In addition, the com-
pounds may also directly influence lipid homeostasis in WAT and liver, both of which 
express e.g. the CB1R (36,37). 
Also in humans BAT activity may be linked to lipid storage in WAT and liver. Previous 
 studies have shown that BAT activity negatively correlates with BMI and percentage of fat 
mass. As mentioned above, an exciting recent study provided direct evidence that activation 
of BAT by means of cold acclimation lowers fat mass in human subjects (25). In addition, a 
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 activity and hepatic steatosis (75), even after correction for several confounders such as BMI. 
Furthermore, genetic polymorphisms of UCP1 were also associated with hepatic steatosis (76). 
POTENTIAL ROLE OF BROWN ADIPOSE TISSUE IN 
THE DISADVANTAGEOUS METABOLIC PHENOTYPE 
OF SOUTH ASIANS
As discussed in CHAPTER 3, in South Asians a disadvantageous metabolic profile that consists 
of central obesity, insulin resistance, and dyslipidemia, is highly prevalent. It is commonly 
assumed that an ethnic susceptibility towards a disturbed energy homeostasis (e.g. lower 
oxidation of glucose and FA by mitochondria) might underlie this phenotype (77). Indeed, 
in CHAPTER 12, we showed that thermoneutral REE was as much as 32% lower in healthy 
lean Dutch South Asian compared to Dutch white Caucasian adolescents. Intriguingly, 
we  demonstrated by means of cold-induced 18F-FDG PET-CT scans that the South Asian adoles-
cents had 34% lower BAT volume compared to the Caucasians. Moreover, as reported previously 
(17,78), in white Caucasian subjects cold exposure resulted in increased serum free FA levels, 
lipid oxidation, and NST, the latter aiming at preventing a drop in core body temperature. In 
South Asians, all of these responses were lower. It is tempting to speculate that the lower 
BAT volume might underlie the smaller increase in NST in South Asians, although we could 
not find a significant correlation between BAT volume and NST, as has been shown previously 
(23,79), albeit not consistently (2,80).
It is interesting to speculate on potential mechanisms that could underlie the decreased 
BAT volume in South Asians. The fact that this is already found in healthy, lean adolescents, 
could point to an inborn defect in BAT development. This is further supported by our 
 findings in CHAPTER 9 in which we show that South Asians already express higher fat mass, 
dyslipidemia and hyperglycemia at birth. The fact that especially BAT volume and not the 
degree of 18F-FDG uptake in BAT, as shown by SUVmax and SUVmean, was significantly 
reduced in South Asians, could point to a defect in BAT differentiation resulting in lower 
total BAT volume. However, since 18F-FDG uptake only represents glucose uptake by the 
 tissue and not metabolism per se, a dysfunction in oxidative metabolism in the tissue 
 cannot be excluded and should be further investigated, for example with an 11C-acetate 
tracer as described above (5) or by studying BAT biopsies.
Several key molecules have been shown in rodent studies to be importantly involved in 
BAT differentiation, such as bone morphogenetic protein 7 (BMP7) as described in CHAPTER 5 
(81) and nitric oxide (NO). We have previously measured BMP7 levels in several cohorts of 
South Asian subjects including neonates, and we consistently found increased BMP7 levels 
compared to white Caucasians (Boon and Bakker et al., unpublished). Thus, decreased BAT 
volume in South Asians does not seem to be caused by decreased differentiation resulting 
from lower BMP7 availability. NO has been recently linked to BAT, as mice that lack the 
enzyme NO synthase, crucial for catalyzing the conversion of L-arginine to NO, have fewer 
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and smaller mitochondria in BAT and lower energy expenditure leading to obesity (82). 
Recently, healthy South Asian adolescents were shown to have lower flow-mediated vaso-
dilation compared to matched Caucasians (83), which points to lower bioavailability of NO. 
Thus, an inborn reduction in NO bioavailability might underlie the lower BAT volume and 
activity in South Asians and is an interesting subject for future studies. In addition, cold 
acclimation has been recently shown to recruit BAT in healthy subjects (84) and may thus 
also be of interest in the South Asian population as a tool to enhance their BAT volume with 
the eventual aim to improve their metabolic phenotype and lower their risk to develop type 
2 diabetes and cardiovascular disease.
CONCLUDING REMARKS AND FUTURE DIRECTIONS
Since its rediscovery in 2009, many studies have focused on investigating the physiology and 
therapeutic relevance of BAT for combating obesity. Murine studies, including those 
described in this thesis, have shown that activation of BAT markedly enhances energy 
expenditure resulting in attenuation of obesity, dyslipidemia, and even atherosclerosis. Thus, 
BAT may be regarded the ‘holy grail’ of metabolic disease as everybody can potentially benefit 
from this tool. Indeed, we found a marked increase in NST in healthy white Caucasian 
 subjects upon cold exposure, suggesting that BAT may contribute to total energy expenditure 
when stimulated. Intriguingly, cold acclimation of healthy subjects has been recently shown 
to enhance NST and lower fat mass pointing towards a direct role for BAT in energy balance 
(25). The next few years will likely be as exciting as the past few years for metabolic research 
as we will now start investigating whether targeting BAT in obese  subjects can be used to 
treat obesity and related diseases such as type 2 diabetes and even atherosclerosis. 
Several promising therapeutic strategies to enhance BAT activation have arisen from the 
present thesis, and now is the time to investigate their efficacy in humans. Among the most 
promising candidates are peripheral CB1R antagonists (CHAPTER 7) although it is crucial to 
first assess whether the CB1R is also present in human BAT. However, the pharmaceutical 
industry may be hesitant to develop novel CB1R blockers, even those that would only act 
peripherally, because of the previous failure of rimonabant. Another promising candidates 
to activate BAT are MC4R agonists, that currently receive a lot of positive attention. In 
CHAPTER 8, we showed that inhibition of the central MC3/4R impaired BAT function accom-
panied by reduced energy expenditure. This suggests that enhancing MC3/4R signaling 
 promotes BAT activation and may induce weight loss. Indeed, a recent phase 2 trial in 
12 obese, insulin resistant monkeys showed that only 4 weeks of treatment with a MC4R 
agonist resulted in 13% lower body weight, improvement of insulin sensitivity and enhance-
ment of energy expenditure, which may point to higher BAT activation (Van der Ploeg et al., 
unpublished). Phase 2 trials in humans are currently being performed, and are needed to 
demonstrate whether MC4R agonists are novel therapeutics to treat obesity and associated 
disorders, and whether their effects are exerted via activating BAT. 
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Of note, several mouse studies (85,86), including our study described in CHAPTER 5, 
have shown that enhancing BAT thermogenesis results in a compensatory increase in food 
intake. This is likely a counteracting mechanism to restore energy balance and may be 
 mediated by several neuronal factors such as NPY. Therefore, energy intake is an important 
factor to take into account when considering BAT activation as a therapeutic strategy, as 
people can only benefit from BAT activation when they do not increase their energy intake 
to compensate for increased expenditure. We, therefore, speculate that in the coming years, 
studies will also focus on investigating the efficacy of combining BAT activation with other 
treatment strategies, such as those that lower energy intake (i.e. dietary interventions or 
appetite-suppressing compounds). A promising group of compounds in this respect are 
GLP-1 analogs or GLP-1 receptor agonists, such as exendin-4. GLP-1 is an incretin hormone 
produced by intestinal L cells and its endogenous action is to enhance insulin secretion by 
pancreatic ß cells (87). Therefore, it is currently used in the clinic for treatment of type 2 
 diabetes. Of note, besides beneficial effects on glucose metabolism, GLP-1 analogs also 
induce weight loss (88). At least part of the mechanism involves lowering of caloric intake 
(89), and whether it also affects energy expenditure remains to be determined. Interestingly, 
central administration of GLP-1 in mice activates BAT (90), making GLP-1 analogs a class of 
drugs that could potentially target both sides of the energy balance. Future studies should 
elucidate whether GLP-1 analogs also activate BAT in humans. In order to lower dyslipidemia, 
combining BAT activation with well-established lipid-lowering strategies may also prove to 
be very beneficial.
As described in CHAPTER 9, BAT activation results in increased delipidation of TRLs in BAT 
and subsequent hepatic clearance of the remnants, which is crucial to induce lowering of 
plasma cholesterol and atherosclerosis development. Therefore, combining BAT activation 
with a treatment strategy that enhances hepatic remnant clearance, i.e. statins or PCSK9 
inhibitors, may be very promising in lowering dyslipidemia and atherosclerosis development. 
Future studies are needed to investigate this further. 
Finally, a striking finding from the present thesis is that South Asians have lower BAT 
volume compared to Caucasian subjects. Therefore, a next step would be to investigate the 
metabolic effects of BAT-directed strategies specifically in the South Asian population, 
which may result in marked improvement of their disadvantageous metabolic phenotype 
and prevention of development of type 2 diabetes and cardiovascular disease. Whether a 
BAT directed strategy is even more effective in South Asians as compared to white 
Caucasians also remains to be determined. 
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SUMMARY
In 1551, the Swiss naturalist Konrad Gessner first described brown adipose tissue (BAT) as 
being “neither fat, nor flesh (nec pinguitudo, nec caro), but something in between”. Now, 
some 460 years later, we know that Gessner had guessed the origin of brown adipocytes 
correctly – they are not typical fat-storing cells or flesh (muscle cells), but rather have 
 characteristics of both white adipocytes and muscle cells, as well as several characteristics 
unique to brown fat cells. A unique property of the brown adipocyte is its capacity to 
 dissipate energy stored in triglycerides (TG) as heat, which is mediated via the uncoupling 
protein UCP1. The recent discovery that active BAT is present in human adults meant the 
beginning of an exciting new area in metabolic research. BAT is currently regarded as a 
potential target to combat obesity and related diseases by inducing a sustained increase in 
energy expenditure. Interestingly, South Asians have lower energy expenditure, which may 
thus theoretically be caused by a reduction in BAT activity. The studies of which the results 
are described in this thesis were aimed at 1) gaining more insight into the physiology of BAT, 
2) identifying novel tools and targets that may activate BAT, and 3) investigating the involve-
ment of BAT in metabolism in humans with a focus on potential differences between South 
Asians and white Caucasians. 
CHAPTER 1, CHAPTER 2 and CHAPTER 3 in the first part of the thesis serve as a general intro-
duction to the physiology of BAT, its potential role in metabolic disease as well as an outline 
on the disadvantageous metabolic phenotype of the South Asian population.
In the second part of the thesis, we investigated the role of BAT in metabolism and 
 obesity using mouse models. Fatty acids (FA) are the main fuel for thermogenesis in BAT and 
intracellular triglyceride (TG) stores are rapidly depleted upon BAT activation. Therefore, BAT 
is required to take up FA from the plasma in order to replenish its intracellular energy stores. 
In CHAPTER 4, we investigated the mechanism by which BAT takes up TG-derived FA from 
lipoproteins by performing kinetic studies using glycerol tri[3H]oleate and [14C]cholesteryl 
oleate double-labeled TG-rich lipoprotein -like emulsion particles. We showed that BAT takes 
up TG-derived FA by means of selective FA uptake, thereby generating remnant particles that 
are subsequently taken up by the liver. Large chylomicron-sized particles showed higher 
retention in BAT than small VLDL-sized particles, the mechanism of which is still unclear.
Next, we focused on compounds, receptors and intracellular pathways that may activate 
BAT, thereby enhancing energy expenditure and clearance of plasma TG, and the underlying 
mechanisms. Based on the discovery that BMP7 can activate BAT, in CHAPTER 5, we investi-
gated the mechanism by which BMP7 activates BAT with special focus on the role of the 
sympathetic nervous system. Hereto, we treated high-fat diet fed lean mice and diet-
induced obese mice with BMP7 at 21°C and 28°C, the latter being the thermoneutral 
 temperature of mice at which sympathetic activation of BAT is largely diminished. We found 
that, at 21°C, BMP7 enhanced interscapular BAT volume and activity as well as energy 
expenditure, and reduced white adipose tissue (WAT) mass. Of note, all these effects were 
blunted at 28°C. Furthermore, BMP7 resulted in massive ‘browning’ (i.e. appearance of beige 
adipocytes) of the WAT depot, independent of environmental temperature. Furthermore, 
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treatment of diet-induced obese mice with BMP7 led to an improved metabolic phenotype, 
consisting of decreased fat mass, liver lipids and dyslipidemia. We concluded that 1) sympa-
thetic activation of interscapular BAT is required for the effects of BMP7 on this BAT depot, 
suggesting at least in part a central mode of action of BMP7; 2) BMP7 has therapeutic 
potential to lower obesity and dyslipidemia by inducing recruitment and activation of inter-
scapular BAT as well as browning.
In CHAPTER 6, the mechanism by which the anti-diabetic drug metformin lowers plasma 
TG was investigated in dyslipidemic APOE*3-Leiden.CETP transgenic mice, a well-established 
model for human-like lipoprotein metabolism. We showed that metformin did not affect 
liver lipids or hepatic VLDL-TG production. Rather, metformin enhanced plasma clearance of 
glycerol tri[3H]oleate-labeled VLDL-like emulsion particles by inducing selectively enhanced 
uptake of [3H]oleate by BAT. This was accompanied by enhanced activity of AMP-activated 
protein kinase (AMPK) 1 as well as higher HSL activity and decreased intracellular lipid 
droplet size in BAT. In vitro studies using T37i differentiated brown adipocytes showed that 
metformin exerts a direct effect on brown adipocytes by increasing AMPK and HSL activities 
and promoting lipolysis. Collectively, our results identified BAT as an important player in the 
TG-lowering effect of metformin and intracellular AMPK may be the crucial intracellular 
mediator of this effect. 
Rimonabant is a systemic cannabinoid 1 receptor (CB1R) blocker that has been previously 
shown to induce sustained weight loss and lowering of plasma TG levels in obese patients. 
In CHAPTER 7, we investigated whether the TG-lowering effect of rimonabant was due to 
activation of BAT. To this end, we treated diet-induced obese APOE*3-Leiden.CETP transgenic 
mice with rimonabant and showed that, next to a massive lowering in body weight and 
plasma TG levels, rimonabant enhanced energy expenditure while only transiently decreasing 
food intake. Kinetic studies with glycerol tri[3H]oleate-labeled VLDL-like emulsion particles 
showed that rimonabant selectively increased uptake of radiolabel by BAT, accompanied by 
decreased lipid droplet size in BAT, all pointing to increased BAT activity. Of note, the results 
could be fully recapitulated at thermoneutral temperature, suggesting that the mechanism 
involves peripheral rather than central activation of BAT. Indeed, we demonstrated that 
the CB1R is highly expressed in BAT and that in vitro blockade of the CB1R in cultured brown 
 adipocytes increases UCP1 content and lipolysis. Furthermore, treatment of mice with 
the strictly peripheral CB1R antagonist AM6545 resulted in lowering of body weight and 
plasma VLDL-TG, together with enhanced BAT activation as evidenced by enhanced energy 
expenditure, uptake of VLDL-TG derived FA by BAT and UCP1 content in BAT. All together, we 
concluded that the TG-lowering effect of rimonabant is due to peripheral blockade of the 
CB1R on BAT. 
Melanocortin 4 receptor (MC4R) deficiency is the most common monogenic cause of 
obesity. Therefore, in CHAPTER 8, we aimed to investigate the role of the melanocortin system 
in BAT function. We treated APOE*3-Leiden.CETP transgenic mice with the MC3/4R antagonist 
SHU9119 or vehicle for 2 weeks via continuous infusion into the lateral ventricle. We found 
that blockade of the central MC3/4R increases food intake and body weight and markedly 
diminishes fat oxidation, as well as impairs the uptake of [3H]oleate from glycerol tri[3H]
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oleate-labeled VLDL-like emulsion particles by BAT. Furthermore, central MC3/4R blockade 
decreased UCP1 protein levels in BAT and induced large intracellular lipid droplets in the 
 tissue, all pointing to lower BAT activity. All these effects were independent of the increased 
food intake induced by central MC3/4R blockade as mice that received SHU9119 while being 
pair-fed to the vehicle-treated group still exhibited these effects. We concluded that inhibition 
of central MC3/4R signaling impairs BAT function accompanied by reduced energy expenditure 
thereby promoting adiposity.
To investigate whether BAT activation could protect against atherosclerosis development, 
in CHAPTER 9, we treated dyslipidemic APOE*3-Leiden.CETP mice fed a Western-type diet with 
the ß3-adrenergic agonist CL316243. We found that CL316243 induces a massive increase in 
BAT activation, accompanied by increased energy expenditure, lower body fat mass and 
plasma TG levels, lower plasma cholesterol levels and reduced development of atherosclerosis. 
Kinetic studies showed that BAT activation enhanced the selective uptake of fatty acids 
from glycerol tri[3H]oleate-labeled VLDL-like emulsion particles into BAT. Importantly, the 
cholesterol and atherosclerosis lowering effects of BAT activation were dependent on a 
functional hepatic apoE-LDLr clearance pathway, as BAT activation in apoe-/- and ldlr-/- mice, 
while lowering triglyceride levels, did not attenuate hypercholesterolemia and atherosclerosis. 
We concluded that activation of BAT is a novel tool to improve dyslipidemia and protect 
against atherosclerosis.
In the third part of the thesis, human studies on metabolism, obesity and BAT were 
 performed. A well-known cause of obesity is long term high-fat feeding, which can result in 
development of insulin resistance and eventually type 2 diabetes. Recent studies have 
 demonstrated elevated macrophage markers in skeletal muscle of obese subjects, which 
inversely related to insulin sensitivity. In CHAPTER 10, we aimed to investigate whether a 
short term high-fat high-calorie diet (HCD) diet already increases macrophage markers and 
affects glucose metabolism in skeletal muscle of healthy lean subjects. We found that 
5 days of HCD markedly increases mRNA expression of several general macrophage markers 
as well as the M1 macrophage marker MARCO in muscle biopsies taken before and after the 
diet intervention. This was accompanied by downregulation of genes involved in uptake and 
storage of glucose, and elevation of plasma glucose and insulin levels together with HOMA-
IR. We concluded that recruitment of macrophages into muscle may be an early event in 
development of insulin resistance in the course of obesity. 
The South Asian population is especially prone to develop obesity and related disorders, 
such as type 2 diabetes and cardiovascular disease (CVD). In CHAPTER 11, we investigated 
whether the high CVD risk in the South Asian population may be due to an ethnic suscepti-
bility to develop endothelial activation. To this end, we measured markers for endothelial 
activation (E-selectin, intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion 
 molecule 1 (VCAM-1)) in cord blood of South Asian and white Caucasian neonates. We found 
that plasma E-selectin levels are markedly higher in South Asian neonates, while levels of 
ICAM-1 and VCAM-1 do not differ from those in white Caucasian neonates. Strikingly, the 
South Asian neonates had hyperinsulinemia, dyslipidemia and higher C-reactive protein 
 levels, the latter pointing to inflammation. Based on these data, we drew two important 
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conclusions: 1) in South Asian neonates, a sign for endothelial activation is already present in 
early life; 2) signs of the disadvantageous metabolic phenotype of South Asians are already 
present at birth.
Since endothelial activation may be the consequence of disturbed HDL function, in 
CHAPTER 12 we investigated whether HDL dysfunction may be present in the South Asian 
population by measuring different measures of HDL functionality in 3 cohorts of South 
Asian subjects and matched white Caucasian subjects (i.e., neonates, adolescents and 
adults). The cholesterol efflux capacity of HDL was comparable between groups. We found 
that the anti-oxidative capacity of HDL is lower in South Asian adults, while at younger ages 
this function is still comparable between both ethnicities suggesting that this function 
decreases over time. In contrast, the anti-inflammatory capacity of HDL was markedly lower 
in South Asian neonates, a difference that disappeared at adolescent and adult age. We 
 concluded that South Asians exhibit disturbed HDL function compared to Caucasians, 
which may contribute to their endothelial activation and excess CVD risk. 
The highly prevalent disadvantageous metabolic phenotype consisting of obesity, 
 dyslipidemia and insulin resistance likely also underlies the high CVD risk in the South Asian 
population. Since an ethnic susceptibility towards a disturbed energy homeostasis may 
underlie this phenotype, we investigated in CHAPTER 13 resting energy expenditure (REE) as 
well as BAT volume and activity by means of cold-induced 18F-FDG PET-CT scans in healthy 
lean Dutch South Asian and matched white Caucasian subjects. We demonstrated that REE 
is a marked 32% lower in healthy lean Dutch South Asian compared to Dutch Caucasian 
adolescents. Furthermore, cold exposure significantly increased non-shivering thermogenesis 
(NST) in white Caucasians, but not in South Asians. Moreover, though SUVmax and SUVmean 
did not differ, BAT volume was markedly lower in South Asians. Our study suggests that 
South Asians have lower REE and BAT volume as compared to matched Caucasians, which 
might underlie their high susceptibility to develop the disadvantageous metabolic pheno-
type at later age. 
The 18F-FDG PET-CT scan is currently the ‘gold standard’ to determine BAT volume and 
activity, but its use is limited by cost and radiation exposure. The eventual product of BAT 
thermogenesis is heat production. Therefore, in CHAPTER 14 we investigated whether supra-
clavicular skin temperature as measured via iButtons or core body temperature as measured 
via a telemetric capsule may serve as a quantitative measure of 18F-FDG uptake in human 
subjects. We found that cold-induced supraclavicular skin temperature positively correlates 
with both total and clavicular BAT volume and clavicular SUVmax, while core body tempe-
rature did not. Therefore, we concluded that supraclavicular skin temperature as measured 
by iButtons is a potential novel non-invasive tool for qualitative BAT detection in adult 
humans. 
Taken together, the studies described in this thesis show that BAT is a promising target 
to combat obesity, dyslipidemia, and even atherosclerosis. We demonstrated that BAT is an 
important player in VLDL-TG metabolism by selective uptake of FA from plasma. Treatment 
of mice with BMP7, rimonabant, metformin or CL316243 enhances BAT activation, accom-
panied by reduction of fat mass and plasma TG levels. On the other hand, blockade of the 
Proefschrift_MB.indb   302 05-05-14   11:59
16
SUMMARY AND NEDERLANDSE SAMENVATTING
303 
central MC3/4R causes BAT dysfunction and development of obesity. These findings suggest 
that pharmacological activation of BAT is feasible, possibly also in humans. We provided 
 evidence that BAT may be of significance in adult humans by showing that South Asians, 
which are very prone to develop obesity, dyslipidemia and type 2 diabetes, exhibit a marked 
reduction in BAT volume together with lower NST and REE as compared to matched white 
Caucasians. The finding that supraclavicular skin temperature correlates with 18F-FDG 
uptake in human subjects may be developed into a surrogate marker for BAT activity in the 
future. This is highly relevant as BAT is currently targeted as a novel strategy to comBAT 
 obesity and related diseases such as type 2 diabetes and atherosclerosis. 
NEDERLANDSE SAMENVATTING
In 1551 beschreef de Zwitserse naturalist Konrad Gessner bruin vet als “geen vet, en ook geen 
vlees (nec pinguitudo, nec caro), maar iets ertussenin”. Nu, zo’n 460 jaar later, weten we dat 
Gessner de oorsprong van bruine vetcellen goed had geraden – het zijn geen typische 
opslagcellen voor vet of ‘vlees’ (spiercellen), maar hebben juist kenmerken van zowel witte 
vetcellen als spiercellen, evenals verscheidene kenmerken die uniek zijn voor bruine vet-
cellen. Eén van de unieke eigenschappen van bruin vet is de mogelijkheid om energie die 
opgeslagen is in vet (‘triglyceriden’, TG) te verbranden tot warmte, een proces waarvoor het 
ontkoppelingseiwit UCP1, dat specifiek in bruin vet voorkomt, mede verantwoordelijk is. De 
recente ontdekking dat bruin vet zowel aanwezig als actief is in volwassenen betekende het 
begin van een fascinerend nieuw onderzoeksgebied in het veld van metabolisme. Omdat 
bruin vet grote hoeveelheden vet letterlijk kan oplossen, en op die manier in belangrijke 
mate bijdraagt aan ‘energieverbruik’, wordt bruin vet momenteel beschouwd als een mogelijk 
aangrijpingspunt om obesitas en aan obesitas gerelateerde stoornissen in de stofwisseling 
tegen te gaan zoals type 2 diabetes en hart- en vaatziekten (HVZ). Interessant is dat 
Hindoestanen, een bevolkingsgroep die ten opzichte van blanke Kaukasiërs erg gevoelig is 
voor het ontwikkelen van type 2 diabetes en HVZ, een lager energieverbruik hebben wat in 
theorie dus veroorzaakt zou kunnen worden door een verlaagde activiteit van het bruin vet. 
De studies waarvan de resultaten in dit proefschrift beschreven staan hadden tot doel om 
1) meer inzicht te verwerven in de fysiologie van bruin vet, 2) nieuwe methoden en aan-
grijpingspunten die bruin vet kunnen activeren te identificeren, en 3) te onderzoeken in hoe-
verre bruin vet betrokken is bij de stofwisseling in mensen, met name gericht op mogelijke 
verschillen tussen Hindoestanen en blanke Kaukasiërs. 
HOOFDSTUK 1, HOOFDSTUK 2 en HOOFDSTUK 3 fungeren als een algemene introductie op de 
fysiologie van bruin vet, de mogelijke rol van bruin vet in stofwisselingsziekten en geven 
tevens een overzicht van het ongunstige metabole fenotype van de Hindoestaanse bevolking. 
In het tweede deel van het proefschrift onderzochten we de rol van bruin vet in de 
 stofwisseling en obesitas in muismodellen. Vetzuren vormen de belangrijkste brandstof 
voor de warmteproductie (‘thermogenese’) in bruin vet en activatie van bruin vet leidt tot 
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snelle uitputting van intracellulair TG. Bruin vet moet daarom vetzuren opnemen uit het 
bloed om zijn energievoorraad aan te vullen. Het was al bekend dat bruin vet TG opneemt 
vanuit bolvormige deeltjes die vet door het bloed transporteren (zogenaamde ‘lipoproteïnen’), 
maar het mechanisme was nog niet opgehelderd. In HOOFDSTUK 4 onderzochten we het 
onderliggende mechanisme door gebruik te maken van emulsiedeeltjes die het biologisch 
gedrag vertonen van lipoproteïnen, en waarvan TG en cholesterolesters radioactief gemerkt 
kunnen worden met respectievelijk glycerol tri[3H]oleaat en [14C]cholesterololeaat. We toon-
den aan dat bruin vet veel meer [3H]oleaat opneemt dan [14C]cholesterololeaat, wat erop 
wijst dat bruin vet selectief vetzuren uit TG van lipoproteïnen onttrekt. Hierdoor ontstaan 
overblijfsels van lipoproteïnen (zogenaamde ‘remnants’) die vervolgens kunnen worden 
opgenomen door de lever. 
Vervolgens bestudeerden we geneesmiddelen, receptoren en intracellulaire routes die 
bruin vet zouden kunnen activeren, als ook onderliggende mechanismen. Geïnspireerd door 
een eerdere ontdekking dat het eiwit BMP7 (‘bone morphogenetic protein 7’) bruin vet kan 
activeren, onderzochten we in HOOFDSTUK 5 het mechanisme waarmee BMP7 bruin vet 
 activeert waarbij we ons met name focusten op de rol van het sympathisch zenuwstelsel. 
Hiertoe behandelden we slanke muizen die een vetrijk dieet kregen en dikke muizen na een 
vetrijk dieet met BMP7. We toonden aan dat BMP7 het volume en de activiteit van het bruin 
vet tussen de schouderbladen (‘interscapulair’) verhoogde, evenals het energieverbruik, 
 terwijl behandeling met BMP7 de hoeveelheid wit vet juist deed afnemen. Opvallend was 
dat deze effecten van BMP7 niet optraden als we de muizen huisvestten bij een omgevings-
temperatuur van 28°C, de ‘thermoneutrale’ temperatuur waarbij de hersenen geen signaal 
meer sturen naar bruin vet door zogenaamde ‘sympathische activatie’ om de muis warm te 
houden. Tevens leidde behandeling met BMP7 tot aanzienlijke vorming van beige vetcellen 
in het witte vet (zogenaamde ‘browning’), onafhankelijk van de omgevingstemperatuur. 
Ook verbeterde BMP7 het metabole fenotype van obese muizen; het verminderde de 
 hoeveelheid vet in vetweefsel en in de lever en verlaagde de vetconcentratie in het bloed 
(‘dyslipidemie’). We concludeerden daarom dat BMP7 bruin vet grotendeels activeert door 
sympathische activatie vanuit de hersenen. BMP7 kan dus mogelijk worden toegepast om 
obesitas en dyslipidemie te verminderen door vermeerdering en activatie van bruin vet en 
door vorming van beige vetcellen. 
Metformine is een geneesmiddel dat in de kliniek wordt toegepast bij de behandeling 
van type 2 diabetes. Het verbetert de glucosestofwisseling maar verlaagt ook de TG con-
centratie in het bloed en veroorzaakt een geringe afname van het lichaamsgewicht. In 
HOOFDSTUK 6 werd het onderliggende mechanisme onderzocht waardoor metformine TG 
verlaagt door gebruik te maken van dyslipidemische APOE*3-Leiden.CETP transgene muizen, 
een goed gevalideerd muismodel met een vetstofwisseling die sterk overeenkomt met die 
van de mens. We lieten zien dat metformine TG niet verlaagt door de productie van VLDL-TG 
door de lever te verminderen. In plaats daarvan verhoogde metformine selectief de opname 
van [3H]oleaat vanuit glycerol tri[3H]oleaat-gelabelde VLDL-achtige emulsiedeeltjes door 
bruin vet. Dit ging gepaard met een verhoogde activiteit van zowel het AMP-geactiveerde 
proteïne kinase (AMPK) 1 als de activiteit van het hormoon-sensitieve lipase (HSL) in bruin 
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vet en het ontstaan van kleinere intracellulaire vetdruppels in het weefsel. In vitro studies 
met gedifferentieerde bruin vetcellen (zogenaamde ‘T37i cellen’) toonden aan dat metformine 
een direct effect op bruine vetcellen uitoefent door AMPK te activeren en daarmee de activiteit 
van HSL te verhogen en de afbraak van intracellulair TG (‘lipolyse’) te stimuleren. Al met al 
 lieten onze resultaten zien dat bruin vet een belangrijke speler is in de effecten van metfor-
mine op TG en dat activatie van intracellulair AMPK daarbij een rol speelt.
Behandeling van obese patiënten met rimonabant, een remmer van de cannabinoid 1 
receptor (CB1R), leidde tot langdurig gewichtsverlies en verbetering van hun dyslipidemie. 
Het werd echter in 2008 van de markt gehaald vanwege psychiatrische bijwerkingen. Om 
meer inzicht te krijgen hoe rimonabant zo’n groot en langdurig effect op obesitas kon 
 hebben onderzochten we in HOOFDSTUK 7 of rimonabant ook in staat zou zijn bruin vet te 
activeren. Hiertoe behandelden we dieet-geïnduceerde obese APOE*3-Leiden.CETP transgene 
muizen met rimonabant. We lieten zien dat rimonabant niet alleen leidde tot een behoor-
lijke verlaging in lichaamsgewicht en TG niveaus in het bloed, maar ook het energieverbruik 
verhoogde terwijl het slechts tijdelijk de voedselinname remde. Studies met glycerol tri[3H]
oleaat-gelabelde VLDL-achtige emulsiedeeltjes lieten zien dat rimonabant selectief de 
opname van [3H]oleaat door bruin vet verhoogde en de vetdruppels in bruin vet verkleinde, 
wat allebei wijst op een verhoogde activiteit van het weefsel. Opvallend was dat we dezelfde 
resultaten verkregen bij thermoneutraliteit. Dit suggereert dat rimonabant waarschijnlijk 
niet de sympathische aansturing vanuit de hersenen moduleert maar direct aangrijpt op 
het bruin vet. Inderdaad konden we aantonen dat de CB1R in hoge mate tot expressie komt 
in bruin vet en dat in vitro remming van de CB1R in de T37i cellen leidde tot een verhoging 
van zowel de hoeveelheid UCP1 als de intracellulaire TG afbraak. Behandeling van muizen 
met de CB1R antagonist AM6545 die de hersenen dus niet kan bereiken (‘strikt perifere 
 antagonist’) leidde ook tot verlaging van het lichaamsgewicht en TG, wat samenging met 
 verhoogde bruin vet activatie. Dit laatste bleek uit een verhoogd energieverbruik, verhoogde 
opname van vetzuren vanuit VLDL-TG door bruin vet en tevens een verhoogde hoeveelheid 
UCP1. Samenvattend concludeerden we dat het effect van rimonabant op TG en lichaams-
gewicht grotendeels toe te schrijven is aan directe remming van de CB1R in bruin vet. 
Melanocortine 4 receptor (MC4R) deficiëntie is de meest voorkomende monogene oor-
zaak van obesitas. In HOOFDSTUK 8 onderzochten we daarom de rol van het melanocortine-
systeem in de functie van bruin vet. We behandelden APOE*3-Leiden.CETP transgene muizen 
met de MC3/4R antagonist SHU9119 of placebo gedurende 2 weken door middel van continue 
infusie in de laterale ventrikel in de hersenen omdat het melanocortinesysteem aldaar 
tot expressie komt. We toonden aan dat remming van de centrale MC3/4R leidde tot een 
verhoging van zowel de voedselinname als het lichaamsgewicht, een aanzienlijke verlaging 
in vetoxidatie, en een verlaagde opname van [3H]oleaat vanuit glycerol tri[3H]oleaat- 
gelabelde VLDL-achtige emulsiedeeltjes door bruin vet. Verder leidde remming van de 
 centrale MC3/4R tot verlaagde UCP1 eiwit niveaus in bruin vet en leidde het tot de vorming 
van grote intracellulaire vetdruppels in het weefsel, beide wijzend op een verlaagde activiteit 
van het bruin vet. Al deze effecten waren onafhankelijk van de verhoogde voedselinname 
dat het gevolg was door centrale MC3/4R remming aangezien deze effecten nog steeds 
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optraden in muizen die behandeld werden met SHU9119 terwijl ze dezelfde hoeveelheid 
voedsel ontvingen als de controlemuizen. We concludeerden dat remming van centrale 
MC3/4R signalering de functie van bruin vet en het energieverbruik vermindert, wat leidt tot 
een toename van adipositas.
Om te onderzoeken of activatie van bruin vet zou kunnen beschermen tegen de ontwik-
keling van atherosclerose, hebben we in HOOFDSTUK 9 dyslipidemische APOE*3-Leiden.CETP 
muizen behandeld met CL316243, een agonist van de ß3-adrenerge receptor die normaal-
gesproken door stimulatie van het sympathische zenuwstelsel wordt geactiveerd. CL316243 
leidde tot een opvallende activatie van het bruin vet en induceerde ‘browning’. Tevens leidde 
CL316243 tot een toename van het energiegebruik, een verlaging van de hoeveelheid 
lichaamsvet en TG niveaus in het bloed, een verlaging van cholesterolniveaus in het bloed 
en beschermde het tegen de ontwikkeling van atherosclerose. Kinetische studies lieten zien 
dat activatie van de ß3-adrenerge receptor de selectieve opname van vetzuren vanuit glycerol 
tri[3H]oleaat-gelabelde VLDL-achtige emulsiedeeltjes door het bruin vet verhoogde. Een 
belangrijke bevinding was tevens dat de verlaging van zowel cholesterol als atherosclerose 
ten gevolge van bruin vet activatie afhankelijk waren van de opname van gegenereerde 
lipoproteïnen remnants via het apolipoproteïne apoE door de LDL receptor op de lever. 
Activatie van bruin vet in muizen die het apoE of de LDL receptor niet tot expressie brengen 
leidde namelijk wel tot verlaging van TG niveaus maar niet tot vermindering van hyper-
cholesterolemie en atherosclerose. Aangezien de APOE*3-Leiden.CETP transgene muis een 
beter model is voor de menselijke lipoproteïnenstofwisseling dan de apoE-deficiënte muis 
en de LDL receptor-deficiënte muis konden we concluderen dat activatie van bruin vet een 
veelbelovende nieuwe methode is om dyslipidemie te verbeteren en te beschermen tegen 
atherosclerose.
In het derde deel van het proefschrift werden studies uitgevoerd rondom de stofwisseling, 
obesitas en bruin vet in mensen. Het langdurig eten van voeding dat veel vet bevat is een 
bekende oorzaak van obesitas en kan leiden tot de ontwikkeling van insulineresistentie en 
uiteindelijk type 2 diabetes. Recente studies hebben laten zien dat in spierweefsel van obese 
mensen merkers van bepaalde ontstekingscellen (‘macrofagen’) in verhoogde mate voor-
komen en dat deze omgekeerd gerelateerd zijn aan insulinegevoeligheid. In HOOFDSTUK 10 
onderzochten we of een kortdurend dieet dat rijk is aan vet en calorieën al zou leiden tot 
verhoging van macrofaagmerkers en effecten op de glucosestofwisseling in de skeletspier 
van gezonde slanke mensen. Door spierbiopten af te nemen voor en na de dieetinterventie 
konden we aantonen dat 5 dagen dieet al leidde tot een opvallende verhoging in de mRNA 
expressie van diverse algemene macrofaagmerkers waaronder de M1 macrofaagmerker 
MARCO. Tevens waren genen die betrokken zijn bij opname en opslag van glucose verlaagd, 
terwijl plasmaniveaus van glucose en insuline verhoogd waren. We concludeerden dat de 
vroege instroom van macrofagen in spieren een oorzaak zou kunnen zijn voor de latere 
 ontwikkeling van insulineresistentie bij dieet-geïnduceerde obesitas. 
De Hindoestaanse populatie is in het bijzonder gevoelig voor de ontwikkeling van obesitas 
en verwante stoornissen zoals type 2 diabetes en HVZ. In HOOFDSTUK 11 onderzochten we of 
het hoge risico op HVZ in deze populatie verklaard kan worden door een etnische gevoelig-
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heid voor het ontwikkelen van nadelige endotheelactivatie. Hiertoe maten we E-selectine, 
het intercellulaire adhesiemolecuul 1 (ICAM-1) en het vasculaire adhesiemolecuul 1 (VCAM-1) 
als merkers voor endotheelactivatie in navelstrengbloed van Hindoestaanse en blanke 
Kaukasische neonaten. We toonden aan dat plasmaniveaus van het E-selectine aanzienlijk 
verhoogd waren in de Hindoestaanse neonaten, terwijl de plasmaniveaus van ICAM-1 en 
VCAM-1 niet verschilden van die van blanke Kaukasische neonaten. Opvallend was dat 
Hindoestaanse neonaten zich al presenteerden met hyperinsulinemie, dyslipidemie en 
 verhoogde plasmaniveaus van het C-reactieve proteïne (CRP), waarbij het laatste wijst op 
verhoogde ontsteking. Gebaseerd op deze data konden we concluderen dat Hindoestanen 
bij geboorte al tekenen vertonen van zowel endotheelactivatie als een ongunstige meta-
bool fenotype.
Omdat activatie van endotheel het gevolg kan zijn van een verstoorde functie van het 
hoge-dichtheids lipoproteïne (HDL) onderzochten we in HOOFDSTUK 12 de HDL functionaliteit 
van Hindoestanen. Hiertoe bepaalden we verschillende maten van HDL functionaliteit in 
neonaten, adolescenten en volwassenen van Hindoestaanse en blanke Kaukasische komaf. 
De functie van het HDL met betrekking tot het opnemen van cholesterol uit macrofagen 
was vergelijkbaar tussen de etniciteiten. De functie van het HDL om te beschermen tegen 
oxidatie was lager in Hindoestaanse ten opzichten van blanke Kaukasische volwassenen, 
terwijl deze functie op jongere leeftijden nog vergelijkbaar was tussen beide etniciteiten. 
Dit suggereert dat deze functie met de leeftijd vermindert. Aan de andere kant was de capa-
citeit van HDL om te beschermen tegen ontsteking opvallend lager in de Hindoestaanse ten 
opzichte van blanke Kaukasische neonaten, een verschil dat in de adolescenten en volwas-
senen niet meer aantoonbaar was. We concludeerden dat Hindoestanen een verstoorde 
HDL functie hebben in vergelijking met blanke Kaukasiërs, en dat dit zou kunnen bijdragen 
aan endotheelactivatie en hun verhoogde risico op HVZ. 
Het is waarschijnlijk dat het zeer veel voorkomende ongunstige metabole fenotype van 
Hindoestanen bestaande uit obesitas, dyslipidemie en insulineresistentie ook bijdraagt aan 
hun hoge risico op HVZ. Aangezien een etnische gevoeligheid voor het ontwikkelen van een 
verstoord energiemetabolisme de onderliggende reden kan zijn van dit fenotype, onder-
zochten we in HOOFDSTUK 13 het energieverbruik in rust (‘resting energy expenditure’, REE) 
evenals het volume en de activiteit van bruin vet door middel 18F-fluorodeoxyglucose (FDG) 
PET-CT scans in gezonde slanke Nederlandse Hindoestanen en gematchte blanke Kaukasiërs, 
nadat we hun bruin vet maximaal activeerden door afkoeling tussen watergekoelde 
 matten. We toonden aan dat REE maar liefst 32% lager was in de Hindoestanen vergeleken 
met de blanke Kaukasiërs. Verder leidde blootstelling aan kou tot een significante verhoging 
van ‘non-shivering’ thermogenese (NST) in blanke Kaukasiërs, maar niet in Hindoestanen. 
Bovendien was het bruin vet volume behoorlijk lager in Hindoestanen, terwijl er geen 
 verschil was tussen de maximale opname (SUVmax) en gemiddelde opname (SUVmean) van 
18F-FDG door het bruin vet tussen de etniciteiten. Wij konden concluderen dat Hindoestanen 
verlaagde REE en bruin vet volume hebben vergeleken met gematchte blanke Kaukasiërs 
en dat dit onderliggend zou kunnen zijn aan hun hoge gevoeligheid voor het ontwikkelen 
van een ongunstig metabool fenotype op latere leeftijd. 
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De 18F-FDG PET-CT scan is momenteel de ‘gouden standaard’ voor het bepalen van het 
volume en de activiteit van bruin vet, maar het gebruik ervan wordt beperkt door hoge 
 kosten en de stralingsbelasting voor de proefpersonen. Het uiteindelijke product van thermo-
genese is de productie van warmte. Daarom hebben we in HOOFDSTUK 14 onderzocht of 
supraclaviculaire temperatuur van de huid en/of de kerntemperatuur van het lichaam, die 
we kunnen meten met respectievelijk iButtons en telemetrische capsules, een kwantitatieve 
maat zouden kunnen zijn voor de opname van 18F-FDG in mensen. We vonden dat de 
 koude-geinduceerde supraclaviculaire huidtemperatuur positief correleerde met zowel het 
totale bruin vet volume als het claviculaire bruin vet volume en claviculaire SUVmax, terwijl 
de koude-geinduceerde kerntemperatuur niet correleerde met deze variabelen. We conclu-
deerden daarom dat de supraclaviculaire huidtemperatuur gemeten met iButtons een 
mogelijke nieuwe niet-invasieve methode is voor de kwalitatieve detectie van bruin vet in 
mensen. 
De studies beschreven in dit proefschrift laten zien dat bruin vet een veelbelovend 
 aangrijpingspunt kan zijn om obesitas en dyslipidemie tegen te gaan. We toonden aan dat 
bruin vet een belangrijke speler is in het metabolisme van TG-rijke lipoproteïnen doordat 
het selectief vetzuren uit deze lipoproteïnen onttrekt. Behandeling van muizen met BMP7, 
rimonabant, metformine en CL316243 leidde tot een verhoging van de activiteit van bruin 
vet en als een gevolg daarvan tot een vermindering in het lichaamsvet en plasmaniveaus 
van TG. Daarentegen leidde vermindering van de functie van bruin vet, door remming van 
het centrale melanocortinesyteem, tot de ontwikkeling van obesitas. Gezamenlijk geven 
deze bevindingen aan dat bruin vet farmacologisch geactiveerd kan worden, en mogelijk 
ook in mensen. Tevens toonden we aan dat bruin vet een belangrijke rol kan spelen in de 
stofwisseling van volwassenen, aangezien we hebben aangetoond dat Hindoestanen, die 
zeer gevoelig zijn voor het ontwikkelen van obesitas, dyslipidemie en type 2 diabetes, een 
sterke vermindering hebben van hun bruin vet volume evenals een verminderde NST en REE 
vergeleken met gematchte blanke Kaukasiërs. De bevinding dat de koude-geinduceerde 
supraclaviculaire huidtemperatuur correleert met 18F-FDG opname in mensen kan in de 
 toekomst mogelijk leiden tot de ontwikkeling van een surrogaat merker voor de activiteit 
van bruin vet. Dit is zeer relevant aangezien bruin vet inmiddels beschouwd kan worden 
als de nieuwe strategie om obesitas en aanverwante stoornissen zoals type 2 diabetes en 
atherosclerose te bestrijden.
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